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ABSTRACT 
 
Chronic visceral pain affects millions of individuals worldwide, remains poorly 
understood, and current therapeutics are constrained by undesirable adverse 
events. Inflammation and distension of visceral organs are common causes of 
pain, suggesting drugs targeting these signalling pathways may be efficacious 
visceral treatments. The voltage-gated sodium channel subtype 1.9 (NaV1.9) has 
been strongly associated with the development of inflammatory pain by rodent 
studies and more recently, by the identification of channelopathies in man. The 
aim of these studies was to investigate the role of NaV1.9 in visceral afferent 
signalling in the gut. Data from this thesis demonstrates that NaV1.9 is 
expressed by approximately half of gut-projecting rodent dorsal root ganglia 
sensory neurons. Consistent with significant expression in visceral afferents, 
NaV1.9 is required for normal mechanosensation, and for the direct excitation 
and mechanical hypersensitisation of mouse colonic afferents by inflammatory 
mediators applied as an inflammatory soup (bradykinin, ATP, histamine, PGE2, 
and 5HT) or derived from man (as inflammatory bowel disease tissue 
supernatants). Additionally, the importance of P2Y receptor activation in both 
rodent and human gut to algogenic purinergic signalling was demonstrated. 
Collectively, these results demonstrate that NaV1.9, is required for persistence 
of responses to intense mechanical stimulation, contributes to inflammatory 
mechanical hypersensitivity, and is essential for activation by noxious 
inflammatory mediators, including those from diseased human bowel. These 
findings suggest that NaV1.9 represents a high-value target for development of 
visceral analgesics. 
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HCN hyperpolarisation-activated cyclic nucleotide gated channel 
HRP horseradish peroxidase 
HT high threshold 
IB4 Griffonia simplicifolia isolectin B4 
IBD inflammatory bowel disease 
IBS irritable bowel syndrome 
IGLE intraganglionic laminar ending 
IHC immunohistochemistry 
IL interleukin 
IMA intrmuscular array 
IMG inferior mesenteric ganglion 
IMN intermesenteric nerve 
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IPAN intrinsic primary afferent neurone 
IR immunoreactivity 
IS inflammatory soup 
ISH in situ hybridisation 
KCa calcium-activated potassium channel 
Kir inwardly rectifying potassium channel 
KV voltage-gated potassium channel 
LSN lumbar splanchnic nerve 
LT low threshold 
NACC National Association for Colitis and Crohn's Disease 
NaV voltage-gated sodium channel 
NF200 neurofilament (heavy) 
NG nodose ganglia 
NGF nerve growth factor 
NSAID non-steroidal anti-inflammatory drug 
P2X ionotropic P2X purinoceptor 
P2Y metabotropic P2Y purinoceptor 
PAR protease-activated receptor 
PBS phosphate buffered saline 
PFA paraformaldehyde 
PG pelvic ganglion 
PGE2 prostaglandin E2 
PKA protein kinase A 
PKC protein kinase C 
PLC phospholipase C 
PNS peripheral nervous system 
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PVG pre-vertebral ganglia 
rIGLE rectal intraganglionic laminar ending 
RMP resting membrane potential 
RT-PCR real-time polymerase chain reaction 
SMG superior mesenteric ganglion 
SNRI serotonin-norepinephrine reuptake inhibitor 
SP substance P 
SSRI selective serotonin reuptake inhibitor 
TCA tricyclic antidepressant 
TG trigeminal ganglia 
TNBS 2,4,6-trinitrobenzenesulfonic acid 
TNF tumour necrosis factor 
trkA high-affinity nerve growth factor receptor 
TRP transient receptor potential channel 
TTX-S/R tetrodotoxin-sensitive/resistant 
UC ulcerative colitis 
UDP uridine-5'-diphosphate 
UTP uridine-5'-triphosphate 
VIP vasoactive intestinal polypeptide 
VMR visceromotor reflex 
WDR wide dynamic range 
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CHAPTER 1: INTRODUCTION  
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1.1 CLINICAL IMPACT OF VISCERAL PAIN IN INFLAMMATORY 
BOWEL DISEASE  
 
Chronic visceral pain affects millions of individuals worldwide, is a leading 
reason for presentation to a surgeon or gastroenterologist (Bhuiya, Pitts, & 
McCaig, 2010; Bonica, 1990) and is often the first indication of more serious 
disease, including appendicitis, cancer, ischaemia and gastritis. One group of 
patients where visceral pain incurs distinct morbidity is in those suffering from 
inflammatory bowel disease (IBD), such as Crohn’s disease (CD) and ulcerative 
colitis (UC). This disease, which affects approximately 240,000 in the UK, is a 
chronic and relapsing inflammatory condition caused by a hyperinflammatory 
T-cell response to certain commensal enteric bacteria (Sartor, 2006). The 
disease presents clinically as diarrhoea, bleeding, fatigue and abdominal pain 
(Mowat et al., 2011). Abdominal pain is rated highly as a negative impact on 
patient’s lives (R. Driscoll, 2008; Ghosh & Mitchell, 2007), and is more strongly 
associated with Crohn’s disease than ulcerative colitis (Aghazadeh et al., 2005; 
Castro et al., 2008; Ghosh & Mitchell, 2007; Kim et al., 2010; Singh et al., 2011; Y. 
Wang, Ouyang, & group, 2007). A survey conducted by the National Association 
for Colitis and Crohn’s Disease (NACC) of 2527 of its members, found strong 
associations with the intensity of pain experienced and disease activity (R. 
Driscoll, 2008). Indeed, 72% of patients described the pain as an indication that 
a ‘flare-up’ was occurring. As such, a significant proportion of IBD patients 
experience visceral allodynia to physiological bowel movements and 
inflammatory hyperalgesia is associated with the vast majority of patients. The 
pain experienced is not limited to active disease or ‘flare-ups’, with up to half of 
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patients also reporting abdominal pain during remissive states (Bielefeldt, 
Davis, & Binion, 2009; R. Driscoll, 2008; Singh et al., 2011). Furthermore, 
continued pain during disease acquiescence indicates long-term mechanistic 
changes to nociceptive sensory pathways, resulting in visceral hypersensitivity. 
The cause of pain in IBD is poorly understood, however chronic serosal and 
mucosal inflammation is likely to result in peripheral nerve sensitisation, 
resulting in visceral hypersensitivity to physiological gastrointestinal (GI) 
function and in some patients, secondary irritable bowel syndrome (Grover, 
Herfarth, & Drossman, 2009; Knowles & Aziz, 2009). Central sensitisation and 
psychological factors will also significantly impact pain thresholds (Mowat et 
al., 2011). These factors are perpetuated by distension and obstruction caused 
by occlusions and strictures as a result of the disease (Bielefeldt et al., 2009).  
With almost a third of patients having been admitted to hospital at least twice 
because of pain (R. Driscoll, 2008), current medical practices are not able to 
effectively provide management of abdominal pain in these patients. Given the 
complex factors affecting abdominal pain in IBD, the treatments used to manage 
pain are equally diverse, including pharmacological, behavioural and 
procedural methods. In early stage disease, the use of standard of care IBD 
treatments (e.g. corticosteroids, aminosalicylates, antibiotics, enteral therapy, 
immunomodulators and biological response modifiers) can reduce intestinal 
inflammation and drive a large subset of patients into remission. This may also 
reduce associated abdominal pain, but as mentioned previously, continued 
visceral hypersensitivity, discomfort and pain can persist in up to half of 
patients. As such, it is likely that there exists a subset of patients in which 
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abdominal pain is discontinuous to inflammation and disease activity. 
According to the NACC patient survey, the most commonly prescribed 
medicines specifically for pain relief in IBD were paracetamol (44%), ibuprofen 
(24%), anti-spasmodics (24%) and tramadol (11%) (R. Driscoll, 2008). These 
medicines represent the major classes of pharmacological interventions in IBD 
pain management; however each drug category is constrained in both 
effectiveness and use by associated negative adverse effects (see Table 1). 
Common non-steroidal anti-inflammatory drugs (NSAIDs), whilst effective at 
reducing abdominal pain and IBD-related musculoskeletal symptoms, have 
been linked with an exacerbation of disease activity and an increased likelihood 
of flares and relapse (Bonner, Walczak, Kitchen, & Bayona, 2000; Evans, 
McMahon, Murray, McDevitt, & MacDonald, 1997; Kefalakes, Stylianides, 
Amanakis, & Kolios, 2009; Mowat et al., 2011). Indeed, increased concern about 
the correlation between NSAIDs and IBD exacerbation led to the use of selective 
cyclooxygenase-2 (COX-2) inhibitors (including celecoxib, rofecoxib and 
etoricoxib) in IBD, which lack COX-1 activity, the proposed mechanism for 
inducing disease activity. The effectiveness of this class of drug remains 
controversial and, as yet, has failed to demonstrate robust anti-inflammatory 
effects and have further been associated with a 7-16% increase in disease 
exacerbation (Biancone, Tosti, De Nigris, Fantini, & Pallone, 2003; Mahadevan, 
Loftus, Tremaine, & Sandborn, 2002). In irritable bowel syndrome (IBS), anti-
spasmodics (such as hyoscyamine) have proven effective in the management of 
abdominal pain and may be used to reduce pain evoked by intestinal 
inflammation or partial obstruction (Ford et al., 2008). No equivalent evidence 
exists for their usage in IBD (Makharia, 2011), although anti-spasmodics are 
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commonly used when remission is induced in IBD patients. However, side 
effects must be monitored, with complete obstruction and worsening of gut 
dysmotility both possible outcomes. The chronic use of narcotics also has 
negative impacts on morbidity and mortality due to their effects on 
gastrointestinal function and dysmotility in IBD patients, alongside established 
concerns around abuse (Cross, Wilson, & Binion, 2005; Edwards, Radford-
Smith, & Florin, 2001; Mowat et al., 2011). Reported use of narcotics is as high 
as 70% in hospitalised IBD patients, with between 5-13% of patients prescribed 
chronic narcotics as outpatients (Edwards et al., 2001; Long, Barnes, Herfarth, & 
Drossman, 2012). As such, the adverse effects associated with different 
analgesic classes significantly limits the therapeutic options available for 
treating visceral pain in IBD. 
Other medications that are used in the management of visceral pain in IBD and 
associated visceral hypersensitivity include psychotropic agents. The use of 
these medications stems out of current IBS literature, with the targeting of 
serotonin and noradrenaline purported to modulate visceral motility and 
sensation (Grover & Drossman, 2011). Whether benefits arise from direct 
effects on nociception or from psychological improvements to depression and 
anxiety, which are often associated with chronic abdominal pain, remains an 
unknown. The use of low-dose tricyclic antidepressants has proven to be 
effective in alleviating abdominal pain in IBS, and qualitative evidence exists for 
their effectiveness in IBD (Mikocka-Walus et al., 2007; Rahimi, Nikfar, Rezaie, & 
Abdollahi, 2009). Studies investigating the use of selective serotonin-reuptake 
inhibitors (SSRIs) in both IBS and IBD are less convincing, but suggest that 
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SSRIs may have utility in the treatment of functional abdominal pain associated 
with IBD (Walker, Gelfand, Gelfand, Creed, & Katon, 1996). Finally, the use of 
centrally-acting gabapentin and pregabalin, which show efficacy in the 
treatment of neuropathic pain, also likely have relevance in the treatment of 
centrally and inflammatory-mediated visceral hypersensitivity (Gale & 
Houghton, 2011; Srinath, Walter, Newara, & Szigethy, 2012). In addition, 
procedural approaches have benefit in some patients, including acupuncture, 
nerve blocks and transcutaneous electrical nerve stimulation (Srinath et al., 
2012). Classical psychological pain management aimed at modulating central 
pathways influencing sensory processing is also applicable to patients with IBD 
and may include cognitive behavioural therapy, hypnotherapy and stress 
management (Srinath et al., 2012).  
Given that chronic visceral pain is a debilitating and poorly treated component 
of IBD, there is a clear need for novel pain therapies to provide benefit to those 
suffering from these conditions (R. Driscoll, 2008). 
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Drug class Example drugs Mechanism of action Role in IBD pain management Possible complications/ limitations 
     
Pharmacological     
Anti-spasmodics Hyoscyamine 
Dicyclomine 
Nonselective inhibitor of 
acetylcholine receptors 
Smooth muscle relaxant, reducing intestinal 
spasm associated with inflammation or 
partial obstruction 
Fulfilment obstruction/ worsening 
of gut dysmotility  
NSAIDs Ibuprofen 
Diclofenac 
Nonselective inhibitor of COX 
enzymes 
Provides analgesic and anti-inflammatory 
effects in GI tract and associated 
musculoskeletal pain  
May exacerbate IBD activity, induce 
relapse and increase frequency of 
flares 
COX-2 inhibitors Celecoxib 
Etoricoxib 
Rofecoxib 
Selective inhibitor of COX-2 
enzyme 
Limited; purported to provide analgesic and 
anti-inflammatory effects 
May exacerbate IBD activity 
Narcotics Morphine 
Tramadol 
Hydromorphone 
 
Modulators of opioid receptors Useful for post-operative and severe chronic 
pain 
Nausea, vomiting, constipation, 
intestinal pseudo-obstruction and 
reduced GI motility, alongside 
addiction and substance abuse 
     
Psychotropic     
TCAs Amitriptyline 
Desipramine 
Dosulepin 
Nonselective SNRIs and 
inhibitors of 5-HT receptors, 
amongst others 
May decrease comorbidities of anxiety and 
depression; may affect nociception by 
modulating visceral motility and sensation 
Inconclusive supporting evidence; 
may be ineffective for non-
depressed patients 
SSRIs Paroxetine 
Citalopram 
Inhibitors of SERT Similar proposed mechanism to TCAs Inconclusive supporting evidence; 
may be ineffective for non-
depressed patients 
SNRIs Duloxetine 
Venlafaxine 
Inhibitors of NET Similar proposed mechanism to TCAs Inconclusive supporting evidence; 
may be ineffective for non-
depressed patients 
Gabapentin/ 
Pregabalin 
Gabapentin 
Pregabalin 
Modulators of voltage-gated 
calcium channels 
Centrally acting analgesic Side effects are mild; no extensive 
supporting evidence in IBD pain 
 
Table 1. Pharmacological treatment of IBD pain. COX, cyclooxygenase; NET, norephinephrine transporter; NSAIDs, non-steroidal anti-
inflammatory drugs; SERT, serotonin transporter; SNRI, selective norephinephrine reuptake inhibitor; SSRI, selective serotonin reuptake 
inhibitor; TCA, tricyclic antidepressants. 
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1.2 CHARACTERISTICS OF VISCERAL PAIN 
 
Visceral pain is a sensation that forms part of the body’s defence strategy 
against harmful stimuli, specifically those affecting hollow organs. Noxious 
stimuli are transduced by primary afferents via spinal pathways to the parts of 
the brain responsible for integrating different aspects of the sensory 
experience, including discrimination, emotion and cognition. In IBD, visceral 
pain is associated with active disease, and with visceral hypersensitivity driven 
by sensitising processes in visceral pain pathways. As such, chronic visceral 
pain in IBD may be considered a function of inflammatory and neuropathic pain 
resulting from GI peripheral nerve injury. Ongoing primary afferent input is 
likely to be critical for maintaining such chronic pain sensations (Haroutounian 
et al., 2014). Therefore, the processing of visceral nociception and transduction 
of noxious stimuli by visceral sensory receptors will be covered in more detail, 
specifically focusing on visceral afferent signalling and processing relevant to 
chronic visceral pain associated with IBD. 
Visceral afferent fibres transduce conscious sensations and act to regulate 
autonomic function from the vast majority of mammalian visceral organs. The 
activation of visceral afferents resulting in reflex actions occurs mainly at the 
subconscious level, with some solid organs such as the lungs or liver being 
insensitive to pain. Indeed, the activation of pulmonary stretch receptors or 
hepatic chemoreceptors is not consciously perceived (Cervero, 1985), and as 
such considerable damage may occur before detection. By contrast, in hollow 
viscera relatively mild inflammation or tonic contraction of smooth muscle can 
cause intense pain. Whilst it is not possible to withdraw from such stimuli as 
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you would with the rapid movement of a limb from noxious somatic stimuli, 
protective mechanisms in the form of long-term behavioural coping strategies 
are often evoked by such pain (e.g. nausea, changes to water and food intake, 
and general inactivity). Within the gastrointestinal tract, in conjunction with 
autonomic regulation (absorption, secretion and propulsion), afferent fibres 
contribute to conscious sensations such as fullness, bloating, urgency, and 
following noxious stimulation, pain (Knowles & Aziz, 2009). These sensations 
are the combination of innervation originating from intrinsic sensory neurones, 
pre-vertebral ganglia projecting viscerofugal fibres, and both spinal and vagal 
extrinsic afferents (Grundy, 2002). Visceral afferents of the gastrointestinal 
tract may encode stimuli ranges in the innocuous or noxious domains, as well as 
intensity encoding across the full intensity range. This is demonstrated where 
innocuous rectal sensation may rapidly evolve into pain and discomfort if 
maintained (Cervero, 1988). The sensory modalities familiar to the skin of 
touch, wetness, prickle, temperature and pain are mediated by specific 
receptors for mechanosensation, chemosensation and thermosensation, which 
differ both anatomically and molecularly from those associated with visceral 
sensation. Indeed, pain is the only sensation that may be evoked by the majority 
of visceral organs. In conscious man, stimulation by balloon distension can 
evoke pain throughout the GI tract, whilst other stimuli such as cutting, 
pinching, local stretching and electrical stimulation all fail to elicit pain (Bentley 
& Smithwick, 1940; Ray & Neill, 1947; "The Goulstonian Lectures ON THE 
SENSIBILITY OF THE ALIMENTARY CANAL IN HEALTH AND DISEASE," 1911). 
This is consistent with the stimulation of bowel mesentery causing painful 
sensation and the inability to perceive temperature in the lower GI tract (Ray & 
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Neill, 1947). Whilst the GI tract is extensively innervated, the sensation of pain 
is primarily transduced by spinal afferents, as shown by its absence following 
bilateral sympathectomy (Ray & Neill, 1947). These studies highlight 
specialisation in visceral afferent signalling to noxious stimuli and processing 
that are unique to the viscera.   
Visceral sensation and pain is poorly graduated and localised, with no specific 
pathway present within the central nervous system (CNS) processing visceral 
nociceptive signals (G. F. E. Gebhart, 1995). Visceral unmyelinated afferent 
neurones project centrally over multiple spinal segments and diffusely across 
the dorsal horn. This is in contrast to cutaneous unmyelinated afferent 
neurones, which are much more restricted in their central arborisations (Jänig, 
1996). Visceral afferent fibres may also possess multiple peripheral receptive 
fields (Berthoud, Lynn, & Blackshaw, 2001). As such, the low density of visceral 
afferent innervation, in conjunction with the non-existent organotopic 
representation and broad segmental projection on the dorsal horn, all 
contribute to the generalisation and poor graduation of visceral sensation 
(Jänig, 1996). The poor definition of visceral pain in the CNS leads to the 
manifestation of pain in unaffected areas of the body, including left lower 
quadrant, neck and left arm, dependent on the visceral organ affected (Sikandar 
& Dickenson, 2012). This is also contributed to by viscera-somatic convergence 
in ascending afferent pathways (Cervero, Laird, & Pozo, 1992), with patients 
experiencing referred visceral pain in associated somatic structures. Visceral 
pain may also evoke involuntary non-specific motor responses and is strongly 
associated with autonomic reflexes, including symptoms such as sweating, 
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nausea, changes in body temperature and heart rate (Knowles & Aziz, 2009). 
Finally, there exists a strong affective component to visceral pain, which may be 
reinforced by psychological conditions such as depression or anxiety (Knowles 
& Aziz, 2009). Collectively, the divergent characteristics of visceral pain and the 
activation of associated CNS and autonomic pathways present challenges for the 
identification of visceral nociceptors, when compared to the more discrete pain 
pathways present for somatic systems (Cervero & Laird, 2004). However, by 
investigating the specific anatomical and molecular pathways mediating the 
transduction of visceral pain in conditions such as IBD, it will be possible to 
identify novel mechanisms relevant to visceral nociception and inflammatory 
pain. Specifically, Crohn’s disease primarily presents as an ileocecal condition 
whilst ulcerative colitis is typically localised more distally; both activating the 
spinal afferent pathways to evoke painful sensation, through which little other 
conscious sensation is encoded from the gut. Therefore it is necessary to 
understand the basis of nociception in these specific spinal pathways in order to 
study visceral pain in these conditions. 
1.3 NEUROANATOMY OF THE GI TRACT 
 
The transduction of physiological and noxious stimuli is mediated by the 
extrinsic innervation in the GI tract. This can be split into three main pathways, 
spinal thoracolumbar, spinal lumbosacral and vagal. Vagal afferents innervate a 
wide range of organs in the viscera, including the heart, trachea, liver, pancreas 
and upper and lower GI tract (Berthoud & Neuhuber, 2000). The density of 
vagal innervation decreases in a proximo-distal gradient throughout the GI 
tract, with minimal innervation in the distal colon (Berthoud, Jedrzejewska, & 
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Powley, 1990). In parallel, spinal thoracolumbar afferents innervate the 
oesophagus, stomach, small intestine and proximal colon via the great 
splanchnic and lesser splanchnic nerves. Spinal fibres of the lumbar splanchnic 
nerve innervate the mid to distal colon. The distal colon and rectum are 
principally innervated by the lumbosacral pelvic pathway although, as with all 
three pathways, anatomical overlap does occur (Figure 1).   
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Figure 1. Neuroanatomy of the mammalian gastrointestinal tract. The three main 
afferent pathways innervating the gut are shown; vagal, thoracolumbar and 
lumbosacral. Vagal afferent fibres originate from cell bodies located in the nodose 
ganglia (NG) and project centrally to the medulla oblongata, and peripherally to the 
upper and lower GI tract. Thoracolumbar afferent fibres originate in dorsal root 
ganglia neurones (T7-L1) and project centrally to the dorsal horn and peripherally to 
the upper and lower GI tract. Thoracolumbar afferents pass through and arborise 
with, pre-vertebral sympathetic ganglia, including the celiac ganglia (CG), superior 
mesenteric ganglia (SMG) and inferior mesenteric ganglia (IMG). Lumbosacral 
afferents possess somata in dorsal root ganglia (L6 and S1), project centrally to the 
dorsal horn and project peripherally to the distal colon and rectum, passing through 
the pelvic ganglia (PG). 
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1.3.1 SPINAL AFFERENT INNERVATION OF THE GUT 
 
The spinal innervation of the gut comprises of the thoracolumbar and the 
lumbosacral pathway. Their cell bodies reside in dorsal root ganglia (DRGs) in 
the thoracic, upper lumbar and sacral spinal vertebrae and project into the 
spinal cord and peripherally through sympathetic pre-vertebral ganglia to the 
gut wall (Cervero & Sharkey, 1988; Jänig & McLachlan, 1987). Centrally, 
afferents project to laminae I, II and V of the dorsal horn bypassing lamina III 
and IV (Figure 2)(Cervero & Connell, 1984). In some instances, they will project 
contralaterally to lamina V and X (De Groat, 1986). From here, second-order 
neurones in the spinal cord project to thalamic and parabrachial structures in 
the brain. The major spinal innervation of the gut is bimodally distributed 
across DRG vertebral levels, with peak innervation between thoracic 10 through 
to lumbar 1 (T10-L1; thoracolumbar) and lumbar 6 to sacral 1 (L6-S1; 
lumbosacral) (Christianson, Traub, & Davis, 2006; Robinson, McNaughton, 
Evans, & Hicks, 2004). Thoracolumbar afferent fibres innervate the mid-distal 
colon via the lumbar splanchnic nerve (Figure 1) and lumbosacral afferent 
fibres innervate the rectum, anus and very distal colon. Indeed, 3-15% of total 
DRG neurones project to the gut with the remainder terminating in superficial 
cutaneous or deep somatic tissues (Brierley et al., 2008; Cervero, Connell, & 
Lawson, 1984; Grundy, 2002; Jänig & Morrison, 1986; Perry & Lawson, 1998). 
Spinal afferents of the gut can be characterised by the location of their receptive 
field and their responses to mechanical stimuli (including von Frey hair probe, 
distension, circumferential stretch and light stroke). Specifically, distinct classes 
of afferent fibre can be identified based on these responses: muscular (those 
responding to low intensity circumferential stretch (≤5g), but not fine mucosal 
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stroking); mucosal (those responding to light von Frey hair stroking of the 
mucosa), mesenteric (those responding to focal compression of the mesentery) 
and serosal (those responding to focal compression of the colon wall, but not 
mucosal stroking or low intensity circular stretch). Of these, serosal and 
mesenteric subtypes are believed to represent major populations of visceral 
nociceptors. In addition, a population of mechanically insensitive afferent fibres, 
which may become mechanical sensitive following inflammation, is also present 
in both thoracolumbar and lumbosacral pathways (Feng & Gebhart, 2011). The 
characterisation of all these afferent types, both functionally and 
morphologically, is discussed below. Their relative proportions also differ 
significantly between the thoracolumbar and lumbosacral pathways, and is 
likely to be representative of the different functional requirements of sensory 
innervation in these different gut regions (Brierley, Jones, Gebhart, & 
Blackshaw, 2004).  
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Figure 2. C-fibres (somatic and visceral) and the dorsal horn of the spinal cord. 
Schematic showing central terminations of the two main groups of somatic and 
visceral C-fibres in the spinal cord. Somatic C-fibres differ by their content of 
peptides, receptors and site of termination within the spinal cord. Peptidergic 
somatic C-fibres terminate in laminar I, whilst non-peptidergic C-fibres terminate in 
laminar II. Visceral C-fibres are predominantly peptidergic with diffuse and multiple 
central terminations in laminae I, II, V and X, some project contralaterally to laminar 
V and X (Hunt & Rossi, 1985; Sugiura, Terui, & Hosoya, 1989). (CGRP, calcitonin 
gene-regulated peptide; DRG, dorsal root ganglia; GFRα, glia cell line-derived 
neurotrophic factor family receptor alpha; IB4, IB4-lectin binding site; P2X3, 
purinoceptor; SP, substance P; trkA, tyrosine receptor kinase A; TRPV1, transient 
receptor potential vanilloid 1). 
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1.3.2 SPINAL THORACOLUMBAR PATHWAY 
 
1.3.2.1 Splanchnic serosal and mesenteric afferents 
 
The encoding of traction and stretch of the mesentery (both established noxious 
stimuli) is achieved by subsets of afferent fibres which are strongly associated 
with mesenteric arteries branch points and blood vessels innervating the gut 
(Bessou & Perl, 1966; Jänig, 1996; Ray & Neill, 1947). These types of vascular 
afferents are also common to other viscera, including the spleen, ovary, bladder, 
and pancreas (Berthoud, 2004; Floyd & Morrison, 1974). As well as responding 
to compression of their receptive fields by von Frey hair probe, these afferents 
also encode much higher intensities of circumferential stretch and balloon 
distension (~50mmHg (Brierley et al., 2008; Hughes et al., 2009)) than so-called 
muscular afferents identified in the distal colon. They are also thought to 
comprise a major class of nociceptor, responsive to ischaemia, hypoxia and 
inflammatory insult (Haupt, Jänig, & Kohler, 1983; Longhurst & Dittman, 1987; 
Longhurst, Kaufman, Ordway, & Musch, 1984). These afferents have been sub-
characterised into serosal and mesenteric based on the location of their 
receptive fields in flat-sheet ex vivo colonic preparations (Brierley et al., 2004). 
Anatomically in guinea-pig, afferent endings have not been localised to serosal 
layers, and it is likely that such serosal afferents correlate with sensory endings 
on intramural arterioles within the submucosa, however comparable studies 
have yet to be undertaken in other species (Song et al., 2009). As such the term 
‘serosal’ afferent may represent a misnomer. It has been proposed that the term 
‘vascular’ afferent be used to encapsulate both serosal and mesenteric afferent 
subtypes (Brookes, Spencer, Costa, & Zagorodnyuk, 2013; Zagorodnyuk, 
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Brookes, & Spencer, 2010). Whilst it is likely that ‘serosal’ may prove not to be 
the best descriptor of this afferent subtype, there remain significant functional 
differences between those afferents terminating in the mesentery and in the 
intramural colon wall. For example, they are differently altered in ASIC2 -/- 
mice, as well as having different wild-type sensitivities to distension and von 
Frey hair probe (Page, Brierley, et al., 2005; Song et al., 2009). This suggests 
that specialisation may exist within vascular afferents, dependent on the 
localisation of the receptive field, or that the local environment infers specific 
functional characteristics. What is clear is that serosal and mesenteric afferents 
populate the majority of the splanchnic innervation of the colon (80-90% 
(Brierley et al., 2004)) and that these afferents are functionally distinct to both 
muscular and mucosal afferent subtypes.  
Importantly, as well as providing mechano-transduction sites, serosal and 
mesenteric afferents express receptors for a vast array of chemical mediators, 
including ATP, bradykinin, glutamate, nerve growth factor, histamine, 
prostaglandins and 5-HT (Blackshaw & Gebhart, 2002; Brierley, Carter, et al., 
2005; Brunsden & Grundy, 1999; Grundy, 2004; Hicks et al., 2002; Maubach & 
Grundy, 1999; Rong, Spyer, & Burnstock, 2002). They are also sensitive to 
inflammatory cytokines including IL-1β, IL-6 and TNF-α (Andratsch et al., 2009; 
Binshtok et al., 2008; Y. Li, Ji, Weihe, & Schäfer, 2004).  Indeed, mechanically 
insensitive afferents, which make up almost a third of thoracolumbar spinal 
afferents innervating the colon and are thought to represent a population of 
‘silent’ serosal-like afferents, may be sensitised by addition of inflammatory 
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mediators and become mechanically sensitive (Feng & Gebhart, 2011; Feng, La, 
Schwartz, et al., 2012). 
1.3.2.2 Splanchnic muscular afferents 
  
Limited anatomical evidence exists detailing the peripheral projections of 
dorsal root ganglia afferents; however this has been examined for the gastro-
oesophageal junction and pylorus (Clerc & Mazzia, 1994; Lindh, Aldskogius, & 
Hökfelt, 1989). Functionally, spinal afferent innervation of the oesophagus is 
split into wide dynamic range mechanoreceptors that encode into noxious 
distension ranges (threshold ~3mmHg), and high threshold (>30mmHg) 
mechanoreceptors (Sengupta & Gebhart, 1994; Sengupta, Saha, & Goyal, 1990). 
In the colon, muscular afferents, which respond to low intensity stretch, make 
up ~10% of mechanosensory afferents (Brierley et al., 2004). It is possible that 
muscular afferents represent a population of distally-projecting wide dynamic 
range mechanoreceptors comparable to those observed in the oesophagus. 
Currently, no morphological characterisation of these fibre types has been 
undertaken and questions still remain over their likely function. That they 
encode across a range of stimulus intensities into the noxious range suggests 
they will play a role in nociception. However, their contribution and therefore 
impact on whole-nerve afferent outflow from the distal colon will be limited by 
the relative low population of this afferent subtype.  
1.3.2.3 Splanchnic mucosal afferents 
 
Mucosal afferents have been reported in recordings from the splanchnic nerves 
of both the mouse (4% (Brierley et al., 2004)) and rat colon (23% (Lynn & 
Blackshaw, 1999)). These are not responsive to stretch but are to light stroking 
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with von Frey hairs. These afferents are sensitive to 5-HT (Hicks et al., 2002), 
however their characterisation in the presence of other chemical mediators and 
during inflammation has not been extensively studied (Brierley et al., 2004; 
Hughes et al., 2009). It is unlikely that splanchnic mucosal afferents are 
involved in nociceptive signalling pathways.   
1.3.3 LUMBOSACRAL AFFERENTS  
 
The lumbosacral pelvic afferents compose the second major spinal innervation 
of the colon; characterisation of these afferents has revealed a number of 
functionally distinct subtypes comparable to those seen in the thoracolumbar 
pathway. These spinal afferent endings were originally described as having 
unspecialised bare nerve endings (Cervero, 1994; Jänig, 1996) but have recently 
been  suggested to possess morphological specialisation in some pelvic afferent 
endings and may resemble specialised vagal endings (Lynn & Brookes, 2011; 
Lynn, Olsson, Zagorodnyuk, Costa, & Brookes, 2003; Olsson, Costa, & Brookes, 
2004). Specifically, lumbosacral pelvic afferents regulate complex defecatory 
processes as well as being the primary pathway mediating experimental 
visceromotor reflexes following colorectal distension paradigms (Kyloh, 
Nicholas, Zagorodnyuk, Brookes, & Spencer, 2011). 
1.3.3.1 Rectal intraganglionic laminar endings (rIGLEs)  
  
Structures termed rectal intraganglionic laminar endings, which are 
comparable to vagal intraganglionic laminar endings (IGLEs) with basket-like 
endings encapsulating myenteric ganglia, have been identified in lumbosacral 
pelvic nerves that terminate at rectal myenteric ganglia in guinea pig (Olsson et 
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al., 2004). Spinal rectal IGLEs seem capable of encoding stretch over a wide 
dynamic range with a low-threshold of activation (Lynn et al., 2003). In this 
respect, they are comparable to muscular subtypes and are likely 
representative of pelvic muscular afferents recorded from pelvic nerve of cat, 
rat and mouse, which are responsive to relatively low levels of 
distension/stretch (Brierley et al., 2004; Jänig & Koltzenburg, 1991; Sengupta & 
Gebhart, 1994). These afferents are probably responsible for the transduction 
of important parasympathetic defecatory reflexes, but also contribute to 
encoding noxious stimuli. Following anterograde dye fills of pelvic nerves, 
rIGLE-like structures were not clearly distinguishable in mouse myenteric 
ganglia of the colorectum (Spencer, Kerrin, Singer, et al., 2008), suggesting that, 
at least, morphologically these structures may be species-dependent.   
1.3.3.2 Pelvic and rectal intramuscular endings 
 
Anterograde labelling of nerves innervating the colorectum have identified 
significant afferent arborisation within both circular and longitudinal muscle 
layers (Olsson et al., 2004). In mice that lack enteric ganglia, there remains a 
subset of mechanoreceptors that transduce stretch stimuli, which suggests that 
a population of intramuscular rectal mechanoreceptors exists, independent of 
endings arborising at rectal myenteric ganglia (rIGLEs) (Spencer, Kerrin, 
Zagorodnyuk, et al., 2008). Functionally, in mouse, muscular wide dynamic 
range afferents that encode innocuous and noxious stimuli intensities have 
been reported to make up approximately 21% of pelvic innervation of the colon 
(Brierley et al., 2004). Whether this corresponds to a combination of rIGLE- and 
rectal intramuscular ending-like afferents is currently unknown. Anatomical 
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structures of rectal intramuscular ending-like afferents have been identified in 
the guinea pig external anal sphincter, which is in symmetry to the localisation 
of vagal intramuscular endings within sphincters of the upper GI (Berthoud, 
Patterson, Neumann, & Neuhuber, 1997; Lynn & Brookes, 2011).  Very little 
physiological data exists on the putative function of these receptors in the distal 
colon and rectum, however their ability to encode across the full spectrum of 
stimuli intensities suggests their sensitisation may be relevant to inflammatory 
pain. 
1.3.3.3 Mucosal and muscular-mucosal afferents 
 
Of the total mechanoreceptive fibres in the mouse pelvic nerve, approximately 
20% are characterised as mucosal afferents, which are sensitive to light 
mucosal stroking but not circumferential stretch (Brierley et al., 2004). A 
further subtype of muscular-mucosal afferents represent a group of fibres that 
are activated by both light mucosal distortion, and by stretch or contraction of 
the bowel and make up about a quarter of pelvic fibres (Brierley et al., 2004). 
No such muscular-mucosal afferent subtype exists in the splanchnic 
thoracolumbar pathways (Brierley et al., 2004). The transduction of stretch and 
light stroke stimuli in muscular-mucosal afferents may occur at distinct 
separate sites, or alternatively, endings that are located in the sub-epithelial 
plexus may be capable of transducing both stimuli (Brierley et al., 2004; 
Brookes et al., 2013). Whilst this remains to be determined, muscular-mucosal 
afferents likely detect movement of luminal content over the surface of the GI 
tract, and as such may be relevant to the development of visceral 
hypersensitivity. 
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1.3.3.4 Pelvic serosal afferents 
 
Finally serosal-like afferents can be observed in recordings from the pelvic 
nerve and contribute to approximately a quarter of total fibres (Brierley et al., 
2004). These fibres are responsive to focal compression with von Frey hair 
probe and also to very high levels of circumferential stretch and distension 
pressures (Brierley et al., 2004; Brierley et al., 2008; Hughes et al., 2009). In 
addition, almost a quarter of pelvic lumbosacral afferents are mechanical 
insensitive and are likely to represent a population of ‘silent’ pelvic serosal 
afferents. Like thoracolumbar counter-parts, these may be mechanically 
sensitised by addition of an inflammatory soup (Feng & Gebhart, 2011). No 
lumbosacral equivalent of mesenteric afferents exists in the pelvic nerve 
(Brierley et al., 2004), suggesting that noxious mesenteric traction or stretch is 
not perceived by the distal colorectum. 
1.3.4 VAGAL PATHWAYS 
 
In conjunction with the spinal extrinsic innervation of the colon, vagal afferents 
also innervate visceral organs, conveying predominantly physiological stimuli 
such as satiety and nausea, but may also encode noxious stimuli (Grundy, 2002; 
S. Yu, Undem, & Kollarik, 2005). Vagal cell bodies are located in the nodose 
ganglia and project centrally to supraspinal pathways in the brain stem, 
hypothalamus and amygdala; structures associated with the behavioural and 
emotional aspects of sensory processing (Jänig, 1996). Whilst vagal afferents 
primarily transduce innocuous stimuli, they are believed to play a modulatory 
role in the central inhibitory control of nociception and pain. For example, 
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responses to noxious thermal sensation in rat hind-paw can be inhibited or 
enhanced through vagal afferent stimulation (Khasar, Green, Miao, & Levine, 
2003; Randich & Gebhart, 1992). There are three morphologically distinct 
endings found on vagal afferents: mucosal, intraganglionic laminar endings 
(IGLEs) and intramuscular endings (Berthoud et al., 2001; Berthoud & 
Neuhuber, 2000; Berthoud et al., 1997; Berthoud & Powley, 1992; Neuhuber, 
1987; F. B. Wang & Powley, 2000). Functional electrophysiological recordings 
have identified three types of vagal afferent in the upper GI tract that are 
responsive to differing stimuli; these are mucosal (responsive to mucosal 
stroking and luminal chemical stimuli), low threshold stretch-sensitive 
muscular (stimulated during contraction and distension of the bowel and 
saturating within physiological levels of distension) and high threshold 
distension-sensitive afferents (IGGO, 1955; Ozaki, Sengupta, & Gebhart, 1999; 
Page, Martin, & Blackshaw, 2002; Sengupta et al., 1990; S. Yu et al., 2005; 
Zagorodnyuk, Chen, Costa, & Brookes, 2003). The evidence for building 
structure-function relationships based on these data is outlined below. 
1.3.4.1 Vagal intraganglionic laminar endings 
 
As described for lumbosacral pathways, vagal intraganglionic laminar 
mechanoreceptors (IGLEs) are morphologically comparable to anatomical 
structures in the rectum. Specifically, IGLEs possess basket-like endings that 
encapsulate myenteric ganglia, interacting with neuronal and non-neuronal 
tissues (E. A. Fox, Phillips, Martinson, Baronowsky, & Powley, 2000). They act as 
tension-sensitive mechanoreceptors and are found at all vagal afferent-
myenteric plexi interfaces, from the oesophagus through to the distal colon, 
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although less extensively in more distal regions (Berthoud et al., 1997; E. A. Fox 
et al., 2000; F. B. Wang & Powley, 2000). They likely transduce the compression 
of the ganglia by surrounding gut wall layers and signal gastric distension after 
a meal (Berthoud & Neuhuber, 2000). These mechanoreceptors are significantly 
modulated by biological mediators, including the neurotransmitters, ATP, 
glutamate and GABA, and the hormone ghrelin, which are capable of both 
excitation and inhibition of IGLEs (Kentish et al., 2012; Page, Young, et al., 2005; 
Smid, Young, Cooper, & Blackshaw, 2001; Zagorodnyuk et al., 2003). Vagal 
IGLEs are low-threshold, slow-adapting afferents that distally respond to 
physiological distension of the gut caused by the normal movement of 
gastrointestinal contents. Responses by vagal IGLEs in electrophysiological 
recordings of distended rat jejunum initiate and plateau within the first 10-
20mmHg (Booth, Kirkup, Hicks, Humphrey, & Grundy, 2001). These properties, 
of intense responses saturating at innocuous low distension thresholds, are 
consistent with previously described vagal ‘tension mechanoreceptors’, which 
at least in the guinea pig oesophagus are representative of nodose A-fibres 
(Blackshaw, Page, & Partosoedarso, 2000; Sengupta, Kauvar, & Goyal, 1989; S. 
Yu et al., 2005). These characteristics differ from rIGLEs, which seem capable of 
encoding over a wide dynamic range and may reflect pathway-specific 
differences. As such, vagal IGLEs are unlikely to encode noxious stimuli from the 
GI tract. 
1.3.4.2 Vagal intramuscular endings 
 
In circular and longitudinal muscle, vagal afferents branch and run in parallel to 
smooth muscle nerve bundles forming intramuscular arrays (IMAs) (Berthoud 
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& Powley, 1992; E. A. Fox et al., 2000). IMAs have a distinct distribution within 
the GI tract with predominance in the fundus, lower oesophageal sphincter and 
pyloric sphincter (F. B. Wang & Powley, 2000). IMAs have been purported to 
detect stretch rather than tension during distension events but there remains 
limited functional evidence to support this (Phillips & Powley, 2000). A 
population of mechanosensitive vagal afferents with wide dynamic range and 
graded firing into noxious distension pressures in the oesophagus may in fact 
possess IMA-like endings and represent a population of nociceptive fibres (S. Yu 
et al., 2005). However, disparity between the anatomically distinct distribution 
of IMAs (e.g. fundus, lower oesophageal sphincter and pyloric sphincter) and 
the relatively extensive presence of wide dynamic range mechanosensitive 
afferents along the guinea pig oesophagus, suggests that functions attributed to 
IMAs should be applied cautiously.  
1.3.4.3 Vagal mucosal afferents  
 
Anterograde tracings from nodose ganglia have identified non-specialised 
endings in villi of the mid-gut (Berthoud, Kressel, Raybould, & Neuhuber, 1995; 
R. M. Williams, Berthoud, & Stead, 1997). These vagal mucosal afferents are 
sensitive to gentle stroking or compression of the mucosa, but not distension or 
stretch (Page & Blackshaw, 1998). Vagal mucosal afferents are often strongly 
associated with enteroendocrine cells found in the mucosa and are activated by 
mediators released from these cells, including 5-hydroxytryptamine and bile 
salts (Grundy, 2004; Page et al., 2002). The modulation of vagal mucosal 
afferent terminals acts to regulate satiety, occurring predominantly through the 
release of enteroendocrine mediators including cholecystokinin (CCK), 
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glucagon-like peptide 1 (GLP1), apolipoprotein A-IV, enterostatin, gastrin-
releasing peptide, oxyntomodulin, amylin and peptide YY (Grundy, 2004). 
Mucosal afferent sensitivity to compression of the mucosa enables the 
transduction of food bolus movements along the upper gut but is unlikely to 
contribute to nociceptive signalling.  
1.3.5 CONSOLIDATION OF FIBRE SUBTYPES 
 
As outlined above, earlier investigators have attempted to define visceral 
afferents into discrete subtypes, based on structure and function (Brierley, 
2010; Grundy, 2002; Leek, 1977). The heterogeneity of visceral afferents under 
investigation throughout the GI tract, and differences in in vivo and in vitro 
mechanical stimuli used to characterise afferents, has resulted in non-
standardised nomenclature. A recent review by Brookes et al. has attempted to 
consolidate earlier classifications into five major afferent subtypes that 
encompass all the afferent fibres of the vagal, thoracolumbar and lumbosacral 
anatomical pathways (Brookes et al., 2013). The five afferent subtype model 
includes (1) intraganglionic laminar mechanoreceptors, (2) mucosal afferents, 
(3) muscular-mucosal afferents, (4) intramuscular afferents and (5) vascular 
afferents (Figure 3). 
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Figure 3. Visceral afferent innervation of the gastrointestinal tract. 
Five afferent subtype model. Vagal and spinal extrinsic pathways and intrinsic 
viscerofugal innervation of prevertebral ganglia (PVG). 
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Whilst this approach is undoubtedly the most appropriate, limited evidence 
exists where function has been successfully attributed to structural 
characteristics (Lynn et al., 2003; Song et al., 2009; Spencer, Kerrin, Singer, et 
al., 2008). Further still, challenges clearly exist in the translation of structural 
findings between species, especially into murine models, where anatomical 
structures appear less well defined. As such, it is likely that this model 
represents an oversimplification of what is a complex system. Importantly, and 
in the context of IBD, the thoracolumbar anatomical pathway, and specifically, 
serosal and mesenteric afferent subtypes can be considered the major 
nociceptive signalling pathway in these conditions.  
1.3.6 EFFERENT FIBRES 
 
The vagal and spinal nerves described above also contain an efferent 
component. These are relevant as they coordinate the regulation of visceral 
organs and have a direct impact on afferent activity and vice versa. In the vagus, 
efferent fibres, which are outnumbered 9 to 1 by afferent fibres, have their cell 
bodies in the dorsal motor nucleus and nucleus ambiguus of the brain stem 
(Jänig, 1996; Leek, 1977). In the splanchnic and pelvic nerves, afferent:efferent 
ratios are 3:1 and 1:1, respectively (Leek, 1977). The efferent sympathetic 
innervation of the gut is formed from the ‘sympathetic chain’ of pre-vertebral 
ganglia (PVG), of which three are important to the lower GI tract: the inferior 
mesenteric (IMG), the superior mesenteric (SMG) and the celiac (CG) ganglia. 
Efferent neurones are responsible for the regulation of motility, secretion, 
absorption and blood flow to these tissues. In efferent function, the two spinal 
nerves differ greatly, with the pelvic nerve forming the major parasympathetic 
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innervation and the splanchnic nerve being the prominent sympathetic 
innervation to the lower GI tract. Collaterals of afferent fibres passing through 
pre-vertebral ganglia arborise with cell bodies residing there and provide local 
feedback loops to regulate bowel function.   
1.3.7 INTRINSIC NEURONAL PROJECTIONS 
 
In addition to extrinsic innervation, within the myenteric and submucosal 
layers of the gut wall resides a dense network of neurones that form the 
intrinsic enteric nervous system (ENS). These neurones are responsible for the 
local control and complex coordination of GI motor and secretory function 
(Costa, Brookes, & Hennig, 2000). Specifically, they regulate local blood flow, 
mucosal transport and secretion, motor, immune and endocrine function (Costa 
et al., 2000). The ENS is critical for myogenic rhythmic activity, migrating motor 
complexes and content-dependent functions, such as the accommodation and 
propulsion of luminal contents. A reflexive feedback loop exists from the gut to 
the sympathetic chain, with retrograde tracer studies labelling a population of 
neurones that reside in the intestine and project to pre-vertebral ganglia (Miller 
& Szurszewski, 1997) (Figure 3). Such viscerofugal fibres provide important 
feedback from enteric neurones on gut volume to sympathetic pathways, and 
mark the pre-vertebral ganglia as sites of coordination mediating mechano-
gastrointestinal function (Szurszewski, Ermilov, & Miller, 2002). These fibres 
are important to note as electrophysiological recordings from the lumbar 
splanchnic nerve may contain small proportions of these fibres (Luckensmeyer 
& Keast, 1995). Another class of viscerofugal fibres that may influence lower GI 
function are rectospinal neurones. These fibres, that originate in the myenteric 
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plexus and project to the spinal cord, have been reported to participate in the 
defecation reflex, although their physiological stimulus is not fully understood 
(Neuhuber et al., 1993). 
1.4 CHARACTERISATION OF VISCERAL NOCICEPTORS 
 
In the viscera, as elsewhere, the encoding of noxious, high intensity and 
normally painful stimuli is undertaken by nociceptors, which represents a 
heterogeneous population of afferent fibres. In somatic pathways, certain 
characteristics and markers identify nociceptors from non-nociceptive 
neurones. These include electrophysiological characteristics and a correlate 
between cell size, myelination and conduction velocity (CV), and the expression 
of protein markers. In the viscera, such correlations are poorly defined and 
classical nociceptive markers or characteristics must be applied with care. 
Indeed, significant populations of visceral afferents are intensity encoding and 
transduce both noxious and physiological stimuli, and therefore are not 
specialised to a solely nociceptive phenotype. 
Somatic nociceptive neurones develop significantly broader action potentials 
(AP), have larger AP overshoots and longer afterhyperpolarisation than non-
nociceptive neurones (Fang, McMullan, Lawson, & Djouhri, 2005). Furthermore, 
nociceptive neurones fall into two predominant categories of fibre type; 
unmyelinated C-type, with CVs <2.0 m/s, and thinly myelinated Aδ-type, with 
CVs of 2-30 m/s (Fang, McMullan, et al., 2005). Faster conducting (>30 m/s), 
and therefore more highly myelinated, Aα/β fibres, almost exclusively encode 
non-noxious stimuli (Fang, McMullan, et al., 2005). Axon myelination state and 
conduction velocity is significantly correlated to soma size and axonal diameter, 
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with small somal neurones having unmyelinated slow conducting axons 
(Harper & Lawson, 1985a; Yoshida & Matsuda, 1979).  Whilst conduction 
velocity is not a perfect predictor of nociceptive phenotype, less than 10-20% of 
C-fibre and Aδ-fibre neurones have been characterised as non-nociceptive 
(Fang, McMullan, et al., 2005). 
Protein markers have also been shown to associate with nociceptive neuronal 
phenotypes and may be used to identify putative nociceptors. Such markers 
include trkA (a receptor for nerve growth factor(NGF)), IB4 binding (the 
isolectin B4 isolated from Griffonia simplicifolia that binds specific sugar 
residues), CGRP (calcitonin gene-related peptide), TRPV1 (transient receptor 
potential V1 receptor) and P2X3 receptor expression (Fang, Djouhri, et al., 2005; 
Fang et al., 2006; Hunt & Mantyh, 2001; Wirkner, Sperlagh, & Illes, 2007). 
Classically, unmyelinated C fibres can be split into two broad classes; a 
population that expresses trkA, the receptor for NGF, and contains peptidergic 
neurotransmitters, such as substance P and CGRP; and the non-peptidergic 
population, which do not express peptidergic neurotransmitters or trkA, but do 
have P2X3 positive immunoreactivity and bind isolectin B4 (Hunt & Rossi, 
1985).  
In the viscera, the same distinctions do not exist. Visceral projections are almost 
exclusively unmyelinated C-fibres with some thinly myelinated A fibres (20-
40%) and vagal afferents are considered to be exclusively unmyelinated C-
fibres (<2m/s)(Cervero & Sharkey, 1988; Malin, Christianson, Bielefeldt, & 
Davis, 2009; Ozaki et al., 1999; Sengupta & Gebhart, 1994; Sengupta et al., 
1990). As such, the lack of a discrete innocuous pathway in the viscera 
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necessitates the encoding of physiological stimuli by C- and A-fibres. 
Furthermore, viscerally projecting neurones are almost exclusively peptidergic 
and have high expression of CGRP and TRPV1 compared to somatic neurones 
(Christianson et al., 2006; Robinson et al., 2004; Wall & Melzack, 1999). The 
purportedly nociceptive marker of IB4 binding is significantly less in the viscera 
at 5-20% of colonic DRG neurones, and those that are IB4-positive almost 
exclusively co-label with CGRP (Christianson et al., 2006; Robinson et al., 2004). 
This contrasts to somatic populations where CGRP and IB4 are predominantly 
thought to represent mutually exclusive C-fibre populations. In the absence of 
extensive evidence linking functionally defined visceral nociceptors to specific 
protein markers, the translation of protein markers associated to somatic 
nociceptors onto visceral populations should be treated with caution. As such, 
visceral afferents of a nociceptive phenotype are typically defined by their 
functional responses or receptive field location (e.g. the mesenteric subtype). 
1.5 REGULATING VISCERAL AFFERENT EXCITABILITY  
 
The encoding of noxious stimuli occurs through the propagation of action 
potentials from the peripheral nerve terminal of a visceral afferent to the cell 
body and central arbor. Importantly, in some patient groups, the therapeutic 
inhibition of mechanosensitivity in visceral afferents has proven to be 
efficacious in treating pain (Verne, Robinson, Vase, & Price, 2003; Verne, Sen, & 
Price, 2005). Specifically, topical rectal application of lidocaine is capable of 
treating visceral pain associated with IBS. This suggests that pharmacological 
modulation of excitability in visceral afferents is an approach likely to be 
successful in the development of novel analgesics. Neurones are maintained at a 
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constant polarised state of approximately -60mV (resting membrane potential; 
RMP) by the active movement of ions (including Na+ and K+) across the plasma 
membrane to generate a potential gradient. A variety of receptors and channels 
encode external cues into changes in membrane potential that may ultimately 
lead to the trigger of an action potential (AP) and depolarisation of the cell. 
Visceral neurones are heterogeneous with respect to their sensitivity to 
differing stimuli. The relative likelihood of initiating an AP in any given cell is 
dependent on its state of excitability. This sensitivity to stimuli is plastic and 
prone to modulation, especially during inflammation (Brierley, Carter, et al., 
2005; Brierley, Jones, Xu, Gebhart, & Blackshaw, 2005; Feng & Gebhart, 2011; 
Feng, La, Schwartz, et al., 2012; Hughes et al., 2009). Indeed, a subset of 
previously mechanically insensitive afferents, which make up approximately a 
third of thoracolumbar spinal afferents (Feng & Gebhart, 2011), may be 
sensitised by addition of an inflammatory soup (consisting of bradykinin, 5-HT, 
histamine, prostaglandin E2 and protons (pH 6.0)) to the receptive field. 
Experimental colitis is also associated with sensitisation of colonic afferents and 
to in vivo visceral hypersensitivity to distension (Feng, La, Schwartz, et al., 2012; 
Feng, La, Tanaka, et al., 2012; Hughes et al., 2009), with such changes in 
sensitivity the product of the modulation of molecular receptors and channels 
present on visceral afferents.  
Several candidate mechanisms have been identified that are known to regulate 
sensory neuronal excitability (including T-type calcium channels, TRP channels 
and HCN2)(Caterina et al., 1997; Emery, Young, Berrocoso, Chen, & 
McNaughton, 2011; Sekiguchi & Kawabata, 2013). In addition, voltage-gated 
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sodium and potassium channels are critical to the generation and propagation 
of the AP, and significantly contribute to visceral afferent excitability.      
1.5.1 ROLE OF VOLTAGE GATED SODIUM CHANNELS IN ACTION POTENTIAL 
GENERATION 
 
The activity of voltage gated sodium channels (NaV) underpins electrogenesis in 
excitable cells. The nine genes (SCN1A-SCN5A and SCN8A-SCN11A) encoding the 
NaV1.1-NaV1.9 α-subunit isoforms exhibit regional and temporal distributions 
and describe membrane proteins of varying biophysical characteristics (Goldin 
et al., 2000). A tenth α-subunit (NaX encoded by SCN7A) lacks the voltage sensor 
and is involved in sodium homeostasis (Goldin et al., 2000). The Na+ currents 
generated by these channels contribute significantly to the resting membrane 
potential (RMP) and principally to the rising phase of the action potential. Each 
voltage-gated sodium channel subtype contributes to the regulation of neuronal 
excitability in different ways. Pore-forming α-subunits are structured as four 
homologous domains (I-IV) each consisting of six α-helical transmembrane 
segments (S1-S6), with a re-entrant loop partially entering transmembrane 
regions between segments S5 and S6 (Catterall, 2000). Extracellular loops 
connect the re-entrant loop with either S5 or S6 of each domain and can interact 
with other transmembrane proteins. Significantly larger intracellular loops 
describe an inactivation region, phosphorylation modulation sites and connect 
the four domains. Whilst expression of the isolated α-subunit is capable of 
producing the necessary characteristics of a sodium channel (i.e. voltage-
dependent activation, rapid inactivation and selective ion conductance 
(Hodgkin & Huxley, 1952)), most α-subunits require co-expression with 
auxiliary membrane proteins to develop physiologically-relevant currents (P. B. 
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Bennett, Makita, & George, 1993; Isom, De Jongh, & Catterall, 1994; Isom et al., 
1992; Isom et al., 1995). Importantly, the formation of sodium channel 
complexes with auxiliary membrane proteins, such as β-subunits, is cell-type 
specific. For example, skeletal muscle α-subunits (NaV1.4) have altered gating in 
the absence of β-subunits (P. B. Bennett et al., 1993), by contrast, the influence 
of β-subunits on channel function of NaV1.6 α-subunits in sensory neurones is 
relatively weak (Zhao, O'Leary, & Chahine, 2011). A number of other proteins 
interact with sodium channels, including p11, ankyrin and Nedd4, to influence 
current characteristics and channel expression (Okuse et al., 2002; Shao, Okuse, 
& Djamgoz, 2009; Zhao et al., 2011).  Together these data highlight the 
importance of the cellular environment in the functional expression of sodium 
channel currents. 
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Figure 4.Voltage-gated sodium channel (NaV) schematic. 
The four domain α-subunit has conserved intracellular phosphorylation sites which 
are substrates of Protein Kinase A and C (PKA & PKC). The α-subunit can couple to 
one of four β-subunits localising the channel in the membrane. 
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In broad terms, sodium channel α-subunits can be characterised by their tissue 
of primary expression. For NaV1.1, NaV1.2, NaV1.3 and NaV1.6 this is considered 
to be neurones of both the central nervous system (CNS) and peripheral 
nervous system (PNS). NaV1.4 and NaV1.5 are expressed by skeletal muscle and 
cardiac muscle myocytes, respectively. Finally, NaV1.7, NaV1.8 and NaV1.9 are 
expressed primarily in neurones of the PNS. Nonetheless, most channels will 
have some expression in other tissues. As such, multiple sodium channels 
coordinate to regulate the relative excitability of any individual cell. The 
comparative importance of specific α-subunits to excitability in different cell 
types is clear from the clinical manifestations of known sodium channelopathies 
(see Table 2). For example, mutations in skeletal NaV1.4 cause hyperkalemic 
periodic paralysis and paramyotonia congenita in familial periodic paralysis 
syndromes (McClatchey et al., 1992; Ptácek et al., 1992; Ptácek et al., 1991; 
Rojas et al., 1991). Long QT syndrome type 3 is produced by cardiac NaV1.5 
mutations resulting in impaired inactivation and hyperexcitability (P. B. 
Bennett, Yazawa, Makita, & George, 1995; Q. Wang et al., 1995). Pain 
phenotypes (such as primary erythromelalgia, paroxysmal episodic pain 
syndrome, painful neuropathy and congenital insensitivity to pain) have been 
associated with mutations arising in peripherally expressed sodium channels 
(NaV1.7 (Fischer & Waxman, 2010), NaV1.8 (Faber et al., 2012; Huang et al., 
2013) and NaV1.9 (Huang et al., 2014; Leipold et al., 2013; Zhang et al., 2013). 
Furthermore, mutations in the auxiliary β1 subunit is causal in inherited febrile 
seizures directly modulating brain sodium channels (Wallace et al., 1998). The 
importance of this cell type specific expression was elegantly demonstrated by 
Rush et al., where a single mutation in NaV1.7 (F1449V) which manifests 
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clinically as primary erythromelalgia, can cause hyperexcitability in dorsal root 
ganglia (DRG) neurones and hypoexcitability in sympathetic neurones (Rush et 
al., 2006). These differential functional effects of the mutation go some way to 
explain the varied symptoms present in these patients. The co-expression of 
NaV1.8 in DRG, but not sympathetic, neurones is a major contributor to this 
effect, due to its availability for activation at depolarised membrane potentials 
(Rush et al., 2006). Therefore, the actions of a single α-subunit should be taken 
in context, not only with its colocalisation with auxiliary subunits but also with 
the expression of other α-subunits within the cell. This has important 
implications when inferring the functional consequences of sodium channel 
expression across diverse cell types. 
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Type Gene Primary tissue Major inherited diseases References 
NaV1.1 SCN1A CNS Generalised epilepsy with febrile seizures Reviewed in (Catterall, Kalume, & Oakley, 2010) 
   Dravet syndrome (severe myoclonic epilepsy in 
infancy) 
 
   Benign neonatal convulsions  
   Familial hemiplegic migraine type III  
NaV1.2 SCN2A CNS Benign familial neonatal-infantile seizures (Heron et al., 2002) 
NaV1.3 SCN3A CNS   
NaV1.4 SCN4A Skeletal muscle Hypokalaemic periodic paralysis type II (Struyk & Cannon, 2007) 
   K+-sensitive normokalaemic periodic paralysis (Sokolov, Scheuer, & Catterall, 2008) 
   Hyperkalaemic periodic paralysis (Ptácek et al., 1991; Rojas et al., 1991) 
   Paramyotonia congenita (Ptácek et al., 1992) 
NaV1.5 SCN5A Cardiac muscle Long QT syndrome type III (P. B. Bennett et al., 1995; Q. Wang et al., 1995) 
   Brugada syndrome (Terrenoire, Simhaee, & Kass, 2007) 
NaV1.6 SCN8A CNS   
NaV1.7 SCN9A PNS Erythromelalgia Reviewed in (Fischer & Waxman, 2010) 
   Paroxysmal extreme pain disorder (Fertleman et al., 2006) 
   Congenital insensitivity to pain (Cox et al., 2006; Goldberg et al., 2007) 
   Anosmia (Weiss et al., 2011) 
   Bladder pain syndrome (Reeder et al., 2013) 
NaV1.8 SCN10A DRG neurones Painful neuropathy (Faber et al., 2012; Huang et al., 2013) 
NaV1.9 SCN11A PNS Congenital insensitivity to pain (Leipold et al., 2013) 
   Familial episodic pain (Zhang et al., 2013) 
   Painful neuropathy (Huang et al., 2014) 
NaX SCN6A Astrocytes, 
hypothalamus 
  
 
Table 2. Mammalian sodium channel α subunits and major inherited diseases. 
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1.5.2 SODIUM CHANNEL EXPRESSION PLASTICITY 
 
As well as regional specificity in expression, sodium channels are also under 
significant temporal regulation. During development and following 
pathogenesis, sodium channel isoform expression displays significant plasticity. 
This is particularly relevant in the visceral hypersensitivity to colorectal 
distension observed in some patients, where functional up-regulation of sodium 
channel currents following inflammation contribute to visceral afferent 
hyperexcitability to non-noxious stimuli. In parity to other proteins, these 
alterations in expression are regulated at the transcriptional, translational and 
post-translational level.  Analysis of 5’ flank regions of NaVs have revealed 
multiple sites for transcriptional regulation (Schade & Brown, 2000; P. Yang, 
Kupershmidt, & Roden, 2004), with examples of conservation between α-
subunits (Martin, Tang, Ta, & Escayg, 2007). Importantly, growth factors and 
hormones can developmentally modulate NaV transcription (Boixel, Gavillet, 
Rougier, & Abriel, 2006; Fjell et al., 1999; Okuse et al., 1997; Shang & Dudley, 
2005). The regulation of mRNA stability, cellular and subcellular localisation 
and translation are also mediated by known NaV splice variants (S. D. Dib-Hajj, 
Tyrrell, & Waxman, 2002; Shang & Dudley, 2005). MicroRNAs may also 
influence post-transcriptional/pre-translational NaV mRNA regulation (Bushati 
& Cohen, 2007). In addition, post-translational modifications and intracellular 
trafficking take place during the maturation and functional expression of the 
sodium channel (Stocker & Bennett, 2006; Zhou et al., 2002). For example, 
aldosterone does not alter mRNA transcription or protein expression levels of 
NaV1.5 but acts to promote protein membrane externalisation (Boixel et al., 
2006). The implications of this high degree of regulation are exemplified during 
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DRG neuronal development, where the transient expression of sodium 
channels, namely NaV1.3, is thought to mediate spontaneous activity observed 
during late-stage embryogenesis (Benn, Costigan, Tate, Fitzgerald, & Woolf, 
2001). Furthermore, the reciprocal later-stage developmental down-regulation 
of NaV1.3, alongside an up-regulation of NaV1.8 and NaV1.9 suggests 
convergence of regulatory mechanisms and the presence of a highly 
coordinated process (Benn et al., 2001; Black, Langworthy, Hinson, Dib-Hajj, & 
Waxman, 1997).  
The expression of NaVs is also significantly altered during disease and injury. 
Following axotomy and spinal cord injury a down-regulation of tetrodotoxin-
resistant (TTX-R) sodium channels (NaV1.8 and NaV1.9) occurs (Benn et al., 
2001; Decosterd, Ji, Abdi, Tate, & Woolf, 2002; S. D. Dib-Hajj et al., 1999; S. D. 
Dib-Hajj, Tyrrell, Black, & Waxman, 1998). In contrast, NaV1.3 is up-regulated in 
peripheral sensory neurones following axotomy and chronic constriction injury 
(CCI) of the sciatic nerve (Black et al., 1999; S. D. Dib-Hajj et al., 1999; Waxman, 
Kocsis, & Black, 1994). Although highly expressed during embryonic 
development (Felts, Yokoyama, Dib-Hajj, Black, & Waxman, 1997), NaV1.3 is 
almost completely absent in adult neurones (Fukuoka et al., 2008; Waxman et 
al., 1994). As such, the up-regulation of NaV1.3 during spinal cord injury, which 
results in neuronal hyperexcitability, is thought to be a key driver in the 
development of neuropathic pain (Waxman & Hains, 2006).  Changes are also 
observed after inflammatory insult, where an up-regulation of both NaV1.3 and 
NaV1.7 occurs after a few days and, in contrast to neuropathic pain models, 
NaV1.8 is also up-regulated (Black, Liu, Tanaka, Cummins, & Waxman, 2004).  
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Changes in sodium channel isoform expression extend beyond direct neuronal 
insult and are also seen following experimental-induced diabetic neuropathy 
and in pathologies associated with non-excitable cells (Craner, Klein, 
Renganathan, Black, & Waxman, 2002). For example, the degree of invasive 
metastasis in cancer cells correlates with the re-emergence of an embryonic 
neuronal phenotype and the up-regulation of sodium channel expression 
(Brackenbury, Djamgoz, & Isom, 2008). This is thought to enable cancer cells to 
utilise existing migratory cellular machinery and increase their invasiveness 
(Brackenbury et al., 2008). Specific changes in the expression levels of sodium 
channel isoforms during development or following injury, fine tune cellular 
excitability and form the complex networks required for tissue function (Rush, 
Cummins, & Waxman, 2007). When this coordinated expression patterning is 
dysregulated or hijacked by aberrant cellular processes during pathogenesis, 
then considerable morbidity and disruption to normal behaviour can ensue. Of 
the primarily peripherally expressed sodium channels, NaV1.9 is significantly 
associated with pain phenotypes in man.  Alongside NaV1.9 channelopathies, 
expression in nociceptive sensory neurones and multiple roles in rodent pain 
behaviours have implicated the channel in the regulation of neuronal 
excitability and transduction of noxious stimuli. This is particularly true for 
inflammatory pain, where NaV1.9 plays a significant role (Amaya et al., 2006). 
1.5.3 BIOPHYSICAL CHARACTERISTICS OF NAV1.9 
 
The TTX-resistant NaV1.9 isoform is expressed primarily by small diameter 
neurones of the peripheral nervous system and is implicated in nociception (S. 
D. Dib-Hajj et al., 1998). The channel possesses unique biophysical 
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characteristics producing a large persistent sodium current, with slow 
activation and inactivation kinetics, and a hyperpolarised voltage-dependent 
activation, close to the resting membrane potential (Coste, Osorio, Padilla, Crest, 
& Delmas, 2004; Cummins et al., 1999; S. Dib-Hajj, Black, Cummins, & Waxman, 
2002; Ostman, Nassar, Wood, & Baker, 2008). The slow kinetics of NaV1.9 
activation likely precludes the channel from contributing to the action potential 
‘up-swing’ (Ostman et al., 2008). Indeed the sub-threshold membrane potential 
activation of NaV1.9 current and wide activation/inactivation gating overlap 
characteristics, implicate the channel in the regulation of neuronal excitability 
and nerve terminal sensitivity (Baker, Chandra, Ding, Waxman, & Wood, 2003; 
Herzog, Cummins, & Waxman, 2001; Priest et al., 2005). Importantly, the 
channel is also required for inflammatory pain sensation (Amaya et al., 2006; 
Priest et al., 2005). 
Combinations of inflammatory mediators such as bradykinin, ATP, histamine, 
prostaglandin E2 and noradrenaline are capable of potentiating the NaV1.9 
current, which can result in moderate depolarisation of DRG neurones and 
increased excitability (Maingret et al., 2008). Indeed, individual mediators 
including ATP, PGE2 and TNF-α have been shown to result in NaV1.9 Na+ current 
up-regulation (Baker, 2005; X. Chen et al., 2011; Rush & Waxman, 2004). From 
the literature it is currently unclear as to whether a singly applied inflammatory 
mediator is an adequate stimulus to evoke such current potentiation or whether 
a combined inflammatory soup is required (Maingret et al., 2008). What is clear 
is the link between inflammatory pathways evoking protein kinase C and G 
protein-dependent signal transduction and an increase in NaV1.9 Na+ current 
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(Baker, 2005; Baker et al., 2003; Maingret et al., 2008; Rush & Waxman, 2004). 
For example, when GTPγS, a hydrolysis-resistant GTP analogue, is included in 
the internal pipette solution during patch-clamp recordings, NaV1.9 current is 
significantly potentiated (Baker et al., 2003; Maingret et al., 2008). Specifically, 
intracellular GTPγS causes an approximate twofold greater current density 
after whole-cell rupture and dialysis for 15-20 minutes (Maingret et al., 2008; 
Vanoye, Kunic, Ehring, & George, 2013). The accompanying voltage dependence 
of activation is unchanged in GTPγS-stimulated human NaV1.9, however a 
+10mV shift in voltage dependence of inactivation was observed (Vanoye et al., 
2013). In murine NaV1.9 currents, a hyperpolarising shift in activation voltage 
dependence was seen following both GTPγS and PGE2 stimulation (Maingret et 
al., 2008; Rush & Waxman, 2004). These disparities are likely species, agonist, 
or cell-type dependent. Single-channel analysis of NaV1.9 in the presence of 
GTPγS shows that potentiation of the Na+ current is mediated, not by an 
increase in channel permeation, but by an increase (~2.7x) in channel open 
probability and mean open time (Vanoye et al., 2013). This mechanism of 
NaV1.9 current up-regulation (as opposed to increased expression or changes in 
tempero-spatial distribution) explains the larger peak and persistent current 
typical after relatively acute exposure (~10mins) to exogenous inflammatory 
mediators. This is significant as potentiated steady-state NaV1.9 currents are 
purported to be large enough to depolarise the membrane potential and induce 
action potential firing (Baker et al., 2003; Baker & Wood, 2001). 
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1.5.4 ROLE OF NAV1.9 IN BEHAVIOURAL PAIN PHENOTYPES 
 
The regulation of sensory neurone excitability mediated by NaV1.9 currents 
significantly impacts behaviour pain phenotypes in rodent models. Indeed, 
behavioural pain experiments have been conducted on multiple transgenic 
knock-out NaV1.9 mice or following knock-down of NaV1.9 to assess the 
contribution of NaV1.9 to nociception. The majority of studies have focused on 
somatic mechanical, thermal or inflammatory paradigms, as well as neuropathic 
models. In line with changes observed to the NaV1.9 Na+ current following 
stimulation by inflammatory mediators, these studies provide evidence for the 
involvement of NaV1.9 predominantly in inflammatory mechanical 
hypersensitivity, whilst showing no obvious role in neuropathic pain.  
Pain hypersensitivity (measured through paw mechanical thresholds to von 
Frey hair probing and 50oC hotplate response latency) elicited to intraplantar 
administration of prostaglandin E2, bradykinin, interleukin-1, capsaicin, P2X3 
and P2Y receptor agonists was reduced or absent in NaV1.9 -/- mice (Amaya et 
al., 2006). However, NaV1.9 does not contribute to mechanical and thermal 
basal pain thresholds or to mechanical hypersensitivity after nerve injury; with 
nerve growth factor (NGF: a known mediator in neuropathic pain) still able to 
elicit distinct hypersensitivity even in NaV1.9 -/- mice (Amaya et al., 2006; Priest 
et al., 2005). NaV1.9 is also required for thermal hypersensitivity and 
spontaneous behaviours after peripheral inflammation. When the general 
inflammatory agent, complete Freud adjuvant (CFA), is injected into the 
hindpaw, the induced thermal hypersensitivity is absent in NaV1.9 -/- animals, 
whilst in contrast to injection of individual mediators, a mechanical 
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hypersensitivity was observed (Amaya et al., 2006; Priest et al., 2005). This 
suggests that some stimuli may rely on alternative pathways independent of 
NaV1.9. Using a model of sub-acute and chronic inflammation (intraplantar 
carrageenan and CFA-induced monoarthritis, respectively), NaV1.9 proved to be 
an effector of both thermal and mechanical hypersensitivity (Lolignier et al., 
2011). Furthermore, NaV1.9 intrathecal antisense treatment and intraplantar 
carrageenan injection in rats also induced reductions in thermal and pressure 
pain thresholds (Lolignier et al., 2011). Leo et al., found that NaV1.9 contributed 
to the 2nd phase of formalin-induced pain behaviours (Leo, D'Hooge, & Meert, 
2010). However, they failed to show any meaningful differences in carrageenan 
and CFA-induced pain behaviours in their model (Leo et al., 2010).  
NaV1.9 has little impact on neuropathic pain models (in both spared nerve 
injury model and partial sciatic nerve injury model) and changes in mechanical 
thresholds were the same irrespective of genotype (Amaya et al., 2006). 
However, Priest et al. reported altered thermal hypersensitivity and Leo et al. 
also described a decreased sensitivity to cold stimulus under neuropathic pain 
conditions (Leo et al., 2010; Priest et al., 2005). In rat antisense 
oligodeoxynucleotides NaV1.9 knock-down studies, there appeared to be no 
effect on nerve injury-induced behavioural responses (Porreca et al., 1999). 
Collectively these data show that NaV1.9 is involved in the generation of 
inflammatory, but not neuropathic, hypersensitivity although the exact stimulus 
and knock-out line used seems to have an impact on the phenotypic 
manifestation. 
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1.5.5 NAV1.9 IN VISCERAL NEURONES AND BEHAVIOURAL STUDIES 
 
In visceral pain studies, the role for NaV1.9 remains controversial. Behaviour 
models seem to suggest a robust visceral phenotype post-inflammation, with a 
lack of hypersensitivity to colorectal or bladder distension observed in NaV1.9 
knock-out mice (Martinez & Melgar, 2008; Ritter, Martin, & Thorneloe, 2009). 
This is confirmed by expression studies showing the presence of NaV1.9 mRNA 
transcripts in colon-projecting DRG neurones and NaV1.9 immunoreactivity in 
the majority of colon-projecting sensory neurones (Hillsley et al., 2006; King, 
Macleod, & Vanner, 2009). However, persistent TTX-R Na+ currents have been 
challenging to record in visceral back-labelled DRG neurones, with proportions 
reported at 0-13% (Beyak, Ramji, Krol, Kawaja, & Vanner, 2004; Gold, Zhang, 
Wrigley, & Traub, 2002). Further, NaV1.9 has not been associated with neuronal 
hyperexcitability induced by chronic colonic inflammation (Beyak et al., 2004; 
Hillsley et al., 2006).  
In an in vivo colorectal distension (CRD) model of visceral pain, normal pain 
responses were comparable between NaV1.9 +/+ and NaV1.9 -/- animals 
(Martinez & Melgar, 2008). After intracolonic instillation of an acute 
inflammatory stimulus (toll-like receptor 7 activator, R-484), responses to 
phasic CRD were increased by 62% in wild-type animals, however in NaV1.9 -/- 
animals these responses remained unchanged. The animals still mounted an 
inflammatory response against R-484, with cytokine levels and macroscopic 
histopathology similar irrespective of genotype (Martinez & Melgar, 2008). In a 
study of pelvic innervation, this time in bladder afferents, again no difference in 
basal urodynamics was observed in NaV1.9 -/- animals.  However, following 
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intravesicular administration of PGE2, pelvic afferent recordings showed a 
sensitisation in the wild-type animal that was not observed in NaV1.9 knock-out 
mice. In addition, in vivo treatment with cyclophosphamide did not evoke a 
reduction in bladder capacity in NaV1.9 -/- animals but did in NaV1.9 +/+ mice, 
again implicating NaV1.9 in pelvic afferent sensitisation to inflammatory 
mediators (Ritter et al., 2009). By contrast, intraperitoneal acetic acid injection 
in a ‘writhing response’ model of visceral pain caused a doubling in recorded 
writhes in NaV1.9 -/- mice compared to controls over a 15 minute period (Leo et 
al., 2010). 
There have been two studies examining chronic colonic inflammation and the 
role of NaV1.9 in colon-projecting DRG neurone hyperexcitability. In a resolved 
post-infectious inflammatory model, back-labelled spinal neurones from  
NaV1.9 -/- and NaV1.8 -/- animals were compared to wild-type animals. 20-24 
days post-Nippostrongylus brasiliensis (Nb)-induced jejunitis, isolated DRG 
neurones exhibited marked hyperexcitability, as measured by the number of 
action potentials elicited at 2x rheobase. This excitability was absent in NaV1.8 -
/- mice but unchanged in NaV1.9 -/- animals, suggesting that NaV1.8, but not 
NaV1.9, is involved in regulating visceral neuronal hyperexcitability post-
infection (Hillsley et al., 2006). It is likely that the whole-cell current-clamp 
paradigm used may bias the study towards observing changes in action 
potential number at steady-state plateau during current injection. As such, with 
a 2x rheobase current injection, NaV1.9’s function at sub-threshold levels and 
for self-sustaining plateau depolarisations will be circumvented perhaps 
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explaining the lack of genotype-specific changes observed (Maingret et al., 
2008).   
Using colon retrograde-labelled DRG neurones from trinitrobenzenesulfonic 
acid (TNBS)-treated and control mice, Beyak et al. examined acute chronic 
visceral hyperexcitability (Beyak et al., 2004). TNBS-induced colitis produced a 
thickening of the colon and ulceration, which was associated with a significant 
hyperexcitability in small DRG neurones innervating the colon. Of the mouse 
colonic DRG neurones examined, < 15% expressed a persistent TTX-R INav 
consistent with that produced by NaV1.9 (Beyak et al., 2004). In this model, the 
authors found no obvious difference in the number of neurones expressing 
NaV1.9 currents or their magnitude between control and TNBS-treated animals 
(Beyak et al., 2004). It is difficult, however, to draw conclusions from this study 
as the number of cells where a persistent TTX-R INav were recorded are low (N = 
2 and N = 4 from NaV1.9 +/+ and NaV1.9 -/- animals, respectively), suggesting 
that a more detailed study specifically targeting NaV1.9 in colonic DRG neurones 
is required. Indeed, methodological considerations around recording solutions, 
functional channel states and the rapid disappearance of the current, may all 
contribute to the variability in demonstrating the presence of NaV1.9 currents 
by patch-clamp electrophysiology (Baker et al., 2003; Cummins, Sheets, & 
Waxman, 2007; Leffler, Herzog, Dib-Hajj, Waxman, & Cummins, 2005).  
In summary these data suggest that NaV1.9 is involved in afferent 
hypersensitivity to a variety of inflammatory stimuli. Behavioural models also 
implicate NaV1.9 in visceral afferent hypersensitivity following exposure to 
inflammatory stimuli, although this has yet to be shown conclusively with the 
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experimental paradigms currently employed. As a consequence the 
contribution of NaV1.9 to visceral afferent sensitivity remains to be defined.  
1.6 NOXIOUS STIMULATION OF COLONIC VISCERAL AFFERENTS  
 
In order to assess the role of NaV1.9 in visceral afferent function, relevant 
stimuli exposed to GI tract nerve termini during pathology must be considered. 
Such stimuli will likely participate in the pathogenesis of visceral pain 
associated with IBD also. These stimuli can be split into four broad categories. 
Firstly, direct noxious mechanical stimuli, such as that caused by distension or 
occlusion of the bowel. Mechanical stimuli will directly activate ion channels at 
the nerve ending and evoke action potential firing. Secondly, neurotransmitters, 
such as ATP, released into the nerve terminal microenvironment by mechanical 
stimuli, will excite and potentially sensitise afferent fibres. Thirdly, the effect of 
acute inflammatory mediators on afferent excitability and sensitivity must be 
assessed. Finally, chronic inflammation and a potentially differing set of 
inflammatory mediators will also impact visceral afferent function. Each of 
these is addressed in more detail below and the role NaV1.9 plays in modulating 
responses evoked by these stimuli is studied in subsequent chapters.   
1.6.1 DIRECT NOXIOUS STIMULI – MECHANOSENSATION AND 
MECHANOTRANSDUCTION 
 
The molecular transduction of mechanical stimuli by visceral afferents is central 
to the ability to convey gastrointestinal sensations and, in particular, is the 
primary cause of pain. Numerous molecular entities have been implicated in 
mechanotransduction in sensory neurones, some with apparent preferential 
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expression and function in visceral afferents. Mechanical stimuli can be 
transduced directly by mechanical modalities (e.g. compression, distension, 
etc.) opening mechanically-gated ion channels. These mechanically-gated 
channels are pore-forming and open very rapidly (< 5ms) (Brierley, 2010). 
Alternatively, mechanically-sensitive channels may trigger intracellular 
signalling pathways leading to the activation of downstream ion channels. The 
ability for a mechanical stimulus to evoke action potential firing from an 
afferent ending is also dependent on neuronal sensitivity, which is dramatically 
affected by acute or chronic inflammation. Candidate mechanically-gated ion 
channels for visceral mechanosensation are detailed below, including Acid 
Sensing Ion Channels (ASIC) and Transient Receptor Potential (TRP) ion 
channels, as well as modulators of afferent sensitivity.  
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Figure 5. Receptor mechanisms on visceral afferent endings in the gastrointestinal 
tract. Mechanical stimuli are directly transduced through mechanically-gated 
channels (e.g.TRPV4, TRPA1, ASIC2) leading to depolarisation of the afferent 
ending. G-protein coupled receptors (GPCRs) and cytokine receptors for 
inflammatory mediators activate intracellular signalling pathways leading to both 
depolarisation and sensitisation of the ending, potentially through the post-
translational modification of NaV, KV and/or non-selective ion channels (e.g. P2X, 
TRPV1). BK, bradykinin receptor; EPR, prostaglandin receptor; NaV, voltage-gated 
sodium channel; KV, voltage-gated potassium. 
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1.6.1.1 Acid Sensing Ion Channels (ASIC) 
 
The degenerin/epithelial Na+ channel family of cation channels (DEG/ENaC) 
were first identified as mechanotransducers in Caenorhabditis elegans (M. 
Driscoll & Chalfie, 1991). In mammals, three members of the ENaC family, 
ASIC1, ASIC2 and ASIC3, have been linked to visceral mechanotransduction by 
their expression on mechanosensitive neurones and mechanosensory deficits in 
mutant null mice (Page, Brierley, et al., 2005). ASIC channels form pore-forming 
trimeric heteromultimers which are activated by protons and both mechanical 
and chemical stimuli.  
ASIC1 is expressed in 30% of thoracolumbar afferents innervating the colon 
(Hughes, Brierley, Young, & Blackshaw, 2007) and ASIC1 knock-outs have a 
modest increase in the sensitivity of both vagal gastro-oesophageal 
mechanoreceptors and spinal splanchnic afferents (Page et al., 2004; Page, 
Brierley, et al., 2005). This is in contrast to cutaneous mechanoreceptors where 
sensitivity in ASIC1 null mice is unchanged (Page et al., 2004). ASIC2, however, 
does have a role in somatic mechanosensation with its loss leading to decreased 
sensitivity of slowly and rapidly adapting mechanoreceptors (Price et al., 2000). 
Approximately half of splanchnic DRG neurones and vagal gastro-oesophageal 
neurones express ASIC2 (Hughes et al., 2007; Page, Brierley, Martin, Hughes, & 
Blackshaw, 2007). Interestingly, loss of ASIC2 leads to opposing effects in these 
afferent populations, with an increase in the mechanosensory responses of 
serosal splanchnic afferents and a decrease in those of vagal IGLEs or ‘tension’ 
receptors (Page et al., 2004; Page, Brierley, et al., 2005).  By contrast, 
mesenteric splanchnic afferents were unaffected by deletion of ASIC2 (Page, 
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Brierley, et al., 2005). This suggests that molecular specialisation in 
mechanotransducers may exist between mesenteric and serosal afferents. In 
somatic models, ASIC3 knock-out reduces Aδ fibre mechanosensitivity and 
increases rapidly adapting mechanoreceptor sensitivity (Price et al., 2001). 
However in the viscera, consistent deficits in mechanosensation are observed in 
vagal ‘tension’ receptors, mesenteric and serosal vascular splanchnic afferents 
and pelvic muscular/mucosal afferents (Bielefeldt & Davis, 2008; Page, Brierley, 
et al., 2005).  This is in agreement with significant expression in almost three-
quarters of splanchnic thoracolumbar DRG neurones (Hughes et al., 2007) and a 
significantly reduced visceromotor response to colorectal distension in vivo 
(Jones, Xu, & Gebhart, 2005). Therefore ASICs represent a significant 
contribution to specific aspects of both visceral and somatic 
mechanotransduction, and will likely influence the encoding of noxious 
mechanical stimuli. 
1.6.1.2 Transient Receptor Potential (TRP) channels 
  
TRP channels are non-selective cation channels consisting of six 
transmembrane domains and are transducers of mechanical, thermal and 
chemical stimuli. TRP channel activities are also significantly modulated by 
inflammatory mediators and contribute to afferent hypersensitivity following 
inflammatory insult. Of the 7 members of the TRP family (TRPA, TRPC, TRPM, 
TRPML, TRPN, TRPP and TRPV), a number have been associated with visceral 
mechanotransduction, including Transient Receptor Potential Vanilloid 1 
(TRPV1), Transient Receptor Potential Vanilloid 4 (TRPV4), and Transient 
80 
 
Receptor Potential Ankyrin 1 (TRPA1) (Brierley et al., 2009; Brierley et al., 
2008; Jones et al., 2005).  
TRPV1 is expressed in over 80% of thoracolumbar DRG neurones and between 
50-60% of lumbosacral colonic DRG neurones (Christianson et al., 2006; 
Robinson et al., 2004). Gastro-oesophageal, jejunal and pelvic colonic 
distension-sensitive afferents consistently show reduced mechanosensitivity in 
TRPV1 null mice (Bielefeldt & Davis, 2008; Jones et al., 2005; Rong et al., 2004). 
This contrasts with somatic mechanosensory function, where no difference is 
observed following deletion of TRPV1 (Caterina et al., 2000). Interestingly, 
TRPV1 is not thought to be mechanically gated and therefore may influence 
mechanosensation by indirectly affecting neuronal excitability or via 
interactions with other TRP channels, ion channels or receptors.  
TRPV4 appears to have a more direct role in visceral mechanotransduction, 
with greater TRPV4 mRNA expression in visceral-projecting neuronal 
populations compared to the whole DRG population (Brierley et al., 2008). 
Colonic serosal and mesenteric afferent mechanosensory responses were also 
reduced by deletion of TRPV4 or by the application of an TRP antagonist 
(Brierley et al., 2008). However, pelvic mucosal, muscular and 
muscular/mucosal afferents, as well as vagal gastro-oesophageal 
mechanoreceptors, were unaffected by loss of TRPV4. The specific deficits 
observed in these knock-out mice suggest that TRPV4 may play a specialised 
role in the mechanotransduction of high-threshold nociceptor-like afferents in 
the colon (Brierley et al., 2008). These reductions in mechanosensory function 
are also apparent during in vivo visceromotor responses to colorectal distension 
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in both TRPV4 null mice and following small interfering RNA (siRNA) knock-
down of TRPV4 also in mouse (Brierley et al., 2008; Cenac et al., 2008).  
TRPA1 represents another member of the TRP family required for visceral 
mechanotransduction. Specifically TRPA1 contributes to mechanotransduction 
in serosal, mesenteric and mucosal afferents but not those afferents responsive 
to stretch (Brierley et al., 2009). TRPA1 is expressed by just over half of gastro-
oesophageal, splanchnic colonic and pelvic colonic DRG neurones (Brierley et 
al., 2009). Decreased visceral motor reflex (VMR) to CRD in TRPA1 null mice 
was also confirmed in rat by intrathecal injection of TRPA1 antisense 
oligodeoxynucleotide (Brierley et al., 2009; J. Yang et al., 2008). In conjunction 
with TRPA1’s involvement in normosensation, it also appears to play a central 
role in bradykinin-induced mechanical hypersensitivity in both guinea-pig 
oesophagus and mouse colon. However, direct chemosensory responses to 
bradykinin are unchanged suggesting a sensitising role for TRPA1 (Brierley et 
al., 2009; S. Yu & Ouyang, 2009). 
Other TRP channels that have been implicated in mechanotransduction include 
the cold-sensing TRPM8 channel, as well as TRPN1 and TRPC3/C6 (Harrington 
et al., 2011; Quick et al., 2012; Vollrath, Kwan, & Corey, 2007). Further studies, 
including those in knock-out mice, are required to fully understand the 
mechanosensory functions of this diverse family of channels in visceral 
afferents. 
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1.6.1.3 Other putative mechanotransducers 
 
The recently identified mechanically activated Piezo family of cation channels 
may also prove to be relevant to visceral mechanosensory function. This new 
class of membrane protein contain 24-36 transmembrane segments, with a 
similar structure to voltage-gated sodium channels, are described as 
transducers for rapidly-adapting mechanosensitivity in DRG neurones (Coste et 
al., 2010). However, it remains to be seen whether Piezo null mice will possess 
deficits in visceral mechanosensory function.   
How NaV1.9 impacts on visceral afferent function during mechanical stimulation 
remains poorly understood. Normosensation appears largely unaffected during 
somatic behavioural models in NaV1.9 -/- mice, suggesting that the channel may 
not be critical to the direct transduction of mechanosensation (Amaya et al., 
2006; Priest et al., 2005). Utilising multiple mechanical stimuli, including ramp 
distension, phasic distension and von Frey hair probing of the colorectum, will 
facilitate a more comprehensive understanding of NaV1.9 in visceral 
mechanotransduction. 
1.6.2 STIMULUS RELEASED MEDIATORS - ROLE OF PURINERGIC SIGNALLING IN 
VISCERAL AFFERENT FUNCTION 
 
Visceral hypersensitivity in response to balloon distension of the colorectum 
correlates with severe pain in irritable bowel syndrome patients (Kuiken, 
Lindeboom, Tytgat, & Boeckxstaens, 2005). One algogenic mediator which has 
been shown to be particularly relevant to the activation of visceral nociceptors 
during distension is ATP. George Burnstock proposed that in hollow visceral 
organs, e.g. tubes (intestines, ureter, bile duct, salivary duct) and sacs (lung, 
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urinary bladder, gall bladder), mechanical stress, and therefore distension, can 
trigger the release of ATP from the epithelial lining leading to the stimulation of 
visceral nociceptors (Burnstock, 1999, 2009a). In addition, release of ATP by 
colorectal distension is greatly enhanced during colitis suggesting a more 
prominent role for this pathway during inflammation (Calvert, Thompson, & 
Burnstock, 2008; Shinoda, Feng, & Gebhart, 2009; Wynn, Ma, Ruan, & 
Burnstock, 2004). With regards to purinergic signalling, application of ATP has 
been shown to enhance NaV1.9 currents, and the mechanical hypersensitivity to 
intraplantar injections of purinergic ligands (α,β-methylATP and UTP) is lost in 
NaV1.9 knock-out mice (Amaya et al., 2006; Baker, 2005). Given the importance 
of ATP as a signalling molecule for visceral pain, it is likely that NaV1.9 may 
represent a novel transduction mechanism of visceral afferent sensitisation for 
purinergic stimuli.  
1.6.3 ACUTE INFLAMMATORY MEDIATORS – EFFECT OF EXPERIMENTAL 
INFLAMMATORY SOUP  
 
During tissue damage and inflammation, multiple mediators are released that 
act to sensitise afferent terminals (Grundy, 2004; Su & Gebhart, 1998). Indeed, 
recurrent bouts of acute mucosal inflammation will undoubtedly repeatedly 
excite and sensitise visceral nerve termini in IBD patients. The mediators 
responsible may include bradykinin, ATP, PGE2, histamine and 5-HT, which are 
released by damaged or stressed cells, as well as the immune and vascular 
systems. Together these act to hypersensitise afferents to mechanical stimuli 
and drive direct stimulation of afferent endings (Grundy, 2004). Experimental 
inflammatory soups, consisting of a combination of inflammatory mediators, 
have been used to study changes in visceral afferent sensitivity to inflammatory 
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stimuli. Indeed inflammatory soup applied intracolonically increases resting 
afferent activity and the magnitude of firing in rat (Su & Gebhart, 1998). 
Inflammatory soups have also been used to investigate mechanically insensitive 
afferents by sensitising otherwise ‘silent’ fibres (Feng & Gebhart, 2011). The 
functional up-regulation of NaV1.9 current amplitudes by inflammatory 
pathways suggest that NaV1.9 will significantly contribute to afferent 
excitability following acute stimulation by inflammatory mediators (Baker, 
2005; Maingret et al., 2008).   
1.6.4 CHRONIC INFLAMMATORY MEDIATORS - EFFECT OF IBD ON VISCERAL 
AFFERENT FUNCTION AND LIKELY ROLE FOR NAV1.9  
 
In addition to acute inflammatory phases, advanced late-stage IBD represents a 
disease paradigm with patients suffering from chronic inflammation and 
chronic pain. A central component of the pain experienced in IBD is so called 
IBS-associated post-inflammatory hypersensitivity (Grover et al., 2009). 
Experimentally, visceral hypersensitivity in IBS is observed to colorectal 
distension (Lembo et al., 1994; Ritchie, 1973) and is likely the result of long-
term mechanistic changes in sensory nerve terminal sensitisation by 
inflammatory mediators. Using visceral rodent models, supernatants derived 
from inflamed and normal human bowel tissues have been used to study the 
impact of human-derived inflammatory milieu on visceral afferent modulation 
in an acute setting. Faecal supernatants from diarrhoea-predominant IBS 
patients when instilled into the colorectum of mice induce colonic 
hypersensitivity (Annaházi et al., 2009). Indeed, visceral hyperalgesia is also 
evoked by supernatants derived from colonic mucosal biopsies of IBS patients 
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(Cenac et al., 2007). Similar disease supernatants, but not normal controls, are 
capable of increasing nerve discharge from rat mesenteric afferents (Barbara et 
al., 2007), suggesting that an inflammatory milieu released by the mucosal 
lining is capable of exciting and sensitising visceral afferents transducing pain. 
IBS-like symptoms, including diarrhoea and abdominal pain, disproportionate 
to the degree of active inflammation, may be experienced by IBD patients 
(Grover et al., 2009; Isgar, Harman, Kaye, & Whorwell, 1983; Minderhoud, 
Oldenburg, Wismeijer, van Berge Henegouwen, & Smout, 2004). By contrast, a 
subset of IBD patients, in a remissive and quiescent state, appear 
normosensitive or even hyposensitive to colorectal distension (Bernstein et al., 
1996; Chang et al., 2000). This has been reinforced by ulcerative colitis faecal 
supernatants causing colonic hyposensitivity when infused in the colorectum of 
mice (Annaházi et al., 2009). Differences in the sensitivity of IBD patients to 
distension and the apparent ability for IBD supernatants to evoke 
hyposensitivity in mice likely reflect the spectrum of disease progression and 
severities encompassed by ‘inflammatory bowel disease’. Consequently, the 
inflammatory environment that the nerve terminal is exposed to is also likely to 
change significantly over the course of disease progression. 
These changes in visceral afferent function have been associated with multiple 
inflammatory mediators, including those released by mast cells, such as 
histamine, tryptase and trypsin (Annaházi et al., 2009; Barbara et al., 2007; 
Cenac et al., 2007). It is likely that the combination of inflammatory mediators 
released by the chronically damaged mucosal lining of the gut during IBD differs 
significantly from those released during more acute inflammation. Whilst the 
86 
 
specifics of the mechanism leading to changes in visceral sensitivity is 
unknown, differing combinations of inflammatory mediators acting at ion 
channels and GPCRs will likely lead to visceral afferent modulation. Given that 
NaV1.9 contributes significantly to the regulation of afferent sensitivity suggests 
that NaV1.9 may play an important role in the development of visceral pain 
during conditions such as inflammatory bowel disease. 
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1.7 PRINCIPAL AIM 
 
To investigate the role of NaV1.9 in visceral afferent activation to noxious 
inflammatory, mechanical and human-disease derived stimuli, relevant to 
inflammatory bowel disease. 
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CHAPTER 2: LOCALISATION OF NAV1.9 IN 
VISCERAL AFFERENT FIBRES 
89 
 
2.1 INTRODUCTION 
2.1.1 EXPRESSION OF NAV1.9 IN MAMMALIAN TISSUES 
 
The tetrodotoxin-resistant (TTX-R) NaV1.9 isoform is primarily expressed 
within neurones of the peripheral nervous system (PNS), however low level 
expression is observed in the CNS. In mouse, NaV1.9 was identified by 
quantitative RT-PCR in both brain and spinal cord, whilst in guinea pig, a very 
low level of expression to no expression, was seen in brain tissues (Hillsley et 
al., 2006; Kwong et al., 2008). In adult rat, NaV1.9 protein is expressed in areas 
containing central projections of sensory neurones (e.g. dorsal horn of the 
spinal cord) by immunohistochemistry (IHC) (Amaya et al., 2000; S. Dib-Hajj et 
al., 2002), however mRNA transcripts were not observed in spinal cord samples 
(S. D. Dib-Hajj et al., 1998). Furthermore, expression by RT-PCR showed NaV1.9 
mRNA expression in cerebral hemispheres but not the cerebellum, suggesting 
specific regional distributions (S. D. Dib-Hajj et al., 1998). Perhaps the most 
convincing evidence for functional expression of NaV1.9 within the CNS is the 
inhibition of brain derived neurotrophic factor (BDNF)-evoked sodium currents 
in rat hippocampal neurones by antisense NaV1.9 treatment (Blum, Kafitz, & 
Konnerth, 2002). Importantly, no evidence has been found for NaV1.9 
expression in any other naïve adult excitable cell types or mammalian tissues. 
These include skeletal and cardiac muscle, spleen, lung, liver, kidney, uterus, 
testis and adrenal gland, following investigation by quantitative RT-PCR, 
Northern blot and in situ hybridisation (ISH) (S. D. Dib-Hajj et al., 1998; Kwong 
et al., 2008).     
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In the peripheral nervous system (PNS), NaV1.9 expression is restricted to the 
cell bodies and projections of sensory neurones and the enteric nervous system. 
Interestingly, given the contrasting effects of NaV1.7 mutant expression in 
dorsal root ganglia (DRG) versus sympathetic neurones on neuronal 
excitability, it is of relevance that sympathetic neurones do not appear to 
express NaV1.9 (S. D. Dib-Hajj et al., 1998; Rush et al., 2006). In the dorsal root, 
nodose and trigeminal ganglia, NaV1.9 is expressed by the vast majority of small 
diameter neuronal cell bodies and in their central terminal arborisations in 
dorsal horn lamina II of the spinal cord as well as the spinal trigeminal nucleus 
in the medulla (Amaya et al., 2000; S. D. Dib-Hajj et al., 1998; Kwong et al., 
2008). There is also evidence for NaV1.9 in extrinsic primary afferent 
innervation of the viscera, with significant expression within both the vagal 
innervation and gut-projecting sensory DRG neurones (King et al., 2009; Kwong 
et al., 2008). Expression of NaV1.9 in peripheral projections has been identified 
by immunohistochemistry (IHC) in fibres innervating the skin (S. Dib-Hajj et al., 
2002; Liu et al., 2001; Lolignier et al., 2011; Padilla et al., 2007), cornea (Fjell et 
al., 2000) and molar (Padilla et al., 2007).  In addition, both unmyelinated and 
myelinated teased sciatic nerves (S. Dib-Hajj et al., 2002; Fjell et al., 2000; Liu et 
al., 2001) and lung-specific nodose neurones (Kwong et al., 2008) also exhibit 
specific expression of NaV1.9. Analysis by IHC of the enteric nervous system 
shows NaV1.9 expression in myenteric and submucosal enteric neurones in 
mouse colon (Padilla et al., 2007; Rugiero et al., 2003); specifically interplexus 
fibres and axonal projections passing through all layers of the bowel wall 
(longitudinal muscle, myenteric plexus, circular muscle, submucosal plexus and 
mucosa) (Padilla et al., 2007).  
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2.1.2 EXPRESSION OF NAV1.9 IN SENSORY NEURONES 
 
Although NaV1.9 is found to some extent in other mammalian tissues, the 
expression in approximately 82% of small DRG neurones has focused research 
to this predominantly nociceptive phenotype (S. D. Dib-Hajj et al., 1998; 
Fukuoka et al., 2008). NaV1.9 expression by in situ hybridisation (ISH) and IHC 
is found in approximately 40-70% of DRG neurones (see Table 3) with 
considerably higher levels in small neurones (diameter <30µm: 81.6-82.9%) 
and significantly lower levels are observed in larger neurones (≥30µm: 18.8-
27.4%) (S. D. Dib-Hajj et al., 1998; Fukuoka et al., 2008). Whilst IHC and ISH 
techniques suggest a relatively high degree of expression, functionally the 
recording of NaV1.9 currents by patch-clamp suggests there are a smaller 
proportion of neurones expressing NaV1.9. For example, Baker et al. report 1 in 
6 small neurones possess NaV1.9 currents (Baker, 2005; Baker et al., 2003). 
Cummins et al. suggest approximately 60% of small NaV1.8-null neurones 
develop persistent sodium currents consistent with that mediated by NaV1.9 
(Cummins et al., 1999). Within the colon-projecting DRG neuronal population 
this disparity is far greater, with persistent TTX-R Na+ currents, attributed to 
NaV1.9, recorded from between 0-13% of cells (Beyak et al., 2004; Gold et al., 
2002).  
Importantly, the presence of NaV1.9 mRNA and protein has been detected, but 
yet not quantified, in retrogradely-labelled neurones from the colon, suggesting 
the channel is expressed (Hillsley et al., 2006; King et al., 2009). In agreement 
with this, NaV1.9 -/- mice fail to develop post-inflammatory visceral 
hypersensitivity; again implicating NaV1.9 in visceral projecting neuronal 
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function (Martinez & Melgar, 2008; Ritter et al., 2009). As such, quantifying the 
extent of NaV1.9 expression within colonic DRG neurones will help to 
understand why persistent Na+ currents were recorded at such low frequency 
in this population. 
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NaV1.9 Expression levels in DRG 
neurones  
(% of) 
Comments References 
                    Diameter   
    Total <30µm ≥30µm   
By in situ hybridisation   
    58.8 -61.5 81.6 27.4 Rat DRG (Fukuoka et al., 2008) 
    69.5 82.9 18.8 Rat DRG (S. D. Dib-Hajj et al., 
1998) 
By immunohistochemistry   
    38 - - Naïve rat DRG (Decosterd et al., 2002) 
    41 - - Adult rat DRG (Benn et al., 2001) 
    - 56 - Dissociated rat 
DRG neurones 
(Fjell et al., 2000) 
 
Table 3. Expression of NaV1.9 in DRG neurones 
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Interestingly, NaV1.9 is not found in all nociceptive neurones (64% of C-fibre 
nociceptors and 54% of Aδ-fibre nociceptors), but where is it expressed it does 
contribute to membrane properties consistent with a nociceptive phenotype 
(Fang et al., 2002; Tate et al., 1998). Where functional identification (such as 
firing in response to noxious stimuli) of a nociceptive phenotype is not possible, 
protein markers are often used to further characterise neurones and identify 
nociceptive populations. For example, expression of neurofilament heavy 
(NF200) and peripherin can differentiate between large myelinated A-fibre and 
small unmyelinated C-fibre neurones, respectively (Goldstein, House, & Gainer, 
1991; Lawson & Waddell, 1991). C-fibres can be further segregated into two 
broad, likely overlapping populations: those non-peptidergic neurones that 
bind isolectin-B4 (IB4) from the plant Griffonia simplicifolia, and those 
peptidergic neurones that express calcitonin-regulated gene product (CGRP) 
and/or substance P (SP) (Hunt & Mantyh, 2001). Importantly these two groups 
terminate in different layers of the dorsal horn: lamina I-II(outer) for 
peptidergic and lamina II(inner) for non-peptidergic (Hunt & Rossi, 1985). 
Whilst both groups of neurones respond to noxious stimuli and express the 
TRPV1 receptor, a known noxious thermal and mechanical transducer, they do 
differ in their expression of other nociceptive markers (Hunt & Mantyh, 2001). 
In addition to binding IB4, non-peptidergic neurones also largely express P2X3 
and receptors for glial cell line-derived neurotrophic factor (GDNF), whilst 
peptidergic populations express the nerve growth factor (NGF) receptor trkA. 
Importantly, both trkA expression and IB4 binding have been directly 
associated with a nociceptive phenotype in vivo (Fang, Djouhri, et al., 2005; 
Fang et al., 2006). Binding of IB4 to α-D-galactose residues on the extracellular 
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membrane of sensory neurones is shown to correlate exclusively with 
unmyelinated C-fibre nociceptors (Fang et al., 2006; Gerke & Plenderleith, 
2001) and strong trkA expression is observed in DRG nociceptors (Fang, 
Djouhri, et al., 2005). 
There is significant colocalisation of NaV1.9 with the small unmyelinated C-fibre 
protein marker peripherin, in both DRG neurones and in peripheral projections 
to skin (S. Dib-Hajj et al., 2002; Lolignier et al., 2011). Practically all IB4 binding 
neurones also express NaV1.9 (>98% (Fukuoka et al., 2008)), though some 
neurones positive for expression of NaV1.9 (NaV1.9-positive; NaV1.9+) do not 
bind IB4 (60% - 73% IB4-positive of total NaV1.9-positive (Amaya et al., 2000; 
Benn et al., 2001; Fjell et al., 2000; Fukuoka et al., 2008)). This is consistent with 
co-expression of NaV1.9 and IB4 in central sensory neuronal projections in 
lamina II of the dorsal horn (S. Dib-Hajj et al., 2002).  
Whilst NaV1.9 is expressed by the majority of IB4 binding non-peptidergic C-
fibres, there is also a subset of trkA-positive, likely peptidergic, neurones in 
which it is expressed. ISH and IHC evidence suggest that ~45-70% of trkA-
positive neurones express NaV1.9 (Amaya et al., 2000; Benn et al., 2001; 
Fukuoka et al., 2008). However, the intensity of NaV1.9 expression within a DRG 
neurone correlates with the intensity of IB4 binding but not trkA expression, 
consistent with regulation of NaV1.9 expression by GDNF, but not NGF (Fang, 
Djouhri, et al., 2005; Fang et al., 2006; Fjell et al., 1999).  
NaV1.9 appears to have complex patterning within sensory neurones but what 
is clear is its primary expression in small C-fibre nociceptors classified as either 
peptidergic or non-peptidergic. NaV1.9 is strongly associated with IB4, yet is 
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also found in a subset of trkA-positive neurones. Remaining NaV1.9 expression 
can be explained by non-nociceptive expression in a minority of large slowly-
conducting A-fibre neurones. 
2.1.3 PROTEIN MARKER CHARACTERISATION OF VISCERAL SENSORY NEURONES 
 
As outlined above, nociceptors are strongly associated with various biochemical 
and electrophysiological characteristics. In nearly all cases, this has focussed on 
stimulus-response functions to non-visceral innocuous and noxious sensations, 
including touch, pinch, heat, cut, crush and vibration. However, visceral 
afferents transduce unique sensations including bloating, distention, nausea 
and dyspnea, alongside pain. As such, visceral nociceptors are not required to 
encode sensations such as cutting or excessive heat, but are instead activated by 
obstructive, inflammatory, ischaemic or infiltrative processes (Knowles & Aziz, 
2009). This has important implications for defining the visceral nociceptor, as 
nociceptors in the viscera are unlikely to represent a distinct and independent 
pathway that respond only to noxious stimuli (although mesenteric afferents 
may encode little other consciously perceived stimuli). Rather, the majority of 
visceral afferents innervating the gut are likely capable of encoding noxious, 
high intensity and normally painful stimuli. Alternatively, there is a lack of 
innocuous stimulus sensing Aα/β fibre innervation in the viscera, with nearly 
all visceral afferents of C-fibre (60-80%) and Aδ-fibre (20-40%) subtypes 
(Sengupta & Gebhart, 1994; Sengupta et al., 1990). By contrast almost 70% of 
cutaneous and muscle innervation from the sciatic nerve are Aα/β-fibres, with 
C- and Aδ fibres making up approximately 15% and 12%, respectively (Harper 
& Lawson, 1985a, 1985b). Within the lumbosacral pathway, a subset of visceral 
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afferents are specifically activated by high-threshold stimuli, and even those 
activated by low-threshold stimuli are intensity-encoding and respond through 
a range of innocuous to noxious stimuli (G. F. Gebhart, 2000). In the splanchnic 
nerve, almost all (80-90%) afferent fibres are of serosal and mesenteric 
subtype, which are thought to represent a major type of nociceptor (Brierley et 
al., 2004; Brookes et al., 2013). Furthermore, the significant ability for visceral 
afferents to sensitise following chemical stimulation by inflammatory 
mediators, with ‘silent’ nociceptors or mechanically insensitive afferents 
acquiring mechanosensitivity following inflammation, suggests pronounced 
plasticity in the sensitivity of visceral afferents, which likely underlies their 
concurrent function as nociceptors (Feng & Gebhart, 2011).   
As such the application of known nociceptive protein markers to visceral 
afferents, in the absence of functionally defined visceral-nociceptor populations, 
are discussed below. In line with the focus of this thesis, the emphasis of 
discussion will be on spinal colonic innervation. Retrograde labelling studies of 
the rodent colon suggest that between 3 and 15% of DRG neurones project to 
the colon, with a bimodal distribution amongst spinal cord levels: one at spinal 
cord level T8-L1 in mouse (T8-L2 in rat) and the other comprising L6-S1 in 
mouse (L6 – S1 in rat) (Brierley et al., 2008; Christianson et al., 2006; Jänig & 
Morrison, 1986; Perry & Lawson, 1998; Robinson et al., 2004). The 
thoracolumbar pathway corresponds to afferent fibres tracking with the 
splanchnic nerve and the lumbosacral pathway that of afferent fibres tracking 
with the pelvic nerve.  
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Whilst Aα/β-fibres are rare in viscerally projecting populations, neurofilament-
heavy markers have proven useful in defining the thinly myelinated Aδ-fibre 
visceral afferent population (between 19-26% of visceral afferents 
(Christianson et al., 2006; Perry & Lawson, 1998)). In contrast are non-visceral 
C-fibres, where there is a significant peptidergic bias in visceral afferents, such 
that around 80-81% of colon-projecting neurones express CGRP (Christianson 
et al., 2006; Robinson et al., 2004) and this rises to 99% when whole splanchnic 
nerve retrograde labelling is performed (Perry & Lawson, 1998). This is 
consistent with significant expression of CGRP in peripheral projections along 
vasculature of the intestinal mesentery and submucosa (Song et al., 2009). The 
vast majority of these fibres also express substance P (~80%) (Perry & Lawson, 
1998). With that in mind, the binding of IB4 (purported correlate of non-
peptidergic C-fibres) is markedly less than that observed in non-visceral 
afferents. In colonic projecting afferents this is as low as 5-20% (Christianson et 
al., 2006; Robinson et al., 2004). Therefore the protein markers IB4 and CGRP 
do not segregate visceral afferents into distinct groups as observed in non-
visceral afferents, and in fact IB4-positive visceral afferents almost always 
additionally express CGRP (90-100% (Christianson et al., 2006; Robinson et al., 
2004)). 
Given the strong correlation between IB4 binding and NaV1.9 expression in 
cutaneous nociceptive neurones, it is necessary to characterise whether this 
correlation holds true in visceral afferents also (Fang et al., 2006).  To address 
this and provide support for a functional role of NaV1.9 in visceral afferent 
sensitisation, in situ hybridisation and immunohistochemistry for NaV1.9 mRNA 
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and protein was performed on retrograde-labelled DRG neurones from the 
colon.  
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2.2 AIMS 
 
1. The relatively low frequency of NaV1.9 persistent currents recorded by 
patch-clamp of colon projecting neurones is in contrast to both substantial 
behavioural phenotypes observed in NaV1.9 -/- mice and existing qualitative 
expression data. As such, the first aim of this study is to determine the level 
of NaV1.9 expression within colon-projecting DRG neurones using both in 
situ hybridisation and immunohistochemical techniques. 
2. There exists a strong correlation between IB4 binding and NaV1.9 
expression in somatic nociceptors. However, IB4 expression is significantly 
lower in visceral sensory neurones and does not separate from peptidergic 
markers, such as CGRP, but rather colocalises with them. The second aim of 
this study is to further characterise the expression of NaV1.9 using the 
protein markers IB4 and CGRP, in comparison with known expression 
patterns in somatic projecting neurones.  
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2.3 METHODS 
2.3.1 RETROGRADE LABELLING OF COLONIC TISSUES 
 
Fast Blue (FB: 2% in saline, Polysciences Gmbh, Germany) was injected into the 
wall of the distal colon of NaV1.9 +/+ and NaV1.9 -/- mice and male Sprague-
Dawley rats (150-250g). The NaV1.9 -/- construct and breeding strategy for 
these animals is described in detail in Chapter 3 (3.3.1 NaV1.9 knock-out mice). 
Animals were anaesthetised with isofluorane then an approximate 1.5cm 
laparotomy performed. Five injections of 0.2µl FB per site, at a rate of 0.4 
µl/min via a microinfusion pump, were made into the wall of the distal colon 
using a fine-pulled glass needle. The muscle layer was sutured and the skin 
secured with Michel clips. Post-operative analgesia (buprenorphine 0.05-
0.1mg/kg daily) and care (monitoring body weight and soft diet) was provided. 
After three or seven days, animals were euthanised with sodium pentobarbital 
(200mg/kg i.p.) and transcardially perfused with saline (0.9%) followed by 
paraformaldehyde (PFA; 4% in 0.1M phosphate buffer; pH 7.4). Dorsal root 
ganglia (DRG; NaV1.9 +/+ and NaV1.9 -/- mice, T7-L4; rats, T7-L4) were 
removed and post-fixed in 4% PFA for 2 hours and cryoprotected in 30% 
sucrose (w/v phosphate buffered saline (PBS)). Cryostat sections (10µm) were 
collected sequentially across 10 slides per DRG.  
2.3.2 IMMUNOHISTOCHEMISTRY 
 
Sections were blocked in antibody diluent (10% horse serum and 0.2% (v/v) 
Triton X-100 in 0.1M PBS) for 1 hour, followed by overnight incubation with 
primary antibodies (rabbit anti-NaV1.9 antibody (1:1000; Alomone, Israel) and 
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goat anti-CGRP antibody (1:2000; Abcam, UK)) and a 4 hour incubation with 
fluorophore-conjugated secondary antibodies (donkey anti-rabbit IgG-
Alexafluor-488 and donkey anti-goat IgG-Alexafluor-568 (1:1000; Invitrogen, 
UK)) and/or isolectin B4 (IB4) from Griffonia simplicifolia-Alexafluor-647 
(2.5µg/ml: Invitrogen, UK).   
2.3.3 ISOTOPIC IN SITU HYBRIDISATION 
 
Oligonucleotide probes complementary to bases 968-1001 (Probe 1) and 2641-
2674 (Probe 2) of the mouse SCN11A sequence, accession number NM 
011887.3, were synthesised (Sigma, UK) and hybridized to DRG sections using 
previously described protocols, and were visualised by silver grain 
development in radiographic emulsion (Michael et al., 1997). Probes were 
labelled at the 3’ end with 35S-dATP (Perkin Elmer, UK) and terminal 
transferase (Promega, WI, USA). Equipment was cleaned using 1M NaOH and 
Diethylpyrocarbonate (DEPC)-treated H2O to inactivate RNase enzymes. 
Sections were first acetylated in 0.25M acetic anhydride/0.1M triethanolamine 
(in DEPC Phosphate Buffered Saline (PBS)), passed through a dehydrating 
ethanol series (70-100%) and then delipidated with chloroform for 5 minutes. 
Hybridisations occurred overnight at 37°C using a probe concentration of 2nM. 
The probe was diluted in hybridisation buffer (2X Denhardts solution (Sigma, 
UK), 4X SSC (1X SSC = 150mM sodium chloride, 15mM sodium citrate, pH 7.0), 
50% deionised formamide, 10% dextran sulphate (Pharmacia Biotech, UK), 
100μg/ml Poly A+ (Sigma, UK), 100μg/ml sheared salmon sperm DNA 
(Boehringer, Germany), 20mM dithiothreitol (DTT)) and briefly (5 minutes) 
heated to 65°C. After hybridisation, sections were washed twice in 2x SSC 
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(containing 0.4% β-mercaptoethanol) at room temperature, then twice in 1X 
SSC at 50°C and once in 0.2X SSC at 50°C. Sections were washed for an 
additional hour in 1X SSC at room temperature, dehydrated with ethanols (70-
100%) and allowed to air dry, before dipping in autoradiographic emulsion (K5 
Nuclear Emulsion, Process Supplies, UK). Sections were exposed for 2-3 weeks, 
developed, counterstained with Giemsa counterstain and coverslipped. No 
specific labelling was observed in DRG sections of NaV1.9 -/- mice hybridised 
with SCN11A probes; reactions where an excess of unlabelled probe was used 
resulted in only background signal.  
2.3.4 ISOTOPIC IN SITU HYBRIDISATION PROBE SELECTION 
 
34 base oligonucleotide probes complementary to bases 968-1001 (Probe 1), 
2641-2674 (Probe 2) and 5041-5074 (Probe 3) of the mouse SCN11A sequence, 
accession number NM 011887.3, were selected with 52.9% GC content. 
Oligonucleotide probes were checked for self-dimerisation and hairpin 
formation, alongside homology to other mRNA sequences (Kibbe, 2007). 
Furthermore, homology to rat SCN11A sequence, accession number  
NM 019265.2, was also established (see Table 4), for potential utility in rat DRG 
sections.  
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 Complementary base sequence GC % Secondary 
structure 
Homology to rat 
SCN11A 
Probe 1 GAGGACTTCATAATGTGTGGCAACTGGCTCGGCA 52.9 None 91% 
Probe 2 TGAGAGTAGAGACACAGCCACCCTGGATACAAGG 52.9 None 29% 
Probe 3 GGATGTTCTCTTTGCTTTCACCACCAGGGTCCTC 52.9 None 97% 
 
Table 4: In situ hybridisation probes against mouse SCN11A 
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2.3.5 CHROMOGENIC IN SITU HYBRIDISATION  
 
Retrograde-labelled DRG sections were prepared as described for isotopic in 
situ hybridisation, target probes against SCN11A mRNA hybridised for two 
hours and expression visualised using RNAscope Brown Detection Kit 
(Advanced Cell Diagnostics, Inc., USA). The chromogenic in situ hybridisation 
assay uses a proprietary signal amplification system to specifically detect 
probes hybridised to the tissue. Presence of the target mRNA transcript is 
detected by punctate dots of chromogen precipitate (brown). Specifically, 
sections were washed (0.1M PBS), endogenous enzyme activity blocked (10 
minutes; room temperature (RT)) and antigen retrieval performed (0-20 
minutes; 40°C) before probe hybridisation. The SCN11A probe was designed by 
ACD (SCN11A-C1(catalogue #403531)) and targets NM_011887.3, 349-1283bp, 
with 6-10 short oligonucleotide pairs, covering approximately 50 bases of the 
target mRNA per oligonucleotide. After hybridisation, multiple amplification 
steps were performed, culminating in the addition of horse radish peroxidase 
(HRP)-labelled probes. Addition of a chromogenic substrate produced the 
brown product identifying expression. Sections were counterstained (Giemsa) 
and coverslipped, before imaging.     
2.3.6 NAV1.9 ANTIBODY 
 
The rabbit anti-NaV1.9 antibody used in these studies (Alomone ASC-017) was 
raised against an epitope on the intracellular C-terminus domain of the rat 
NaV1.9 channel (amino acid residues 1748-1765, accession number O88457). 
Although 83% sequence homology exists between mouse and rat NaV1.9 
channels, significant non-specific labelling was present in pilot experiments in 
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mouse NaV1.9 -/- DRG sections. As such, the antibody was only used in rat 
tissues, where control experiments indicated specific labelling of NaV1.9 (see 
Figure 11). 
2.3.7 IMAGING AND QUANTITATION 
 
Relative intensities of reaction products in immunostaining for NaV1.9 and 
other markers and NaV1.9 mRNA in situ hybridisation were determined for all 
DRG cells with visible nuclei (ImageJ 1.45S analysis software, NIH, USA). The 
mean background absorbance of each section was subtracted prior to analysis 
to control for variability in illumination. Percentage relative intensities of 
background-subtracted cell absorbance were determined by comparison with 
least intensely (0%) and most intensely (100%) labelled profiles. Relative 
intensity of DRG cells was measured in NaV1.9-/- sections to set the threshold 
(Tpos) for positive labelling in wild-type mice. Cells with intensity values greater 
than the mean intensity of the ten cells with the highest background intensity 
values in NaV1.9-/- sections plus two times its standard deviation (SD), were 
considered positively labelled (Tpos = 22%). For NaV1.9, CGRP and IB4-like 
immunoreactivity, intensity of staining was scored on a scale of 0-5 by two 
independent observers, with 0 representing negative and 5 strongly positive. 
The mean absorbance of these cells taken from ImageJ analysis correlated 
significantly with staining scores (e.g. Pearson r = 0.87; p < 0.0001; n = 149) and 
a threshold for positive staining was determined as performed by Fang et al. 
(e.g. mean absorbance for NaV1.9 ≥ 32%) (Fang et al., 2002). In mice neurones 
were classified as small (<400μm2 (diameter ~<20μm)) or large (≥400μm2 
(diameter ~≥20μm)), according to their cross-sectional area. In rat these 
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classifications were: small, <900μm2 (diameter ~<30μm); and large, ≥900μm2 
(diameter ~≥30μm) (S. D. Dib-Hajj et al., 1998).  
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2.4 RESULTS 
2.4.1 VALIDATION OF COLONIC FAST BLUE LABELLING OF DRG NEURONES 
 
The specificity of Fast Blue uptake by thoracolumbar colon-projecting afferents 
was first investigated qualitatively. Following transcardial perfusion with 
fixative (4% PFA), dorsal root ganglia from mice and rats were removed from 
spinal levels thoracic 3 (T3) – T13, lumbar 1 (L1)-L4. The distal colon was also 
removed at this time. The colon was opened along the antimesenteric border 
and multiple light and fluorescent images were taken and combined together to 
determine the position of Fast Blue (FB) injection sites relative to likely 
splanchnic and pelvic afferent receptive fields. In Figure 6A, multiple FB 
injection sites can be seen as a faint yellow under light microscopy (red 
arrows). During surgery, efforts were made to ensure injection sites were made 
primarily within regions of the colon likely to be innervated by the lumbar 
splanchnic nerve (LSN), therefore FB injections were not made more distally. 
Once microdissected, individual DRG from FB-labelled mice and rats were 
imaged under fluorescent microscopy to confirm uptake of FB into cells (Figure 
6B). In DRG T5-L2, fluorescing white cells could be seen under UV illumination, 
with maximal frequency in L1 (Figure 6B&C). Importantly, none, or very few 
(<2 cells/DRG) retrograde-labelled cells were observed in DRG T4, L3 and L4 
(Figure 6B&C). This is consistent with the expression pattern observed in 
previous studies and provides confirmation that off-target labelling of non-
visceral tissues is unlikely to have occurred (Christianson et al., 2006; Robinson 
et al., 2004). As such, no alterations to surgical procedures (e.g. position or 
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number of injection sites, concentration or amount of FB injected) were made 
other than to optimise survival time post-surgery (see below).  
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
  
Figure 6. Validation of colonic Fast Blue labelling of DRG neurones. Fast Blue (FB) 
injection into the colon wall of mouse and rat and retrograde transport to dorsal 
root ganglia. A Mouse colon from anus (bottom) to splenic flexure (top) was 
removed post-fixation (4% PFA) and opened along the anti-mesenteric border. 
Multiple light (i) and fluorescent (ii) images were taken and combined to form this 
representative image. Example FB injection sites have been highlighted (red 
arrows). For illustrative purposes, typical afferent innervation of the lumbar 
splanchnic (LSN) of the colon is indicated. Scale bar 3mm. Inset, close-up of FB 
injection site. Scale bar 1mm. Representative light and fluorescent images of whole 
DRG removed from retrograde-labelled mice (Bi & ii) and rat (C). DRG from spinal 
level L1 contains significant fluorescing FB-labelled cells, corresponding to the 
splanchnic afferent pathway, whilst DRG T4 and L4 contain none, or very few (<2 
cells/DRG), fluorescing cells. *L2 for rat (C) is shown due to species differences in 
maximal LSN innervation. Scale bars 100µm. 
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2.4.2 QUANTITATIVE ASSESSMENT OF FB COLONIC LABELLING OF DRG 
NEURONES 
 
To further optimise the retrograde-labelling procedure, two survival time 
points post-surgery were investigated: 3 and 7 days. A shorter post-surgery 
period was chosen to minimise the duration of post-operative care and 
potential stressors exposed to the animal (e.g. twice daily analgesic injections). 
A shorter survival had also been shown previously to produce comparable 
labelling frequencies, and to increase neuronal intensity of FB (Perry & Lawson, 
1998). DRG from mice, having undergone surgery 3 or 7 days prior, were 
removed and counts were made of neuronal FB-positive (FB+) profiles from 
DRG sections. At the 7 day time point, FB+ cells made up 8.1 ± 0.0% of the total 
profiles counted across all DRG (N = 2)(Figure 7). In DRG with maximal 
frequency of colonic projecting neurones, this increased to 13.3 ± 0.0% for L1 
(Figure 7). Numbers of FB+ cells in 3-day survival time animals were 
comparable when examining counts from T13 and L1 DRG (N = 3-4, Figure 7), 
although due to the low N number for 7-day survival time mice statistical 
analysis was not conducted. Size-frequency analysis of neuronal profiles from 
T13 & L1 DRG (3-day survival time) revealed a broad distribution of FB+ cells, 
with a larger area mean (619 ± 62 µm2) compared to all T13 & L1 profiles (442 
± 18 µm2, N = 4, Figure 7). The distribution revealed the majority of FB+ profiles 
as small or medium in size (cross sectional area <800 μm2) with very few cells 
considered large (cross sectional area >800 μm2).  
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Figure 7. Effect of survival time on FB colonic labelling of mouse DRG neurones. A 
Distribution of FB labelling across DRG levels from T7-L4 in mouse with peak 
frequency at L1, reflecting the lumbar splanchnic afferent innervation, with 7 days 
survival time. B Distribution of FB labelling across DRG levels T13 and L1 in mouse 
after 3 days survival time. C Cross-sectional area-frequency histogram of FB+ 
profiles superimposed on all T13&L1 DRG neuronal profiles from 3 day survival time 
mice.  
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2.4.3 RETROGRADE FAST BLUE LABELLING OF COLONIC TISSUES IS UNAFFECTED 
BY NAV1.9 KNOCK-OUT 
 
In later studies, NaV1.9 -/- mice were used to investigate the functional role of 
NaV1.9 in visceral afferent pathways and to confirm the specificity of in situ 
hybridisation techniques. Therefore in order to confirm that NaV1.9 knock-out 
was not altering the extent of colonic innervation by extrinsic afferent fibres, 
comparisons of the proportions of FB+ profiles from NaV1.9 +/+ and NaV1.9 -/- 
mice were made. During comparable surgical procedures and survival times (3 
days), the extent of FB labelling of T13 & L1 DRG did not significantly differ 
(unpaired t-test, p = 0.48, Figure 8B). Indeed, size-frequency analysis revealed 
similar distributions (2-way ANOVA, p = 0.11) and area means (NaV1.9 +/+: 619 
± 62 µm2 vs NaV1.9 -/-: 628 ± 33 µm2, unpaired t-test, p = 0.90) of FB+ profiles 
from NaV1.9 +/+ and NaV1.9 -/- mice. 
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Figure 8. Comparison of FB colon labelling from NaV1.9 +/+ and NaV1.9 -/- mice. 
Comparison of total number of colon-projecting FB labelled neuronal profiles in 
NaV1.9 +/+ and NaV1.9 -/- mice from DRG T13 and L1. A Example brightfield and 
fluorescent images of NaV1.9 +/+ and NaV1.9 -/- DRG sections showing FB labelling 
of cells. Scale bar 100µm. B Scatter plot of FB+ profiles as a percentage of total 
profiles (mean of 1-2 DRG per animal, N = 4 per genotype). C Mean frequency of 
cross-sectional area of profiles (in 50µm2 divisions) from NaV1.9 +/+ and NaV1.9 -/- 
mice.  
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2.4.4 EXPRESSION OF NAV1.9 IN MOUSE COLON-PROJECTING DRG NEURONES 
BY IN SITU HYBRIDISATION 
 
Next the expression of NaV1.9 mRNA transcripts in colon-projecting 
thoracolumbar DRG sections of mouse was examined using in situ hybridisation. 
The thoracolumbar spinal innervation of the colon was studied because this is 
thought to transduce predominantly nociceptive stimuli from the colon. Under 
polarised light, NaV1.9-positive staining was observed as clusters of silver 
grains visible over cells and was present in 69.0 ± 3.0% of all neurones (Figure 
9). Injections of FB retrograde tracer into the colon wall labelled 6.7 ± 1.8% of 
neurones in NaV1.9 +/+ mice (Figure 9A) and of these, 50.5 ± 3.3% expressed 
NaV1.9 transcripts. Size-frequency analysis of all neurones revealed that NaV1.9 
mRNA was expressed to a higher extent in small (<400 µm2 cross-sectional 
area, 83.4 ± 2.9%) compared to larger (≥400 µm2, 50.2 ± 2.9%) neurones 
(Figure 9E). The cross-sectional area mean of NaV1.9-positive (NaV1.9+) 
neurones was also significantly smaller than that of all profiles (NaV1.9+ 
profiles, 378 ± 12 µm2 vs all profiles, 442 ± 18 µm2, unpaired t-test, p < 0.05, N = 
4). In the FB+ population, a similar, although less robust trend towards 
expression of NaV1.9 in small (71.1 ± 10.9%) rather than larger cells (44.5 ± 
3.6%) was observed (Figure 9D). Area mean of NaV1.9+/FB+ profiles did not 
significantly differ from those of FB+ profiles (NaV1.9+/FB+ profiles, 553 ± 56 
µm2 vs FB+ profiles, 619 ± 62 µm2, unpaired t-test, p = 0.46, N = 4). Interestingly, 
the relative intensity of NaV1.9 mRNA staining was significantly greater in the 
FB- compared to FB+ neuronal population (unpaired t-test, p < 0.0001, Figure 
9F). 
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Figure 9. Expression of NaV1.9 mRNA in colon-projecting DRG neurones in mouse. 
Radiographic in situ hybridisation of NaV1.9 mRNA transcript expression (bright-
field with Giemsa counterstain, i; polarised light, iii) in thoracolumbar dorsal root 
ganglia section from NaV1.9 +/+ (A) and NaV1.9 -/- (B) mice combined with 
retrograde labelling of sensory neurones from the colon with Fast Blue (FB only, ii; 
merge, iv; scale bar 50µm). C Expanded top-right region of NaV1.9 +/+ ganglia 
section (A) showing four retrogradely labelled sensory neurones (Scale bar 30µm). 
Yellow arrows indicate colon projecting neurones positive for NaV1.9 mRNA 
expression. Yellow arrowheads indicate colon projecting neurones negative for 
0-
50
50
0-
55
0
10
00
-1
05
0
15
00
-1
55
0
>2
00
0
0
5
10
15
20
25
NaV1.9 +ve profiles
All profiles
214 profiles
1-2 DRGs per N
N = 4
Cross-sectional area of profiles (m2)
N
u
m
b
e
r 
o
f 
F
B
+
 P
ro
fi
le
s
Na
V
1.9 -/-
FB
FB
Na
V
1.9
Na
V
1.9
Na
V
1.9 FB
Na
V
1.9 FB
ii
Bi ii iii iv
DCi
0-
50
50
0-
55
0
10
00
-1
05
0
15
00
-1
55
0
>2
00
0
0
100
200
300
400
500
NaV1.9 +ve profiles
All profiles
3050 profiles
1-2 DRGs per N
N = 4
Cross-sectional area of profiles (m2)
N
u
m
b
e
r 
o
f 
N
e
u
ro
n
a
l P
ro
fi
le
s
FB- FB+
0.0
0.2
0.4
0.6
***
Neuronal Profiles
N
a
V
1
.9
 R
e
la
ti
ve
 I
n
te
n
si
ty
E
F
117 
 
NaV1.9 mRNA expression. Cross-sectional area histogram of FB+ (D) and all (E) 
neuronal profiles from NaV1.9 +/+ mice showing NaV1.9 mRNA transcript expression 
super-imposed on top (white bars). F Relative intensity of NaV1.9 mRNA transcript 
expression in FB-negative (FB-) versus FB-positive (FB+) neuronal profiles (3050 
profiles, N = 4, unpaired t-test, ***p < 0.0001). 
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The specificity of in situ hybridisation for NaV1.9 was confirmed by identical 
expression distribution patterns for NaV1.9 mRNA using three separate NaV1.9 
probes (Probe 1, 64.7% NaV1.9+; Probe 2, 61.8% NaV1.9+; Probe 3, 73.5% 
NaV1.9+, Figure 10A). Probe 3 labelled less efficiently than both Probe 1 and 
Probe 2, and was not used in subsequent studies. Furthermore, controls using 
an excess of unlabelled probe on NaV1.9 +/+ sections produced only 
background signal (Figure 10B). And finally, expression was not observed in 
NaV1.9 -/- sections (Figure 9B).  
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Figure 10. In situ hybridisation controls. A Similar expression patterns were 
detected using three different NaV1.9 mRNA probes on NaV1.9 +/+ DRG sections. 
Fluorescence (FL) polarised-light images of silver-grains were superimposed on 
brightfield (BF) images. Scale bar 100µm. B Control in situ hybridisation reactions 
with excess unlabelled probe produced only background signal. Scale bar 50µm. 
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2.4.5 EXPRESSION OF NAV1.9 IN RAT COLON-PROJECTING DRG NEURONES BY 
IMMUNOHISTOCHEMISTRY 
 
To further characterise NaV1.9 expression and confirm mRNA distribution, a 
commercially available NaV1.9 antibody was used in rat DRG sections, in 
conjunction with two protein markers of neuronal subpopulations: CGRP and 
IB4. Both markers, CGRP, present in small peptidergic nociceptors and IB4, 
expressed in small nonpeptidergic nociceptors, have been used previously to 
characterise viscerally projecting neuronal populations (Robinson & Gebhart, 
2008). Multiple commercially available polyclonal NaV1.9 antibodies (Alomone 
Labs [ASC-017], Sigma Aldrich [S2196] and abcam [ab84086]) were initially 
characterised on both mouse and rat DRG tissue. Of these, Alomone Labs NaV1.9 
antibody performed most effectively, producing expression patterns predicted 
from existing literature (Amaya et al., 2000). The use of the Alomone Lab 
antibody in rat DRG tissue had been previously validated by both the 
manufacturer and in the literature (Y. Q. Yu, Zhao, Guan, & Chen, 2011); 
however the specificity of the selected antibody in mouse tissues was unknown. 
As such, pilot labelling experiments were performed on mouse DRG sections of 
both NaV1.9 +/+ and NaV1.9 -/- animals. Non-specific labelling was observed in 
NaV1.9 -/- tissue suggesting that the Alomone Lab antibody was not useful in 
specifically labelling NaV1.9 in mouse tissues. Therefore subsequent 
experiments were performed in rat DRG tissue. NaV1.9 immunoreactivity was 
observed in a similar proportion of total neurons to ISH experiments (64.5 ± 
2.4%, Figure 11A), with a significantly smaller area mean compared to all 
profiles (642 ± 14 µm2 vs 767 ± 25 µm2, unpaired t-test, p < 0.05). No specific 
staining was seen in control experiments following preincubation with excess 
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antisera peptide for NaV1.9 antibody or when primary NaV1.9 antibody was 
omitted (Figure 11). Furthermore, western blot analysis of NaV1.9 
immunoreactivity on rat DRG lysates identified a principal band at the 
predicted molecular weight for NaV1.9 of ~205kDa; two fainter bands at larger 
molecular weights could also be observed, possibly reflecting glycosylated 
forms of the channel (Figure 11). Colonic injection of FB labelled 9.2 ± 1.6% of 
rat sensory neurons, and in agreement with ISH data, of this FB+ population, 
51.9 ± 5.8% of cells stained positive for NaV1.9 (Figure 12). The area mean of 
FB+ profiles was almost equal to that of all cells (786 ± 86 µm2 vs 767 ± 25 µm2, 
unpaired t-test, p = 0.84). Further, in congruence with ISH studies, the relative 
intensity of NaV1.9 immunoreactivity was significantly less in FB+ versus FB- 
neuronal profiles (unpaired t-test, p < 0.0001). 
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Figure 11. Example NaV1.9 protein expression in rat colon-projecting DRG neurones. 
A NaV1.9 immunoreactivity (IR) on DRG section. Pre-incubation controls with excess 
protein antisera (B) and without primary NaV1.9 antibody (C) resulted in only 
background signal. Scale bar 100μm. High magnification images of NaV1.9-IR (D), FB 
tracer (E) and merge (F). Scale bar 50μm. G Western blot analysis of NaV1.9-IR on 
rat DRG lysates showing a band at the predicted molecular weight of ~205kDa.  
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Figure 12. Quantitation of NaV1.9 protein expression in rat colon-projecting DRG 
neurones. Cross-sectional area histogram of NaV1.9-positive (NaV1.9+; A) and FB+ 
(B) neuronal profiles superimposed on all profiles. C Cross-sectional area histogram 
of FB+/NaV1.9+ profiles superimposed on FB+ profiles. D Comparison of relative 
intensities of NaV1.9+ profiles from FB- and FB+ populations (2803 profiles, N = 3, 
***p < 0.0001). 
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2.4.6 CO-EXPRESSION OF NAV1.9 WITH CGRP AND IB4 IN RAT COLON-
PROJECTING DRG NEURONES BY IMMUNOHISTOCHEMISTRY 
 
The protein markers, CGRP and IB4 were used to further characterise neuronal 
populations. IB4 binding (IB4+) occurred in 51.4 ± 1.6% of all cells, 
predominantly in small neurones (96.6% of area < 900μm2 neurones are IB4+), 
such that the area mean of IB+ profiles is significantly smaller than that of all 
cells (559 ± 17 μm2 vs all profiles, unpaired t-test, p < 0.01, Figure 14Ai). In FB+ 
neurones, IB4 binding was observed in a smaller population compared to all 
neurones (26.0 ± 5.3 %, Table 5), consistent with the enriched peptidergic 
population present in colon-projecting neurones. This is also revealed by a 
greater proportion of CGRP-expressing cells in the FB+ population 
(FB+/CGRP+: 80.6 ± 8.3%) compared to all neurones (34.8 ± 1.1%, Figure 
14Bii). The expression of CGRP is localised to comparatively smaller neurones 
than the average neuronal area (639 ± 26 μm2 vs all profiles, unpaired t-test, p < 
0.05, Figure 14Bi).  
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Figure 13. Co-expression of NaV1.9 with neuronal protein markers, IB4 and CGRP. A 
Multiple fluorescent immunohistochemistry for NaV1.9, CGRP and IB4 in dorsal root 
ganglia from rat. Scale bar 100μm. B High magnification IHC for NaV1.9, CGRP and 
IB4 combined with retrograde labelling of sensory neurons from the colon. Filled 
arrows indicate FB+ve neurons colocalising for NaV1.9, CGRP and IB4 (white) or 
NaV1.9 and CGRP (orange). Open arrows indicate example FB-ve neurons 
colocalising for NaV1.9, CGRP and IB4 (white) or NaV1.9 and IB4 (blue). Scale bar 
50μm. 
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In situ hybridisation 
 Colonic (FB+; N = 4, n =  214)  Unlabelled (FB-; N = 4, n = 2836)  
NaV1.9 expression 50.5 ± 3.3 %  69.0 ± 3.0 % 
 
Immunohistochemistry 
  
 Colonic (FB+; N = 4, n = 247)  Unlabelled (FB-; N = 4, n = 2556)  
NaV1.9-IR 51.9 ± 5.8 %  65.9 ± 3.0 % 
CGRP-IR 80.6 ± 8.3 %  30.0 ± 0.4 % 
IB4-binding 26.0 ± 5.3 %  54.1 ± 0.9 % 
 % of NaV1.9 % of CGRP  % of NaV1.9 % of CGRP 
NaV1.9 & CGRP-IR 89.6 ± 7.8% 57.7 ± 5.1 %  32.7 ± 1.1% 71.7 ± 3.5 % 
 % of NaV1.9 % of IB4  % of NaV1.9 % of IB4 
NaV1.9-IR & IB4 binding 34.7 ± 7.3% 68.5 ± 7.7 %  73.4 ± 3.5% 89.2 ± 2.1 % 
 % of NaV1.9 % of CGRP % of IB4  % of NaV1.9 % of CGRP % of IB4 
NaV1.9 & CGRP-IR & IB4 binding 32.9 ± 7.4% 21.5 ± 4.9% 64.2 ± 4.0%  16.9 ± 2.6% 36.5 ± 4.4% 20.2 ± 2.3% 
 % of CGRP % of IB4  % of CGRP % of IB4 
CGRP-IR & IB4 binding 31.1 ± 5.4 % 95.7 ± 4.4 %  42.8 ± 5.5 % 23.7 ± 2.9 % 
Table 5. Summary of NaV1.9 expression and colocalisation with IB4 and CGRP protein markers. In situ hybridisation was performed isotopically 
in mouse. Immunohistochemistry was performed in rat. 
127 
 
The colocalisation of CGRP and IB4 on unlabelled (FB-) neurones is relatively 
infrequent and two distinct populations can be identified by these markers (see 
Table 5: 23.7 ± 2.9 % of FB-/IB4+ profiles are also CGRP+, Figure 15A). 
Interestingly, in FB+ neurones, the vast majority of IB4+ neurones also express 
CGRP (95.7 ± 4.4 % of FB+/IB4+ profiles are also CGRP+), and those that do not 
express CGRP are NaV1.9+. As such, it is not possible to split colon-projecting 
neurones into two distinct populations based on CGRP and IB4 expression. 
Rather, colon-projecting neurones should be considered a non-homogenous 
population of CGRP-positive neurones; a quarter of which also co-express IB4. 
Similar to NaV1.9 expression levels, the relative intensity of IB4-binding was 
significantly reduced in FB-/IB4+ neurones compared to FB+/IB4+ neurones 
(unpaired t-test, p < 0.0001, Figure 14Aiii). Interestingly, the relative intensity 
of CGRP-immunoreactivity did not differ between FB- and FB+ neuronal 
populations (unpaired t-test, p = 0.084). 
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Figure 14. Histograms showing cross-sectional area of IB4+, CGRP+ and 
IB4+&CGRP+ neuronal profiles. Cross-sectional area histogram of IB4+ (Ai), CGRP+ 
(Bi) and CGRP+&IB4+ (Ci) superimposed on all neuronal profiles. FB+ specific 
labelling by IB4, CGRP and colocalisation of both is shown in (ii) of A, B and C. 
Comparison of relative intensities of IB4+ (Aiii) and CGRP+ (Biii) profiles from FB- 
and FB+ populations. ***p < 0.0001 
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The extensive colocalisation of NaV1.9 with IB4 staining predicted by previous 
studies was also observed in FB- neurons (73.4 ± 3.5% of NaV1.9+ profiles; 
Table 5) (Fang et al., 2006). By contrast, NaV1.9/IB4 colocalisation was less 
extensive (34.7 ± 7.3% of NaV1.9+ profiles) in FB+ colonic populations, with an 
enrichment of colocalisation with CGRP (from FB-: 32.7 ± 1.1% to FB+: 89.6 ± 
7.8% of NaV1.9+ profiles, Figure 15). It is worth bearing in mind that the 
unlabelled (FB-) population of neurones will also contain a small proportion of 
colon-projecting neurones that have not been successfully labelled by the Fast 
Blue tracer injections. The differences in NaV1.9 expression relative to CGRP and 
IB4 protein markers in colon-projecting (FB+) and unlabelled (FB-) neurones is 
clearly exemplified in the proportional Venn diagrams shown in Figure 15.  
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Figure 15. Colocalisation of NaV1.9, CGRP and IB4 in neuronal populations. 
Proportional Venn diagram of colocation of NaV1.9, CGRP and IB4 in colonic (FB+; A) 
and unlabelled (FB-; B) neuronal populations in rat. Approximately 13.3% of FB+ 
and 21.6% of FB- neurones were negative for NaV1.9, CGRP and IB4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NaV1.9NaV1.9 
& IB4
NaV1.9
& CGRP
& IB4
NaV1.9
& CGRP
CGRP
& IB4
CGRP
IB4
A B Unlabelled neurones (FB-)
NaV1.9
NaV1.9 
& IB4
NaV1.9
& CGRP
& IB4 NaV1.9
& CGRP
CGRP
& IB4
CGRP
Colonic (FB+)
131 
 
2.4.7 NON-ISOTOPIC IN SITU HYBRIDISATION TO DETERMINE EXPRESSION OF 
NAV1.9 MRNA TRANSCRIPTS 
 
A secondary in situ hybridisation method was also used to verify isotopic 
techniques. Using a RNA oligomer signal amplification system and an enzymatic 
chromogenic reaction, greater sensitivity could be achieved with DRG sections. 
Importantly, using this technique yielded comparable results to those from 
isotopic techniques, but in a greatly attenuated experimental timeframe (8 
hours vs. 3-4 weeks for isotopic ISH). As such, in a single NaV1.9 +/+ DRG 
section, 65.6% of profiles expressed NaV1.9 mRNA transcripts, with 66.7% of 
small cells positive for NaV1.9 (Figure 16). Interestingly, the degree of probe 
binding and subsequent chromogenic reaction product was heavily influenced 
by protease pre-treatment of DRG sections, with greater signals observed 
following 30 minute pre-treatments (Figure 16). No signal was seen without 
any protease pre-treatment (Figure 16). In isotopic ISH techniques, adequate 
signal was observed without protease pre-treatment, although signal-to-noise 
ratio may have been improved by short protease digestion, to further reveal 
sense complementary bases.  
In NaV1.9 -/- sections, chromogenic signal was also dependent on protease 
digestion. Whilst no specific signal above background had been observed in 
isotopic ISH experiments in NaV1.9 -/- sections (Figure 9), protease pre-
treatment and chromogenic ISH did reveal mRNA expression (Figure 16). The 
intracellular localisation of mRNA signal, however, differed greatly from that 
seen in NaV1.9 +/+ sections (Figure 16). Staining was observed predominantly 
in the nucleus of cells, with very limited expression seen in cytoplasmic regions 
(consisting of punctate isolated brown DAB particles), compared to a more 
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homogeneous cytoplasmic and nuclear expression distribution in NaV1.9 +/+ 
sections. This is consistent with reduced nuclear export and processing of 
mutant pre-mRNA, which may be occurring given the loss of exons 4 and 5 from 
the SCN11A allele in NaV1.9 -/- mice, and the subsequent production of mutant  
mRNA  (see Chapter 3, 3.3.1 NaV1.9 knock-out mice for more details). It is 
interesting to note that isotopic techniques were unable to detect the nuclear 
signal above background, suggesting either an increased dependence on 
protease digestion or increased sensitivity of the chromogenic amplification 
techniques.  
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Figure 16. Non-isotopic in situ hybridisation of NaV1.9 in mouse DRG sections. Low 
magnification images of DAB chromogenic reaction products (brown) of NaV1.9 
mRNA in situ hybridisation on protease pre-treated (20 mins) NaV1.9 +/+ (Ai) and 
NaV1.9 -/- (Bi) mouse DRG sections counterstained with Giemsa. Scale bar 250μm. 
High magnification images of same sections (NaV1.9 +/+, Aii (scale bar 50μm) and 
NaV1.9 -/-, Bii (scale bar 25μm)). No protease pre-treatment is shown in C (i, low 
mag (scale bar 250μm); ii, high mag (scale bar 50μm)) on NaV1.9 +/+ DRG sections.  
Examples of positively labelled cells are highlighted with arrows, whilst unlabelled 
cells are marked with arrowheads. D Chromogenic ISH of NaV1.9 +/+ section (i, 
protease pre-treatment 30 mins) with colon-labelled Fast Blue neuronal profiles (ii) 
and merge (iii). Scale bar 50μm. Examples of FB+ neurones with positive labelling 
for NaV1.9 are highlighted with red arrows and FB+ neurones negative for NaV1.9 
labelling are highlighted with red arrowheads. 
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2.5 SUMMARY OF KEY FINDINGS  
2.5.1 VALIDATION AND QUALIFICATION 
 
1. Injection of retrograde neuronal marker Fast Blue into the colon of 
mouse and rat labelled a population of neurones within thoracolumbar 
DRGs 
2. There was no significant difference in degree of labelling in harvesting 
DRG after 3 days compared to 7 days from Fast Blue injection 
3. Fast Blue injection into the colon labelled approximately 5-10% of DRG 
neurones, the vast majority of which were small-medium in size. 
4. No difference was observed in the extent or size-frequency distribution 
of Fast Blue DRG neurone labelling from NaV1.9 +/+ and NaV1.9 -/- mice 
2.5.2 IN SITU HYBRIDISATION FOR NAV1.9 MRNA TRANSCRIPT EXPRESSION 
 
1. NaV1.9 mRNA was observed in 69.0 ± 3.0% of all mouse DRG neurones. 
Over 80% of small neurones expressed NaV1.9 mRNA. 
2. Of Fast Blue-positive colon-projecting neurones, NaV1.9 mRNA was 
expressed in 50.5 ± 3.3% of DRG neurones. 
3. Using isotopic in situ hybridisation, DRG sections from NaV1.9 -/- mice 
did not express NaV1.9 mRNA signal above background levels.  
4. The NaV1.9 was expressed by a range of FB+ neuronal cell sizes. Those 
FB+ profiles expressing NaV1.9 had a comparable area mean to all FB+ 
profiles.  
5. The degree of expression of NaV1.9 mRNA was significantly less in colon-
projecting neurones compared to non-colon-projecting neurones. 
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2.5.3 EXPRESSION OF NAV1.9 PROTEIN BY IMMUNOHISTOCHEMISTRY AND CO-
EXPRESSION WITH PROTEIN MARKERS, CGRP AND IB4 
 
1. 65.9 ± 3.0 % of profiles exhibited NaV1.9-immunoreactivity in rat DRG 
sections, the majority of which could be considered small in size. 
2. In congruence to ISH experiments, NaV1.9 protein was expressed by just 
over half of colon-projecting DRG neurones in rat. The FB+ neuronal 
population was predominantly small-medium in size and had an area 
mean comparable to that of all profiles. 
3. Extensive colocalisation of NaV1.9 with IB4 staining was also observed in 
FB- neurons, with three-quarters of NaV1.9+ neurones also expressing 
IB4. By contrast, NaV1.9/IB4 colocalisation was less widespread (~30%) 
in FB+ colonic populations. 
4. IB4 binding was less frequent in FB+ neurones (~25%) compared to FB- 
neurones (~50%). Although when it was expressed by a FB+ neurones, it 
was almost always (>95%) co-expressed with CGRP.  
5. The vast majority of colon-projecting neurones expressed CGRP 
compared to only about a third of all neurones, indicative of the presence 
of an enriched peptidergic population. 
6. Interestingly, whilst the relative intensity of NaV1.9 and IB4 was on 
average significantly less in FB+ neurones, the relative intensity of 
CGRP+ neurones was comparable to FB- neurones.  
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2.6 DISCUSSION 
 
The data presented here demonstrates significant expression of NaV1.9 within a 
subset of colon-projecting visceral afferent fibres. Firstly, the retrograde 
labelling of colon-projecting afferent fibres by Fast Blue injection into the 
serosal wall of the distal colon was validated.  
2.6.1 VALIDATION OF RETROGRADE LABELLING OF COLON IN MOUSE AND RAT 
 
Colon labelled neurones were identified in DRG from mouse and rat. Labelled 
neurones were observed in DRG from thoracolumbar regions of the spinal cord 
(T7-L3) with a modal peak at L1 (n.b. L2 for rat). Importantly, DRG L4 and L5, 
which receive mainly somatosensory input from the leg, were void of 
retrograde-labelled cells. This is in line with previous studies examining colon 
projecting sensory neurones (Christianson et al., 2006; Robinson et al., 2004). 
Kyloh et al. provide an association between the position of dye injection sites 
along the colon and the DRG primarily retrogradely labelled in mouse (Kyloh et 
al., 2011). In the distal colon (9-15mm from anus) of mouse, labelling was seen 
predominantly in DRG of the lumbosacral regions of the spinal cord (L6-S1), 
whilst in mid to proximal colon dye injections (30-75mm from anus), labelling 
was primarily of the thoracolumbar levels (T6-L2) (Kyloh et al., 2011). The 
labelling of T7-L3 populations observed in the current study is in line with the 
range of injection sites over the mid to mid-distal colon (~17–50mm from anus; 
see Figure 6). This population of visceral afferents represents a distinct 
anatomical pathway innervating the colon, with sensory afferent fibres 
originating in thoracolumbar DRG tracking with the lumbar splanchnic nerve 
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(Brierley et al., 2004; Jänig & Morrison, 1986). This pathway has unique 
mechanosensory characteristics that transduce differing physiological 
sensations. For example, thoracolumbar visceral afferents encode pain and 
discomfort, alongside spinal intestino-intestinal reflexes. This differs from more 
distal lumbosacral visceral afferents, which act to regulate the evacuation and 
storage functions of the pelvic organs, in conjunction with transducing 
physiological and pathophysiological sensations (Jänig, 1996). This is further 
reflected in the differences in mechanosensory fibre types present in 
thoracolumbar and lumbosacral visceral populations (Brookes et al., 2013; Song 
et al., 2009; Zagorodnyuk et al., 2010). The cross-sectional area of dye-labelled 
colon-projecting neurones was consistent with previous studies and 
represented a predominantly small to medium neuronal size, consistent with C 
– Aδ fibre types (Beyak et al., 2004; Christianson et al., 2006; Robinson et al., 
2004). Reduction in retrograde labelling survival times from 7 days post-
surgery to 3 days post-surgery provided adequate labelling within the primary 
region of interest: thoracolumbar DRG. By reducing survival times it was 
possible to minimise handling of the animal and optimise the experimental 
design. Significant retrograde labelling from visceral tissues had been 
previously shown at 2-3 days (Perry & Lawson, 1998). 
2.6.2 EXPRESSION OF NAV1.9 IN COLON-PROJECTING VISCERAL AFFERENT 
FIBRES 
 
Having confirmed that surgical microinjection of Fast Blue into the colon wall of 
mice and rats was labelling visceral afferent fibres consistent with the known 
anatomical innervation of the lumbar splanchnic nerve; identical procedures 
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were performed on NaV1.9 -/- mice. Whilst no overt phenotype, other than 
diminished hyperalgesia to inflammatory stimuli, had been described for NaV1.9 
-/- mice, retrograde labelling confirmed that no loss or lesion of visceral 
sensory neurones had occurred (Ostman et al., 2008; Priest et al., 2005). The 
relative numbers of FB+ neurones and their cross-sectional area distributions 
were comparable between homozygous genotypes. This suggests that 
subsequent functional effects observed in NaV1.9 -/- mice were due to activity 
of the channel rather than changes in the developmental innervation of mouse 
tissues. Whilst developmental changes resulting from knock-out of NaV1.9 
cannot be discounted, in addition to comparable colonic innervation, NaV1.9 -/- 
mice also exhibit normo-mechanosensation in behavioural models, suggesting 
this is unlikely to be the case (Martinez & Melgar, 2008; Priest et al., 2005; 
Ritter et al., 2009). Furthermore, this shows that NaV1.9 -/- DRG sections could 
be used as a negative control for expression analysis.  
In all sensory neurones from thoracolumbar DRG, NaV1.9 expression was 
observed in approximately 69% by both in situ hybridisation and 
immunohistochemistry. The specificity of both techniques was confirmed by 
multiple controls, including staining in sections from NaV1.9 -/- mice and the 
use of competition controls. Furthermore, experiments where in situ 
hybridisation was combined with immunohistochemistry indicated a 
correlation between expression of NaV1.9 mRNA and NaV1.9 protein 
immunoreactivity, although this was not studied in detail (see Appendix 1). 
Importantly, the extent of NaV1.9 expression observed in the current study was 
very similar to previous studies (Table 3) and suggests that the techniques 
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utilised were reliably labelling NaV1.9. Any disparity between the current study 
(ISH: 69% NaV1.9+) and those undertaken previously (ISH: 58-69% NaV1.9+) 
may be attributable to species differences (e.g. Dib-Hajj et al. and Fukuoka et al. 
both performed ISH in rat), the anatomical regions under investigation (e.g. 
nearly all studies have been performed on L4 DRG) and/or methodological 
considerations relating to the design of the ISH probe, the IHC antibody used, 
and the determination of thresholds for positive staining (S. D. Dib-Hajj et al., 
1998; Fang et al., 2002; Fukuoka et al., 2008). Efforts were taken to ensure that 
a non-arbitrary objective threshold was used in both ISH and IHC experiments 
(see 2.3.7). NaV1.9 expression by ISH was also shown in the vast majority of 
small neurones (~80%) in line with previous studies (see Table 3 (S. D. Dib-Hajj 
et al., 1998; Fukuoka et al., 2008)). It is important to note that NaV1.9 
expression is not restricted to small diameter cells and approximately 25% of 
medium and large cells also express NaV1.9.  
In colon-projecting sensory neurones, approximately 50% expressed NaV1.9 by 
in situ hybridisation or immunohistochemistry. The mean cross-sectional area 
of FB+/NaV1.9+ neurones did not significantly differ from that of FB+ cells, 
suggesting a relatively even distribution within the population (see Figure 9 
and Figure 11). The extent of NaV1.9 labelling, as determined by the 
development of silver grains during in situ hybridisation and immunoreactive 
products during immunohistochemistry techniques, was significantly less 
(~15%) in colon-projecting cells compared to non-colon-projecting cells. It 
suggests, at least in a naïve state, that whilst NaV1.9 is expressed in FB+ 
neurones, proportionally it is not expressed to the same extent as in other cells. 
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This lower somal expression of NaV1.9 may, to some extent, explain the 
challenges observed in recording NaV1.9 currents in isolated colon-projecting 
neurones (Beyak et al., 2004; Gold et al., 2002).  However, patch-clamp 
methodologies are likely to represent the greatest influence on observations of 
NaV1.9 current in vitro (Cummins et al., 1999; Rugiero et al., 2003).  
Isotopic in situ hybridisations performed on NaV1.9 -/- DRG sections did not 
show any signal over background. This was confirmed in DRG sections from 
multiple mice and using Probes 1 and 2 independently, as well as in a separate 
experiment using a combination of both Probes 1 and 2 (Figure 10). In contrast, 
subsequent experiments using non-isotopic chromogenic in situ hybridisations 
to label NaV1.9 -/- sections did see significant expression of NaV1.9 mRNA. To 
explain this disparity, it is necessary to examine how the NaV1.9 -/- mice 
utilised in this study were developed. In the NaV1.9 knock-out originally 
developed by Ostman et al., bases 538-764, relating to exons 4 & 5 of the NaV1.9 
mRNA, were replaced with a neomycin selection cassette (Ostman et al., 2008). 
This led to a frameshift mutation in the mRNA and the introduction of a stop 
codon during translation, and as such the NaV1.9 channel is not expressed. 
Importantly, the truncated NaV1.9 mRNA is still transcribed by sensory 
neurones as seen by RT-PCR and the sequencing of reaction products (Ostman 
et al., 2008). As the isotopic probes used in the present study are 
complementary to regions of NaV1.9 mRNA unaffected by genetic manipulation 
(Probe 1: bases 968-1001 & Probe 2: 2641-2674), it is likely that these would 
still bind accessible NaV1.9 mRNA in NaV1.9 -/- DRG sections. However, the lack 
of expression in NaV1.9 -/- DRG sections suggests that NaV1.9 mRNA is not able 
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to be accessed by these isotopic probes. This is in agreement with the observed 
intracellular expression pattern of NaV1.9 mRNA in NaV1.9 -/- DRG sections 
following non-isotopic chromogenic in situ hybridisations. Here, chromogen 
deposits are predominantly located within the nucleus, with very low levels 
observed in the cytoplasm. This is consistent with the incomplete processing of 
the transcribed NaV1.9 pre-mRNA  into a nuclear export-ready mature mRNA 
(Alberts, Wilson, & Hunt, 2008). This nuclear expression is only revealed by 
protease treatment and the partial digestion of fixed cellular proteins. As such, 
it may be that isotopic in situ hybridisations were unable to access the nuclear 
pre-mRNA sufficiently to provide a signal in NaV1.9 -/- DRG sections. The non-
isotopic chromogenic technique may be more sensitive due to the protease 
treatment and can therefore label these oligomers. Furthermore, due to the 
proprietary nature of the non-isotopic chromogenic in situ hybridisation 
methodology (Advanced Cell Diagnostics RNAScope 2.0), the exact 
complementary sequences of the probes used are unknown and likely 
contribute to the differences in specificities observed between techniques. 
Further studies using protease pre-treatments prior to isotopic in situ 
hybridisations may reveal a similar nuclear retention in NaV1.9 -/- sections. 
Furthermore, the co-labelling for nuclear export factors may help to rationalise 
why nuclear export efficiency is reduced.      
2.6.3 CO-EXPRESSION OF NAV1.9 WITH PROTEIN MARKERS CGRP AND IB4 
 
The protein markers, CGRP and IB4, have been used extensively in the past to 
identify small diameter peptidergic and non-peptidergic nociceptive 
populations, respectively. The characterisation of CGRP-positive or IB4-positive 
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visceral afferents as nociceptors has not been comprehensively studied. 
However, the vast majority of visceral afferents are likely to transduce stimuli 
into the noxious range and, as such, these markers will be relevant to visceral 
nociceptors. In congruence with existing literature, over 80% of FB+ neurones 
in the current study expressed CGRP and 25% bound IB4, representative of the 
predominant peptidergic innervation of the colon (Christianson et al., 2006; 
Perry & Lawson, 1998; Robinson et al., 2004; Song et al., 2009). Importantly, 
unlike somatic-projecting C-fibres, IB4 did not label a separate population to 
CGRP in colon-projecting neurones. In fact, almost all FB+/IB4+ neurones were 
also positive for CGRP (see Figure 15 and Table 5). Original studies highlighting 
the differences between peptidergic and non-peptidergic primary afferent 
pathways suggest very limited co-expression of protein markers for these two 
populations (n.b. previously fluoride-resistant acid phosphatase (FRAP), now 
IB4) (Hunt & Rossi, 1985; Nagy & Hunt, 1982). However, it is clear from more 
recent studies that CGRP and IB4 are not mutually exclusive and some overlap 
in expression does occur (Ambalavanar & Morris, 1992; Bergman et al., 1999; 
Hwang, Oh, & Valtschanoff, 2005). Both Robinson et al. and Christianson et al. 
report similar colocalisation of CGRP and IB4 in colon-projecting neurones 
(Christianson et al., 2006; Robinson et al., 2004). Indeed, Hwang et al. suggests 
that CGRP+ and IB4+ neurones represent largely the same population in 
bladder-projecting neurones, markers that were previously thought to be 
independent (D. L. Bennett, Dmietrieva, Priestley, Clary, & McMahon, 1996; 
Hwang et al., 2005);  this is supported by data generated from the current study. 
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These classifications are important as nociceptor sub-populations differ 
anatomically and rely on different growth factors during development and 
maturity (Snider & McMahon, 1998). However, whilst somatic peptidergic and 
non-peptidergic primary afferents project centrally to restricted termination 
sites within the spinal cord (lamina I and lamina II, respectively) and likely play 
differing roles in nociception, visceral primary afferents exhibit far more 
divergent central projections across lamina I, V and X (and occasionally 
contralaterally to lamina V) and have far less functional specialisation (Hunt & 
Rossi, 1985; Jänig, 1996; Sugiura et al., 1989). The high, and convergent, 
expression of nerve growth factor (NGF) receptor TrkA within CGRP+ visceral 
neurones highlights their reliance on this trophic factor (D. L. Bennett et al., 
1996; McMahon, Armanini, Ling, & Phillips, 1994). This is particularly relevant 
to sodium channel expression, where NaV1.9 expression has been shown to be 
regulated by glia cell line-derived neurotrophic factor (GDNF), rather than NGF, 
in sensory neurones (Cummins, Black, Dib-Hajj, & Waxman, 2000; Fjell et al., 
1999). Although Trk receptor subtypes are predominantly expressed in 
viscerally projecting afferent fibres, there is evidence for GDNF receptor 
expression within a population of high-threshold TRPV1-positive visceral 
afferents (D. L. Bennett et al., 1996; Malin et al., 2009; McMahon et al., 1994). 
Whilst the extent of NaV1.9 expression is reported to correlate with IB4 binding, 
a significant subset of TrkA-positive neurones are also NaV1.9-positive (Fang, 
Djouhri, et al., 2005; Fang et al., 2006). As stated in the introduction, NaV1.9 is 
expressed by both peptidergic and nonpeptidergic non-visceral neuronal 
populations of C-fibres. The present data shows that in colon-projecting 
neurones, approximately 90% of NaV1.9+ cells express CGRP and a third of 
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these also bind IB4. A speculative extrapolation of these data would suggest that 
colon projecting neurones primarily consist of populations dependent on NGF 
and a combination of NGF and GDNF; and NaV1.9 is expressed by both of these 
populations. However, a more comprehensive study is required to understand 
this patterning, using specific, not surrogate, markers for growth factor 
dependence and the inclusion of other known growth factors, e.g. BDNF and 
TrkB.  
Given the established correlation between IB4 binding and GDNF receptor 
expression, it is tempting to infer that NaV1.9 is also expressed by the subset of 
TRPV1+ high threshold units identified by Malin et al. (Malin et al., 2009). 
Interestingly, a knock-out of GFRα3 in mouse ameliorates inflammation-
induced colorectal afferent hypersensitivity; a phenotype that would fit with 
our current understanding of NaV1.9 function (Amaya et al., 2006; Tanaka, 
Shinoda, Feng, Albers, & Gebhart, 2011). However, single-unit intracellular 
recordings of colon sensory neurones using dye-fills and post-functional 
labelling for NaV1.9 will be required to confirm this association.  
The current study quantifies the extent of NaV1.9 expression within the lumbar 
splanchnic afferent pathway and provides colocalisation data with key markers 
of nociceptive populations. That NaV1.9 is expressed by approximately half of 
colon-projecting neurones indicates functional specialisation. The role of NaV1.9 
in specific fibre types is studied in greater detail in subsequent chapters.  
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CHAPTER 3: THE ROLE OF NAV1.9 IN 
MECHANOSENSITIVITY OF GUT VISCERAL 
AFFERENT FIBRES  
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3.1 INTRODUCTION 
3.1.1 SENSATION EVOKED BY MECHANICAL ACTIVATION OF VISCERAL 
AFFERENTS 
 
The mechanosensitivity of visceral afferents is central to the relay of sensation 
in response to bowel distension, stretch or mesenteric traction. Specifically, 
pain is thought to arise following distension or contraction around a faecal 
bolus in the partially or fully occluded bowel (Brookes et al., 2013). The 
sensitivity of visceral afferents to mechanical stimuli can be significantly 
modulated by inflammatory mediators. Indeed, visceral hypersensitivity to 
barostat balloon distension is observed in a subset of irritable bowel syndrome 
(IBS) patients (Mertz, Naliboff, Munakata, Niazi, & Mayer, 1995). In fact, the 
diagnosis of functional gastrointestinal disorders using the ROME III criteria 
relies extensively on visceral pain as an important criterion (Foundation, 2006). 
In pain arising from the GI tract, the activation of visceral primary afferents is 
relayed to the brain by multiple pathways, including the spinoreticular, 
spinomesencephalic, spinohypothalamic and spinothalamic tracts (Almeida, 
Roizenblatt, & Tufik, 2004). Conscious sensation is mainly mediated via the 
spinothalamic tract, with thalamic projections to the insula, anterior cingulate 
cortex and somatosensory cortex (SI/II) (Almeida et al., 2004). Collectively, 
these pathways provide localisation and intensity of the stimulus, alongside 
affective pain behaviours and integration into higher autonomic motor 
responses. The spinoreticular, spinomesencephalic and spinohypothalamic 
tracts mainly activate unconscious or autonomic responses to visceral sensory 
input. These pain pathways can be robustly activated by balloon distension of 
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the gastrointestinal tract. In man, distension to pressures of 15 to 40mmHg in 
the upper colon (>16cm above the anal sphincter) and small intestine evokes 
graded pain, which is abolished following bilateral sympathectomy from T7 to 
L3 (Bentley & Smithwick, 1940; Ray & Neill, 1947). By contrast, pain caused by 
distension of the anal canal (within 16cm of the sphincter) is unaffected by 
sympathectomy, highlighting the dual innervation of the GI tract (splanchnic 
versus pelvic nerves) (Ray & Neill, 1947). In an attempt to model visceral pain, 
many surrogates of consciously perceived pain have been used in animals. 
These include pseudoaffective and visceromotor reflexes in vivo, visceral 
afferent nerve firing ex vivo and changes in phosphorylation states of 
transcription factors or intracellular signalling proteins relevant to nociceptive 
processing (e.g. ERK). In addition, various types of stimuli have been used to 
activate visceral pain pathways, such as slow ramp versus rapid phasic 
distension by balloon inflation or fluid fill of the bowel, chemically-induced 
contraction of the bowel around a fixed inflated balloon and ex vivo blunt probe, 
circumferential stretch and stroke of discrete receptive fields of afferent fibres. 
Together these methodologies have enabled the successful identification of 
numerous biochemical and mechanistic pathways relevant to human visceral 
pain. However, it is important to understand both the limitations of and the 
rationale behind the use of each stimulus in order to maximise its utility when 
interrogating visceral afferent function; in this case specifically the role of 
NaV1.9. Functionally, how NaV1.9 deletion impacts afferent fibres of the 
splanchnic nerve has been investigated and is reported below. The afferent 
subtypes present in the splanchnic nerve and the types of stimuli used to 
stimulate them are discussed in more detail. 
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3.1.2 VISCERAL AFFERENT SUBTYPES 
 
The terminals of visceral afferents transduce mechanosensory function, such as 
contraction, relaxation and distortion of the bowel wall, movement of the 
mesentery, evacuation of the rectum and movement of gas. They are also 
responsible for the transduction of pain, as well as the regulation of local blood 
flow and reflexes. These were described in detail in Chapter 1. Here, the major 
afferent subtypes present in the splanchnic nerve are reiterated; of which there 
are four characterised functionally: serosal, mesenteric, muscular and mucosal. 
3.1.2.1 Mucosal afferents 
 
Mucosal afferents are activated by light stroking or compression of the mucosa 
but not distension or contraction of the gut (Blackshaw & Gebhart, 2002; 
Brierley et al., 2004). The arborisation of endings in the mucosal villi and in 
close proximity to the epithelial lining of the GI tract enable mucosal afferents 
to encode physiological information relating to luminal content as well as 
osmotic and pH changes (Grundy, 2002). Spinal mucosal afferent terminals are 
found in both thoracolumbar splanchnic and lumbosacral pelvic pathways, 
although are significantly more frequent in the latter (Brierley et al., 2004). 
They appear to serve a similar nutrient and luminal content-sensing function as 
vagal mucosal afferent more proximally located.    
3.1.2.2 Muscular afferents 
 
Evidence from flat-sheet colonic preparations indicate very few (< 10%) 
afferent fibres responsive to low intensity stretch in the splanchnic nerve 
(Brierley et al., 2004). This is in contrast to significant proportions of 
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lumbosacral afferent endings identified in the internal anal sphincter and 
rectum that are sensitive to low distension pressures (<20mmHg (Malin et al., 
2009)) and low intensity stretch stimuli (<3g (Hughes et al., 2009)). 
Interestingly, during in vivo recordings of jejunal mesenteric afferents from 
vagotomised animals approximately 50% of single units responded to low 
distension pressures and continued to encode into the noxious range; 
characteristics used in other studies to define muscular afferents (Booth et al., 
2008). This suggests that a significant proportion of thoracolumbar spinal 
afferents may be responsive to low distension pressures and highlights the 
methodological differences attributed to the use of stretch in a flat-sheet 
preparation versus distension in a tubular preparation. The structure and 
location of thoracolumbar muscular afferent endings remain to be determined. 
3.1.2.3 Spinal serosal and mesenteric afferents 
 
Spinal serosal and mesenteric afferents represent the vast majority (80-90%) of 
splanchnic afferent fibres identified by functional studies (Brierley et al., 2004; 
Lynn & Blackshaw, 1999). These endings are strongly associated with branch 
points of mesenteric arteries and can be activated by local compression of both 
the mesentery and the wall of the gut (Brierley et al., 2004; Song et al., 2009). 
They act to encode traction on the mesentery and contraction and distension of 
the gut wall (Bessou & Perl, 1966; Jänig, 1996). These endings are sensitive to 
ischaemia, hypoxia and capsaicin and represent a major type of nociceptor 
(Haupt et al., 1983; Longhurst & Dittman, 1987; Longhurst et al., 1984). Serosal 
and mesenteric afferents respond to much higher intensities of colorectal 
distension (>40mmHg (Brierley et al., 2008)) and stretch (>9g (Hughes et al., 
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2009)), in addition to compression of their receptive field by von Frey hair 
probe. Recent evidence of ‘serosal’ afferents associated with vascular vessels 
penetrating as far as the submucosa in the colon wall of guinea-pig suggests 
that this nomenclature may be misleading. As of yet detailed structure-function 
anatomical studies have not been performed in mouse (Hughes et al., 2009; 
Song et al., 2009). It should be noted that following dye fills of pelvic nerve 
rectal IGLE-like structures were only clearly distinguishable in guinea-pig but 
not mouse. This suggests that anatomical differences exist between these 
species, which may also extend to other spinal afferent sub-classes including 
serosal (Olsson et al., 2004; Spencer, Kerrin, Singer, et al., 2008). 
As well as being associated with arterial branching points of the mesentery, 
these endings continue into the colon wall and innervate arteries and second-
order arterioles of the submucosa (Song et al., 2009). As well as providing 
mechano-transduction sites intra- and extra-murally, these afferents may also 
branch collaterals to myenteric and submucosal enteric ganglia (Lynn et al., 
2003; Song et al., 2009; Takaki & Nakayama, 1989).  
Serosal and mesenteric afferents are chemosensitive to a wide variety of 
algogenic mediators released during tissue damage. These may act to depolarise 
afferents (such as ATP, 5-hydroxytryptamine, prostaglandins, histamine and 
those mediators released from mast cells) and/or have a sensitising role (such 
as adenosine, PGE2 and nerve growth factor) (Blackshaw & Gebhart, 2002; 
Grundy, 2004). Furthermore, they express receptors for inflammatory 
cytokines including IL-1β, IL-6 and TNF (Andratsch et al., 2009; Binshtok et al., 
2008; Y. Li et al., 2004). During experimental inflammation, the excitability of 
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mesenteric and serosal afferents in ex vivo preparations are significantly 
modulated (Hughes et al., 2009). This effect is mirrored in vivo by increased 
post-inflammatory visceromotor reflexes to colonic distension, which may be 
attributed to the sensitisation of afferent terminals by inflammatory mediators 
and also more long-term alterations in expression levels of relevant receptors 
(Gschossmann et al., 2004; Sengupta, Snider, Su, & Gebhart, 1999).  
Often experimental inflammation leads to the sensitisation of afferents that 
were previously insensitive to mechanical stimuli (Brierley, Carter, et al., 2005; 
Brierley, Jones, et al., 2005; Feng & Gebhart, 2011; Feng, La, Schwartz, et al., 
2012). These ‘silent’ or mechanically insensitive afferents constitute 
approximately 33% of thoracolumbar and 24% of lumbosacral spinal afferents 
(Feng & Gebhart, 2011). Following localised application of inflammatory soup 
to the receptive field, it is possible to sensitise about a quarter of silent 
afferents, identified in both the lumbar splanchnic nerve (LSN) and the pelvic 
nerve (PN), to mechanical stimuli (Feng & Gebhart, 2011). In some instances, 
silent afferents may remain mechanically insensitive but respond directly to 
chemical activation (for example, following application of bradykinin, α,β-
meATP and inflammatory soup) (Brierley, Jones, et al., 2005; Feng & Gebhart, 
2011). Long-term sensitisation of colonic afferents may also occur after 
intracolonic 2,4,6-trinitrobenzenesulfonic acid (TNBS) or zymosan treatment in 
mice and is associated with a persistent colorectal hypersensitivity to 
distension (Feng, La, Schwartz, et al., 2012; Feng, La, Tanaka, et al., 2012; 
Hughes et al., 2009). In both zymosan and TNBS models, there is a marked 
reduction in the proportions of mechanically insensitive (silent) afferents in 
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pelvic nerve, with a corresponding increase in the proportion of serosal 
afferents during the acute phases of inflammation (< 14 days after instillation) 
(Feng, La, Schwartz, et al., 2012; Feng, La, Tanaka, et al., 2012). This increase in 
the proportion of serosal afferents is also observed in the splanchnic nerve, 
although it is unclear whether this corresponds to the sensitisation of 
previously silent afferents or not (Hughes et al., 2009). The effects of chronic 
inflammation on afferent responses seem to vary dependent on the subtype and 
nerve under investigation. For example, the degree of afferent firing to von Frey 
probing in serosal units is reduced during the acute phase in TNBS models, but 
subsequently increases during the recovery period (~28 days) (Feng, La, 
Tanaka, et al., 2012; Hughes et al., 2009). However, responses of splanchnic 
muscular afferents to stretch are unaffected by TNBS-instillation (Hughes et al., 
2009). This suggests that within the splanchnic nerve there exists significant 
plasticity in the sensitivity of serosal, but possibly not muscular afferent 
subtypes to inflammatory insult. It also suggests that those silent afferents that 
gain mechanical sensitivity post-inflammation likely represent a population of 
serosal afferents.  
3.1.2.4 Viscerofugal enteric primary afferents 
 
Viscerofugal enteric primary afferents project from the enteric nervous system 
to prevertebral ganglia and form a reflexive feedback loop from the gut to the 
sympathetic chain (Miller & Szurszewski, 1997). This enables feedback on gut 
volume to sympathetic pathways innervating the gut and marks the 
prevertebral ganglia as sites of coordination mediating mechano-
gastrointestinal function (Szurszewski et al., 2002). Whilst these fibres are not 
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extrinsic in origin, a component of electrophysiological recordings from colonic 
nerves will be viscerofugal (Hibberd, Zagorodnyuk, Spencer, & Brookes, 2012). 
This will be a small proportion given that approximately 20 fibres per 5mm of 
colon project to prevertebral ganglia and 50% of these fibres terminate at the 
inferior mesenteric ganglia (IMG) (Luckensmeyer & Keast, 1995). Rectospinal 
neurones which originate in the myenteric plexus of the rectum and project to 
the spinal cord also represent a subset of viscerofugal fibres. These are thought 
to participate in the defecation reflex, though their physiological stimulus is not 
fully understood (Neuhuber et al., 1993).  
3.1.3 EXPERIMENTAL STIMULATION 
 
3.1.3.1 In vivo colorectal distension 
 
The activation of pelvic pain pathways during in vivo animal models is 
monitored using pseudoaffective and visceromotor reflexes (VMR) to colorectal 
distension (CRD) (Ness & Gebhart, 1990). Typical experimental protocols for 
VMR to CRD consist of either sets of phasic balloon inflations (e.g. 15, 30, 45, 60 
or 75mmHg) at 5-10 minute intervals or repetition of a single distending 
pressure (Shinoda et al., 2009). Responses characteristically decrease initially 
and then stabilise after 4-8 distensions, at this point the intervention (e.g. 
pharmacological agent) is applied (Kamp, Jones, Tillman, & Gebhart, 2003; 
Sivarao, Langdon, Bernard, & Lodge, 2007).   
Evidence from decerebration indicates that visceromotor reflexes do not 
require higher central processing in rat, but do involve both ascending and 
descending pathways of the brainstem (Ness & Gebhart, 1988). This response is 
mediated by lumbosacral pathways in normal mouse colon with the severing of 
154 
 
splanchnic pathways having little effect on reflex responses (Kyloh et al., 2011). 
However, following inflammation thoracolumbar pathways also contribute to 
the VMR during CRD (Traub, 2000). To target the thoracolumbar pathways 
more effectively, balloon distension of the more proximal colon (30-75mm from 
the anus in mouse) is required. This is reflected in the more distal innervation 
of the lumbosacral pathway (9-15mm from the anus) (Kyloh et al., 2011). 
Consistent with this, in man pain evoked by distension of the colon at 16cm 
above the anal sphincter is mediated by the thoracolumbar pathway (Ray & 
Neill, 1947). By contrast pain evoked by balloon distension within 16cm of the 
anal sphincter was unaffected by bilateral sympathectomy (T7-L3), implicating 
a pelvic pathway (Ray & Neill, 1947). As such, typical VMR models applied 
during CRD replicate activation of pelvic pathways but poorly model 
thoracolumbar activation and associated behavioural responses.  
Splanchnic pathways predominantly consist of serosal and mesenteric afferent 
fibres (>80%; (Brierley et al., 2004)), whilst pain evoked by rectal distension is 
likely mediated by a combination of rectal intraganglionic laminar endings 
(rIGLES) and rectal muscular-mucosal endings. These studies show that pain 
originating from the rectum is mediated by pelvic pathways, whilst more 
proximal pain is driven through splanchnic pathways. 
Rectal distension in man evokes different sensations dependent on pressure, at 
low pressures this manifests predominantly as urge, and at high pressures, the 
sensation of pain (Kwan, Mikula, Diamant, & Davis, 2002). Further to this, in 
studies of patients with spinal cord lesions, slow ramp distension activates 
pelvic pathways with urge preceding discomfort, however painful rapid rectal 
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distension is mainly detected by splanchnic pathways (Lembo et al., 1994). 
Indeed, relaxation of the anal sphincter in rat occurs at approximately 13mmHg 
distending pressure, which is superseded by visceromotor responses at a 
threshold of 22mmHg (Ness & Gebhart, 1988). During in vivo rodent recordings 
from S1 primary afferents and from jejunal mesenteric afferents, rapid phasic 
distension of the bowel evoked significantly greater nerve discharge than a slow 
ramp distension (Booth et al., 2008; Sengupta & Gebhart, 1994). This shows 
that both splanchnic and pelvic pathways in rodents are activated more 
significantly by phasic compared to ramp distensions and suggests that 
differences in pain sensation experienced in man are dependent on the 
temporal aspect of the stimuli and are not due to differences in stimulus 
activation thresholds between pelvic versus splanchnic pathways. The shape of 
response-profiles and fibre-type frequency remains consistent whether using 
balloon inflation or liquid fill of the colon, however overall pelvic nerve fibre 
firing rate is increased (~2x) when distending by fluid (Sengupta & Gebhart, 
1994; Su & Gebhart, 1998). This is also true of jejunal mesenteric afferents, 
where increases in responses following liquid fill of the intestine were ascribed 
to combined circumferential and longitudinal distortion of the bowel (Booth et 
al., 2008).  Comparable rodent data in vivo on afferent response profiles to 
distension does not exist for the splanchnic nerve, likely due to its 
inaccessibility during surgical procedures.  
These studies suggest that the sensations of urge and pain are mediated by 
functionally distinct pathways in man, through either the activation of the pelvic 
vs. splanchnic pathways or through the preferential activation of certain 
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afferent subtypes in a stimuli-dependent manner. This advocates that in rodent 
models, different pathways may be activated by differing distension protocols, 
or by the positioning of the distending balloon.   
3.1.3.2 Ex vivo colorectal preparations 
 
In addition to in vivo behavioural responses and afferent firing to noxious 
colorectal distension, colonic preparations have been developed ex vivo in a 
tissue bath setting. These include recordings of the pelvic and splanchnic 
pathways innervating the distal colon either in a tubular preparation or opened 
along the anti-mesenteric border in a flat-sheet preparation. Both techniques 
have facilitated the further study of mechanical activation of primary afferents 
innervating the colon, particularly to noxious stimulus. For example, 
intracellular recordings of colonic L6 DRG neurones in an ex vivo preparation 
combines the characterisation of high or low threshold pelvic mechanosensors 
with TRPV1 immunohistochemistry (Malin et al., 2009). Chemically-induced 
contraction of unparalysed mouse colon provides another mechanical stimulus, 
which may better model the partial or complete occlusion observed during 
diseases of the human bowel (Zagorodnyuk, Kyloh, Brookes, Nicholas, & 
Spencer, 2012).  
In order to study the properties of individual afferent terminals, flat-sheet 
preparations have been used to great effect. Using direct mechanical activation 
of afferent receptive fields with von Frey hair, stroke or circumferential stretch, 
the role of key molecular pathways in mechanotransduction have been 
investigated, including that of ASIC, TRPV4 and TRPA1 channels (Brierley et al., 
2009; Brierley et al., 2008; Page, Brierley, et al., 2005). Direct mechanical 
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probing of the receptive field with von Frey hair provides a highly robust and 
reproducible stimulus, enabling studies of mechanical sensitivity, including  
following application of TRPV4 ligands (ruthenium red and 5,6-
epoxyeicosatrienoic acid) or TRPA1 ligands (allyl-isothiocyanate and trans-
cinnamaldehyde) (Brierley et al., 2009; Brierley et al., 2008). This has also been 
investigated following acute application of inflammatory mediators such as 
bradykinin, and following chronic inflammation of the colon by TNBS (Brierley, 
Jones, et al., 2005; Hughes et al., 2009). The combination of functional data from 
afferent receptive fields, with nerve dye fills and immunohistochemistry has 
vastly improved the understanding of structure-function relationships of 
visceral afferent terminals (Lynn et al., 2003; Song et al., 2009).  
Importantly, efforts have been made to understand the correlation of responses 
to both von Frey hair probe and circumferential stretch of receptive fields in 
flat-sheet preparations with in vivo distension or physiology of the bowel. In 
splanchnic nerve recordings, serosal and mesenteric afferent subtypes, 
identified by their relatively low sensitivity to stretch and also receptive field 
locale, were shown in tubular preparations to have response thresholds to 
distension of 53 ± 4 mmHg and 56 ± 4 mmHg, respectively (Hughes et al., 2009). 
The corresponding mean circumferential stretch activation threshold for 
serosal afferents in a flat-sheet preparation was ~9g, with only a fraction 
recruited even at 11g of stretch. This differs significantly to the stretch 
activation threshold of muscular afferents in the same preparation, which 
respond at low threshold (< 3 g, with all recruited by 4g) (Hughes et al., 2009). 
This relationship between stretch and intraluminal pressure has also been 
158 
 
back-engineered using the formula, Pressure = 2πForce/(LD), where L is colon 
length and D is the circumference (Shinoda et al., 2009). In this study, 170mN 
ramped circumferential stretch was mathematically converted to ~45mmHg 
distension (Shinoda et al., 2009). However, it is clear that neither probe by von 
Frey hair nor circumferential stretch, are physiological in their representation 
of afferent activation in the colon. Given the different sensations evoked by 
varying mechanical stimuli in vivo (e.g. urge, discomfort, pain, etc.), it seems 
highly likely that experimental stimuli such as von Frey hair probe or 
circumferential stretch will preferentially activate certain visceral pathways 
over others. This may lead to stimulus-dependent bias in the relative 
importance of a molecular pathway. In fact, these models suggest that multiple 
mechanical stimuli and models of visceral pain should be employed in order to 
understand the role of a particular pathway in painful sensation. The critical 
translational link is to ensure that changes in afferent terminal sensitivity or 
firing rates translate to behavioural differences in pain sensation in man. 
3.1.4 VISCERAL MECHANOSENSITIVITY AND MECHANOTRANSDUCTION 
 
The use of experimental models has been invaluable in our ability to 
understand the molecular entities responsible for mechanotransduction at the 
afferent terminal. This has implicated a number of mechanically-gated ion 
channels in visceral mechanosensation, as described in the introduction, 
including TRPV4, TRPA1 and ASICs. In addition to these, receptors that are 
mechanically-sensitive yet do not directly gate ions may trigger intracellular 
signalling pathways to modulate afferent terminal mechanosensitivity, such as 
G-protein coupled receptors angiotensin II type 1 or bradykinin B2 receptors 
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(Chachisvilis, Zhang, & Frangos, 2006). Also, the overall neuronal sensitivity of 
the afferent terminal which is significantly regulated by inflammation will 
contribute to mechanosensitivity. How mechanosensitive receptors influence 
the function of voltage-gated ion channels and neuronal sensitivity is detailed 
below, with a particular focus on sodium channels and the modulatory role of 
NaV1.9.  
3.1.4.1 Indirect regulation of mechanosensitivity 
 
In addition to the direct gating of mechanical stimuli, the sensitivity of afferent 
endings to mechanosensation can be modulated by ion channels that are non-
mechanically-gated, such as voltage-gated K+ and Na+ ion channels and P2X 
receptors. The indirect regulation of these ion channels by second-messenger 
pathways downstream of inflammatory receptors, act to regulate afferent 
baseline activity and excitability to mechanical stimuli. For example, the release 
of ATP following tissue damage activates P2X receptors and other 
purinoceptors, which can lead to increases or decreases in intestinal afferent 
mechanosensory function (Kirkup, Booth, Chessell, Humphrey, & Grundy, 1999; 
Rong, Keating, Sun, Dong, & Grundy, 2009; Wynn, Rong, Xiang, & Burnstock, 
2003). Voltage-gated K+ ion channels contribute to the regulation of activation 
thresholds, firing rates and the sustained discharge of action potentials (Takeda 
et al., 2011). Two currents have been shown to play important roles in these 
functions; transient IA type currents, likely mediated by KV 1.4 or 4.2 in 
nociceptive DRG neurones, and sustained delayed rectifier (IK) currents. The 
dominant channel subtype responsible for the IK current in small DRG neurones 
is still to be determined but likely candidates are KV 1.1, 1.2, 1.5, 1.6, 2.1, 2.2 and 
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3.1 (Choe, 2002). In a number of models of chronic visceral inflammation, 
including peptic ulcer, ileitis and cystitis, IA currents are significantly reduced 
(Dang, Bielefeldt, & Gebhart, 2004; Stewart, Beyak, & Vanner, 2003). Further to 
this, IK currents are also decreased following certain inflammatory insults, 
including TNBS-induced intestinal colitis in guinea-pig (Stewart et al., 2003).  
As mentioned in Chapter 1, multiple voltage-gated Na+ channels contribute to 
action potential electrogenesis in sensory neurones. In the viscera, total 
tetrodotoxin-resistant (TTX-R) Na+ current is increased and the activation curve 
shifted in a hyperpolarising direction following gastric ulceration (Bielefeldt, 
Ozaki, & Gebhart, 2002). TNBS-induced GI inflammation evoked similar changes 
to TTX-R Na+ current in DRG neurones, with no effect on tetrodotoxin-sensitive 
(TTX-S) Na+ currents (Beyak et al., 2004; Stewart et al., 2003). The dominant 
TTX-R sodium channel current is mediated by NaV1.8 and contributes to 
nociceptor action potential properties (Djouhri et al., 2003). The role of NaV1.9 
in inflammation-induced changes in TTX-R current is less defined and is 
discussed in more detail below. The contribution of NaV1.8 current up-
regulation to afferent hypersensitivity during inflammation is demonstrated by 
NaV1.8 null mice exhibiting normal nociceptive behaviour to noxious visceral 
stimuli but reduced behaviours to sensitising stimuli (Laird, Souslova, Wood, & 
Cervero, 2002). In addition to the effects seen in chronic inflammatory in vivo 
models, acute application of inflammatory mediators, such as PGE2, ATP and 
serotonin to dissociated somatic DRG neurones can increase TTX-R Na+ 
currents (Baker, 2005; Cardenas et al., 1999). This is also true for colon-
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projecting neurones, where PGE2 evoked a robust increase in TTX-R Na+ 
currents (Gold et al., 2002). 
3.1.4.2 Mechanical hypersensitivity induced by artificial inflammatory 
soup 
 
As such, during inflammation, afferent hypersensitivity is significantly regulated 
by the coordinated reduction of both IA and IK currents and increased TTX-R Na+ 
currents. These effects are dependent on both post-translational and 
transcriptional events downstream of inflammatory mediator receptor 
activation. Multiple mediators released during tissue damage and inflammation 
act in synergy to hypersensitise afferent endings and, as such, single mediators 
in isolation are unlikely to recapitulate an adequate stimulus in animal models 
(Su & Gebhart, 1998). Artificial inflammatory soups (IS), typically consisting of 
mediators such as bradykinin, ATP, PGE2, histamine and 5-HT, are capable of 
inducing robust afferent hypersensitivity to mechanical stimuli and direct 
stimulation of afferent fibres. In the viscera, inflammatory soups have been 
used to investigate how inflammation may influence afferent function and to 
characterise ‘silent’ afferents. For example, the intracolonic instillation of IS 
increases resting activity and the magnitude of afferent firing to CRD in 
approximately 60% of fibres (Su & Gebhart, 1998). IS also reduced activation 
thresholds for a subset of high-threshold fibres (Su & Gebhart, 1998) and 
consistent with this effect, IS has also been used to sensitise ‘silent’ 
mechanically insensitive afferents, with 23% of splanchnic and 71% of pelvic 
afferents acquiring mechanosensitivity after application (Feng & Gebhart, 
2011). Furthermore, inflammatory soups have been used to correlate in vivo 
hypersensitivity to CRD following TNBS treatment with in vitro afferent 
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hypersensitivity studies (Kiyatkin, Feng, Schwartz, & Gebhart, 2013; Tanaka et 
al., 2011).    
3.1.4.3 Modulation of mechanical sensitivity by human tissue 
supernatants 
 
Post-inflammatory hypersensitivity is a hallmark of functional bowel disorders, 
such as irritable bowel syndrome (IBS) (Knowles & Aziz, 2009). A subset of 
patients with IBS show significant visceral hypersensitivity to colorectal 
distension (Lembo et al., 1994; Ritchie, 1973), which is likely the result of 
visceral afferent modulation by low grade inflammation, release of mast cell 
mediators or stress hormones. Artificial inflammatory soups therefore provide 
a useful experimental methodology to investigate visceral hypersensitivity in 
animal models. In conjunction with this, supernatants derived from inflamed 
and normal human tissues have also provided an opportunity to modulate 
afferent function in a way more analogous to in vivo pathophysiology. Indeed, 
intracolonic infusion of faecal supernatants from diarrhoea-predominant IBS 
patients into the colorectum of mice can induce colonic hypersensitivity 
(Annaházi et al., 2009). Furthermore, supernatants derived from colonic 
mucosal biopsies of IBS patients, but not healthy controls, are capable of 
evoking nerve discharge from rat mesenteric afferents (Barbara et al., 2007) 
and causing visceral hyperalgesia in mice (Cenac et al., 2007). Multiple 
inflammatory mediators have been implicated in the pathogenesis of visceral 
hypersensitivity associated with IBS, including those released by mast cells, 
such as histamine, tryptase and trypsin (Annaházi et al., 2009; Barbara et al., 
2007; Cenac et al., 2007).   
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Interestingly there appears to be some contradiction in the literature regarding 
visceral hypersensitivity to distension in inflammatory bowel disease (IBD). For 
example, remissive and quiescent ulcerative colitis (UC) and Crohn’s disease 
(CD) patients are either normosensitive or hyposensitive to colorectal distension 
(Bernstein et al., 1996; Chang et al., 2000). This is mirrored by UC faecal 
supernatants evoking colonic hyposensitivity in mice, an effect purported to be 
mediated by the interplay of proteinase-activated receptor (PAR)-2 and PAR-4 
signalling pathways (Annaházi et al., 2009). By contrast, IBS-like symptoms, 
including visceral hypersensitivity, can occur in IBD patients before disease 
onset, during active disease and during periods of disease quiescence (Grover et 
al., 2009; Isgar et al., 1983; Minderhoud et al., 2004). Whilst more evidence is 
required to determine the causality of changes in visceral sensitivity in IBD, the 
use of tissue supernatants enables this investigation to occur without bias to the 
constituents of an artificial inflammatory soup. 
3.1.5 UP-REGULATION OF NAV1.9 CURRENT BY INFLAMMATORY MEDIATORS 
 
NaV1.9 contributes a slowly inactivating persistent sodium current to the total 
TTX-R current observed in DRG neurones. The NaV1.9 current is activated at 
voltages close to the resting membrane potential and is thought to regulate 
nerve terminal excitability (Baker et al., 2003). The NaV1.9 sodium current is 
enhanced by inflammatory mediators such as ATP, PGE2, and TNF-α, acting 
through G-protein coupled pathways, suggesting that NaV1.9 may also play an 
important role in the activation of sensory nerves by inflammatory mediators 
(Baker, 2005; X. Chen et al., 2011; Maingret et al., 2008; Rush & Waxman, 2004). 
This hypothesis is supported for somatic pain by behavioural studies 
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demonstrating reduced hypersensitivity to inflammatory stimuli in rodents 
where NaV1.9 has been deleted or knocked down (Amaya et al., 2006; Lolignier 
et al., 2011; Priest et al., 2005).  
Whilst the presence of NaV1.9 has been reported in visceral afferents (Beyak et 
al., 2004; Hillsley et al., 2006), evidence for a role of NaV1.9 in visceral pain 
processing is controversial, with behavioural studies in NaV1.9 knock-out mice 
reporting either reduced or enhanced pain behaviours to noxious stimuli (Leo 
et al., 2010; Martinez & Melgar, 2008; Ritter et al., 2009). The contribution of 
NaV1.9 to the sensitivity of visceral afferent endings to noxious stimuli thus 
remains unclear. Given the lack of information of afferent responses to differing 
mechanical paradigms from the splanchnic nerve in mouse, there is a necessity 
to define the mechanosensitivity of splanchnic afferents and to understand the 
role of NaV1.9 in these subtypes.  
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3.2 AIMS 
 
1. To investigate the effects of NaV1.9 gene deletion in mouse on the 
response of visceral afferents to mechanical distension of the intact 
colon 
2. To characterise mechanosensory function in afferent subtypes of the 
colonic splanchnic pathway in NaV1.9 -/- mice 
3. To investigate the effects of inflammatory soup on direct excitation and 
mechanical hypersensitivity of afferent subtypes in NaV1.9 -/- mice  
4. To investigate the effect of NaV1.9 deletion on afferent excitation and 
mechanical hypersensitivity to human-derived inflammatory bowel 
disease supernatants  
166 
 
3.3 METHODS 
 
All experimental studies were performed in accordance with the UK Animal 
(Scientific Procedures) Act 1986. Human tissue was collected and used with 
approval of the East London and The City HA Local Research Ethics Committee 
(NREC 10/H0703/71). 
3.3.1 NAV1.9 KNOCK-OUT MICE 
 
NaV1.9 -/- mice were re-derived from NaV1.9 +/- breeding pairs and originally 
generated by homologous recombination on a C57/BL6 background as 
described previously (Ostman et al., 2008). The NaV1.9 knock-out was 
generated by replacing exons 4 and 5 of the SCN11A gene with a neomycin 
resistance cassette at intronic restriction sites. This removed the domain I, S4 
voltage sensor from the translated NaV1.9 protein. Ostman et al. confirm the 
subsequent knock-out allele produced a mutant mRNA lacking exons 4 and 5. 
Specifically, through cDNA sequencing of the transcript they show that the 
splicing machinery skips the neomycin selection cassette and splices exon 3 to 
exon 6. During translation this leads to a frameshift mutation which results in 
the introduction of stop codons in exon 6 (Ostman et al., 2008). NaV1.9 KO mice 
were healthy and fertile (Ostman et al., 2008). An alternate NaV1.9 KO strain 
(B6.129P2-Scn11atm1Dgen/J), commercially available from The Jackson 
Laboratory mouse repository, does not possess significant differences in 
lifespan, fertility, blood chemistry, length or weight (Priest et al., 2005). 
Furthermore necropsy and histology did not differ between genotypes. NaV1.9 -
/- mice and NaV1.9 +/+ littermate controls were initially derived from a 
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heterozygous mutant (+/-) x heterozygous mutant (+/-) breeding pair strategy. 
Mice generated from these pairings were primarily used during pilot studies, 
early experiments refining protocols and in the establishment of subsequent 
pairings. Approximately four wild-type (+/+) x wild-type (+/+) and four knock-
out (-/-) x knock-out (-/-) breeding pairs were established and maintained 
during subsequent studies, typically producing litters of 4-9 pups every 6 
weeks. The divergence of genetic lines (genetic drift) and likelihood of 
development of inbred sub-strains was limited by ensuring mutants were 
backcrossed onto the parental inbred strain every 10 generations (in this case 
standard C57BL/6 strain) (J. G. Fox, 2007). All mice used in these studies were 
within 10 generations from any heterozygous mutant (+/-) x heterozygous 
mutant (+/-) pairing. Mice were maintained in a 12 hour light/dark cycle and 
had ad libitum access to food and water. Pinna biopsies were obtained at 
weaning (21 days) for use in genotyping. 
3.3.1.1 Genotyping 
 
Pinna biopsies were lysed in 500μl lysis buffer (0.1M Tris-HCl pH 8.5, 5mM 
ethylenediaminetetraacetic acid (EDTA), 0.2% sodium dodecyl sulphate (SDS), 
20mM NaCl, 50μg proteinase K) for 6 hours at 50°C. Non-digested organic 
material was pelleted by brief centrifugation and 500μl of isopropanol added to 
the supernatant. The supernatant was subsequently centrifuged at 4°C for 15 
minutes followed by addition of 500μl 70% ethanol. After a final centrifugation 
at 4°C for 10 minutes, the supernatant was removed and the pellet allowed to 
dry overnight. Re-suspension of the extracted genomic DNA in 40μl sterile 
water enabled quantification of DNA concentration by Nanodrop 
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spectrophotometer (Thermo Scientific, UK). Approximately 50-70ng of DNA 
was added to two 10μl PCR reactions (HotStar TAQ PCR Master Mix, Qiagen). A 
common 5’ primer was used for both reactions (5’-
ATGTGGCACTGGGCTTGAACTC - 3’), whilst the 3’ primer was either specific for 
the deleted exons 4 and 5 (wild-type: 5’ – AACAGTCTTACGCTGTTCCGATG - 3’) 
or the inserted neomycin gene (mutant: 5’- CTCGTCGTGACCCATGGCGAT - 3’). 
The reaction used was 35 cycles of 95°C for 1 minute, 57°C for 1 minute and 
72°C or 2 minutes, with a preceding 15 minute hot-start at 95°C. PCR reactions 
were subsequently separated by gel electrophoresis on a 1% agarose gel 
containing 0.5% ethidium bromide or RedSafe nucleic acid stain (Chembio, UK) 
at 100V for 25 minutes. Under UV illumination, a band at 300 base pairs (bp) 
was visible for the wild-type gene and at 600 bp for the mutated gene.  
3.3.2 IN VITRO MOUSE COLONIC SPLANCHNIC AFFERENT PREPARATIONS  
 
Adult NaV1.9 +/+ or NaV1.9 -/- mice of either sex were euthanised by rising 
concentration of CO2 and the distal colon with associated lumbar splanchnic 
nerves removed. Specifically the distal colon from the ascending/descending 
inflexion point to anus, inclusive of rectum, was removed. Simultaneously, the 
skeletal muscle and neurovascular bundles (including the aorta) were cut 
ventrally from the spinal column whilst retaining the inferior mesenteric artery 
and lumbar splanchnic innervation of the colon. The lumbar colonic nerve was 
then traced into the aortic neurovascular bundle at the point of the iliac 
bifurcation, and the inferior and superior mesenteric ganglia identified (see 
Figure 17C). Suction electrode recordings were made from one of the two 
intermesenteric nerves between these two ganglia, rostral to the inferior 
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mesenteric ganglion (see Figure 17D). For whole-nerve experiments, tissues 
were cannulated, luminally perfused (100µl/min) and serosally superfused 
(7ml/min; 32-34oC) with carbogenated Kreb’s buffer (in mM: 124 NaCl, 4.8 KCl, 
1.3 NaH2PO4, 2.5 CaCl2, 1.2 MgSO4.7H2O, 11.1 glucose, and 25 NaHCO3) 
supplemented with nifedipine (10 µM) and atropine (10 µM) to block smooth 
muscle contraction, and indomethacin (3 µM) to reduce on-going inflammation 
(see Figure 17A). For teased-fibre recordings, tissues were treated similarly, 
however the colon was opened along the anti-mesenteric border and pinned 
flat mucosal side up (see Figure 17B), as described previously (Brierley et al., 
2004; Brierley et al., 2008). Extraneous skeletal muscle and connective tissues 
were removed from the neurovascular bundle allowing unrestricted access to 
the intermesenteric nerve. Using fine forceps, this bundle was teased apart into 
5-8 fibres for electrophysiological teased-fibre recordings. 
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Figure 17. Schematics of the two electrophysiological recording techniques used to 
investigate visceral afferent function. A Whole-nerve multi-unit recording of lumbar 
splanchnic nerve activity. The colon was cannulated and perfused in an oral to 
aboral direction. The lumbar splanchnic nerve was dissected free and whole-nerve 
suction electrode recordings made of nerve activity. B Teased-fibre recordings were 
performed by opening the colon along the anti-mesenteric border and pinning the 
colon flat. The lumbar splanchnic nerve was teased apart under microscopic 
dissection into 5-8 teased fibres. These were individually isolated in the suction 
electrode and single receptive fields characterised by von Frey probe, 
circumferential stretch or light stroke. C Photo of the dissection pinned in the 
recording chamber. Along the bottom the colon and mesentery can be seen, with 
the inferior mesenteric artery and lumbar splanchnic nerve (LSN) entering the aortic 
neurovascular bundle at the iliac bifurcation. Typically six pins were used to secure 
the bundle ventral side up during blunt dissection of the intermesenteric nerve. D 
Close-up photo of inferior and superior mesenteric ganglia during 
electrophysiological recordings.  
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3.3.3 ELECTROPHYSIOLOGICAL RECORDINGS AND CHARACTERISATION OF 
COLONIC SPLANCHNIC AFFERENT PROPERTIES 
 
Multi-unit activities were recorded from whole lumbar splanchnic nerves 
(rostral to the inferior mesenteric ganglia) or single-fibre activities were 
recorded from teased lumbar splanchnic nerves using a borosilicate glass 
suction electrode. Signals were amplified, band pass filtered (gain 5K; 100-1300 
Hz; Neurolog, Digitimer Ltd, UK) and digitally filtered for 50Hz noise (Humbug, 
Quest Scientific, Canada). Raw traces were digitised at 20 kHz (micro1401; 
Cambridge Electronic Design, UK) and action potential firing counts were 
determined using a threshold of twice the background noise (typically 100µV). 
All signals were displayed on a PC using Spike 2 software. In multi-unit tubular 
preparations, the colon was tied, using fine thread, to two cannulas, and 
perfused with Kreb’s buffer at 0.1ml/min (Figure 17A). The pressure was set to 
baseline and an end pressure of ~2mmHg applied before initiating the 
experimental protocols. Preparations were left for approximately 45 minutes or 
until stable baseline was observed. In teased-fibre recordings from flat sheet 
preparations (Figure 17B), individual teased nerve bundles were brought into 
the suction electrode and nerve activity assessed. If none, or almost none, 
ectopic nerve discharge was observed, then a mechanical search strategy was 
employed to identify receptive fields. Specifically, gentle application of a cotton 
bud was systematically used to stimulate the mesentery and mucosal surface of 
the colon wall. Where action potentials were elicited by mechanical probe then  
distinct receptive fields were identified and characterised according to 
previously published classifications, detailed below (Brierley et al., 2004; 
Harrington et al., 2011; Hughes et al., 2009). Ideal recordings possessed no 
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more than a single mechanically sensitive action potential waveform, however 
where ectopic background activity was present, minimal (<3) action potential 
waveforms should be observed and these should be easily distinguishable from 
the waveform of interest. This receptive field was subsequently characterised 
by graded stimulus-response to punctate von Frey hair (vFh) probing (0.07g, 
0.16g, 0.4g, 1g and 2g; each applied 3 times for a period of 3s), circumferential 
stretch (0g, 5g & 10g; each weight applied for 1 min, with an interval of 1 min 
between applications) and mucosal stroking with light vFh (0.16g; applied 10 
times). A cantilever system was used to apply stretch via a thread attached with 
a purpose-made claw to the tissue adjacent to the receptive field. Addition of 
weights to the end of the cantilever system initiated colonic stretch. Four 
distinct classes of afferent fibre were identified based on these responses: 
muscular (those responding to low intensity circumferential stretch [≤5g], but 
not fine mucosal stroking); mucosal (those responding to light vFh stroking), 
mesenteric (those responding to focal compression of the mesentery) and 
serosal (those responding to focal compression of the colon wall, but not low 
intensity stroke or low intensity circular stretch. Recent literature suggests that 
‘serosal’ and ‘mesenteric’ afferent classes have their transduction sites on, or 
close to, blood vessels, including submucosal vessels, in guinea-pig, and that 
classification as ‘vascular’ may be more appropriate (Brookes et al., 2013; 
Hughes et al., 2009; Song et al., 2009). In the absence of detailed anatomical 
classification in mouse and to provide continuity with existing studies, the 
current nomenclature of serosal and mesenteric afferent endings will be used 
for the purposes of this study. In addition, conduction velocity was calculated 
for serosal and mesenteric units by dividing evoked action potential latency 
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elicited following electrical stimulation (0.5Hz, 15V, 1ms) of the receptive field 
with concentric stimulating electrodes, by the distance from the recording 
electrode to receptive field. This also confirmed the single fibre nature of the 
recording, correlating the receptive field to the evoked action potential. 
Typically, identified receptive fields in the mesentery and colonic wall were 
highly localised (<1mm2), however in some instances, mesenteric or non-
stretch responsive colon wall units could be stimulated in multiple (2-3) 
distinct and discontinuous receptive fields over an area of ~15mm2. Where 
such multiple areas of stimulation for a single action potential waveform were 
identified then the characterisation and subsequent chemical challenge was all 
performed on one such receptive field area.  
3.3.4 GENERATION OF HUMAN TISSUE SUPERNATANTS 
 
Resected human colon was obtained after full written consent from patients 
undergoing elective surgery at Barts Health NHS Trust, London after approval 
by the local Research Ethics Committee (NREC 10/H0703/71). Macroscopically 
normal colon (> 10cm from tumour) was obtained from patients undergoing 
colectomy as part of their normal surgical treatment for bowel cancer, whilst 
chronically inflamed colon or intestine was obtained from patients undergoing 
operations as part of their standard surgical treatment for Crohn’s disease or 
ulcerative colitis (see Table 6). Tissue samples were subsequently incubated in 
fresh carbogenated Kreb’s buffer at 37 oC for 25 minutes at a fixed volume of 
2.5ml/g of tissue. Following incubation, the tissue was removed and the buffer 
centrifuged at 2000g for 10 minutes. The remaining supernatant was aliquoted 
and stored at -80oC until use.  
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# Disease Operation Age Sex Cytokine analysis Whole nerve Teased fibre 
1 Cancer Laparoscopic anterior resection 50 F Y Y  
2 Cancer Right hemicolectomy 76 M Y Y  
3 Cancer Subtotal colectomy 57 M Y Y  
  Mean age / M:F ratio 61 2:1    
4 Crohn’s Disease Right hemicolectomy 21 F Y Y Y 
5 Crohn’s Disease Redo right hemicolectomy 30 F Y Y Y 
6 Crohn’s Disease Right hemicolectomy 21 M Y Y  
7 Crohn’s Disease Completion colectomy 25 M  Y  
8 Crohn’s Disease Subtotal colectomy 30 M   Y 
9 Crohn’s Disease Small bowel resection 24 F   Y 
10 Crohn’s Disease Small bowel resection 42 M   Y 
11 Crohn’s Disease Colectomy & end Ileostomy 28 M   Y 
12 Crohn’s Disease Extended right hemicolectomy 16 M   Y 
13 Crohn’s Disease Subtotal colectomy 64 M   Y 
  Mean age / M:F ratio 30 2.3:1    
14 Ulcerative colitis Subtotal colectomy 21 M Y Y  
15 Ulcerative colitis Restorative proctocolectomy 20 M Y Y  
16 Ulcerative colitis Subtotal colectomy 30 M Y Y  
17 Ulcerative colitis Restorative proctocolectomy 18 M Y Y  
  Mean age / M:F ratio 22 4:0    
Table 6. Patient details of human tissue used in the present studies. Supernatants generated from these tissues may have been used for 
inflammatory cytokine quantification (Cytokine analysis), 20mL bath superfusion of whole-nerve recordings from the lumbar splanchnic nerve 
(whole-nerve) or discrete ring application to characterised receptive fields in a flat-sheet preparation and single-fibre recording from the 
lumbar splanchnic nerve (teased-fibre).  
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3.3.5 INFLAMMATORY CYTOKINE QUANTIFICATION 
 
Quantitative analysis of protein cytokine levels was performed on supernatant 
samples using capture sandwich immunoassay and magnetic microsphere 
methodology. Samples were prepared as per manufacturer’s instructions 
(Invitrogen, UK) and analysed using the Luminex MAGPIX detection system 
(Luminex, TX, USA) for IL-1β, IL-6, GM-CSF, TNF-α and IL-8. 
3.3.6 PROTOCOLS FOR TUBULAR PREPARATION OF MOUSE COLON  
 
For ramp distensions, luminal outflow cannula was blocked and a subsequent 
increase in pressure observed, until the desired maximum pressure was 
reached (e.g. 80 or 145mmHg). It took approximately 4-5 minutes to reach 
145mmHg. In some instances, ramp distensions occurred following a return to 
baseline activity after drug application. Sets of six, rapid phasic ramp 
distensions (0-80mmHg, 60sec at 9 minute intervals) were implemented in 
separate experiments. In multi-unit experiments, supernatants were applied 
after a stabilising period by bath superfusion of a 20ml volume. Where repeat 
concentrations of drugs were given, a minimum 60 minute interval was 
maintained. Supernatants derived from Crohn’s disease (CD), ulcerative colitis 
(UC) and control tissues were applied by 20ml bath superfusion in separate 
colonic preparations. In separate experiments, mechanical sensitisation of 
responses to noxious ramp distensions was investigated by intraluminal 
perfusion of an inflammatory soup (consisting of 1 µM bradykinin, 1 mM ATP, 
10 µM histamine, 10 µM  prostaglandin E2 and 10 µM 5HT) 20 minutes prior to, 
and during, subsequent 0-80mmHg ramp distension.  
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3.3.7 PROTOCOLS FOR FLAT-SHEET PREPARATION MOUSE COLON 
 
In single-fibre experiments, receptive fields were identified by systematic 
probing of the colon wall and mesentery. Once identified, receptive fields were 
characterised as described above by location and response to mucosal stroking 
and circumferential stretch. Only muscular, mesenteric and serosal receptive 
fields were investigated in this study. In separate experiments, mesenteric and 
serosal units were probed by 2g von Frey hair, followed by placement of a small 
brass ring over the receptive field. The ring contents were aspirated and either 
an inflammatory soup (consisting of 1 µM bradykinin, 1 mM ATP, 10 µM 
histamine, 10 µM  prostaglandin E2 and 10 µM 5HT; 2 minutes) or Crohn’s 
Disease inflammatory supernatant (see above; 5 minutes) applied. After which 
the ring was once again aspirated, removed and the receptive field re-probed by 
2g von Frey hair. 
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Figure 18. Diagram of protocols used during whole-nerve and teased fibre 
recordings. Whole-nerve recordings were made using protocols A, B, C and D. A Six 
rapid phasic distensions to 80mmHg for 60 sec at 9 minute intervals. B Slow ramp 
distension to 80mmHg followed by superfusion of 20ml IBD supernatant. C Pre-
treatment with intraluminal perfusion of inflammatory soup (20mins) and during 
ramp distension to 80mmHg. D Application of 20ml IBD supernatant followed by 
slow ramp distension to 145mmHg. E Protocol for characterising receptive fields 
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during teased fibre recordings; 3x2g probes at 3 sec intervals, 10x70mg strokes, 
stretch for 60 sec (5g and 10g), stimulus response curve (3x 0.07g, 0.16g, 0.4g, 1g, 
2g probes are 60 sec intervals), electrical stimulation (0.5Hz, 15V, 1ms). F Once 
characterised, 3x2g probes were applied before and after application of either 
inflammatory soup (IS) or Crohn’s Disease (CD) supernatant for 2 minutes or 5 
minutes, respectively, by ring application over the receptive field. 
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3.3.8 DATA ANALYSIS 
 
In multi-unit experiments, peak changes and time profiles of 
electrophysiological nerve activity were determined by subtracting baseline 
firing (3 minutes before distension) from increases in nerve activity following 
distension. Changes in nerve activity were compared between NaV1.9 +/+ and 
NaV1.9 -/- animals using Student’s t-test or two-way ANOVA with Bonferroni's 
post-hoc test, as appropriate. During phasic distensions, peak firing was 
determined as the maximal firing rate observed during the distension, typically 
within 10 seconds of pressure increasing. Plateau firing was determined as the 
firing rate at 45 seconds after pressure increasing. For post-hoc single unit 
analysis of 0-145mmHg ramp distensions, multi-unit splanchnic nerve 
recordings contained action potentials that were discernibly different in 
amplitude and waveform to enable accurate discrimination from each other 
using the waveform analysis function of CED Spike 2.0 software, based on 
previous methodologies (Hillsley, Kirkup, & Grundy, 1998). Individual 
waveform templates were derived using those spikes with amplitude greater 
than the set threshold (~ 100μV). The action potential waveforms were 
corrected for DC offset, averaged and assigned to waveform templates. Spikes 
were either matched to a waveform template or left unclassified depending on 
strict sorting criteria; specifically amplitude error was set to 3% and at least 
95% of points had to fall within the template. The pressure activation 
thresholds and average firing frequency of individually identified units were 
determined). With these strict criteria, between 5-16 units were identified per 
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recording, which were subsequently confirmed manually by eye to ensure the 
quality of spike discrimination.  
Response profiles of individual units were used to classify the unit as either 
low-threshold (LT), wide dynamic range (WDR) or high-threshold (HT). To 
enable objective classification, a comparable methodology to that used by Booth 
et al. was employed (Booth et al., 2008). The relative firing at low and high 
distending pressures was determined by expressing the response at 30mmHg 
as a percentage of the response at 80mmHg. Specifically, a linear increase in 
afferent discharge gives a percentage of 37.5%. A response profile with a value 
above this represents greater firing in the low distending range compared to 
higher pressures, and values below this respond at high distending pressures. 
As such response profiles with a ratio of < 15% were considered HT units and 
those with a ratio of > 55% were considered LT units. Afferents between these 
two values were considered to have a more linear increase in afferent firing and 
classified as WDR units (Examples can be seen in Figure 2).  
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Figure 19. Example of post-hoc single unit analysis from multi-unit recording made 
during ramp distention. A Pressure trace of ramp distension to 145mmHg. Single 
unit discrimination based on action potential amplitude and duration was used to 
create waveform templates. All spikes above threshold matching this template 
were considered to represent the same single unit. Example firing rates from three 
units with overlays of 5 action potentials are shown in B, C and D. Specifically, B is 
an example of a low-threshold unit, C is an example of wide dynamic range unit and 
D is an example of a high-threshold unit. Action potential template matching was 
very robust and reliable.  
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In teased-fibre recordings from flat sheet experiments, average spikes/s per 
stimulus were compared between genotype or before and after ring application 
of drugs/supernatants. All cytokine quantification data were analysed non-
parametrically. If detectable levels of cytokines were present in control 
supernatants, Mann-Whitney U-tests were performed, or else Wilcoxon Signed 
Rank tests comparing to a theoretical median of 0.0 were performed. Statistical 
significance was set at p < 0.05. Data have been displayed as mean ± SEM; N = 
number of animals and n = number of observations. 
3.3.9 DRUGS 
 
Stock concentrations of ATP (300mM; water), PGE2 (1mM; ethanol), bradykinin 
(10mM; water), histamine (100mM; water), 5HT (10mM; water), atropine 
(10mM; ethanol), indomethacin (3mM; DMSO) and nifedipine (10mM; DMSO) 
were all purchased from Sigma Aldrich (UK) and prepared as described. 
Inflammatory soup (IS) was prepared in advance and aliquots frozen until use. 
All compounds were diluted to working concentrations in buffer on the day of 
experimentation. 
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3.4 RESULTS 
3.4.1 DELETION OF NAV1.9 INCREASES MECHANOSENSORY ACTIVATION 
THRESHOLDS OF AFFERENT FIBRES AND REDUCES MAINTENANCE OF REPEATED 
RESPONSES 
 
How NaV1.9 influences mechanosensation was first investigated using whole-
nerve recordings of distension responses in a cannulated tubular preparation of 
the distal colon, and subsequently using single-fibre recording techniques in a 
flat sheet preparation. Phasic distension of the bowel to 80mmHg intraluminal 
pressure led to a robust initial increase in afferent activity, subsequently 
reaching a plateau for the remainder of the 1 minute distension (Figure 20C). 
Second and third repeat distensions (at 9 minute intervals) evoked reduced 
peak responses, until a stabilised peak response was reached by the fourth to 
sixth distension. In NaV1.9 -/- mice, peak responses to first distension were 
similar to control animals (p = 0.17, Figure 20C). However, afferent responses to 
subsequent repeat distension in NaV1.9 -/- mice showed greater tachyphylaxis 
with significant reductions observed by the third to sixth distensions (p < 0.001, 
Figure 20E). These deficits appear more pronounced when examining the 
plateau phase of the distension, with reductions in firing rates seen during the 
first distension and significant differences seen in all subsequent distensions 
between genotypes (Figure 20E). 
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Figure 20. Colonic splanchnic nerve responses to repeat phasic distension. Example 
rate histogram of colonic splanchnic nerve response to repeat phasic distension (0-
80mmHg; 60s; 10min intervals) in a NaV1.9 +/+ (A) and NaV1.9 -/- mice (B). Average 
response profiles to the 1st (C) and 6th (D) phasic distension in NaV1.9 +/+ and 
NaV1.9 -/- mice (2-way ANOVA). E Peak change in firing rate during sequential 
phasic distensions (*p < 0.05; **p < 0.01; ***p < 0.001, unpaired t-test). F Change in 
firing rate during plateau phase (time = 45s) of sequential phasic distensions (**p < 
0.01; ***p < 0.001, unpaired t-test). 
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These findings suggested a particular role for NaV1.9 in responses to persistent 
stimuli. To investigate this role further a slow ramp distension paradigm was 
used. Initial ramp distensions up to 80mmHg intraluminal pressure evoked 
maintained responses with an almost linear correlate between afferent activity 
and pressure, reaching a maximum firing rate of 13.3 ± 3.7 spikes/s (N = 6) in 
control animals. NaV1.9 -/- mice, by contrast, elicited virtually no activity during 
comparable ramp distensions (max. 1.4 ± 0.6 spikes/s, N = 6, p < 0.0001, Figure 
21C). Mechanical sensitisation of firing evoked by noxious ramp distension was 
investigated by intraluminal perfusion of inflammatory soup (IS). In NaV1.9 +/+ 
mice, perfusion of IS led to direct activation of basal afferent firing rates, which 
was not observed in NaV1.9 -/- mice (3.8 ± 0.6 spikes/s, N = 5 vs. 0.0 ± 0.4 
spikes/s, N = 6; p < 0.001, unpaired t-test). Responses to ramp distension 
during IS perfusion were potentiated in NaV1.9 +/+ mice (max. 19.4 ± 2.7 
spikes/s, N = 6), an effect not observed in NaV1.9 -/- up to 50mmHg (Figure 
21C). At greater ramp distension pressures, sensitized responses were 
observed in NaV1.9 -/- tissues compared to control experiments (max. 6.5 ± 1.9 
spikes/s, N = 6), which may reflect either the sensitisation of afferent fibres 
negative for NaV1.9 or recruitment of alternative sensitising mechanisms within 
NaV1.9 containing fibres.  
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Figure 21. Colonic splanchnic nerve responses to 0-80mmHg ramp distension.  
Example rate histogram and raw trace of colonic splanchnic nerve response to ramp 
distension (0 to 80mmHg) in NaV1.9 +/+ (A) and NaV1.9 -/- (B) mice with 
intraluminal pressure trace. Average response to ramp distension (0 to 80mmHg) in 
NaV1.9 +/+ and NaV1.9 -/- mice in the absence (C) or presence (D) of intraluminal 
perfusion with inflammatory soup (IS) (p < 0.0001, NaV1.9 +/+ vs. NaV1.9 -/-, 2-way 
ANOVA with Bonferroni’s post-hoc, *p < 0.05; **p < 0.01; ***p < 0.001; p < 0.0001, 
NaV1.9 +/+ in presence of IS vs. NaV1.9 -/- in presence of IS, 2-way ANOVA with 
Bonferroni’s post-hoc, #p < 0.05, ##p < 0.01, ###p < 0.001). 
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It was reasoned that rapid phasic distension in the experiments described 
above develops a more substantial stimulus to mechanoreceptive afferents 
compared to a slow ramp fill, even up to equivalent final pressures (80mmHg), 
something that has been shown in both pelvic and mesenteric nerves previously 
(Booth et al., 2008; Sengupta & Gebhart, 1994). Therefore, it should be possible 
to overcome the lack of response to slow ramp distension by increasing the 
stimulus to supra-physiological distension pressures. The maximum distension 
pressure achievable in mouse colon before rupture was determined at 159.6 ± 
4.3 mmHg (N = 10). Ramp distension to 145mmHg was thus used to provide a 
stronger stimulus. Ramp distensions beyond 80mmHg continued to linearly 
increase afferent firing rates to a maximum of 34.6 ± 7.3 spikes/s in NaV1.9 +/+ 
mice (Figure 22C). However, in NaV1.9 -/- mice, afferent firing remained just 
above baseline (<2 spikes/s) up to ~95mmHg, above which an exponential 
increase in firing was observed reaching firing rates almost comparable to 
NaV1.9 +/+ animals at 145mmHg (25.4 ± 7.8 spikes/s, Figure 22D). 
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Figure 22. Colonic splanchnic nerve responses to 0-145mmHg ramp distension. 
Example rate histogram and raw trace of colonic splanchnic nerve response to ramp 
distension (0 to 145mmHg) in NaV1.9 +/+ (A) and NaV1.9 -/- (B) mice with 
intraluminal pressure trace. C Average response to ramp distension (0 to 
145mmHg), firing rates to distension pressures of <95mmHg were greatly 
attenuated in NaV1.9 -/- animals compared to NaV1.9 +/+ mice (N=6), with an 
increase in firing at greater pressures in NaV1.9 -/- mice (p < 0.0001, 2-way ANOVA 
with Bonferroni’s post-hoc, *p < 0.05; **p < 0.01; ***p < 0.001).  
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Figure 23. Post-hoc single unit analysis of multi-unit recordings made during 0-
145mmHg ramp distensions. Response profiles to single units classified as low 
threshold (A), wide dynamic range (B) and high threshold(C) for both genotypes (2-
way ANOVA with Bonferroni’s post-hoc, *P < 0.05,**P < 0.01,***P < 0.001). D Mean 
response profiles for low threshold, wide dynamic range and high threshold units 
from NaV1.9 +/+ mice presented on the same plot. The three different response 
profiles can clearly be observed. E Analysis of activation thresholds revealed a 
rightward shift and an increase in the proportion of units with activation thresholds 
of > 100 mmHg in NaV1.9 -/- mice (p < 0.0001, Chi-squared test). 
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3.4.2 POST-HOC SINGLE-UNIT ANALYSIS OF MULTI-UNIT RECORDINGS TO RAMP 
DISTENSION AND TEASED SINGLE-FIBRE RECORDINGS OF MECHANICAL STIMULI 
IN LUMBAR SPLANCHNIC NERVE 
 
Deficits in afferent mechanosensation observed in ramp and phasic distension 
protocols could be due to increased adaptation above threshold and/or altered 
thresholds for activation. This was investigated by post-hoc single-unit analysis 
of multi-unit recordings during ramp distension and by teased-fibre recordings 
in a flat-sheet preparation. Using strict action potential sorting criteria, 80 
single units were identified from 0 - 145mmHg ramp distensions in NaV1.9 +/+ 
mice with an average activation threshold of 31.4 ± 3.5 mmHg and average 
firing rate of 1.3 ± 0.1 spikes/s. In the 39 single units identified during ramp 
distension in NaV1.9 -/- mice, there was a significant rightward shift to higher 
activation thresholds (73.1 ± 8.7 mmHg, p < 0.001) whilst the average firing rate 
per unit was reduced (0.6 ± 0.1 spikes/s, p < 0.001). Response profiles were 
compared between genotypes based on relative firing at high and low 
distending pressures and discriminated units were classified as low threshold 
(LT), wide dynamic range (WDR) or high threshold (HT; Figure 23). In NaV1.9 -
/- preparations, response profiles of all three classifications were diminished 
with significant reductions observed in LT and HT units compared to NaV1.9 
+/+ animals (p < 0.001; Figure 23).   
There are four subtypes of lumbar splanchnic nerve afferents characterised by 
their location and responses to stroke, blunt probe and circumferential stretch: 
mucosal, muscular and vascular; the latter of which can be further split into 
mesenteric and serosal afferents (Brierley et al., 2004). To identify which 
distension-sensitive afferent subtype was altered in NaV1.9 -/- mice, established 
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teased single-fibre recording techniques in a colonic flat-sheet preparation 
were used (see Figure 24). 
 
 
 
 
 
 
192 
 
  
Figure 24. Example traces of mesenteric, serosal and muscular afferent LSN 
subtypes. A Von Frey hair mechanical stimulation of a vascular afferent fibre with 
receptive field in the mesenteric attachment. This fibre was unresponsive to 
circumferential stretch at 1g, 5g and 10g, and also to stoke of the mucosal surface 
by fine von Frey hair (10mg). B Example of vascular afferent with receptive field 
located intramurally within the colon wall and classified as serosal. Whilst not 
responsive to low-grade stretch (1g and 5g), a small proportion of serosal afferents 
could be activated by application of 10g stretch. C Example of muscular afferent 
with receptive field within the colon wall and responding to 5g and 10g stretch and 
von Frey hair probing.  
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Afferent fibres classified as mesenteric, serosal and muscular were consistently 
identified in both NaV1.9 +/+ and NaV1.9 -/- mice. Whilst initial efforts were 
taken to identify afferents sensitive to mucosal stroke none were identified. 
Given their scarcity in the splanchnic innervation of the gut (≤4%) and likely 
limited involvement in nociception, their characterisation was not pursued 
(Brierley et al., 2004). As previously described, a small proportion (NaV1.9 +/+: 
~13% & NaV1.9 -/-: ~21%) of serosal afferents also responded to greater (10g) 
circumferential stretch (Hughes et al., 2009). Stimulus-response curves to blunt 
probe with increasing weight of von Frey hairs of serosal and muscular units 
was unchanged between genotype (p = 0.94 and p = 0.24, respectively, see 
Figure 25A & C) with no significant differences observed in either 
mechanosensory thresholds or responses to circumferential stretch of the 
preparation (Figure 25D, F, G & H). A significant reduction in mesenteric 
afferent responses to von Frey hair probing, specifically at lower intensity 
probing (0.16-1g vFh); with a corresponding increase in mechanosensory 
threshold at these intensities observed in NaV1.9 -/- mice compared to wild-
type animals (Figure 25B & E).  
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Figure 25. Stimulus-response curves to von Frey hair probing and circumferential 
stretch for afferent fibre subtypes in NaV1.9 +/+ and NaV1.9 -/- mice. Stimulus-
response curves to von Frey hair probing (0.07g – 2g) for serosal (A), mesenteric (B) 
and muscular (C) afferent fibres (2-way ANOVA with Bonferroni’s post-hoc, *p < 
0.05; **p < 0.01; ***p < 0.001). Associated activation thresholds of von Frey hair 
probing for serosal (D), mesenteric (E) and muscular (F) afferent fibres (Fisher’s 
exact test at each probe weight, **p < 0.01; ***p < 0.001). Responses to 
circumferential stretch (1g, 5g and 10g) in serosal and muscular afferent fibres (2-
way ANOVA with Bonferroni’s post-hoc). 
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Electrical stimulation of characterised single units in teased fibre recordings 
showed there was no difference in conduction velocity between control and 
NaV1.9 -/- mice (serosal, p = 0.50; mesenteric, p = 0.90; muscular, p = 0.35; 
Figure 27), signifying that action potential propagation is unaffected by loss of 
NaV1.9.  
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Figure 26. Conduction velocity determination by electrical stimulation. Conduction 
velocities were estimated by first identifying the afferent receptive field with von 
Frey hair probing (A). Receptive fields were then subjected to electrical stimulation 
(0.5Hz, 15V, 1ms) with concentric stimulating electrodes every second for 5 seconds 
(B; three stimulation artefacts with evoked action potential shown). If less than 
three action potentials were evoked by electrical stimulation, the electrode was 
repositioned and the receptive field re-stimulated. C To determine the conduction 
velocity, the time from stimulation artefact (arrow) to evoked action potential was 
measured (i.e. 33ms). The distance from receptive fields to recording electrode was 
then expressed as a fraction of the time taken for the action potential to travel this 
distance. In this example, this unit has a conduction velocity of 20mm/33ms or 
0.61m/s. D Example waveform template matching. Five von Frey hair evoked action 
potentials (grey) overlaid with two electrically stimulated action potentials (red), 
confirming stimulation of the same unit.  
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Figure 27. Conduction velocity of mechanosensitive afferent fibres in NaV1.9 +/+ 
and NaV1.9 -/- mice. Comparison of conduction velocities of electrically-evoked 
action potentials in serosal (A), mesenteric (B) and muscular (C) afferent fibre 
subtypes of NaV1.9 +/+ and NaV1.9 -/- mice (unpaired t-test). D Histogram of 
conduction velocity in 0.1 ms-1 increments. 
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Together these data suggest that high-intensity mechanical stimulation of 
colonic afferents (e.g. 2g vFh probing, >95mmHg ramp distension and initial 
rapid phasic distension) is unaffected by NaV1.9 gene deletion. However knock-
out of NaV1.9 appears to decrease the sensitivity and firing rates of mesenteric 
afferents to low-intensity stimulation, which likely accounts for the significant 
deficits observed during ramp distension and the post-hoc analysis of the 
associated single units. This is supported by the correlation between von Frey 
hair stimulation and distension of the intact bowel in mechanoreceptors located 
in the mesentery and suggests that this unit subtype comprises a significant 
proportion of the total afferent output during distension of the bowel (Brierley 
et al., 2008). 
3.4.3 EFFECTS OF NAV1.9 DELETION ON RESPONSES OF COLONIC AFFERENTS TO 
INFLAMMATORY SOUP AND SUBSEQUENT MECHANICAL HYPERSENSITIVITY 
 
The role for NaV1.9 in afferent responses to multiple inflammatory mediators 
was next investigated. To achieve this, single-fibre recordings were made in 
colonic flat sheet preparations, and receptive fields in the mesentery and serosa 
were identified. Discrete application of inflammatory soup (IS: bradykinin, ATP, 
histamine, serotonin and prostaglandin E2) for 2 minutes in a small chamber 
surrounding the receptive field led to robust activation in 100% of serosal and 
80% of mesenteric units in NaV1.9 +/+ mice (Figure 28). The increase in firing 
of single afferent fibres after IS was virtually abolished in NaV1.9 -/- mice, and 
only 43% of serosal (p < 0.05) and 56% of mesenteric (p < 0.05) units 
responded (Figure 28C). 
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Figure 28. Chemical and mechanical stimulation of single fibre mechanoreceptive 
fields in mouse colon. Example colonic nerve activity to ring application (2 mins) of 
inflammatory soup (IS) over a receptive field located in the serosa of NaV1.9 +/+ (A) 
and NaV1.9 -/- (B) mice. Probes with von Frey hair (2g) were performed prior to and 
after IS application. C Response to IS ring application in serosal and mesenteric 
receptive fields (*p < 0.05, unpaired t-test). D Afferent hypersensitivity post-IS 
application was observed in NaV1.9 +/+ mice in both serosal and mesenteric units 
(*p < 0.05, paired t-test vs before-IS). This was not present in NaV1.9 -/- mice. 
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After responses to IS, mechanical hypersensitivity of colonic afferents was seen. 
Responses to 2g von Frey hair probing before and after IS application were 
compared in control animals and a significant increase in responses post-IS was 
observed (p < 0.05, Figure 28D). This is consistent with previous studies using 
the application of bradykinin (Brierley, Jones, et al., 2005). IS-induced 
mechanical hypersensitivity to a 2g probe was completely lost in NaV1.9 -/- 
mice (serosal, p = 0.76; mesenteric, p = 0.63, paired t-test), indicating that 
NaV1.9 may directly influence the mechanical hypersensitivity of visceral 
afferents induced by IS. This suggests that the mechanical hypersensitivity 
observed to intraluminal perfusion of inflammatory soup during 0-80mmHg 
ramp distension can be attributed to sensitisation of both serosal and 
mesenteric afferent subtypes. 
3.4.4 NAV1.9 DELETION REDUCES COLONIC AFFERENT RESPONSES TO HUMAN 
TISSUE-DERIVED INFLAMMATORY SUPERNATANTS 
 
Next, it was investigated whether ablation of NaV1.9 would alter responses not 
only to artificially reconstituted IS, but also to supernatants derived from 
inflamed human tissue. To do this, resected bowel tissue from patients 
undergoing surgery for inflammatory bowel disease (IBD: Crohn’s disease (CD) 
and ulcerative colitis (UC)) was incubated in Krebs (see Methods) to generate 
individual IBD supernatants. Separately, macroscopically normal tissue taken 
from bowel cancer resections (> 10cm away from the cancer itself, cancer 
margins and lymph nodes) was used to generate control supernatants. Such 
control supernatants enabled possible excitatory effects caused by surgical 
manipulation, removal of tissue and ischemia to be discounted from afferent 
201 
 
activation driven by inflammatory mediators released from native tissue. 
Importantly, no further steps were taken to concentrate the tissue supernatant 
in any way. To confirm the inflammatory status of the supernatants, cytokine 
quantification for IL-6, IL-8, IL-1β, GM-CSF and TNF-α was performed. In 
control supernatants, there were detectable levels of IL-6 (7.5 ± 3.3 pg/ml) and 
IL-8 (43.4 ± 13.8 pg/ml); with levels of the remaining cytokines below detection 
limits (Figure 29D). Cytokine levels were all significantly elevated in IBD 
supernatants (IL-1β: 35.4 ± 22.7; IL-6: 598.6 ± 276.3; GM-CSF: 37.5 ± 14.9; TNF-
α: 31.5 ± 23.6; IL-8: 3419.3 ± 2083.7 pg/ml; each cytokine vs. control, p < 0.05), 
with cytokine levels greatest in supernatants generated from Crohn’s disease 
tissue compared to that of ulcerative colitis. It should be mentioned that the 
influence of immunosuppressant and anti-TNFα antibody therapies on cytokine 
production was not accounted for during patient selection. Supernatants were 
initially applied to mouse whole-nerve lumbar splanchnic recordings in a 
cannulated tubular preparation. IBD supernatants elicited a robust increase in 
afferent firing compared to control supernatants in wild-type animals (3.5 ± 0.5 
spikes/s vs. control supernatant 0.7 ± 0.1 spikes/s, p < 0.01, Figure 29C). In 
NaV1.9 -/- mice, the response to IBD supernatants was greatly attenuated and 
almost comparable in magnitude to control supernatant response in wild-type 
mice (1.2 ± 0.3 spikes/s, vs. NaV1.9 +/+ mice, p < 0.01).  
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Figure 29. The effect of inflammatory bowel disease (IBD) supernatants on colonic 
nerve activity. A Example rate histograms of colonic nerve activity to control 
supernatant in NaV1.9+/+ mice and to Crohn’s disease (CD) tissue supernatant in 
NaV1.9+/+ and NaV1.9-/- mice. B Example rate histograms of colonic nerve activity 
to ulcerative colitis (UC) supernatant in both NaV1.9+/+ and NaV1.9-/- mice. C Peak 
change in activity following addition of control (N = 3), IBD supernatants in 
NaV1.9+/+ (N = 7) and NaV1.9-/- mice (N = 6). In addition, CD and UC responses are 
plotted separately to the right of the panel (N = 3-4 per genotype). *p < 0.05, **p < 
0.01 vs control; #p < 0.05, ##p < 0.01 NaV1.9+/+ vs NaV1.9-/-. D Cytokine (IL-1β, IL-6, 
GM-CSF, TNF-α & IL-8) levels in IBD (N = 7) and control (N = 3) supernatants applied 
to afferent nerve recordings. *p < 0.05 vs control.  
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After confirming that human tissue-derived inflammatory supernatants could 
indeed excite colonic afferents, the effect of CD supernatants was investigated 
by direct application in a small chamber over isolated receptive fields during 
single-fibre recordings in a flat sheet preparation. Crohn’s disease supernatants 
were chosen over ulcerative colitis supernatants due to the comparatively 
larger afferent excitation evoked during whole-nerve tubular experiments and 
also due to the greater incidence of abdominal pain in Crohn’s disease vs. 
ulcerative colitis patients (see Figure 29). The responses to ring application of 
CD supernatant were less robust and frequent in comparison to experimental IS 
in wild-type animals, with 64% of serosal (1.37 ± 0.36 spikes/20s) and 50% of 
mesenteric afferents (1.13 ± 0.22 spikes/20s) responding (Figure 30D). The 
proportions of units responding in NaV1.9 -/- mice were comparable (p = 1.00, 
Fisher’s exact test, Figure 30D), however the degree of afferent activation 
elicited by ring application of CD supernatants was significantly less (serosal: 
0.31 ± 0.11 spikes/20s, p < 0.05 vs NaV1.9 +/+; mesenteric: 0.42 ± 0.16 
spikes/20s, p < 0.05 vs NaV1.9 +/+). No mechanical hypersensitivity was 
observed after CD supernatant in either NaV1.9 +/+ or NaV1.9 -/- mice to 2g von 
Frey hair probe (Figure 30E & F), regardless of whether or not afferents showed 
direct excitation to the supernatant. It is clear that NaV1.9 contributes to 
visceral afferent excitation by both experimental and natural inflammatory 
milieu of differing composition. 
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Figure 30. Mechanical sensitivity and stimulation of single fibre mechanoreceptive 
fields in mouse colon by human inflammatory supernatant. Example colonic nerve 
activity to ring application (5 mins) of Crohn’s disease inflammatory supernatant 
over a receptive field located in the serosa of NaV1.9 +/+ (A) and NaV1.9 -/- (B) mice. 
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Probes with von Frey hair (2g) were performed prior to and after CD supernatant 
application. C Response to CD supernatant ring application in serosal and 
mesenteric receptive fields (*p < 0.05, unpaired t-test). D Number of responsive 
versus non-responsive serosal and mesenteric units when CD supernatants were 
applied (Fisher’s exact test). E & F Afferent hypersensitivity post-IS application was 
not observed in NaV1.9 +/+ mice in either serosal or mesenteric units, independent 
of whether or not afferents showed direct excitation to CD supernatant (paired t-
test vs before-supernatant). 
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3.5 SUMMARY OF KEY FINDINGS  
3.5.1 COLONIC AFFERENT EXCITATION TO MECHANICAL STIMULI IN NAV1.9 -/- 
MICE 
 
1. In a tubular preparation, rapid phasic distension to 80mmHg evoked 
equivalent colonic afferent excitation in both NaV1.9 +/+ and NaV1.9 -/- 
mice.  
2. Repeat phasic distension led to adaptation in the response in NaV1.9 +/+ 
mice, with responses stabilising by the 4-6 repeat distension.  
3. The degree of run-down of responses to repeat distension was 
significantly greater in NaV1.9 -/- mice. 
4. During slow ramp distension to 80mmHg, NaV1.9 +/+ mice produced a 
linear stimulus-response, with responses in NaV1.9 -/- mice almost 
completely abolished.  
5. Supra-physiological ramp distension to 145mmHg led to increased 
afferent firing in NaV1.9 +/+ mice. Responses in NaV1.9 -/- mice 
remained very low at distension pressures less than 95mmHg. Above 
this pressure, an exponential increase in NaV1.9 -/- afferent firing was 
observed, with responses almost reaching that of NaV1.9 +/+ mice at 
145mmHg. 
6. Intraluminal perfusion of inflammatory soup (IS) led to mechanical 
sensitisation of responses to ramp distension to 80mmHg in NaV1.9 +/+ 
mice. This was also true of responses from NaV1.9 -/- mice, but to a 
lesser extent and not at pressures below 50mmHg.  
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7. Post-hoc analysis of activation thresholds of single units from ramp 
distensions to 145mmHg in NaV1.9 -/- mice were significantly increased 
compared to NaV1.9 +/+ mice, and firing rates were significantly 
decreased. 
8. In teased fibre recordings from flat-sheet preparations, afferent fibres 
characterised as serosal and muscular had comparable stimuli-response 
curves to mechanical stimuli by von Frey hairs and circumferential 
stretch, irrespective of genotype. Activation thresholds were also 
unchanged in these subtypes. 
9. However, mesenteric afferents from NaV1.9 -/- mice exhibited reduced 
von Frey hair stimulus-response curves, and a corresponding rightward 
shift in activation thresholds.  
3.5.2 CONDUCTION VELOCITIES OF COLONIC AFFERENTS FROM NAV1.9 -/- MICE 
 
1. In a flat-sheet preparation, teased fibre recordings of serosal, mesenteric 
and muscular afferents showed no difference in conduction velocities 
between genotypes. 
3.5.3 EFFECT OF INFLAMMATORY SOUP ON THE EXCITATION AND MECHANICAL 
HYPERSENSITIVITY OF COLONIC AFFERENTS IN NAV1.9 -/- MICE 
 
1. Application of inflammatory soup to discrete serosal and mesenteric 
receptive fields in a flat-sheet preparation evoked robust afferent 
discharge in NaV1.9 +/+, but not NaV1.9 -/-, mice.  
2. Post-inflammatory soup mechanical hypersensitivity to 2g von Frey hair 
probe was observed in NaV1.9 +/+ mice. This was completely lost in 
NaV1.9 -/- mice. 
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3.5.4 EFFECT OF HUMAN INFLAMMATORY SUPERNATANTS ON EXCITATION AND 
MECHANICAL HYPERSENSITIVITY OF COLONIC AFFERENTS IN NAV1.9 -/- MICE 
 
1. In a tubular preparation, bath superfusion of both Crohn’s disease and 
ulcerative colitis supernatants, but not control supernatants, evoked 
robust activation of NaV1.9 +/+ colonic afferents, which was lost in 
NaV1.9 -/- mice. 
2. Application of Crohn’s disease supernatants to discrete receptive fields 
in the serosa and mesentery in a flat-sheet preparation from NaV1.9 +/+ 
mice led to modest afferent discharge in approximately 50% of fibres. 
This response was significantly reduced in NaV1.9 -/- mice, although 
equivalent numbers of fibres responded.  
3. No post-Crohn’s disease supernatant mechanical hypersensitivity to 2g 
von Frey hair probe was observed in either NaV1.9 +/+ or NaV1.9 -/- 
mice.  
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3.6 DISCUSSION 
 
The data above shows that NaV1.9 is required for the direct excitatory 
responses of nociceptive colonic afferents to inflammatory mediators from 
diseased tissue, and for mechanical sensitisation by these same mediators. 
NaV1.9 is also involved in determining the mechanosensory thresholds of a 
subset of colonic afferents with receptive fields in the mesenteric attachments, 
and thereby determining responses to rapid and/or intense distension in the 
intact colon. NaV1.9 may also play a role in the persistence of responses to 
repeated noxious distension, which would otherwise attenuate over time.  
Given the polymodal nature of visceral nociceptors, there are likely points of 
convergence in the molecular signalling pathways underlying action potential 
generation at their endings (Su & Gebhart, 1998). These will provide valuable 
targets for future treatments, which could counteract the mechanical 
hypersensitivity induced by ongoing inflammation. Voltage-gated sodium 
channels may represent such a convergence point in this signalling cascade. Of 
the peripherally expressed sodium channels, valuable insight has been obtained 
regarding the function of NaV1.7 and NaV1.8 in visceral chronic pain, not least 
due to causal links to human pain syndromes (Fertleman et al., 2006; Reeder et 
al., 2013). However, the functional evidence for a role of NaV1.9 in visceral 
afferents has not been extensively explored before, despite its appealing 
biophysical characteristics. The data presented here suggests that NaV1.9 
represents an important regulator of specific aspects of sustained visceral 
afferent excitability, especially in response to inflammatory mediators.  
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3.6.1 AFFERENT CHEMOSENSITIVITY IN NAV1.9 -/- MICE 
 
The persistent sodium current defined by NaV1.9 can be greatly enhanced by 
inflammatory mediators acting at GPCRs via Gq/11/PKC and Gi/o/PKA 
intracellular signalling pathways (Baker, 2005; X. Chen et al., 2011; Maingret et 
al., 2008; Rush & Waxman, 2004), which can result in neuronal depolarisation 
and increased afferent excitability. Mediators applied individually to dissociated 
DRG neurones may not be sufficient to evoke such NaV1.9 current 
enhancements, with Maingret et al. suggesting that multiple inflammatory 
mediators are required (Maingret et al., 2008); whilst others have shown that 
ATP or PGE2 applied alone can increase NaV1.9 current amplitudes (Baker, 
2005; Rush & Waxman, 2004). The data presented here extends these 
observations by examining the contribution of NaV1.9 to nociceptor activation 
at the level of the nerve ending. Responses of individual receptive fields in the 
mesentery and serosa to the application of experimental inflammatory soup 
(consisting of bradykinin, histamine, PGE2, ATP and 5HT) were significantly 
attenuated in NaV1.9 -/- mice (see Figure 28). Basal whole-nerve firing rates 
were also significantly reduced following intraluminal perfusion of IS, 
demonstrating that NaV1.9 is required in the activation of nerve fibres by these 
mediators (Figure 21). To explore this further we generated supernatants by 
incubating resected tissue from patients with IBD. These disease derived IBD 
supernatants caused increases in afferent activity in whole nerve recordings 
from mouse colon, and in single unit recordings from serosal and mesenteric 
afferents; both of which were significantly attenuated in NaV1.9 -/- mice (see 
Figure 29). The degree of nerve excitation observed following application of IBD 
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supernatants was comparable to those previously reported following 
application of irritable bowel syndrome supernatants to mesenteric nerve 
recordings of rat (Barbara et al., 2007). The attenuation of responses to human 
IBD supernatants in NaV1.9 -/- mice supports a more general role for NaV1.9 in 
afferent excitability by multiple inflammatory pathways potentially including 
those evoked by disease-relevant cytokines. In whole tissue preparations such 
as those employed in the current study, it is highly unlikely that visceral 
afferent terminals are solely exposed to just IS or IBD supernatant, with these 
experimental mediators likely to act alongside the endogenous inflammatory 
milieu released by adjacent tissues. Given the exposure to multiple mediators, it 
is likely that NaV1.9 current potentiation is occurring in these afferents, 
however these findings do not restrict an unenhanced NaV1.9 current from 
exhibiting significant effects on resting membrane potential, neuronal 
excitability and transduction at visceral afferent terminals. Whilst constituents 
of the inflammatory soup, including ATP and PGE2, can enhance currents 
generated by other sodium (e.g. NaV1.8 (Baker, 2005)) or ion channels 
(Schicker, Chandaka, Geier, Kubista, & Boehm, 2010; Tominaga, Wada, & Masu, 
2001), this data demonstrates that visceral afferent excitability to these 
mediators appears highly dependent on NaV1.9. Collectively, this suggests that 
during human inflammatory disease where multiple inflammatory stimuli are 
present, NaV1.9 contributes significantly to visceral afferent activation. 
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3.6.2 EFFECT OF NAV1.9 DELETION ON MECHANICAL HYPERSENSITIVITY TO 
INFLAMMATORY STIMULI  
 
Deletion of NaV1.9 also caused significant deficits in the development of 
mechanical hypersensitivity following application of inflammatory mediators. 
These deficits were investigated using different mechanical stimuli, including 
von Frey probing of isolated visceral nociceptor receptive fields and ramp 
distension of the colon into noxious pressure range. The response to noxious 
ramp distension was sensitised by intraluminal perfusion of inflammatory soup, 
which, at least during lower distension pressures was dependent on NaV1.9 
(Figure 21). Post-IS mechanical hypersensitivity to von Frey hair probing was 
also observed in both serosal and mesenteric afferent fibre subtypes in wild-
type mice. This was comparable to previously reported mechanical 
hypersensitivity in these afferent subtypes following application of bradykinin 
(Brierley, Jones, et al., 2005). This mechanical hypersensitivity was completely 
lost in NaV1.9 -/- animals and suggests that NaV1.9 has a central role in the 
sensitisation of afferent fibres to mechanical stimuli. Whilst application of 
Crohn’s disease (CD) supernatants did evoke moderate excitation of some 
mesenteric and serosal afferents, CD supernatants did not induce a mechanical 
hypersensitivity to von Frey hair probe in either NaV1.9 +/+ or NaV1.9 -/- mice. 
It is possible that this is due to the combination of inflammatory mediators in 
IBD pathology being unable to evoke mechanical hypersensitivity in these 
afferent fibres, but may also be a result of the relatively weak excitatory 
stimulus provided by these supernatants compared to responses following the 
application of experimental IS. There is certainly a subset of IBD patients that 
are normosensitive or hyposensitive to colorectal distension (Bernstein et al., 
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1996; Chang et al., 2000). Indeed, faecal supernatants from ulcerative colitis 
patients induce hyposensitivity in mice during VMR to CRD (Annaházi et al., 
2009). As such, no change, or even a reduction, in response to von Frey hair 
probe post-CD application may have been predicted in these single-fibre studies 
(see Figure 30). By contrast, IBS supernatants have been shown to robustly 
evoke mechanical hypersensitivity in animal models (Annaházi et al., 2009; 
Cenac et al., 2007). Visceral hypersensitivity is also observed in a subset of IBD 
patients presenting with IBS, in so called IBD-IBS (Grover et al., 2009).  It would 
be interesting to examine IBS-supernatant-induced mechanical hypersensitivity 
in NaV1.9 -/- mice and determine whether these are more analogous to changes 
induced by experimental IS.  Collectively, these data do suggest that 
experimental IS and IBD supernatants evoke their actions through differing 
inflammatory pathways. In both cases, this is consistent with the proposed role 
for NaV1.9 in regulating afferent nerve terminal sensitisation during 
inflammation.  
Further experiments investigating the effect of NaV1.9 deletion on long-term 
chronic inflammation are warranted to fully understand the ability of NaV1.9 to 
modulate afferent excitability. 
3.6.3 MECHANOSENSATION OF COLONIC AFFERENTS IN NAV1.9 -/- MICE 
 
The results also implicate NaV1.9 in the mechanosensation of colonic afferents. 
These were investigated using repeated phasic and ramp distension of the colon 
into a noxious pressure range and by von Frey hair probing of isolated visceral 
receptive fields. Such studies have proven invaluable in the development of our 
current understanding of how noxious mechanical stimulation of the gut is 
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transduced by visceral nociceptors (Booth et al., 2008; Brierley et al., 2008; 
Feng, La, Schwartz, et al., 2012). Von Frey hair probes were used to elicit brief, 
intense and graded mechanical stimuli. There are populations of colonic 
mechanoreceptors with receptive terminals on blood vessels in both the 
mesentery and intramurally within the colon, which respond to high-threshold 
mechanical stimulation and are believed to comprise a major type of nociceptor 
(Brookes et al., 2013). Importantly, these same primary afferents also respond 
to intraluminal distension at pressures that evoke pain in other species in vivo 
(Schmulson, Chang, Naliboff, Lee, & Mayer, 2000; Whitehead et al., 1990). 
Mechanical activation of afferents with receptive fields located in the serosa is 
unaffected by NaV1.9 gene deletion (Figure 25). This is also true of 
mechanoreceptors characterised as muscular, which respond to low intensity 
circumferential stretch (5g) and vFh probing identically, regardless of genotype. 
However, mechanosensory responses of afferents with receptive fields in the 
mesentery are significantly attenuated, with a consistent increase in activation 
thresholds observed in NaV1.9 -/- mice. As mentioned previously, whilst serosal 
and mesenteric sub-populations are thought to represent a common class of 
“vascular” visceral afferent fibre (Brookes et al., 2013), these two classes are 
differently altered not just in NaV1.9 knock-outs, but also in ASIC2 -/- mice 
(Page, Brierley, et al., 2005).  Furthermore, serosal and mesenteric afferents 
have different wild-type sensitivities to distension and von Frey hairs (Song et 
al., 2009). Whether differences in the expression of mechanotransducers, or 
other known regulators of neuronal excitability (such as T-type calcium 
channels or HCN2), present in serosal versus mesenteric afferents contributes 
to the importance of NaV1.9 in regulating afferent firing remains to be seen 
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(Emery et al., 2011; Sekiguchi & Kawabata, 2013). As such, NaV1.9 appears to 
regulate mesenteric afferent excitability to mechanical stimuli to a greater 
extent than when compared to afferents with intramural receptive fields. 
The data shows that excitation of visceral afferents by initial rapid phasic 
distension is unaffected by NaV1.9 deletion. This observation supports the data 
generated using high intensity vFh (2g) stimulation, which produced 
comparable responses across all types of units regardless of genotype. It 
suggests that the reduction in afferent excitability caused by the loss of NaV1.9 
may be overcome by greater mechanical stimulation, and presumably greater 
activation of stimulus transducing channels. In contrast to the initial phasic 
distension, NaV1.9 is required for the maintenance of afferent sensitivity to 
persistent mechanical stimuli. The desensitisation of responses typically seen to 
repeat colorectal distension (Kamp et al., 2003; Sivarao et al., 2007) did not 
stabilise in NaV1.9 -/- mice, but instead continued to decline with subsequent 
distensions (Figure 20). One possible explanation for this observation, that is 
worthy of further investigation, is that repeated mechanical stimuli may 
progressively desensitise activity in mechanosensitive channels, such as TRPV4, 
TRPA1, ASIC3, however a concurrent up-regulation of NaV1.9 maintains a 
consistent level of afferent activation. This mechanism could be crucial in vivo, 
where pain is evoked by repeated contractions of the colon around a bolus or 
stricture, and is amplified in IBS (Brookes et al., 2013). Further, this may be 
relevant in relation to afferent adaptation during experimental models of 
visceral pain, such as the visceromotor response (VMR) to colorectal distension. 
Typically, a set of distensions (e.g. 4-8) is applied to achieve a stable response, 
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at which point the intervention is applied (Kamp et al., 2003; Sivarao et al., 
2007). Therefore the relative importance of mechanosensory pathways in an 
afferent having undergone stimuli adaptation may differ from those present in a 
naïve state. Consistent with this proposed role for NaV1.9 in persistent or 
sustained stimuli, a substantial reduction in the afferent response to ramp 
colorectal distension (0-80mmHg) in NaV1.9-/- tissue was observed at all 
pressures including those within the noxious range. When these pressures were 
extended into the supra-maximal range (100-150mmHg), increases in afferent 
activity were observed in both genotypes. This is in keeping with the previous 
hypothesis that increased stimulus strength may overcome the loss of 
excitability following deletion of NaV1.9. Post-hoc single unit analysis of 
responses to ramp distension showed that units characterised as low-threshold, 
wide dynamic range and high-threshold, demonstrated reduced firing rates. 
This is consistent with the observed changes in activation threshold and 
reduced firing rates of mesenteric afferent fibres to von Frey hair probe in a 
flat-sheet preparation, and suggests that mesenteric afferent response 
contributes significantly to activity evoked by fluid ramp distension at varying 
pressures. It is perhaps important to note that the distension paradigms used, 
rapid phasic vs. slow ramp, model markedly different physiological stimuli and 
will activate a range of afferent subtypes. This is relevant given the preferential 
activation of splanchnic afferents by phasic distension over ramp distension in 
man (Lembo et al., 1994).  
Finally, no difference was observed in conduction velocities of visceral afferent 
fibres between genotypes, suggesting that action potential propagation is not 
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affected by NaV1.9 ablation. The conduction velocities of afferents recorded 
were in the C-fibre range, consistent with previous studies (Bielefeldt & Davis, 
2008; Brierley et al., 2008; Cervero & Sharkey, 1988; Malin et al., 2009). 
3.6.4 ISOLATION OF EXTRINSIC AFFERENT ACTIVITY FROM ENTERIC NERVOUS 
SYSTEM 
 
Considerable efforts were taken to ensure that changes observed in afferent 
activation in this study were not confounded by the loss of NaV1.9 within 
intrinsic primary afferent neurones (IPANs) of the enteric nervous system 
(ENS), which are known to express NaV1.9 (Padilla et al., 2007; Rugiero et al., 
2003). Although the contribution of second order enteric neurones projecting 
out of the gut (intestinofugal fibres) cannot be ruled out in the recordings 
presented here, at the recording site central to the inferior mesenteric ganglia, 
these would proportionally represent a small minority of the total splanchnic 
outflow (Luckensmeyer & Keast, 1995). It is also currently unknown whether 
intestinofugal fibres express NaV1.9.  The potential impact of the loss of NaV1.9 
from IPANs on local reflexes was controlled by the inhibition of intrinsic smooth 
muscle tone by inclusion of both nifedipine and atropine to the perfusion buffer. 
Finally cross-talk between the ENS and extrinsic afferents innervating the colon 
does not mediate extrinsic afferent sensitivity (Mueller et al., 2009). Indeed, in 
the aganglionic rectum of piebald-lethal mice, extrinsic mechanoreceptor 
development and function is largely unaffected by complete loss of enteric 
ganglia (Spencer, Kerrin, Zagorodnyuk, et al., 2008). The methodological steps 
outlined above, in conjunction with both the magnitude of the effects observed 
and the paucity of evidence for cross-talk between the ENS and extrinsic 
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afferents mediating extrinsic afferent sensitivity, would strongly suggest that 
the changes observed are due to modulation of neuronal excitability by NaV1.9 
in visceral extrinsic afferents.  
3.6.5 CONCLUSIONS 
 
In conclusion, these data show that NaV1.9 represents a significant mechanism 
responsible for regulating visceral nociceptor sensitivity to mechanical stimuli, 
and to sensitising inflammatory mediators, including those released by human 
inflammatory bowel disease. The data further supports a role for NaV1.9 in the 
regulation of visceral afferent excitability and sensitivity in nociception (see 
Figure 31). 
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Figure 31. Schematic illustration of NaV1.9 interacting with membrane-bound 
receptors and ion channels in a visceral afferent terminal. When present at the 
visceral afferent terminal, NaV1.9, as well as contributing to setting the resting 
membrane potential acts to amplify generator potentials evoked by 
mechanosensitive channels, and functions as a key transducer of inflammatory 
mediators and other sensitising stimuli. 
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CHAPTER 4: PURINERGIC SIGNALLING 
AND NAV1.9 IN GUT VISCERAL AFFERENT 
FIBRES 
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4.1 INTRODUCTION 
 
Inflammatory bowel disease is characterised by chronic and relapsing 
diarrhoea, fatigue and bleeding accompanied by abdominal pain, which can 
continue during states of disease remission (Bielefeldt et al., 2009). One 
endogenous algogenic mediator of bowel discomfort and pain is adenosine 5’-
triphosphate (ATP), which is released from the mucosal epithelium during 
distension (Burnstock, 1999) and is released in greater amounts during colitis 
(Calvert et al., 2008; Shinoda et al., 2009; Wynn et al., 2004).  Both P2X and P2Y 
receptors may be activated by extracellular ATP, suggesting that they both 
contribute to altered sensation in IBD. Of the reported seven P2X subtypes 
(P2X1-7), P2X2 and P2X3 receptor subunits are widely expressed in peripheral 
neurones and are thought to contribute significantly to the transduction of 
nociceptive visceral signals in the bowel (Burnstock, 1999). The eight members 
of the P2Y receptor family (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14) respond to 
endogenous purinergic nucleotides (ATP, ADP, UTP and UDP) released from 
various tissues into the extracellular environment (Gerevich & Illes, 2004)(see 
Figure 32). Activation of P2Y receptors in sensory neurones is capable of 
evoking action potential firing (Yousuf, Klinger, Schicker, & Boehm, 2011), 
inducing Ca2+ flux (Borvendeg, Gerevich, Gillen, & Illes, 2003; Ceruti, Fumagalli, 
Villa, Verderio, & Abbracchio, 2008) and activating intracellular 
phosphorylative cascades (Molliver, Cook, Carlsten, Wright, & McCleskey, 
2002). In addition, P2Y receptors may activate cutaneous afferent fibres and 
regulate mechanosensitivity (Stucky, Medler, & Molliver, 2004; Tominaga et al., 
2001). As such, P2Y receptor signalling is likely to contribute to 
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mechanosensation and nociception under both physiological and 
pathophysiological conditions. The function and known expression of individual 
purinoceptors is outlined in detail below.  
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Figure 32. Schematic illustration of purinoceptors interacting with ATP and UTP and 
their enzymatic breakdown products. P2X receptors are ionotropic channels. P2Y 
and P1 receptors are metabotropic G-protein coupled receptors (GPCRs). ATP 
broadly interacts with P2X and P2Y receptors subtypes. Of the P2Y receptors, ATP 
has specific affinity for P2Y1,2,11-13. ADP is specific for P2Y1,11-13 and adenosine 
activates all P1 receptors subtypes (A1,A2A,A2B and A3). UTP is specific for P2Y2,4,6 
receptors and its break-down product, UDP, is selective for P2Y6 receptors. ATP and 
UTP may undergo progressive hydrolysis through ADP and UDP, AMP and UMP, to 
adenosine and uridine. 
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4.1.1 PURINORECEPTORS AND VISCERAL PAIN 
 
Following iontophoretic application to human skin and in the human blister 
base model, ATP elicits pain (Bleehen & Keele, 1977; Hamilton, Warburton, 
Bhattacharjee, Ward, & McMahon, 2000). The breakdown products of ATP, 
including adenosine 5’-diphosphate (ADP), adenosine 5’-monophosphate (AMP) 
and adenosine, also all evoke algogenic responses in man (Bleehen & Keele, 
1977; Coutts, Jorizzo, Eady, Greaves, & Burnstock, 1981). As well as nociceptive 
signalling, ATP is involved in mechanosensation, inflammation and in the 
control of vascular tone (Burnstock, 1999; Coutts et al., 1981; Hamilton et al., 
2000). In visceral organs, ATP is released from the mucosal epithelium during 
distension and activates sub-epithelial visceral afferent nerves through specific 
purinoceptors, most notably P2X3 (Burnstock, 1999). This purinergic signalling 
mechanism leads to the transduction of mechanosensation to the central 
nervous system and the activation of pain pathways. Indeed, distension of 
human and guinea-pig ureter, rat lung and colon, and mouse urinary bladder, 
have all led to the pressure-dependent release of ATP (Calvert et al., 2008; 
Knight, Bodin, De Groat, & Burnstock, 2002; Rich, Douillet, Mahler, Husain, & 
Boucher, 2003; Vlaskovska et al., 2001; Wynn et al., 2003). In the ureter, release 
of ATP began at the uroteric pressure threshold for pain (25-30 cm H2O; 
(Risholm, 1954)). Specifically, both sub-epithelial fibroblasts isolated from rat 
intestinal villi and human intestinal epithelial cells are capable of releasing ATP 
(Dezaki, Tsumura, Maeno, & Okada, 2000; Furuya, Sokabe, & Furuya, 2005). In 
addition to mechanosensory transduction, the release of ATP from immune 
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cells and during cell damage implicates purinergic signalling in nociceptive 
pathways during inflammation, injury and/or infection (Burnstock, 2009a). 
The identification of the ligand-gated non-selective P2X3 ion channel in 1995 
led to the proposal that these receptors ‘transduce ATP-evoked nociceptor 
activation’ (C. C. Chen et al., 1995; Lewis et al., 1995). Since then numerous 
studies have shown the importance of homomeric P2X3, and heteromeric P2X2/3 
receptors in pain processing and transduction (Wirkner et al., 2007). Indeed, 
P2X3 receptor expression correlates well with a nociceptive phenotype in 
sensory neurones (IB4 positive and capsaicin-sensitive) (C. C. Chen et al., 1995; 
Lewis et al., 1995) and is also extensively present in human sub-epithelial 
sensory nerves (Calvert et al., 2008).  
P2X3 receptors are expressed by 36% of mouse colonic sensory neurones 
(Brierley, Carter, et al., 2005).  This provides parity with functional responses 
by the selective P2X3 agonist, α,β-methylene-ATP (α,β-meATP), which excites 
visceral pelvic and splanchnic nerves; an effect that can be blocked by P2X 
antagonists including PPADS and TNP-ATP (Brierley, Carter, et al., 2005; Rong & 
Burnstock, 2004). These responses are potentiated by ARL-67156, an ATPase 
inhibitor, limiting the break-down of ATP (Wynn et al., 2003) and by the 
synergistic actions of other mediators including 5-HT, capsaicin and protons 
(Wynn & Burnstock, 2006). Inhibition of P2X3 receptors by TNP-ATP can also 
attenuate acute visceral pain behaviours following intraperitoneal injection of 
acetic acid (Honore et al., 2002). As well as an involvement in direct activation, 
pelvic afferent responses to distension are attenuated in the presence of P2X 
receptor antagonists (Wynn et al., 2004; Wynn et al., 2003), suggesting that P2X 
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receptors contribute significantly to the transduction of noxious mechanical 
stimuli in the gut. This is confirmed by in vivo models, where P2X3 -/- mice 
possess significantly reduced visceromotor reflexes (VMR) during colorectal 
distension (CRD), in conjunction with the loss of zymosan-induced colonic 
hypersensitivity (Shinoda et al., 2009). Indeed, single-fibre recordings of 
afferent responses to circumferential stretch are unaffected by the loss of P2X3, 
but mechanical hypersensitivity induced by inflammatory soup was attenuated 
(Shinoda et al., 2009); further highlighting the role of P2X3 receptors in the 
sensitisation of visceral afferents. Pharmacological inhibition of P2X3 with TNP-
ATP also reversed chronic visceral hypersensitivity in a rat acetic acid model of 
IBS (Xu, Shenoy, Winston, Mittal, & Pasricha, 2008). These findings suggest that 
P2X3 receptors contribute significantly in visceral afferent activation to noxious 
colorectal distension and mechanical hypersensitivity induced by inflammation. 
Whilst there exists compelling evidence for an ATP-mediated 
mechanotransduction pathway, P2X receptors are not mechanically-gated 
cation channels as described in previous chapters. The release of ATP, its 
diffusion and subsequent binding to ligand-gated purinoceptors, is a relatively 
slow mechanism of mechanosensitivity. As such, it is unlikely that P2X 
receptors act to directly gate mechanical stimuli, but rather ATP is probably 
better considered a key mediator responsible for the mechanosensory 
transduction of shear stresses associated with the viscous drag of passing fluids 
(Burnstock, 1999), and with the acute and chronic sensitisation of afferents 
during inflammation and injury. This is confirmed by increased release of ATP 
during colitis following distension in rodent models (Rong et al., 2002; Shinoda 
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et al., 2009). P2X3 receptor expression is also up-regulated following chronic 
visceral inflammation in rat (Xu et al., 2008), and in the enteric nerves of 
inflamed intestines from inflammatory bowel disease (IBD) patients, suggesting 
greater influence of this receptor on afferent sensitivity (Yiangou et al., 2001).  
As mentioned above, P2Y receptors also significantly contribute to the 
activation and modulation of sensory neurones by ATP. In addition to the 
established direct effects of P2Y receptor activation, afferent activation by ATP 
in P2X2/3 and P2X3 knock-out mice indicates additional signalling pathways for 
ATP-mediated effects (Rong et al., 2009; Shinoda et al., 2009). The role of other 
purinoceptors in visceral nociception is poorly understood, with a number of 
potential receptor candidates capable of mediating these effects expressed on 
sensory neurones. These include the metabotropic P2Y receptors and P1 
receptors (A1, A2A, A2B and A3) for the ATP break-down product, adenosine. The 
expression of these receptors and their involvement in nociceptive signalling is 
explained in more detail below (Table 7). 
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 Expression in sensory neurones 
Purinergic receptor subtype Small Medium Large 
P2X3 *** - - 
P2Y1 *** * - 
P2Y2 ** * * 
P2Y4 * * *** 
P2Y6 No evidence 
P2Y11 No rodent ortholog 
P2Y12 ** - - 
P2Y13 ** * * 
P2Y14 ** * * 
A1 *** 
A2A * 
A2B * 
A3 - - - 
 
Table 7. Summary of expression of relevant purinergic receptors in sensory 
neurones. ***high expression, **medium expression and *low expression. For 
adenosine receptors A1, A2A and A2B, expression relative to cell size is not known.  
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4.1.2 P2Y RECEPTORS 
 
P2Y receptors are G-protein coupled receptors that modulate neuronal activity 
by interactions with other receptors and ion channels. It is likely that P2Y 
receptors contribute significantly to the regulation of ATP-mediated afferent 
excitation in the gut; as such the eight P2Y receptor subtypes characterised in 
humans with their varying nucleotide and ligand sensitivities, as well as their 
couplings to intracellular signalling cascades, are detailed below (Table 8).  
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Type Ligands Intracellular Coupling 
P2Y1 ATP, ADP, ADP-β-S, 2-MeSADP, 
MRS2365 
↑PLC/Gq,11 
P2Y2 ATP, UTP, PSB1114 ↑PLC/Gq,11 
P2Y4 UTP ↑PLC/Gq,11 
P2Y6 UTP, UDP ↑PLC/Gq,11 
P2Y11 ATP, ADP, 2-MeSATP ↑PLC/Gq,11 & ↑AC/Gs 
P2Y12 ATP, ADP, ADP-β-S, 2-MeSADP ↓AC/Gi 
P2Y13 ATP, ADP, ADP-β-S, 2-MeSADP ↓AC/Gi 
P2Y14 UDP-glucose ↓AC/Gi 
 
Table 8. The selectivity of P2Y receptor ligands and coupling to intracellular 
signalling pathways. ↑PLC/Gq,11, positively coupled to phospholipase C via Gq,11 
proteins; ↓AC/Gi, negatively coupled to adenylyl cyclase via Gi proteins; ↑PLC/Gq,11 
& ↑AC/Gs, positively coupled to both phospholipase C and adenylyl cyclase via Gq,11 
and Gs proteins; ATP, adenosine 5’-triphosphate; ADP, adenosine 5’-diphosphate; 
ADP-β-S, adenosine 5’-O-(2-thiodiphosphate); 2-MeSADP, 2-methylthio ADP; 
MRS2365, [[(1R,2R,3S,4R,5S)-4-[6-Amino-2-(methylthio)-9H-purin-9-yl]-2,3-
dihydroxybicyclo[3.1.0]hex-1-yl]methyl] diphosphate; UTP, uridine 5’-triphosphate; 
PSB1114, 4-Thiouridine-5'-O-(β,γ-difluoromethylene)triphosphate; UDP, uridine 5’-
diphosphate; 2-MeSATP, 2-methylthio ATP. Summarised from (Gerevich & Illes, 
2004). 
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In contrast to the relatively restricted expression of P2X3 receptors in small 
DRG neurones, P2Y receptors are found much more ubiquitously across the size 
range of sensory neurones. Considerable evidence for the expression of those 
P2Y receptors in sensory neurones is outlined below. In addition to expression 
on sensory neurones, certain P2Y receptor subtypes are expressed by other cell 
types present in neuronal tissues, including satellite glial cells, astrocytes, 
oligodendrocytes and spinal cord microglia (Fam, Gallagher, & Salter, 2000; 
Salter & Hicks, 1994).  
4.1.3 EXPRESSION OF P2Y RECEPTORS IN SENSORY NEURONES 
 
4.1.3.1 P2Y1 
  
RNA transcripts for P2Y1 have been shown to be expressed in rat and mouse 
dorsal root ganglia (DRG) neurones, rat trigeminal ganglia (TG) and nodose 
ganglia (NG) (Moriyama et al., 2003; Ruan & Burnstock, 2003; Sanada et al., 
2002; Tominaga et al., 2001). In situ hybridisation (ISH) techniques show 
approximately 15-20% of neurones express P2Y1 in mouse DRG (Kobayashi et 
al., 2006; Moriyama et al., 2003; Xiao et al., 2002). This expression is neuronal-
specific and is not seen in Schwann or satellite cells and is also not seen in large 
cells (cell area >1200μm2), with an equal distribution across unmyelinated and 
thinly-myelinated neurones (Kobayashi et al., 2006; Nakamura & Strittmatter, 
1996). Immunohistochemical (IHC) staining of DRG, TG and NG in rat neurones 
labelled approximately 80% of small neuronal populations (Fong, Krstew, 
Barden, & Lawrence, 2002; Ruan & Burnstock, 2003). In agreement with ISH 
studies, 34-45% of these showed colocalisation with NF200 (i.e. neurofilament 
positive) neurones (Ruan & Burnstock, 2003). Importantly, 80% of small 
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neurones coexpress, not only both the nociceptive markers P2X3 and TRPV1, 
but also P2Y1 receptors (Gerevich et al., 2004). This correlates well with a 73-
84% colocalisation of P2Y1 with P2X3 receptors (Ruan & Burnstock, 2003). 
Finally, approximately 25% of P2Y1 immunoreactive sensory neurones co-stain 
for CGRP and 62% of P2Y1 immunoreactive neurones were IB4 positive, which 
concurs with the reported high colocalisation with P2X3 (Ruan & Burnstock, 
2003). 
4.1.3.2 P2Y2 
 
P2Y2 RNA transcripts are expressed in mouse DRG, rat DRG and rat TG and NG 
(Moriyama et al., 2003; Ruan & Burnstock, 2003; Sanada et al., 2002). ISH 
expression of P2Y2 mRNA transcripts have been reported in as high as 77% of 
rat DRG neurones, across both small and large cell sizes (Molliver et al., 2002). 
However, multiple studies in mouse have shown considerably lower expression 
(~25%) (Kobayashi et al., 2006; Moriyama et al., 2003). This may be a genuine 
species difference or possibly a discrepancy caused by differences in the 
methodology between the studies. IHC staining of cat DRG shows 35% 
immunoreactivity (IR) for P2Y2, specifically in small-diameter neurones (Ruan 
et al., 2005). P2Y2 IR in large diameter cell bodies is punctate and does not 
colocalise with P2X3, however a significant proportion of small-diameter 
neurones do colabel for P2Y2 and P2X3 receptors (Mo, Peleshok, Cao, Ribeiro-
da-Silva, & Séguéla, 2013). Of P2Y2 mRNA expressing neurones, approximately a 
third coexpressed TRPV1 mRNA (Moriyama et al., 2003), also suggesting a 
nociceptive phenotype. 
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4.1.3.3 P2Y4 
 
The expression of P2Y4 in rat DRG, NG and TG has been confirmed by RT-PCR 
(Ruan & Burnstock, 2003; Sanada et al., 2002). However, using ISH techniques, 
Kobayashi et al. failed to find expression of P2Y4 mRNA in DRG cell bodies 
(Kobayashi et al., 2006). In contrast, single-cell RT-PCR suggests modest 
expression in sensory neurones (see below) (X. Chen, Molliver, & Gebhart, 
2010). The P2Y4 receptor has been observed by immunohistochemical labelling, 
mainly in larger neurones (~70%), with some expression in small sensory 
neurones (Ruan & Burnstock, 2003). In terms of characterising the P2Y4-IR 
population in DRG, 97% of neurones co-express NF200, 10% co-express CGRP 
and 2% co-express IB4. 
4.1.3.4 P2Y6 
  
RT-PCR suggests the presence of P2Y6 in rat sensory ganglia (Ruan & Burnstock, 
2003; Sanada et al., 2002), although ISH to P2Y6 mRNA did not label any 
sensory neurones (Kobayashi et al., 2006). At the present time, no IHC 
expression data exists confirming the expression of P2Y6 in sensory neurones.  
4.1.3.5 P2Y11 
 
The P2Y11 receptor was originally cloned from human placenta and P2Y11 
mRNA has been identified in the human spleen and HL-60 cells (Communi, 
Govaerts, Parmentier, & Boeynaems, 1997). However, no rodent ortholog has 
yet been reported for P2Y11. 
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4.1.3.6 P2Y12, P2Y13 and P2Y14 
 
P2Y12, P2Y13 and P2Y14 were identified in DRGs by RT-PCR (Malin & Molliver, 
2010). ISH of P2Y12, P2Y13 and P2Y14 mRNA revealed localisation in glial cells 
closely associated with neurones (Kobayashi et al., 2006). However, IHC 
showed intense staining of all three receptors in small DRG neurones, with 
P2Y13 and P2Y14 observed in some larger neurones (Malin & Molliver, 2010). As 
yet, the expression profiles of these receptors remains unclear. 
Clearly contradictions in the quantification of expression levels exist in the 
literature, predominantly between ISH and IHC techniques. Given the close 
homology of the P2Y family, the specificity of an antibody for a particular 
subtype must be very critically assessed. This is especially true of polyclonal 
antibodies that bind likely multiple homologous P2Y epitopes, which the vast 
majority of the studies that are outlined above rely on. Whilst these 
discrepancies may be due to the tools used to probe sensory ganglia, the 
possibility of extensive post-transcriptional/pre-translational regulation could 
also account for differences between the reported expression levels of mRNA 
versus protein. Collectively, the data does suggest considerable expression of 
P2Y receptors on sensory neurones, especially P2Y1 and P2Y2, which are both 
positively coupled to phospholipase C through Gq,11 protein and are likely to 
potentiate excitatory afferent responses. This does not discount other P2Y 
receptor subtypes in sensory signalling, but does suggest their actions may be 
indirect and/or involve more complex multicellular pathways.  
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4.1.3.7 Expression in visceral extrinsic sensory nerve populations  
 
To date, only two studies have examined expression of P2Y receptors in visceral 
sensory nerves. Using single-cell RT-PCR of lumbosacral bladder-projecting 
DRG neurones, Chen et al. showed that 47% and 22% express P2Y2 and P2Y4 
receptors, respectively. In thoracolumbar DRG levels, these were reduced to 
38% and 13% for P2Y2 and P2Y4 receptors, respectively (X. Chen et al., 2010). 
There is also evidence of P2Y1 and P2Y2 receptor expression in kidney-
projecting sensory neurones (H. Wang, Wang, & Galligan, 2010).   
4.1.4 P2Y RECEPTORS IN MODULATION OF SENSORY NERVE FUNCTION 
 
The expression of P2Y receptors on sensory nerves correlates with a complex 
range of functional effects. P2Y receptors are capable of evoking action 
potential firing and inducing intracellular calcium flux. Indeed, P2Y1 and P2Y2 
receptor activation depolarises isolated sensory neurones and increases their 
excitability to current injection (Yousuf et al., 2011). The P2Y1, P2Y12 and P2Y13 
agonist ADP, can excite TG neurones and can also induce intracellular Ca2+ 
release from small IB4 positive DRG neurones (Borvendeg et al., 2003; Ceruti et 
al., 2008). In contrast to other sensitising effects, whole-cell patch-clamping 
recordings indicate that P2Y1 receptors can actually inhibit P2X3 receptors in 
DRG neurones (Gerevich, Müller, & Illes, 2005), which provide a further 
desensitising feedback pathway regulating ATP-mediated signalling.  
Behaviourally, P2Y1-mediated increase in intracellular calcium is required for 
inflammatory hyperalgesia in intraplantar CFA models (Andó, Méhész, Gyires, 
Illes, & Sperlágh, 2010; Malin & Molliver, 2010). In addition, the P2Y1 receptor 
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subtype has been shown to transduce ATP-dependent mechanical stimuli and to 
have modulatory effects on TRPV1 activity (Nakamura & Strittmatter, 1996; 
Tominaga et al., 2001). Finally, normal thermal sensation requires P2Y1 
receptors (Molliver, Rau, McIlwrath, Jankowski, & Koerber, 2011; Yajima, Sato, 
Giron, Nakamura, & Mizumura, 2005). This effect is, at least partially, mediated 
by TRPV1 phosphorylation following P2Y1 activation (Kwon et al., 2014). The 
contribution of P2Y1 receptors is increased following inflammation, where up-
regulation of P2Y1 receptors is responsible for normal heat sensitisation in 
cutaneous nociceptors (Jankowski et al., 2012).  
P2Y2 receptor agonists can also evoke excitatory effects in sensory neurones. 
Indeed, the P2Y2 and P2Y4 ligand UTP, can induce calcium influx in small 
nociceptive neurones (Molliver et al., 2002). In cutaneous fibre recordings, UTP 
can excite nociceptive fibres, whilst the selective P2Y6 ligand, UDP, failed to do 
so (Molliver et al., 2002; Stucky et al., 2004). UTP is also capable of depolarising 
neurones and triggering action potentials in current-clamp experiments (Ceruti 
et al., 2008; Molliver et al., 2002; Sanada et al., 2002). Whilst this effect was 
observed irrespective of neuronal size, suggesting that P2Y2 and/or P2Y4 
receptors may be present across a range of small and large neurones (Sanada et 
al., 2002), a mechanical hypersensitivity in cutaneous single fibre recordings 
following UTP application was only observed in a subset of C-fibre nociceptors 
(Lechner & Lewin, 2009). This does however fit with expression patterns 
observed by ISH and IHC (Mo et al., 2013; Molliver et al., 2002). Functional 
implications of the UTP activation of large neurones are yet to be determined. 
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P2Y12 antagonism can attenuate both inflammatory pain behaviours and 
hypersensitivity evoked by partial sciatic nerve ligation in mice (Andó et al., 
2010; Kobayashi et al., 2008). In a different model of neuropathic pain, 
following P2Y12 receptor antagonism and in P2Y12 -/- mice, tactile allodynia was 
significantly reduced (Tozaki-Saitoh et al., 2008). However, in isolated 
neurones, activation of Gi-coupled P2Y12, P2Y13 and P2Y14 receptors actually 
inhibits excitatory signalling (Malin & Molliver, 2010). These effects, in 
contradiction to the inhibitory actions reported by Malin et al. in neurones, are 
mediated by non-neuronal cells in the spinal cord, most probably microglia 
(Kobayashi et al., 2008; Tozaki-Saitoh et al., 2008). In addition to P2Y12 
receptors, microglia are also modulated by P2Y6, P2Y13 and P2Y14 receptors 
(Kobayashi, Yamanaka, Yanamoto, Okubo, & Noguchi, 2012). This supports the 
effects of intrathecal injections of UTP and UDP in neuropathic pain models 
which, in contrast to reported stimulatory effects of UTP in vitro, were both 
capable of reducing mechanical sensitivity and inhibiting induced tactile 
allodynia (Okada, Nakagawa, Minami, & Satoh, 2002).  
The behavioural changes and modulation of neuronal sensitivity by P2Y 
receptor ligands are the result of intracellular coupling to neuronal ion 
channels, including voltage-gated calcium, sodium and potassium channels. 
Specifically, inwardly rectifying K+ channels (Kir3), M-type K+ channel (KV7), 
voltage-activated calcium channels (CaV2) and Ca2+-dependent K+ channels 
(KCa2), are all examples of ion channels known to be coupled to P2Y receptors 
(Filippov et al., 2004; Gerevich et al., 2004; Schicker et al., 2010; Zaika, Tolstykh, 
Jaffe, & Shapiro, 2007). In addition, nucleotide agonists can alter both TTX-
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sensitive and TTX-resistant (TTX-R) sodium currents in dorsal root ganglia 
(DRG) neurones (Park et al., 2004). Hyperpolarising shifts by ADP and UTP in 
the conductance-voltage relationship of the slowly-inactivating TTX-R sodium 
current will likely affect nociceptor sensitivity (Baker, 2005; Baker et al., 2003; 
Park et al., 2004). Potentiation of TRPV1 responses to capsaicin, protons and 
heat by P2Y2 receptor activation in rat DRG neurones also contributes to the 
sensitising effects of ATP (Moriyama et al., 2003; Tominaga et al., 2001). Indeed, 
thermal hyperalgesia in mice to ATP injection was not lost following deletion of 
TRPV1 or P2Y1, however injection of UTP was capable of recapitulating a 
similar phenotype, suggesting P2Y2 involvement (Moriyama et al., 2003). 
Collectively these findings show that P2Y receptors are extensive expressed by 
sensory neurones and act to mediate aspects of thermal, acute and neuropathic 
nociception. However, the data does provide an indication of the complexity of 
P2Y signalling intraneuronally, with multiple receptors acting synergistically to 
regulate neuronal function. Moreover, the role of P2Y receptors on non-
neuronal cell types and the ability to regulate ATP signalling is apparent.  
4.1.5 ROLE OF P2Y RECEPTORS IN VISCERAL AFFERENT SIGNALLING AND THE 
ENTERIC NERVOUS SYSTEM 
 
Evidence for P2Y receptor signalling in visceral afferents is observed in 
projections to the bladder and kidney. Specifically, activation of P2Y2 receptors 
sensitise P2X2, P2X3 and TRPV1 currents present in these neurones, 
contributing to afferent excitability and hypersensitivity (X. Chen et al., 2010; H. 
Wang et al., 2010). In the context of the bladder, increased afferent firing is 
associated with urinary frequency, urgency and pain (Nazif, Teichman, & 
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Gebhart, 2007). In the kidney, local release of ATP could modulate TRPV1 
function and act to regulate the release of vasodilator peptides, increasing 
glomerular filtration rate and sodium/water excretion (H. Wang et al., 2010). In 
addition, this also likely contributes to pain associated with occlusions of the 
kidney ducts. 
Further to the extrinsic visceral afferent function, P2Y receptors are also found 
in enteric neurones, where they contribute to secretomotor reflexes within the 
submucosal plexus. For example, P2Y receptors (and P1 receptors, which will 
be discussed later) are involved in the modulation of mechanosensitive 5-HT 
release, fluid, mucin and ion (Cl-, HCO3- & K+) secretion, amongst other functions 
(Christofi, 2008; Christofi et al., 2004; Hu et al., 2003). Whether these activities 
impact on visceral afferent sensitivity or visceral nociceptive pathways remains 
unclear. As mentioned in the previous chapter, little evidence exists for 
crosstalk between extrinsic afferent projections and the enteric nervous system, 
at least with respect to mechanosensitivity.   
4.1.6 P1 RECEPTORS  
 
Adenosine is an important neuromodulator in the central nervous system (CNS) 
and the periphery, acting through P1 receptor subtypes: A1, A2A, A2B and A3 
receptors. In addition to its release by sensory and sympathetic neurones, 
endothelial cells, immune cells, fibroblasts and mast cells, the 
dephosphorylation of ATP by ectonucleotidases also yields adenosine (Sawynok 
& Liu, 2003). Within the CNS, adenosine facilitates both excitatory and 
inhibitory actions on neuronal function and the central inflammatory processes. 
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Specifically in pain transmission, adenosine can act at spinal, supraspinal and 
peripheral sites to induce both pronociceptive and antinociceptive effects 
(Sawynok, 1998). As mentioned previously, adenosine applied at peripheral 
targets induces pain in somatic (Bleehen & Keele, 1977; Pappagallo et al., 1993) 
and visceral models (Crea et al., 1990; Gaspardone et al., 1995). By contrast, 
activation of adenosine A1 receptors in the spinal cord by intrathecal injection 
of adenosine produces analgesia (Belfrage, Segerdahl, Arnér, & Sollevi, 1999; 
Eisenach, Curry, & Hood, 2002). In peripheral nociceptive afferent fibres, 
adenosine can inhibit or augment firing rates dependent on the actions of 
adenosine A1 or A2A receptors (Aley, Green, & Levine, 1995; Taiwo & Levine, 
1990). Differential coupling of adenosine receptors to neuronal effectors, such 
as ion channels and intracellular signalling pathways, enables adenosine to 
modulate these contrasting effects on neuronal excitability.  
4.1.7 EXPRESSION OF P1 RECEPTORS IN SENSORY NEURONES 
 
In line with the functional effects of adenosine, adenosine receptors have a wide 
expression distribution across multiple tissues, including neuronal and non-
neuronal cell types in the CNS, spinal cord and cardiovascular tissues (Marala & 
Mustafa, 1998), as well as in skeletal muscle (Lynge & Hellsten, 2000) and at 
motor nerve terminals (Baxter, Vega-Riveroll, Deuchars, & Parson, 2005). 
Relevant to afferent nociceptive pathways, adenosine receptors are expressed 
by the somata of sensory neurones. Selective adenosine receptor subtype 
expression within different tissues mediates the contrasting algogenic and 
analgesic effects of adenosine.  
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In sensory neurones, these effects are transduced predominantly by adenosine 
A1 receptors and to some extent A2A and A2B receptors. Indeed, RT-PCR of whole 
DRG reveals significant expression of adenosine A1 receptor compared to 
minimal levels of adenosine A2A and A2B receptor mRNA transcripts. No 
expression of adenosine A3 receptors was detected in DRG (L. Li et al., 2010). 
Quantitatively, in viscerally-projecting DRG neurones, single-cell RT-PCR 
revealed approximately 80% of TRPV1-positive cells also expressed adenosine 
A1 receptors. In these same cells, adenosine A2A and A2B receptor mRNA 
transcripts were detected in less than 22% of cells, whilst no cells expressed 
adenosine A3 receptors (Ru, Surdenikova, Brozmanova, & Kollarik, 2011). 
Immunostaining has also identified adenosine A1 receptors in cultured TG 
neurones and weak adenosine A2A receptor expression in mice DRG neurones 
(Carruthers et al., 2001; L. Li et al., 2010).  In contrast to adenosine A1 receptors, 
mRNA for adenosine A2A receptor appears not to be present in neurones of the 
spinal cord (Kaelin-Lang, Lauterburg, & Burgunder, 1998). 
4.1.8 P1 RECEPTORS IN MODULATING SENSORY AFFERENT FUNCTION 
 
Adenosine released in the periphery exerts effects on nociceptive processing by 
the activation of the four adenosine receptor subtypes (A1, A2A, A2B and A3), 
which in turn are coupled to multiple intracellular signalling pathways. Of 
relevance to afferent function are the opposing effects of adenosine A1 and A2A 
receptor activation, resulting in decreased or increased intracellular cAMP and 
opposing changes in neuronal excitability (Aley et al., 1995; Khasar et al., 1995; 
Taiwo & Levine, 1990). Whilst electrophysiological studies show that A1 
receptor agonists can increase sensory afferent firing innervating the lung 
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(Hong, Ho, Kwong, & Lee, 1998), knee joint (Dowd, McQueen, Chessell, & 
Humphrey, 1998) and mesenteric afferent neurones (Kirkup, Eastwood, 
Grundy, Chessell, & Humphrey, 1998), adenosine-mediated peripheral 
mechanical hyperalgesia is significantly regulated by A2A receptor activation (L. 
Li et al., 2010). Interestingly, adenosine can also directly inhibit TRPV1 Ca2+ 
flux, independent of A2A receptor activation, and may serve as a means of 
regulating excessive TRPV1 activation and nociceptor excitability during 
hyperalgesic states (Puntambekar, Van Buren, Raisinghani, Premkumar, & 
Ramkumar, 2004).   
In the enteric nervous system, adenosine receptors are expressed differentially 
along the GI tract and in neuronal and non-neuronal tissues. In both the 
submucosal plexus and the myenteric plexus, all four receptors are detectable 
by RT-PCR, with lower expression of adenosine A1 and A2A receptors compared 
to adenosine A2B and A3 receptors (Christofi et al., 2001). This is confirmed by 
immunostaining against adenosine A3 receptors in substance P-positive 
submucosal ganglia. By contrast, A2B receptors are expressed predominantly in 
vasoactive intestinal peptide (VIP)-ergic neurones, with A2A receptors split 
between the two populations (Christofi et al., 2001). In addition, adenosine may 
evoke release of secondary mediators from non-neuronal cells within the GI 
tract, including mast cells (Olah & Stiles, 1995). The modulation of afferent 
function by these paracellular influences is unclear and poorly studied. 
Given that multiple purinoceptors, including P2Y and P1 receptors, are 
expressed by sensory neurones innervating the viscera and somatic tissues, it is 
likely that they contribute significantly to the ability of ATP to sensitise 
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afferents during inflammation and injury. As shown in previous chapters, 
voltage-gated sodium channel subtype 1.9 (NaV1.9) contributes greatly to 
afferent chemosensitivity, mechanosensitivity and mechanical hypersensitivity 
during acute inflammatory stimulation. It is likely, therefore, that purinoceptors 
may work in conjunction with NaV1.9 to regulate afferent sensitivity and 
excitability.  
4.1.9 MODULATION OF NAV1.9 BY PURINOCEPTORS 
 
The current mediated by NaV1.9 can be up-regulated in sensory somata by 
activation of G-protein coupled intracellular signalling pathways (Baker, 2005; 
X. Chen et al., 2011; Maingret et al., 2008; Rush & Waxman, 2004). Specifically, 
activation of GPCRs by inflammatory mediators, including extracellular ATP, 
can increase peak NaV1.9 current amplitude in a concentration-dependent 
manner (Baker, 2005). Such up-regulation of NaV1.9 current can lead to 
moderate neuronal depolarisation and increased afferent excitability. In 
contrast, Maingret et al. were unable to evoke NaV1.9 current enhancement 
when ATP was applied independently, but could drive current up-regulation 
with GTP-γ-S and also with an inflammatory cocktail of mediators (bradykinin, 
PGE2, histamine, norepinephrine & ATP) (Maingret et al., 2008). Therefore they 
propose NaV1.9 represents a coincidence detector to inflammatory mediators in 
nociceptors. The exact mechanism by which ATP, either on its own or in the 
presence of other mediators, can cause NaV1.9 current enhancement remains 
unknown. The possibility that NaV1.9 current potentiation by either ATP-
mediated P2Y receptor activation or adenosine-mediated P1 receptor activation 
could significantly contribute to the effects of both ATP and adenosine on 
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neuronal excitability is still to be investigated. This may represent an important 
mechanism by which ATP can act to acutely and chronically sensitise visceral 
afferents.  
245 
 
4.2 AIMS 
 
It is clear from the studies mentioned above that the ability of ATP to modulate 
afferent sensitivity and pain pathways is dependent on the actions of multiple 
purinoreceptors, as well as the regulation of multiple downstream effector 
channels.  
Therefore the aims of this chapter were; 
1. To investigate how deletion of NaV1.9 affects colonic afferent excitability 
to both ATP and its breakdown product, adenosine 
2. To study P2Y receptor activation of colonic afferent fibres 
3. To investigate how NaV1.9 -/- colonic afferent activity is affected by P2Y 
receptor activation 
4. To understand whether P2Y receptor agonists can excite human 
mesenteric afferent fibres 
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4.3 METHODS 
4.3.1 WHOLE-NERVE ELECTROPHYSIOLOGICAL RECORDINGS FROM LUMBAR 
SPLANCHNIC NERVE IN MOUSE DISTAL COLON 
 
Multi-unit activities were recorded from the whole lumbar splanchnic nerve in 
a tubular preparation of the distal colon, as described in detail in Chapter 3. 
Briefly, the distal colon from either NaV1.9 +/+ or NaV1.9 -/- mice was dissected 
free with associated mesentery and neurovasculature. Field potential 
recordings from the lumbar splanchnic nerve were made using a borosilicate 
glass suction electrode, amplified, band-pass filtered (gain 5K; 100-1300Hz) 
and digitally filtered for 50Hz noise. Raw traces were digitised at 20 kHz and 
action potential firing counts determined using a threshold set at twice the 
background noise (typically 100μV). Neurogram and pressure traces were 
displayed on a PC using Spike 2 software (Cambridge Electronic Design, UK). 
The distal colon was tied to two cannulas using thin thread, and both perfused 
intraluminally with Kreb’s buffer at 0.1ml/min and superfused with Kreb’s 
buffer at 7-8ml/min. The pressure was set to baseline and then a ~2mmHg end 
pressure applied before allowing the preparation to stabilise for approximately 
45 minutes.  
4.3.2 PROTOCOLS FOR TUBULAR PREPARATION OF MOUSE COLON 
 
After the stabilising period, drugs were applied by bath superfusion of a 20ml 
volume. Purinergic agonists (ATP [0.1, 1 & 3 mM], ADP [0.1, 1 & 3mM], UTP [0.1, 
1 & 3mM], UDP [1, 3 & 10mM] and adenosine [0.1, 0.3, 1 & 3 mM]) were applied 
in separate experiments, while different concentrations of the same agonist 
were applied consecutively in most cases. Where repeat concentrations of drugs 
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were given, a 60 minute interval was maintained or until activity had stabilised 
to baseline. For antagonist studies, using P2X receptor antagonists, PPADS 
(30μM) and TNP-ATP (10-30μM) and adenosine P1 receptor antagonist, CGS 
15943 (3μM), repeat applications of ATP (1mM or 3mM) were applied. Once 
stable responses to ATP application were achieved, the antagonist (PPADS, 
TNP-ATP or CGS 15943) was applied both immediately prior to the next ATP 
application (by bath superfusion of 20mL volume) and during the ATP 
application. Later, antagonist studies using selective P2Y receptor antagonists, 
MRS2500 (3μM), Ticlopidine (100μM) and AR-C118925X (10μM) were applied 
to separate naive preparations prior to, and in the presence of, a singular 
agonist concentration (ATP [1mM], ADP [1mM] or UTP [1mM]). Selective P2Y 
receptor agonist studies using MRS2365 (10μM) and PSB1114 (3-10μM) were 
undertaken in separate preparations.  
4.3.3 WHOLE-NERVE ELECTROPHYSIOLOGICAL RECORDINGS FROM MESENTERIC 
NERVE OF HUMAN RESECTED BOWEL TISSUES 
 
As described in the previous chapter, resected human colon was obtained after 
full written consent from patients undergoing elective surgery at Barts Health 
NHS Trust, London after approval by the local Research Ethics Committee 
(NREC 10/H0703/71). Macroscopically normal colon, appendix and ileum were 
obtained from patients undergoing colectomy as part of their normal surgical 
treatment for bowel cancer. Specimens were removed away from the tumour, 
resection margins or lymphatic drainage field and were surplus to 
histopathological assessment. Details of the tissues used are described in Table 
9. Once removed, tissues were immediately placed in cold carbogenated Kreb’s 
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buffer prior to sharp dissection of full-thickness colonic wall (~4cm square with 
mesenteric fan down the centre) and depending on length, the appendix was 
split in two or used in its entirety. Tissue was superfused with oxygenated 
Kreb’s buffer (supplemented with 10µM nifedipine and 10µM atropine) at a rate 
of 7mL/min and at a temperature of 32-34oC. Under a dissection microscope, 
the neurovascular bundles in the associated mesentery were blunt dissected 
and mesenteric nerves identified and cleared of connective tissue. 
Electrophysiological recordings were subsequently made in an identical 
manner to that of animal tissues. 
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# Tissue Disease Operation Age Sex 
1 Appendix Cancer Right hemicolectomy 86 M 
2 Sigmoid colon Cancer Laparoscopic anterior resection 59 F 
3 Sigmoid colon Cancer Anterior resection 52 M 
4 Sigmoid colon Cancer Laparoscopic anterior resection 50 F 
5 Appendix Cancer Right hemicolectomy 62 F 
6 Appendix Cancer Laparoscopic right hemicolectomy 81 F 
7 Ileum Cancer Laparoscopic right hemicolectomy 76 M 
8 Appendix Cancer Subtotal colectomy 57 M 
9 Sigmoid colon Cancer Anterior resection 76 M 
   Mean age / M:F ratio 67 1.25:1 
 
Table 9. Patient details of human tissue used in mesenteric nerve recordings 
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4.3.4 PROTOCOLS FOR HUMAN BOWEL TISSUE RECORDINGS 
 
In human tissue experiments, concentrations of ATP (1 and 10mM), ADP (1 and 
10mM) and UTP (1 and 10mM) were applied by bath superfusion of a 20ml 
volume sequentially at 1 hour intervals, in variable total bath volumes 
dependent on tissue type. As such, comparisons between relative nucleotide 
activities should not be over-interpreted. 
4.3.5 CHROMOGENIC IN SITU HYBRIDISATION 
 
Retrograde labelling of colonic tissues was achieved following the same 
protocol as outlined in Chapter 2. In brief, Fast Blue (2% in saline) was injected 
into the wall of the distal colon of naïve C57BL6 mice following laparotomy 
under general anaesthetic. Mice were allowed to recover and dorsal root 
ganglia (T13 and L1) were harvested after three days following transcardial 4% 
paraformaldehyde perfuse fixation. DRGs were post-fixed (2hr, 4% PFA) and 
cryoprotected (30% sucrose) before freezing at -80°C. Cryostat sections (10μm) 
were collected sequentially across 40 slides per DRG, with N=5 animals per 
slide.  
Sections were prepared as required for use in RNAscope 2-plex (Chromogenic) 
Detection Kit (Advanced Cell Diagnostics, Inc., USA). The chromogenic in situ 
hybridisation assay employs two independent signal amplification systems to 
detect RNA-specific probes hybridised to the tissue. Presence of the target RNA 
transcripts was detected by punctate dots of two distinctly coloured chromogen 
precipitates (red and green). Sections were washed in 0.1M PBS followed by 10 
minute endogenous enzyme block (against horseradish peroxidase (HRP) and 
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alkaline phosphatase (AP)) at room temperature (RT). Antigen retrieval was 
performed by incubation at ~100°C in ‘Pretreat 2’ (a sodium citrate buffer) for 
15 minutes and 40 minutes at 40°C in ‘Pretreat 3’, a protease digestion step. 
These steps were optimised empirically in order to provide the maximal 
chromogenic signal whilst minimising structural tissue degradation. The two 
target probes consist of 6-10 short oligonucleotide pairs, covering 
approximately 50 bases of the target mRNA per oligonucleotide, these were 
hybridised for 2 hours at 40°C. The SCN11A probe targets NM_011887.3, 349-
1283bp within exon 3 –exon 10 and the P2Y1 probe targets NM_008772.4, 
1101-2092bp. Probe design and selection was carried out by ACD (Mm-
SCN11A-C1 (catalog #403531) and Mm-P2ry1-C2 (catalog #406061-C2). Once 
hybridised, six amplification steps were performed, culminating in the binding 
of HRP- and AP-labelled probes. Addition of chromogenic substrates produced 
green and red coloured products, respectively. Sections were counterstained 
(50% haemotoxylin and 0.02% ammonia water), dried (60°C, 15mins) and 
coverslipped in EcoMount (BioCare Medical, USA) mounting medium.  
4.3.6 DATA ANALYSIS 
 
In electrophysiological multi-unit recordings, peak changes and time profiles of 
nerve activity were determined by subtracting baseline firing (5 minutes before 
drug application) from increases in nerve activity following drug superfusion. 
Changes in nerve activity were compared between NaV1.9+/+ and NaV1.9-/- 
animals using Student’s t-test or two-way ANOVA with Bonferroni post-hoc test, 
as appropriate. 
252 
 
From the time profiles, six criteria were established, these are outlined in detail 
in Figure 33 and the associated figure legend. Time to onset, time to peak, time to 
80% response, time to 50% response and time to return to baseline of time 
profiles were compared between genotypes by 2-way ANOVA with Bonferroni’s 
post-hoc, as appropriate. In antagonist studies featuring repeat application of 
ATP, paired two-tailed t-tests were used to compare responses to ATP prior to, 
after and in the presence of antagonists (PPADS, TNP-ATP and CGS 15943). In 
later antagonist studies, unpaired t-tests compared existing agonist responses 
(ATP, ADP and UTP) with independent responses, in the presence of an 
antagonist (MRS2500, Ticlopidine and AR-C118925X). All data are expressed as 
mean ± S.E.M. P < 0.05 was taken to indicate statistical significance. 
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Figure 33. Representative time profile of response to drug application and data 
derived from time profiles. The baseline firing was established as the mean nerve 
activity of at least 3 minutes prior to drug application. Peak firing was determined 
as the peak nerve firing minus the baseline activity. (1) Time to onset was 
determined as the time taken for firing to increase above baseline after superfusion 
of drug into the bath began. (2) Time to peak represents the time taken from drug 
entering the bath to activity reaching its peak. (3) Time to 80% response and (4) 
time to 50% response were determined as the time taken for nerve activity, after 
peaking, to reduce to 80% and 50% of the maximal, respectively. (5) Time to return 
to baseline, represents the time taken for nerve activity to recover fully to baseline 
after drug application.  
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4.3.7 IMAGING AND QUANTITATION 
 
The percent of area covered by reaction products in in situ hybridisation 
experiments for NaV1.9 mRNA and P2Y1 mRNA were determined for all Fast 
Blue positive (FB+) DRG cells (ImageJ 1.45S analysis software, NIH, USA). Fast 
Blue and brightfield images at 20x magnification were taken of every 10th 
sequential DRG section (sampling at ~100μm intervals). The two chromogenic 
reaction products (green and red) were sufficiently divergent in chromaticity to 
enable reliable and robust isolation from RGB colour images (Adobe Photoshop 
CS3, USA). Specifically, all other colour hues (orange, yellow, blue and violet) 
were desaturated and the background was subtracted, with only red and green 
pixels corresponding to the presence of NaV1.9 mRNA and P2Y1 mRNA, 
respectively, remaining. Fast Blue-labelled cells were identified using ImageJ 
software and these overlays transposed onto brightfield images. Percent area 
covered of reaction products per FB+ cell was subsequently quantified. A 
background measure was taken from a comparable area size of the image 
containing no tissue, and subtracted from percent area covered of FB+ cells. 
Quantified reaction product of non-soma axon tissue regions was used as a 
threshold to determine positive labelling (~3%) and as the limitations of the 
detection method. This equated to 1-3 chromogen dots per approximately 
equivalent area of 10 cells; with anything with greater expression than this was 
deemed to be positively labelled.  
4.3.8 DRUGS 
 
Adenosine 5’-triphosphate (ATP) disodium salt hydrate, adenosine 5’-
diphosphate monopotassium salt hydrate (ADP), uridine 5’-triphosphate 
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trisodium salt dehydrate (UTP) uridine 5’-diphosphate disodium salt hydrate 
(UDP) were all purchased from Sigma-Aldrich (UK) and made up to a stock of 
300mM in water. Also purchased from Sigma-Aldrich were nifedipine (100mM: 
DMSO), atropine (100mM: EtOH) and indomethacin (30mM: DMSO). 2’-3’-O-
(2,4,6-Trinitrophenyl)adenosine-5’-triphosphate tetra(triethylammonium) salt 
(TNP-ATP), pyridoxalphosphate-6-azophenyl-2’-4’-disulfonic acid tetrasodium 
salt (PPADS), [[(1R,2R,3S,4R,5S)-4-[6-Amino-2-(methylthio)-9H-purin-9-yl]-2,3-
dihydroxybicyclo[3.1.0]hex-1-yl]methyl] diphosphoric acid mono ester 
trisodium salt (MRS2365), (1R*,2S*)-4-[2-Iodo-6-(methylamino)-9H-purin-9-
yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate 
ester tetraammonium salt (MRS2500), 5-[(2-Chlorophenyl)methyl]-4,5,6,7-
tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine) and 4-
Thiouridine-5'-O-(β,γ-difluoromethylene)triphosphate tetrasodium salt 
(PSB1114) were diluted in water and CGS 15943 was diluted in DMSO; all were 
purchased from Tocris Biosciences (UK). AR-C118925X was diluted in DMSO 
and was a kind gift from Novartis UK. All compounds were diluted in Kreb’s 
buffer to appropriate working concentrations on the day of use. 
 
Where possible, concentrations were chosen based on their use in comparable 
ex vivo afferent nerve preparations in the literature (such as jejunal mesenteric 
nerve, bladder pelvic nerve or oesophageal vagal nerve; see Table 10.). If this 
strategy was not possible, then IC50 and EC50 concentrations at the receptor of 
interest were used to estimate an appropriate concentration in the colonic 
afferent preparation. Based on the existing literature, this was typically a 10-
100x increase in concentration from isolated cell protocols (Wynn & Burnstock, 
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2006; Wynn et al., 2004). Wash-out of drug effect, repeat application and 
concentration-dependent effects by increasing 10-fold increments, were all 
used to confirm specific pharmacology in pilot studies.  
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Drug Concentration 
used in current 
study (mM) 
Previous experiments Concentration used in previous 
study (mM) 
Reference 
ATP 0.1, 1, 3 Colonic pelvic nerve 0.1 - 10 (Wynn & Burnstock, 2006; 
Wynn et al., 2003) 
ADP 0.1, 1, 3    
UTP 0.1, 1, 3    
UDP 1, 3, 10    
Adenosine 0.1, 0.3, 1, 3 Oesophageal vagal nerve 0.1 (Ru et al., 2011) 
PPADS 0.03 Splanchnic and pelvic nerves 0.03 - 0.1 (Brierley, Carter, et al., 
2005; Rong et al., 2009; 
Wynn et al., 2003) 
TNP-ATP 0.01 – 0.03 Bladder pelvic nerve 0.03 (Rong et al., 2002) 
CGS 15943 0.003 IC50 – adenosine-stimulated 
adenylate cyclase assay in 
synaptoneurosomes 
0.000003 – 0.000020 
(depending on receptor 
subtype) 
(M. Williams et al., 1987) 
MRS2365 0.01 EC50 - inositol phosphates assay in 
COS-7 cells 
0.0000004 (Chhatriwala et al., 2004) 
MRS2500 0.003 IC50 – ADP-stimulated platelet 
aggregation 
0.00000095 (Cattaneo et al., 2004) 
Ticlopidine 0.1    
PSB1114 0.003-0.01 EC50 – inositol phosphates assay in 
astrocytoma 1321N1 cells 
0.000134 (El-Tayeb, Qi, Nicholas, & 
Müller, 2011) 
AR-C118925X 0.01 IC50 – ATP-γS-induced mucin 
secretion 
0.001 (Kemp, Sugar, & Jackson, 
2004) 
 
Table 10. Rationale for concentrations of purinergic agonists and antagonists used in the present studies. Where agonists or antagonists have 
been used in equivalent ex vivo afferent nerve preparations, these concentrations were applied to the present studies. If no comparable 
studies exist in the literature, then the EC50 or IC50 in a cellular assay was used to estimate an appropriate concentration for application in 
afferent preparations; usually 10-100x greater than the EC50 or IC50.  
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4.4 RESULTS 
4.4.1 COLONIC SPLANCHNIC AFFERENT NERVE RESPONSES TO ATP IN  
NAV1.9 +/+ AND NAV1.9 -/- MICE 
 
To investigate how NaV1.9 affects purinergic signalling pathways in colonic 
visceral afferents, whole-nerve recordings of responses to ATP superfusions 
were made in a cannulated tubular preparation of the distal colon. Sequential 
application of increasing ATP concentrations (0.1mM, 1mM & 3mM) in NaV1.9 
+/+ mice led to concentration-dependent increases in afferent activation (see 
Figure 34). Following 1mM and 3mM ATP application, a significant direct 
excitation was evoked, however, following 0.1mM ATP application, a transient 
(~3mins) decrease in baseline activity was observed, followed by a modest 
increase in afferent activity (Figure 34C). Changing the order of these sequential 
ATP applications still evoked comparable responses. In NaV1.9 -/- mice, 
responses to ATP were attenuated at all concentrations examined (p < 0.0001; 
Figure 34F). Baseline firing prior to ATP application did not differ significantly 
between genotypes (p = 0.19; Figure 35A). The time taken from ATP entering 
the bath to peak firing (Time to peak) and the time taken for an increase in firing 
to occur above baseline (Time to onset) were not significantly longer in NaV1.9 -
/- preparations (p = 0.38 and p = 0.74, respectively; Figure 35B). Perhaps 
unsurprisingly given the reduced peak firing in NaV1.9 -/- mice, the times taken 
for firing to return back to 80% and 50% of maximum firing and the time taken 
to return to baseline following ATP application (Time to 80% response, Time to 
50% response and Time to return to baseline) were significantly reduced at all 
concentrations apart from 0.1mM (p < 0.01, p < 0.01 and p < 0.01, respectively). 
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Even at the highest concentration of ATP tested (3mM), firing rates and nerve 
terminal sensitivity were reduced by 73% in NaV1.9 -/- afferents. This suggests 
that ATP is unable to evoke the same degree of afferent excitation in the 
absence of NaV1.9. 
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Figure 34. Effect of increasing concentrations of ATP on colonic splanchnic nerve 
activity in NaV1.9 +/+ and NaV1.9 -/- mice. Example raw histogram and associated 
neurogram of nerve activity in NaV1.9 +/+ (A) and NaV1.9 -/- (B) mice to 0.1mM, 
1mM and 3mM ATP. Below, expanded traces of activity at baseline and following 
addition of 3mM ATP and example action potential for each genotype. Response 
profiles to addition of 0.1mM ATP (C), 1mM ATP (D) and 3mM  ATP (E) in both 
NaV1.9 +/+ and NaV1.9 -/- mice. F Peak increase in nerve activity following addition 
of 0.1mM, 1mM & 3mM ATP above baseline activity in NaV1.9 +/+ and NaV1.9 -/- 
mice (p < 0.0001, 2-way ANOVA with Bonferroni’s post-hoc, **p < 0.01, ***p < 
0.001). 
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Figure 35. Baseline firing prior to ATP application and duration of responses to ATP 
in colonic splanchnic nerve. A Mean nerve activity over 3 minutes prior to 
application of ATP in NaV1.9 +/+ and NaV1.9 -/- (N = 6, both groups; p = 0.19, 2-way 
ANOVA). B Time taken from ATP superfusion entering the recording bath to an 
increase in mean nerve activity above baseline (N = 6, both groups; p = 0.74, 2-way 
ANOVA). C Time taken from ATP entering the recording bath to reach peak nerve 
activity (N = 6, both groups; p = 0.38, 2-way ANOVA). D Time taken for nerve 
activity to return to 80% of peak response (N = 6, both groups; p < 0.01, 2-way 
ANOVA). E Time taken for nerve activity to return to 50% of peak response (N = 6, 
both groups; p < 0.01, 2-way ANOVA). F Time taken for nerve activity to return to 
baseline (N = 6, both groups; p < 0.01, 2-way ANOVA). 
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4.4.2 P2X RECEPTOR AND P1 ANTAGONISM OF ATP-MEDIATED ACTIVATION OF 
COLONIC SPLANCHNIC AFFERENT NERVE IN NAV1.9 +/+ MICE 
 
To further investigate the purinergic signalling pathways responsible for ATP-
mediated excitation of colonic afferents, cannulated distal colon preparations 
from wild-type NaV1.9 +/+ mice were pre-incubated with antagonists for P2X 
receptors and adenosine P1 receptors. Repeat applications of ATP evoked 
stable responses at both 1mM and 3mM concentrations. Addition of the P2X 
antagonist, PPADS (30µM) or the selective P2X1,2/3,3 antagonist, TNP-ATP (10-
30µM), to repeat concentrations of 1mM ATP in NaV1.9 +/+ animals produced 
no significant change in activity (PPADS: p = 0.23; TNP-ATP:  p = 0.49; Figure 
36). Even at an increased concentration of 30µM TNP-ATP, no change in 
afferent activity to 1mM ATP was observed (N = 2). Following repeat 
applications of 3mM ATP, pre-incubation with the P2X receptor antagonists, 
PPADS (30µM) or TNP-ATP (10µM) resulted in a significant reduction in 
afferent activity (p < 0.05 and p < 0.05, respectively; Figure 36). Pre-incubation 
with the non-selective P1 (adenosine) receptor antagonist CGS 15943 (3µM) to 
repeat applications of 3mM ATP led to a 28.5% reduction in afferent firing (p < 
0.05). Given that complete inhibition of responses to ATP were not achieved by 
supramaximal concentrations of either P2X receptor or non-specific P1 
adenosine receptor antagonists, we investigated the role of P2Y receptors in 
colonic afferent activation.  
263 
 
 
Figure 36. Effect of P2X receptor and P1 (adenosine) receptor antagonism by 
PPADS, TNP-ATP and CGS 15943 on colonic splanchnic nerve activity to ATP. A 
Example rate histogram and raw neurogram of nerve activity following repeat 
application of 3mM ATP prior to and following addition of 30µM PPADS. B Percent 
reduction in peak activity to application of 3mM ATP following pre-incubation with 
30µM PPADS (N = 3), 10-30µM TNP-ATP (N = 3-5) and 3µM CGS 15943 (N = 3). 
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4.4.3 COLONIC SPLANCHNIC AFFERENT NERVE RESPONSES TO P2Y LIGANDS IN 
NAV1.9 +/+ AND NAV1.9 -/- MICE 
 
Using the P2Y receptor agonists, ADP (selective for P2Y1, P2Y12 and P2Y13 
receptors) and UTP (selective for P2Y2, P2Y4 and P2Y6 receptors) the role of 
P2Y receptor-mediated excitation in NaV1.9 +/+ and NaV1.9 -/- animals was 
evaluated. In NaV1.9 +/+ tissues, both ADP and UTP elicited concentration-
dependent increases in afferent firing, although in both instances responses at 
0.1mM were modest (Figure 37 & Figure 39). The response to ADP was 
moderately larger than that of ATP in terms of peak, although the duration of 
response was equivalent (e.g. Time to return to baseline: ATP 3mM, 2322 ± 125 
s; ADP 3mM, 2217 ± 384 s; p = 0.80, two-tailed unpaired t-test; Figure 41A). The 
response to UTP at equivalent concentrations was significantly smaller than 
both ADP and ATP, and was considerably shorter in duration (e.g. Time to 
return to baseline: UTP 3mM, 1337 ± 113 s; vs ATP, p < 0.001, two-tailed 
unpaired t-test; Figure 41A). Responses to ADP were significantly reduced in 
NaV1.9 -/- mice, (p < 0.001; Figure 37), as were responses to UTP (p < 0.001; 
Figure 39). Interestingly, in contrast to baseline firing prior to application of 
both ATP and UTP, a significant difference was observed in baseline firing rates 
of ADP in the absence of NaV1.9 (Figure 38 & Figure 40). As observed for ATP, 
Time to peak and Time to onset of ADP application were not different between 
genotypes (Figure 38B & C). However, following ADP application Time to 80% 
response, Time to 50% response and Time to return to baseline were all 
significantly attenuated in NaV1.9 -/- mice, likely due to not reaching the same 
degree of peak firing observed in NaV1.9 +/+ mice.  
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Figure 37. Effect of increasing concentrations of P2Y1, P2Y12 and P2Y13 agonist, ADP 
on colonic splanchnic nerve activity in NaV1.9 +/+ and NaV1.9 -/- mice. Response 
profiles for addition of 0.1mM ADP (A), 1mM ADP (B) and 3mM ADP (C) in both 
NaV1.9 +/+ and NaV1.9 -/- mice (N = 6, each group). D Peak increase in nerve activity 
following addition of 0.1mM, 1mM & 3mM ADP above baseline activity in NaV1.9 
+/+ and NaV1.9 -/-  mice (N = 6, each group; p < 0.001, 2-way ANOVA with 
Bonferroni’s post-hoc, **p < 0.01). 
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Figure 38. Baseline firing prior to ADP application and duration of responses to ADP 
in colonic splanchnic nerve. A Mean nerve activity over 3 minutes prior to 
application of ADP in NaV1.9 +/+ and NaV1.9 -/- (N = 6, both groups; p < 0.01, 2-way 
ANOVA with Bonferroni’s post-hoc, *p < 0.05). B Time taken from ADP superfusion 
entering the recording bath to an increase in mean nerve activity above baseline (N 
= 6, both groups; p = 0.26, 2-way ANOVA). C Time taken from ADP entering the 
recording bath to reach peak nerve activity (N = 6, both groups; p = 0.42, 2-way 
ANOVA). D Time taken for nerve activity to return to 80% of peak response (N = 6, 
both groups; p < 0.05, 2-way ANOVA). E Time taken for nerve activity to return to 
50% of peak response (N = 6, both groups; p < 0.01, 2-way ANOVA). F Time taken 
for nerve activity to return to baseline (N = 6, both groups; p < 0.01, 2-way ANOVA). 
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Figure 39.  Effect of increasing concentrations of P2Y2, P2Y4 and P2Y6 agonist, UTP 
on colonic splanchnic nerve activity in NaV1.9 +/+ and NaV1.9 -/- mice. Response 
profiles to addition of 0.1mM UTP (A), 1mM UTP (B) and 3mM UTP (C) in both 
NaV1.9 +/+ and NaV1.9 -/- mice (N = 6, each group). D Peak increase in nerve activity 
following addition of 0.1mM, 1mM & 3mM UTP above baseline activity in NaV1.9 
+/+ and NaV1.9 -/-  mice (N = 6, each group; p < 0.001, 2-way ANOVA with 
Bonferroni’s post-hoc, *p < 0.05). 
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Figure 40. Baseline firing prior to UTP application and duration of responses to UTP 
in colonic splanchnic nerve. A Mean nerve activity over 3 minutes prior to 
application of UTP in NaV1.9 +/+ and NaV1.9 -/- (N = 6, both groups; p = 0.20, 2-way 
ANOVA). B Time taken from UTP superfusion entering the recording bath to an 
increase in mean nerve activity above baseline (N = 6, both groups; p = 0.19, 2-way 
ANOVA). C Time taken from UTP entering the recording bath to reach peak nerve 
activity (N = 6, both groups; p = 0.64, 2-way ANOVA). D Time taken for nerve 
activity to return to 80% of peak response (N = 6, both groups; p = 0.62, 2-way 
ANOVA). E Time taken for nerve activity to return to 50% of peak response (N = 6, 
both groups; p = 0.25, 2-way ANOVA). F Time taken for nerve activity to return to 
baseline (N = 6, both groups; p < 0.05, 2-way ANOVA). 
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In order to discount a P2Y6-mediated excitation of colonic afferents by UTP, the 
selective P2Y6 receptor agonist, UDP was superfused into the recording bath. At 
1mM and 3mM, UDP did not robustly excite colonic afferents in NaV1.9 +/+ mice 
(Figure 41A). However, at 10mM concentrations UDP did evoke a small increase 
in afferent firing equivalent to ~17% of a 3mM ATP application (Figure 41B).  
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Figure 41. Comparison of colonic afferent activation by UDP with responses evoked 
by ATP, ADP, adenosine and UTP. A Response profiles for addition of 1mM, 3mM 
and 10mM UDP in NaV1.9 +/+ mice (N = 3). For comparison and on the same axis, 
response profiles to 3mM ATP, 3mM ADP, 3mM adenosine and 3mM UTP are also 
shown (N = 6, each agonist). B Peak increase in nerve activity following addition of 
1mM, 3mM and 10mM UDP and 3mM ATP, 3mM ADP, 3mM adenosine and 3mM 
UTP. 
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4.4.4 EXPRESSION OF P2Y1 AND NAV1.9 IN MOUSE COLON-PROJECTING DRG 
NEURONES BY IN SITU HYBRIDISATION 
 
The excitatory responses observed in multi-unit recordings from the splanchnic 
nerve to ADP and UTP demonstrates significant expression of purinoceptors 
known to bind these nucleotides (i.e. for ADP, P2Y1,11-13 and for UTP, P2Y2,4). To 
investigate this further, the expression of P2Y1 and NaV1.9 in thoracolumbar 
sensory neurones innervating the colon was determined by chromogenic in situ 
hybridisation (Figure 42). Functional electrophysiological data was recorded 
from the splanchnic nerve, the sensory afferent cell bodies of which are located 
in their highest frequency in DRG T13 and L1 (Robinson et al., 2004). Analysis 
of chromogenic reaction products in retrograde-labelled colonic DRG neurones 
from these DRG observed P2Y1-positive expression in 26.9 ± 5.2% of neurones 
(Figure 42G). In the same sections, expression of NaV1.9 was also determined in 
cells retrogradely labelled with Fast Blue by chromogenic in situ hybridisation, 
of which 56.1 ± 4.9% expressed NaV1.9 transcripts. This was comparable with 
isotopic in situ hybridisations for NaV1.9 which labelled 50.5 ± 3.3% of FB+ cell 
bodies (see Chapter 2). In addition, the specificity of chromogenic in situ 
hybridisation for both P2Y1 and NaV1.9 was confirmed by negative probe 
controls (including exclusion of primary probes (Figure 42D & E) and the use of 
a negative control probe against the dapB gene of Bacillus subtilis, which is not 
expressed in mammalian tissues (Figure 42F)). NaV1.9 and P2Y1 expression was 
determined using independent chromogenic reaction products (green and red) 
showing co-expression in 13.7 ± 3.8% of colonic sensory neurones (Figure 
42G).  
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Figure 42. Expression of P2Y1 and NaV1.9 mRNA in mouse colon-projecting DRG 
neurones by chromogenic in situ hybridisation. A Co-expression of NaV1.9 and P2Y1 
mRNA  transcripts in NaV1.9 +/+ mice. B Retrograde Fast Blue (FB) labelling from 
colon in thoracolumbar DRG section. C Combined NaV1.9, P2Y1 mRNA expression 
with FB labelling. Yellow arrowhead indicates a colon projecting neurone positive 
for NaV1.9 but negative for P2Y1 mRNA expression. Yellow arrow indicates a colon 
projecting neurone positive for both NaV1.9 and P2Y1 mRNA expression. D No 
primary probe control for P2Y1. E No primary control for NaV1.9. F Negative control 
using bacterial-specific probe against dabB from Bacillus subtilis. G Relative 
expression values for NaV1.9 and P2Y1 mRNA in FB-positive colon-projecting 
neurones (N = 5 animals, n = 181 FB+ cells). 
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4.4.5 COLONIC SPLANCHNIC AFFERENT NERVE RESPONSES TO ADENOSINE IN 
NAV1.9 +/+ AND NAV1.9 -/- MICE 
 
Next, the deletion of NaV1.9 on activation of colonic splanchnic afferents by 
adenosine was investigated. Adenosine is an enzymatic break-down product the 
of ectonucleotidase activity on ATP. As such, it is relevant to understand the 
contribution of adenosine to the overall excitatory response profile caused by 
ATP in both NaV1.9 +/+ and NaV1.9 -/- mice. Adenosine elicited concentration-
dependent increases in colonic afferent firing across all concentrations tested in 
wild-type animals (Figure 43). In NaV1.9 -/- mice, peak responses were 
significantly attenuated (p < 0.001), although the time taken to reach this peak 
was unaffected (p = 0.09; Figure 44C). In agreement with observations for the 
P2Y ligands, Time to 80% response, Time to 50% response and Time to return to 
baseline were all significantly reduced in NaV1.9 -/- mice as a result of a reduced 
peak response at any given concentration (p < 0.01, p < 0.001 and p < 0.001, 
respectively; see Figure 44). Baseline firing was significantly different between 
NaV1.9 +/+ and NaV1.9 -/- mice (p < 0.05; Figure 44).   
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Figure 43. Effect of increasing concentrations of adenosine on colonic splanchnic 
nerve activity in NaV1.9 +/+ and NaV1.9 -/- mice. Response profiles for addition of 
0.1mM adenosine (A), 0.3mM adenosine (B), 1mM adenosine (C) and 3mM 
adenosine (D) in both NaV1.9 +/+ and NaV1.9 -/- mice (N = 6, each group). E Peak 
increase in nerve activity following addition of 0.1mM, 0.3mM, 1mM & 3mM 
adenosine above baseline activity in NaV1.9 +/+ and NaV1.9 -/-  mice (N = 6, each 
group; p < 0.001, 2-way ANOVA with Bonferroni’s post-hoc, *p < 0.05, **p < 0.01, 
***p < 0.001). 
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Figure 44. Baseline firing prior to adenosine application and duration of responses 
to adenosine in colonic splanchnic nerve. A Mean nerve activity over 3 minutes 
prior to application of adenosine in NaV1.9 +/+ and NaV1.9 -/- (N = 6, both groups; p 
< 0.05, 2-way ANOVA). B Time taken from adenosine superfusion entering the 
recording bath to an increase in mean nerve activity above baseline (N = 6, both 
groups; p < 0.05, 2-way ANOVA). C Time taken from adenosine entering the 
recording bath to reach peak nerve activity (N = 6, both groups; p = 0.09, 2-way 
ANOVA). D Time taken for nerve activity to return to 80% of peak response (N = 6, 
both groups; p < 0.01, 2-way ANOVA). E Time taken for nerve activity to return to 
50% of peak response (N = 6, both groups; p < 0.001, 2-way ANOVA with 
Bonferroni’s post-hoc, **p < 0.01, ***p < 0.001). F Time taken for nerve activity to 
return to baseline (N = 6, both groups; p < 0.001, 2-way ANOVA with Bonferroni’s 
post-hoc, *p < 0.05, ***p < 0.001). 
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4.4.6 ACTIVATION OF HUMAN MESENTERIC NERVES OF THE APPENDIX, COLON 
AND ILEUM BY PURINERGIC LIGANDS 
 
To translate murine activation of colonic visceral afferents by P2Y ligands to 
man, mesenteric nerve recordings were made from resected bowel tissues from 
patients undergoing surgery for inflammatory bowel disease and bowel cancer 
(> 10cm away from the cancer itself, cancer margins and lymph nodes). 
Electrophysiological recordings were made from three tissue regions: ileum, 
colon and appendix. In all tissue types recorded, ATP elicited increases in 
human afferent firing above baseline firing (Figure 45). Similarly, the addition 
of P2Y receptor agonists, ADP and UTP evoked human afferent firing (Figure 
45). 
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Figure 45. Effect of nucleotides, ATP, ADP and UTP, on activity of human mesenteric 
afferents from resected bowel tissues. A Example photomicrograph of section of 
ileum pinned in recording chamber serosa upwards. The mesenteric fan is at the 
top of the photo and a mesenteric nerve has been dissected free. The white arrow 
highlights the suction electrode recording from this mesenteric nerve. B Example 
rate histogram and raw neurogram of nerve activity following addition of 1mM 
UTP. Baseline firing and peak firing following addition of 1mM (N = 3) and 10mM (N 
= 4) ATP (C), 1mM (N = 5) and 10mM (N = 6) ADP (D) and 1mM (N = 5) and 10mM (N 
= 4) UTP (E). *p < 0.05, **p < 0.01, peak firing vs baseline (paired t-test). Of the 14 
independent electrophysiological recordings expressed here, 4 were made by D.C. 
Bulmer and 5 were made by C. McGuire. All analysis and preparation of figures was 
performed by J. Hockley.  
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Further comparison of the baseline firing rates showed no significant difference 
between tissue type (i.e. ileum, colon and appendix) (Figure 46). This suggests 
that the mesenteric nerves being dissected and recorded from were relatively 
consistent in size, ectopic background activity and number of nerve fibres 
irrespective of origin along the gastrointestinal tract. Furthermore, comparison 
of baseline activities prior to the addition of nucleotide agonists (ATP, ADP and 
UTP), show no significant trend or difference, suggesting that a nerve size bias 
was not a likely to explanation for the differences observed in firing frequencies 
between agonists.  
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Figure 46. Comparisons of baseline firing from recordings of human mesenteric 
nerve activity. A Baseline firing segregated by tissue type from which the recording 
was made (appendix, n = 6; colon, n = 6; ileum, n = 2). Baseline firing rate was taken 
prior to the first agonist addition in that recording. B Baseline firing segregated by 
nucleotide agonist addition (ATP, n = 9; ADP, n = 14; UTP, n = 12). Baseline firing 
rate was taken prior to every agonist addition of each recording. 
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4.5 SUMMARY OF KEY FINDINGS  
4.5.1 EFFECT OF NAV1.9 DELETION ON COLONIC AFFERENT RESPONSES TO ATP 
AND ADENOSINE 
 
1. In a tubular preparation, concentration-dependent responses to ATP and 
adenosine were significantly attenuated in NaV1.9 -/- mice compared to 
NaV1.9 +/+ mice. 
4.5.2 ANTAGONISM OF P2X RECEPTORS AND P1 ADENOSINE RECEPTORS ON 
RESPONSES TO REPEAT ATP APPLICATIONS 
 
1. Responses to repeat applications of ATP were reduced by 22% following 
pre-incubation with non-selective P2X receptor antagonist, PPADS. 
2. In similar experiments, ATP responses were inhibited by 18% following 
application of P2X1, P2X3 and P2X2/3 antagonist, TNP-ATP.  
4.5.3 ACTIVATION OF COLONIC AFFERENTS BY P2Y LIGANDS 
 
1. Application of P2Y1, P2Y12 and P2Y13 receptor agonist, ADP evoked 
concentration-dependent increases in afferent firing of a greater 
magnitude than equivalent responses to ATP 
2. Further, P2Y2, P2Y4 and P2Y6 receptor agonist, UTP also elicited 
significant increases in firing, which were both shorter in duration and 
less in magnitude than ATP. 
3. In both instances, responses to ADP and UTP were significantly reduced 
in NaV1.9 -/- mice compared to NaV1.9 +/+ mice. 
4. Application of P2Y6 receptor agonist UDP failed to excite colonic afferent 
firing until reaching 10mM concentrations, where a modest increase in 
firing rate was observed. 
4.5.4 EXPRESSION OF P2Y1 AND NAV1.9 IN COLON SENSORY NEURONES 
 
1. P2Y1 mRNA was observed in 26.9 ± 5.2% and NaV1.9 mRNA was 
observed in 56.1 ± 4.9% of Fast Blue-positive colon-projecting neurones 
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2. Co-localisation of NaV1.9 and P2Y1 receptors was observed in 13.7 ± 
3.8% of colon-projecting neurones 
 
4.5.5 ACTIVATION OF HUMAN COLONIC MESENTERIC NERVES BY PURINERGIC 
AGONISTS 
 
1. Application of ATP, ADP and UTP all evoked concentration-dependent 
increases in afferent firing above baseline in human mesenteric nerve 
preparations from resected bowel tissues. 
2. Baseline firing did not differ significantly regardless of tissue (appendix, 
colon and ileum) or agonist under investigation. 
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4.6 DISCUSSION 
 
Data shown above further supports the role of NaV1.9 in the direct excitatory 
responses of colonic afferents to algogenic mediators. NaV1.9 is required for 
their direct excitation by multiple purinergic mediators, including ATP and 
adenosine. Activation of colonic afferents by P2Y receptor agonists and 
incomplete inhibition of ATP responses by P2X receptor, and adenosine P1 
receptor antagonists indicates that the excitatory action of ATP is evoked by 
activation of multiple purinoceptors. Indeed, the data also shows that ATP, ADP 
and UTP excite human visceral afferents, suggesting, for the first time, that P2Y 
receptor activation of visceral peripheral nerves may be relevant to nociceptive 
pathways in man. 
The increase in visceral afferent activity following exogenous application of ATP 
is significantly attenuated in the distal colon of NaV1.9 -/- mice. In wild-type 
animals, this ATP-mediated excitation of visceral afferents was significantly 
reduced by PPADS and TNP-ATP (P2X receptor antagonists) and CGS 15943 (P1 
adenosine receptor antagonist). Both ADP (P2Y1,12,13 agonist) and UTP (P2Y2,4 
agonist) induce action potential firing, suggesting  that P2Y receptor activation 
can excite visceral afferents. These excitatory effects to ADP and UTP were 
significantly reduced in NaV1.9 knock-out mice. The role of P2Y1-dependent 
activation in this pathway is supported by the co-expression of P2Y1 with 
NaV1.9 in a subset of colonic sensory neurones. Together, these data suggest 
both a prominent role for NaV1.9 in visceral afferent signalling to purinergic 
stimuli and also an important contribution of P2Y receptors to purinergic 
signalling. Given the importance of ATP mediated mechanotransduction and the 
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sensitisation of sensory nerves to visceral hypersensitivity, it is likely that P2Y 
receptors contribute significantly to the discomfort and pain experienced 
during inflammatory bowel disease. 
4.6.1 EFFECT OF EXOGENOUS ATP ON COLONIC AFFERENT FIRING 
 
Consistent with previous studies demonstrating the direct excitation of visceral 
afferents innervating the gastrointestinal tract by ATP; comparable increases in 
nerve discharge were observed following administration of ATP (0.1-3mM) to 
colonic preparations (Brierley, Carter, et al., 2005; Burnstock, 2009a; Kirkup et 
al., 1999; Wynn et al., 2004; Wynn et al., 2003). In vivo and ex vivo preparations 
require relatively high concentrations of ATP to elicit action potential firing 
compared to experiments on dissociated neurones. In isolated cells, the EC50 of 
ATP at P2X3 receptors is 1.2μM (C. C. Chen et al., 1995), with 100μM ATP 
triggering inward currents in most colonic neurones (Shinoda, La, Bielefeldt, & 
Gebhart, 2010). However, the serosal application of 100μM ATP to ex vivo distal 
colon preparations is sub-threshold for pelvic nerve activation, with 
concentrations closer to 1mM ATP required to evoke robust afferent firing 
(Wynn et al., 2003). These differences are even more marked when comparing 
the exogenous concentrations of ATP (~1mM) applied serosally required to 
excite afferent terminals, with recorded levels of ATP released intraluminally 
(~1-3nM) by colonic distension (Shinoda et al., 2010; Wynn et al., 2003). Even 
relatively high concentrations of exogenous ATP (1mM) that are known to 
excite colonic afferents when applied serosally, fail to consistently activate 
colonic pelvic afferents when applied intraluminally (Wynn et al., 2003). This 
data highlights the labile nature of ATP and its propensity for enzymatic 
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degradation by ectonucleotidases. Indeed, around 92% of ATP injected into 
cannulated rabbit ear arteries was not recovered in the venous outflow 
(HOLTON, 1959). The fact that colonic luminal perfusions of ATP did not result 
in consistent afferent activation is perhaps expected given the high metabolic 
activity of the colonic epithelium, and may also explain the low detectable levels 
of ATP following distension. Interestingly though, most neurones contain 
relatively high cytoplasmic concentrations of ATP (~2-5mM), with up to 
100mM ATP observed in synaptic vesicles (Burnstock, 2009b; Novak, 2003). It 
is challenging to ascertain the relative amounts of ATP released by epithelial 
cells to shear stress. As such, it is difficult to predict the likely local 
concentrations of ATP exposed to colonic afferent terminals during 
inflammation or distension. Isolated cell experiments provide detailed 
information on the direct effects of ATP at purinoceptors, but lack the 
complexity of tissue-based assays to investigate this multifaceted 
neurotransmitter. By contrast, ex vivo preparations are likely grossly insensitive 
to physiological concentrations of ATP due to their rapid enzymatic break-
down, but do provide a systems approach capable of evaluating both the effects 
of ATP and the products of its degradation. It should be noted that both models 
may be bias towards the relative importance of different purinoceptor 
subtypes. The highly regulated breakdown and utility of ATP underlines its 
importance as a neurotransmitter by numerous cell types throughout the 
gastrointestinal tract.  
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4.6.2 DELETION OF NAV1.9 ON COLONIC AFFERENT RESPONSES TO CHEMICAL 
STIMULATION BY ATP 
 
In NaV1.9 -/- mice, responses to ATP were substantially inhibited in colonic 
tissue (~83% at 1mM ATP). The magnitude of these effects would suggest that 
NaV1.9 is expressed by the majority of ATP-sensitive afferent fibres. Certainly in 
whole DRG neuronal populations, almost two-thirds of P2X3-immunoreactive 
neurones also express NaV1.9, however whether this colocalisation differs in a 
colon-specific neuronal population remains to be confirmed (Amaya et al., 
2006). Not all thoracolumbar colonic neurones are ATP-sensitive, with 
approximately half of DRG somata depolarised by ATP or α,β-meATP and 
approximately 40% of serosal afferent fibres responding to α,β-meATP 
application (Brierley, Carter, et al., 2005; Shinoda et al., 2010). Further, less 
than 40% of thoracolumbar colonic DRG neurones express P2X3 (Brierley, 
Carter, et al., 2005). As such, NaV1.9 expression may only need to colocalise to 
less than 40-50% of colon-projecting neurones to impact the vast majority of 
ATP-sensitive fibres. Given the known expression pattern for NaV1.9 in colonic 
sensory neurones from Chapter 2, this is a realistic proposition. 
4.6.3 ROLE OF SELECTIVE PURINOCEPTORS IN COLONIC AFFERENT ACTIVATION 
BY ATP 
 
In order to explore the potential impact of P2Y receptor afferent activation, the 
response to ATP in the presence of either P2X receptor or P1 (adenosine) 
receptor blockade was first examined. In this study, the P2X receptor 
antagonists, PPADS and TNP-ATP, reduced afferent firing in response to ATP by 
22% and 18%, respectively. This is in agreement with a similar reduction in the 
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response observed in P2X2/3 dual knock-out mice studies following application 
of ATP or α,β-meATP (Rong et al., 2009). Furthermore, given that adenosine is 
an ectonucleotidase break-down product of ATP and can directly excite 
afferents, we show that the general adenosine P1 receptor antagonist, CGS 
15943, inhibited afferent discharge to ATP by 28%. This is consistent with 
previous reports demonstrating a similar reduction in the presence of the 
general P1 antagonist, 8p-SPT (Kirkup et al., 1998; Wynn et al., 2003). These 
findings suggest that ATP may be synergistically activating colonic afferents via 
P2X- and P1-dependent pathways, and that alternative purinoceptors, such as 
P2Y receptors, may also contribute to this excitation. 
As described above, the activation of specific P2Y receptors (namely P2Y1, P2Y2 
and P2Y4) is excitatory in sensory neurones inducing both Ca2+ flux and action 
potential firing (Ceruti et al., 2008; Molliver et al., 2002). The P2Y1 receptor 
subtype has been shown to transduce ATP-dependent mechanical stimuli and is 
required for thermal hypersensitivity to pain (Molliver et al., 2011; Nakamura & 
Strittmatter, 1996). In skin-saphenous nerve recordings, the P2Y2 and P2Y4 
receptor agonist, UTP excites nociceptor-like fibres and more recently, the P2Y2 
receptor has been associated with the facilitation of bladder sensory function 
(X. Chen et al., 2010; Stucky et al., 2004). This functional activity is consistent 
with the expression of P2Y1, P2Y2 and P2Y4 mRNA transcripts in sensory 
neurones (Kobayashi et al., 2006; Moriyama et al., 2003; Sanada et al., 2002; 
Tominaga et al., 2001). Using chromogenic in situ hybridisation, P2Y1 mRNA 
expression was confirmed in sensory neurones and quantified in just over a 
quarter of colon-projecting neurones. Of these, approximately 51% co-
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expressed NaV1.9 mRNA transcripts. It is perhaps surprising that, given the 
magnitude of the response observed to ADP application, greater expression of 
P2Y1 was not seen. This may be explained by the synergistic actions of multiple 
purinoceptors acting in concert to excite visceral afferents. It is possible that 
ADP and its subsequent break-down product, adenosine, are activating multiple 
P2Y receptors (P2Y1,11-13) and P1 receptors (A1, A2A, A2B and A3). Indeed, this 
can be inferred from the extended time course profiles of whole-nerve 
responses to adenosine, ADP and ATP compared to UTP (Figure 41), which 
suggests that approximately 50% of the ADP response in multi-unit recordings 
may be attributable to adenosine receptor activation. As mentioned above, a 
28% reduction in peak response to ATP following inhibition with the P1 
antagonist, CGS 15943, also implicates a significant contribution of adenosine 
receptor activation to ATP and ADP responses. This may, therefore, account for 
the disparity between the relatively low expression of P2Y1 in colonic neurones 
and afferent responses to ADP. Whilst direct evidence does not exist for other 
P2Y receptor expression in colon specific neuronal populations, expression of 
P2Y2 and P2Y4 receptors have been shown in DRG neurones projecting to other 
visceral organs (X. Chen et al., 2010; H. Wang et al., 2010). Data presented above 
demonstrates the ability of the P2Y receptor agonists, ADP (P2Y1, P2Y12 and 
P2Y13) and UTP (P2Y2, P2Y4 and P2Y6) to excite colonic visceral afferents. It is 
likely that these GPCRs are facilitating excitatory responses in afferents by 
interactions with multiple channels, including P2X2 and P2X3 receptors and Na+ 
and K+ channel subtypes.   
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In NaV1.9 -/- mice, responses to ADP and UTP were significantly reduced by 
between 60-80%. This is suggestive of the significant expression of NaV1.9 on 
afferent fibres responsive to P2Y agonists. These findings are supported by the 
inability to develop mechanical hypersensitivity in NaV1.9 -/- mice following 
intraplantar injection of UTP (Amaya et al., 2006), which suggests that 
sensitisation evoked by UTP is significantly dependent on NaV1.9. Indeed, in 
sensory neurones labelled with Fast Blue from the colon, half of P2Y1+ neurones 
co-expressed NaV1.9 mRNA. The expression profile of other purinoceptors 
(including P2Y2 and adenosine P1 receptors) in relation to NaV1.9 is currently 
unknown. It is unlikely that the activation of P2Y1, and its coupling to NaV1.9, is 
solely responsible for the reductions in responses to ATP and ADP observed in 
NaV1.9 -/- mice. As hypothesised by Baker et al., increased neuronal excitability 
dependent on NaV1.9 current potentiation by ATP will contribute to any change 
in afferent firing rate, in conjunction with established contributions of NaV1.9 to 
both the resting excitability and sensitisation of sensory neurones (Baker, 
2005).  
The peak response observed to ADP was greater than that of UTP in mouse 
colonic splanchnic recordings. This may be due to the differential expression of 
P2Y receptor subtypes, alongside the synergistic activation of P2Y and P1 
receptors, following the break-down of ADP, through AMP, to adenosine. This 
synergy in metabolites is unlikely to occur for UTP, where application of the 
break-down product and P2Y6 receptor agonist, UDP, produced no excitation of 
visceral afferents at concentrations other than at 10mM. It is likely, therefore, 
that P2Y6 receptors do not play a role in direct visceral afferent fibre activation. 
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Furthermore, this would also suggest that UTP, which has limited affinity to 
P2Y6 receptors, is not acting via this mechanism to stimulate colonic afferents in 
the present study. Indeed, this is supported by the limited evidence for 
expression of P2Y6 receptors in sensory neurones (Kobayashi et al., 2006). 
Finally, it was shown that both ADP and UTP, in addition to ATP, are able to 
stimulate visceral afferents innervating isolated human gut, indicating that P2Y 
receptors are likely to be important in sensitising afferent fibres in man. In 
contrast to findings in mouse studies, peak responses in human recordings 
were greater for UTP than ADP. Possible explanations for this include a switch 
in the relative expression of P2Y2 versus P2Y1 receptors in man, compared to 
mouse. Analysis of baseline firing rates dependent on tissue type (appendix, 
colon or ileum) and nucleotide addition (ATP, ADP and UTP), suggest no bias or 
significant difference in the quality or afferent population size recorded from. 
Teased-fibre recordings of characterised afferent fibre subtype (i.e. mesenteric, 
muscular, mucosal and serosal) responses to ADP and UTP in both mouse and 
man will provide evidence for any change in relative expression between the 
species, or in any bias in the populations of the afferent subtypes being 
stimulated.  
4.6.4 CONCLUSIONS 
 
In summary, the data demonstrates that ATP signalling is dependent on the 
presence of NaV1.9 in activation of colonic splanchnic afferents by ATP. The 
findings suggest that in addition to reduced afferent excitability driven by the 
loss of NaV1.9, a P2Y-NaV1.9 coupled pathway may contribute to afferent 
excitation and that P2Y receptor activation is important in its own right, 
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including the translation of P2Y activation into human nerves (Figure 47). Given 
the importance of ATP as a mediator of visceral pain in pathologies 
characterised by both inflammation and mechanical hypersensitivity, the data 
suggests that a mechanistic link between NaV1.9 and P2Y receptors should be 
investigated in more detail. 
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Figure 47. Schematic illustration of NaV1.9 interacting with P2Y receptors in a 
visceral afferent terminal. When present at the visceral afferent terminal, NaV1.9 
may sensitise visceral afferents by interactions with P2Y receptors, possibly by 
potentiation of the peak current density produced by the Na+ channel. Purinergic 
nucleotides will also sensitise visceral afferent terminals by activity at P2X 
receptors.  
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CHAPTER 5: DISCUSSION 
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The data presented here demonstrates that NaV1.9 is a key modulator of 
neuronal excitability and sensitivity in colonic afferents responsive to noxious 
stimuli. NaV1.9 plays an important role in the regulation of visceral afferent 
firing to direct noxious mechanical stimuli and is essential for excitatory 
responses to inflammatory mediators released during acute and chronic 
inflammation. Specifically, we show that NaV1.9 contributes to the 
mechanosensitivity of serosal and mesenteric nociceptors, particularly during 
persistent (repeat phasic distensions) or sustained (ramp distension) noxious 
distension of the colon. NaV1.9 is necessary for the direct activation of visceral 
nociceptors by mediators released during human inflammatory disease and 
mechanical hypersensitivity induced by inflammatory mediators.   
5.1 SUMMARY OF RESULTS 
 
Visceral nociceptors are responsive to a range of noxious mechanical and 
chemical stimuli evoked during human disease (Su & Gebhart, 1998). For 
example, in inflammatory bowel disease, recurrent inflammation leads to 
abdominal pain and visceral hypersensitivity associated with physiological 
bowel movements. As such, the identification of points of convergence in 
signalling pathways common to the activation of visceral afferents by both 
mechanical and inflammatory stimuli will represent attractive drug targets. 
Such regulators of neuronal excitability will likely be capable of modulating the 
transduction of multiple stimuli evoked by on-going inflammation and release 
of inflammatory mediators. Voltage-gated sodium channels offer such a 
convergence point due to their intrinsic involvement in action potential 
generation. Of the sodium channel subtypes, NaV1.9 represents an important 
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molecular candidate capable of fulfilling this role. Indeed, the regulation of 
visceral afferents excitability by NaV1.9 has not been extensively investigated. 
The data presented here demonstrates that NaV1.9 represents an important 
modulator of specific aspects of sustained visceral afferent excitability, 
especially in responses to inflammatory mediators, indicating that NaV1.9 
represents a valuable therapeutic target in the development of visceral 
analgesics.  
Using a combination of in situ hybridisation and immunohistochemistry, NaV1.9 
is present in just over half of colon-projecting sensory neurones. This 
expression profile indicates functional specialisation of afferents projecting to 
the colon and suggests that NaV1.9 may have a greater impact in specific 
afferent subtypes.  
Next the impact of NaV1.9 on mechanosensation was investigated. Multiple 
mechanical stimuli were used to characterise specific afferent subtypes and 
examine mechanosensitivity under different dynamic and persistent paradigms. 
These stimuli included von Frey hair probing and circumferential stretch of 
isolated visceral nociceptor receptive fields, alongside repeated phasic 
distension of the colon at noxious pressures, and ramp distensions of tubular ex 
vivo colon preparations into noxious distension ranges. Such studies of visceral 
afferent mechanosensitivity have been used extensively to further our 
understanding of mechanosensory physiology (Feng, La, Schwartz, et al., 2012) 
and the molecular targets responsible for mechanotransduction in visceral 
afferents (Brierley et al., 2008; Page, Brierley, et al., 2005). The data presented 
in this thesis shows that NaV1.9 contributes to both activation thresholds for 
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mechanical stimuli in a subset of afferents and is required for the development 
of mechanical hypersensitivity to inflammatory mediators. Specifically, 
mechanosensory responses of mesenteric, but not serosal and muscular, 
afferents were significantly attenuated by NaV1.9 deletion in flat-sheet 
preparations. These afferents fibres also exhibited increased activation 
thresholds compared to wild-type controls, suggesting a reduction in 
sensitivity. By contrast, in tubular preparations, high-intensity stimuli including 
initial rapid phasic distension and supra-physiological ramp distension 
pressures are largely unaffected by loss of NaV1.9. Further, high-intensity von 
Frey hair probe of mesenteric afferent fibres did not differ significantly between 
genotypes, indicating that given a strong enough stimuli, it is possible to 
overcome the absence of NaV1.9 depolarisations in these fibres. These findings 
also highlight the importance of the dynamic nature of the stimulus in the 
activation of visceral afferents. The reduction in sensitivity of mesenteric 
afferents to low-intensity stimulation likely accounts for the significant deficits 
observed in whole-nerve recordings during tubular distension paradigms. 
Further, the role NaV1.9 plays in regulating responses to persistent stimuli will 
also impact these recordings, with NaV1.9 contributing significantly to 
mechanosensory responses following repeat phasic distensions.  
Typically in wild-type animals, repeat colorectal distension leads to an initial 
desensitisation of responses that subsequently stabilises over time (Kamp et al., 
2003; Sivarao et al., 2007). Interestingly in NaV1.9 -/- mice, these responses 
continue to decline with subsequent distension, and therefore show that NaV1.9 
is required for the maintenance of responses to persistent stimuli. On-going 
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adaptation to repeat stimuli contributes significantly in vivo, where pain is 
evoked by repeated contractions of the colon around a bolus or stricture, and 
suggests a role for NaV1.9 in the adaptive response (Brookes et al., 2013). 
Further, repeat innocuous distension can rapidly transition from discomfort to 
pain if maintained (Cervero, 1988), suggesting that mechanisms regulating this 
process will be of significant clinical value. The molecular correlates of this 
tachyphylaxis in visceral afferents are poorly understood, but may depend on 
the progressive desensitisation of known visceral mechanosensitive channels to 
repeat stimuli, such as TRPV4, TRPA1 and ASIC3, with a concurrent activity-
dependent functional up-regulation of NaV1.9, resulting in the maintenance of 
afferent activation. In this context, NaV1.9 may be considered an important 
regulator of gain in the primary visceral afferent terminal.  
Next purinergic signalling in visceral afferents was investigated. ATP is released 
from the colorectal epithelial lining following mechanical stress and leads to 
stimulation of visceral nociceptors, primarily mediated by the activation of P2X3 
receptors (Burnstock, 1999, 2009a). Indeed, purinergic mechanotransduction 
contributes to the excitation and sensitisation of sensory nerve terminals 
during distension (Burnstock, 1999). The release of ATP is greatly enhanced 
during colitis supporting a greater role for this pathway during inflammation 
(Calvert et al., 2008; Shinoda et al., 2010; Wynn et al., 2004). Extracellular ATP 
may activate both P2X and P2Y receptors, suggesting that they are both capable 
of contributing to altered sensation in IBD.  The purinergic agonists, ATP and 
adenosine, both significantly excited the colonic visceral afferents of wild-type 
animals in the current studies. Activation of colonic afferents by P2Y receptor 
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agonists and only partial inhibition of ATP responses by P2X, and adenosine P1, 
receptor antagonists indicates a role for multiple purinoceptors in the 
excitatory actions of ATP. Further, the activity of ATP, ADP and UTP in 
recordings from resected human bowel tissues, suggests that P2Y receptor 
activation of visceral afferents may be relevant to human nociception. These 
direct excitatory responses to ADP and UTP were reduced in NaV1.9 -/- mice. 
The role of P2Y1-dependent activation in this pathway is supported by co-
expression of P2Y1 with NaV1.9 in a subset of colonic sensory neurones. These 
data taken together suggest that NaV1.9 plays a significant role in visceral 
afferent signalling to purinergic stimuli and that this is facilitated by P2Y 
receptor signalling.   
Finally, the multiple mediators and human disease-derived stimuli released 
during tissue damage and inflammation, which are known to activate and 
sensitise afferent terminals, were investigated (Su & Gebhart, 1998). In addition 
to ATP, prototypic inflammatory mediators which are released from damaged 
or stressed cells include bradykinin, PGE2, histamine and 5-HT. These have all 
been shown to influence visceral afferent excitation and sensitisation, and are 
associated with human inflammatory disease (Grundy, 2004). The present data 
shows that NaV1.9 is necessary to evoke excitatory firing to an inflammatory 
soup consisting of a cocktail of these mediators (bradykinin, ATP, histamine, 
PGE2 and 5-HT). Further the impact of a human disease-derived inflammatory 
milieu was investigated by application of IBD (Crohn’s disease and ulcerative 
colitis) supernatants to mouse visceral afferent fibres. Excitatory responses to 
these supernatants were significantly attenuated in NaV1.9 -/- mice. The loss of 
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sensitivity to purinergic stimuli, experimental and human disease-derived 
inflammatory mediators supports a more generalised role for NaV1.9 in afferent 
excitability by multiple inflammatory pathways in human disease. Specifically, it 
suggests that NaV1.9 contributes significantly to inflammatory pain sensation 
and to afferent sensitivity in IBD. 
Mechanical hypersensitivity of serosal and mesenteric afferents is observed 
after application of inflammatory soup in wild-type mice, an effect that is lost in 
NaV1.9 -/- mice. The response to noxious ramp distension is also sensitised by 
intraluminal inflammatory soup, which, at least during lower distension 
pressures (<50 mmHg), is entirely dependent on NaV1.9. This further supports 
the hypothesis that NaV1.9 is critical in the sensitisation of afferents to 
inflammatory stimuli. Given that mesenteric afferent subtypes comprise half of 
colonic splanchnic innervation and mechanosensory deficits were only 
observed in this population following von Frey hair probing, it is tempting to 
postulate that this population may be functionally representative of the NaV1.9 
expression pattern (approximately 50% NaV1.9 mRNA and protein) observed 
by in situ hybridisation and immunohistochemical studies (Brierley et al., 
2004). However, chemosensory responses to both experimental and human 
disease-derived inflammatory mediators are significantly reduced in both 
mesenteric and serosal afferent subtypes, suggesting that this is not the case. 
More likely is a complex expression pattern in a sub-population of afferents 
with receptive fields associated with mesenteric and intramural vasculature 
within the colon wall, and further structure-function studies are required to 
confirm this. Whether the deficits in mechanotransduction in mesenteric 
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receptive fields of NaV1.9 -/- mice are due to specialisation in molecular 
channels, including mechanosensitive channels such as TRP and ASICs (Brierley 
et al., 2009; Brierley et al., 2008; Page, Brierley, et al., 2005), or are due to 
structural differences in the transduction of mechanical forces between the 
mesentery and serosa, remains to be seen.  
Collectively, this data supports an important physiological role for NaV1.9 in the 
regulation of visceral afferent sensitivity during inflammation, and one that will 
likely have clinical relevance to human visceral pain. The role of distinct sodium 
channel activity in human afferent function has been indirectly addressed here 
by combining human ex vivo samples with the use of null mutant mice. This 
approach enables the conclusion that NaV1.9 is an important target for the 
treatment of visceral pain (Figure 48).  
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Figure 48. Schematic illustration of NaV1.9 interacting with membrane-bound 
receptors and ion channels in a visceral afferent terminal. When present at the 
visceral afferent terminal, NaV1.9, as well as contributing to setting the resting 
membrane potential, acts to amplify generator potentials evoked by 
mechanosensitive channels, and functions as a key transducer of inflammatory 
mediators and other sensitising stimuli. 
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5.2 THE ROLE OF NAV1.9 IN PAIN PATHWAYS 
 
The data presented here shows that NaV1.9 acts to regulate visceral primary 
afferent sensitivity to multiple noxious mechanical, inflammatory and human 
disease-derived stimuli. The impact of altered excitability of visceral primary 
afferents to human pain pathways and sensation in the gut is significant. Indeed, 
visceral pain associated with IBD may be considered a combination of 
inflammatory and neuropathic pain modalities resulting from afferent nerve 
injury and central sensitisation, coupled to impaired descending pain 
modulation. Primary afferent input is likely to be critical for maintaining such 
chronic pain sensations (Haroutounian et al., 2014) and in some patient groups, 
the inhibition of visceral afferents by topical application of local anaesthetic is 
efficacious in treating visceral pain (Verne et al., 2003; Verne et al., 2005). As 
such, the modulation of viscera-projecting neuronal hyperexcitability by 
therapeutics targeting NaV1.9 is likely to be successful in reducing visceral pain. 
However, the restricted function and expression of NaV1.9 within the cell bodies 
and projections (central and peripheral) of sensory neurones suggests that 
plasticity in spinal and supraspinal contributions to a neuropathic pain 
component may unlikely be directly modulated by NaV1.9 (S. Dib-Hajj et al., 
2002). In contrast to other sodium channels (e.g. NaV1.3), NaV1.9 expression in 
sensory neurones is down-regulated following axotomy and in peripheral nerve 
injury models, and does not contribute to neuropathic pain associated with such 
models (Decosterd et al., 2002; S. D. Dib-Hajj et al., 1999; S. D. Dib-Hajj et al., 
1998). Whether regulation of primary afferent input by inhibition of NaV1.9 is 
sufficient to inhibit spinal cord dorsal horn neuronal hyperexcitability, 
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especially given the convergence of visceral inputs in central pathways, remains 
to be seen (Cervero et al., 1992). Further still, the role of NaV1.9 in the long-term 
chronic sensitisation of both visceral primary afferents and its contribution to 
ascending pain pathways is largely unknown. As such, studies in NaV1.9 null 
mice in chronic visceral hypersensitivity models, including both post-infectious 
(Nippostrongylus brasiliensis) and chemically sensitising protocols 
(trinitrobenzenesulfonic acid (TNBS)) need to be investigated. Finally, 
psychological factors and central sensitisation that contribute to pain 
thresholds in IBS-associated post-inflammatory hypersensitivity (Grover et al., 
2009), are unlikely to be significantly altered by peripherally acting therapeutic 
agents. Therefore, dependent on the relative importance of aberrant aspects 
driving pain in IBD, which will itself be reliant on the degree of disease 
progression for an individual patient, inhibition of NaV1.9 may provide a 
significant mechanism to inhibit pain.  
5.3 NAV1.9 CURRENTS IN COLONIC SENSORY NEURONES 
 
The inability to record significant populations of isolated colonic DRG neurones 
with a NaV1.9 Na+ currents (present in only 0-13% of neurones) has led to the 
suggestion that NaV1.9 does not contribute appreciably to colonic afferent 
function (Beyak et al., 2004; Gold et al., 2002). However, it is likely that such 
reduced frequency of the observed NaV1.9 currents may be attributable to 
patch-clamp recording conditions and electrophysiological protocols used in 
isolating the persistent tetrodotoxin-resistant (TTX-R) Na+ current. Studies 
must take into account the negative activation/inactivation thresholds of 
NaV1.9, alongside its slow kinetics, when interrogating function. It is likely that 
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the -80mV holding potential used by Gold et al. was sufficiently depolarising to 
inactivate any NaV1.9 channels present and likely explains the lack of NaV1.9 
Na+ currents observed in this study (Gold et al., 2002). A second study which 
found low proportions of colonic DRG neurones possessing persistent TTX-R 
Na+ currents by Beyak et al. utilised a holding potential (-120mV) more likely to 
drive NaV1.9 into a resting state, but remark that recordings were made 5 
minutes after going whole-cell (Beyak et al., 2004). It has been suggested 
previously that due to the slow deinactivation kinetics of the channel, that cells 
should be held at very hyperpolarised voltages (e.g. -120mV) for up to 15 
minutes to remove the inactivation block (Cummins et al., 1999). This might 
explain the disparity between behavioural activities and the ability to record 
isolated persistent TTX-R Na+ currents mediated by NaV1.9.  
Another component of these electrophysiological recordings worth noting is the 
use of fluoride as the major intracellular anion in the patch-clamp pipette 
solution. Fluoride is used to aid seal formation during recordings. Intracellular 
fluoride also mimics many of the characteristics of GTPγS, a non-hydrolysable 
GTP analogue, on NaV1.9 current potentiation, resulting in significantly greater 
current densities and a hyperpolarising shift in the voltage dependence of 
activation (Coste et al., 2004; Maingret et al., 2008; Maruyama et al., 2004). In 
fact, given that fluoride, upon binding aluminium ions, is capable of 
constitutively activating G-proteins, it is likely that NaV1.9 currents recorded in 
the presence of fluoride are significantly enhanced and do not represent 
endogenous current densities (Maingret et al., 2008; Matzel, Rogers, & Talk, 
1996; Yatani & Brown, 1991). NaV1.9 appears to feature many unique 
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characteristics attributable to recording conditions. For example, unstimulated 
maximal current amplitude are typically in the picoAmp range, however under 
certain conditions may transiently potentiate to approximately 2-3 nanoAmps 
(Maruyama et al., 2004). Further, in the presence of intracellular GTPγS or 
fluoride, this potentiation may drive NaV1.9 current amplitude up to 4-8 
nanoAmps (Maingret et al., 2008; Maruyama et al., 2004; Vanoye et al., 2013). In 
both studies of colonic DRG neuronal populations, either chloride or 
methanosulphonate were used as the main anion in pipette solutions (Beyak et 
al., 2004; Gold et al., 2002). Whilst more physiologically relevant currents may 
be observed under these conditions, the introduction of fluoride into the pipette 
solution would have potentiated NaV1.9 Na+ currents over a prolonged time 
course and ensured that their presence in an individual colonic sensory 
neurone was not missed (Maingret et al., 2008; Maruyama et al., 2004). Finally, 
a study conducted by Hillsley et al. also highlights the importance of 
experimental design when studying channels such as NaV1.9. By utilising a 2x 
rheobase current injection in current-clamp recordings and recording action 
potential firing rates in isolated colonic sensory neurones from NaV1.9 -/- mice, 
the authors by-pass the proposed role for NaV1.9 in regulating resting 
membrane potential (RMP) and sub-threshold activation (Hillsley et al., 2006). 
As such, the contribution of NaV1.9 to colonic neuronal hyperexcitability is 
probably masked by experimental bias in the recording conditions.   
Deletion of NaV1.9 will affect visceral afferent function in multiple ways. Firstly, 
there exists a wide ‘window’ current driven by the overlapping voltage 
dependence of activation and inactivation for NaV1.9 at, and around, the 
305 
 
proposed resting membrane potential for DRG neurones. As such, afferent 
terminals are likely to be more hyperpolarised in the absence of NaV1.9, and 
hence overall excitability of visceral afferents will be reduced. Secondly, NaV1.9 
would no longer contribute to generator potentials through its voltage 
dependent activation in response to stimulation of mechanosensitive or ligand-
gated ion channels. These contributions are exemplified by self-sustained 
plateau depolarisations and burst firing following stimulation during current-
clamp recordings, which are lost in NaV1.9 -/- DRG neurones (Maingret et al., 
2008). The likely consequence of these effects would be the reduced excitability 
and sensitivity of the afferent to stimuli. This reduction in sensitivity was 
observed in extracellular recordings of splanchnic nerve activity from NaV1.9 -/- 
mice to multiple algogenic and inflammatory stimuli (including purinergic 
ligands (ATP, ADP, UTP and adenosine), following application of supernatants 
derived from inflammatory bowel patients and after discrete application of an 
inflammatory soup (consisting of bradykinin, ATP, histamine, PGE2 and 5-HT) to 
characterised colonic afferent receptive fields.  
In addition to reductions in sensitivity caused by a loss of NaV1.9, patch-clamp 
studies suggest that NaV1.9 Na+ currents can be potentiated by inflammatory 
mediators acting at GPCRs (Baker, 2005; Baker et al., 2003; Rush & Waxman, 
2004). Post-translational modification of NaV1.9 may therefore increase Na+ 
current density and drive significant depolarisations within the cell. In some 
studies, this has required the application of multiple mediators (Maingret et al., 
2008), whereas in other studies, the application of a single mediator is sufficient 
to increase NaV1.9 currents (Baker, 2005; Rush & Waxman, 2004). In NaV1.9 -/- 
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mice, significantly reduced colonic afferent firing was observed to individually 
applied ATP, UTP, ADP and adenosine, even at supra-maximal concentrations, 
demonstrating that NaV1.9 is required for the activation of nerve fibres by these 
mediators. These findings suggest that the application of single mediators is 
sufficient to enhance NaV1.9 currents and trigger action potentials in visceral 
afferents. However, it is important to stress that other inflammatory mediators 
may also be present at the afferent terminal due to ongoing interactions with 
immune cells or gut microbiota. As a consequence, it is not possible to rule out 
the possibility that multiple mediators may be acting to enhance NaV1.9 
currents. Another consideration is that purinergic agonists can enhance 
currents generated by other sodium channels (e.g. NaV1.8 (Baker, 2005)) or ion 
channels (Schicker et al., 2010; Tominaga et al., 2001); however, the data 
presented here suggest that visceral afferent excitability to these mediators is 
highly dependent on NaV1.9.  
The enhancement of persistent NaV1.9 Na+ currents by ATP has been suggested 
to occur via G-protein coupled P2Y receptors (Baker et al., 2003). The 
reductions in afferent responses observed to P2Y receptor agonists, UTP and 
ADP, in NaV1.9 -/- mice would support a mechanistic link between these 
pathways. Furthermore, just over half of P2Y1-expressing colonic DRG neurones 
also express mRNA transcripts for NaV1.9, suggesting that, at least in a subset of 
neurones, such activity may occur. It is important to stress that while loss of 
NaV1.9 Na+ current potentiation by P2Y agonists most likely contributes to the 
deficits observed in NaV1.9 -/- mice, the reduction in sensitivity caused by a loss 
of basal Na+ currents will also impact on neuronal excitability. This will be 
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particularly relevant for the subset of neurones expressing NaV1.9 but not P2Y 
receptors during activation with ATP. Experiments in isolated colonic DRG 
neurones are required to confirm the P2Y receptor subtype(s) that are 
responsible for any potentiation of NaV1.9 Na+ current in visceral afferents, 
which may ultimately contribute to changes in neuronal excitability.   
5.4 NAV1.9 AS A THERAPEUTIC TARGET 
 
Given the strong evidence implicating NaV1.9 in the visceral transduction of 
noxious inflammatory and mechanical stimuli, would a pharmacological 
inhibitor of NaV1.9 be an analgesic effective in the viscera? Three main points 
need to be addressed to begin to answer this question. Firstly, the redundancy 
of molecular channels capable of regulating visceral afferent sensitivity in the 
absence or blockade of NaV1.9. Secondly, the contribution of NaV1.9 to enteric 
nervous system function and thirdly, the phenotype of humans possessing 
NaV1.9 channelopathies need to be further understood.   
5.4.1 REGULATORS OF VISCERAL AFFERENT MECHANOSENSATION AND 
SENSITIVITY 
 
Multiple molecular targets regulating mechanosensation and sensitivity have 
been identified in recent years with preferential expression in primary afferent 
neurones targeting the viscera, and more specifically the colorectum. Given the 
significant deficits in visceral afferent sensitivity observed in NaV1.9 -/- mice, it 
is perhaps valuable to compare the magnitude and patterning of these 
phenotypes to those observed from other null mutant mice, namely TRPV1, 
TRPV4, TRPA1 and ASICs (Brierley et al., 2009; Brierley et al., 2008; Jones et al., 
2005; Page et al., 2004; Page, Brierley, et al., 2005).  
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Using a combination of electrophysiological recordings of pelvic and splanchnic 
nerves from flat-sheet ex vivo colonic preparations and in vivo changes in 
behavioural responses to colorectal distension, the mechanosensory 
contribution of these channels has been identified. Specifically, TRPV4 and 
TRPA1 appear to transduce visceral mechanical stimuli relevant to nociception, 
with large deficits observed in serosal and mesenteric afferent subtype 
responses to von Frey hair probe and in behavioural responses to colorectal 
distension (Brierley et al., 2009; Brierley et al., 2008; Cenac et al., 2008). 
Responses to circumferential stretch in muscular-like afferent subtypes were 
unaffected by loss of either TRPV4 or TRPA1 (Brierley et al., 2009; Brierley et 
al., 2008). By contrast, TRPV1 null mutant mice possess significant reductions in 
responses to circumferential stretch of muscular-like afferents, but no 
difference was observed in other afferent subtypes (Jones et al., 2005). 
Visceromotor reflexes were also reduced in TRPV1 -/- mice, suggesting that 
both stretch-sensitive muscular afferents and serosal/mesenteric afferents 
contribute to the pseudoaffective pain behaviours observed in this model (Jones 
et al., 2005). The role of ASICs in mechanosensation is complicated by their 
ability to form heteromultimers of ASIC1, ASIC2 and ASIC3 subtypes. As such, 
this may explain the minor increases in sensitivity of serosal afferents observed 
following loss of ASIC1 and ASIC2 (Page, Brierley, et al., 2005), with ASIC3 -/- 
mice shown to have reduced responses to both serosal/mesenteric afferents 
and stretch-sensitive muscular-like afferent fibres (Jones et al., 2005; Page, 
Brierley, et al., 2005). Whilst ASIC3 knock-out affected a greater range of 
afferent subtypes, the magnitude of differences observed were less than those 
seen in TRPV4 and TRPA1 knock-outs. Though contributing to the transduction 
309 
 
of mechanical stimuli, ASIC3 knock-out does not alter the direct 
chemosensitivity of visceral afferents to inflammatory soup (Jones et al., 2005). 
Indeed, in visceral afferents individual knock-out of TRPV1 or TRPA1 does not 
impair direct excitatory responses to inflammatory soup or application of 
bradykinin or capsaicin, respectively, while TRPV4 mediates PAR2-dependent 
excitation (Brierley et al., 2009; Brierley et al., 2008; Jones et al., 2005; Sipe et 
al., 2008). This suggests that whilst ASICs and TRP channels are important 
transducers of mechanosensitivity, their contribution to the direct activation of 
visceral afferents by inflammatory mediators is less well understood (with the 
exception to known couplings, such as TRPV4/PAR2). What is clear is that 
TRPV1 and TRPA1, but not ASIC3, mediate mechanical hypersensitivity in 
subsets of afferent fibres (Brierley et al., 2009; Jones et al., 2005; Page, Brierley, 
et al., 2005). By comparison, the data presented here shows that NaV1.9 
regulates direct excitatory responses to a diverse range of inflammatory 
mediators, mediates the subsequent mechanical hypersensitivity and 
contributes to aspects of mechanosensation, especially to persistent stimuli. 
Collectively, the loss of mechanical hypersensitivity, but not direct 
chemosensitivity in TRPV1 and TRPA1 knock-out mice further supports their 
roles as principal mechanotransducers in visceral afferent terminals, with post-
translational modification of these channels likely driving an increased 
sensitivity to mechanical stimuli (Table 11). The impact on both direct 
excitation and mechanical hypersensitivity in NaV1.9 null mutant mice indicates 
a mechanistic role up-stream from, and integrating, mechanotransduction and 
chemosensitivity.  
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 NaV1.9 TRPV1 TRPV4 TRPA1 ASIC3 ASIC2 ASIC1 
Mechanosensory responses        
Splanchnic mesenteric afferents ↓↓  ↓↓↓ ↓↓↓ ↓↓ ⟷ ↑ 
Splanchnic serosal afferents ⟷  ↓↓↓ ↓↓↓ ↓↓ ↑ ↑ 
Splanchnic muscular afferents ⟷       
Splanchnic mucosal afferents        
Pelvic serosal afferents  ⟷ ↓↓↓ ↓↓↓ ⟷   
Pelvic muscular afferents  ⟷ ⟷ ↓ ⟷   
Pelvic muscular/mucosal afferents  ↓↓ ⟷ ⟷ ↓↓   
Pelvic mucosal afferents  ⟷ ⟷ ⟷ ⟷   
        
Chemosensory responses        
Direct excitation ↓↓↓(IS/ATP/PGE2) ⟷(IS) ↓↓(PAR2 ag.) ⟷(BK/Cap) ⟷(IS)   
Mechanical hypersensitivity ↓↓↓ ↓  ↓↓↓ ⟷   
        
Visceromotor response ⟷(basal) 
↓↓↓(sensitised) 
↓↓ ↓↓↓ ↓↓ ↓↓   
References (Hockley et al., 
2014; Martinez & 
Melgar, 2008) 
(Jones et al., 
2005) 
(Brierley et al., 
2008; Cenac et 
al., 2008; Sipe 
et al., 2008) 
(Brierley et al., 
2009) 
(Jones et al., 
2005; Page, 
Brierley, et 
al., 2005) 
(Page, 
Brierley, et 
al., 2005) 
(Page, 
Brierley, et 
al., 2005) 
 
Table 11. Visceral afferent mechanosensation and chemosensation in null mutant mice. The table summarises the effects of ion channel loss 
on spinal afferent mechanosensory and chemosensory responses, and on behavioural responses to colorectal distension. Arrows indicate the 
degree of change, with blank cells indicating that this functional class of afferent or response has not been studied in that null mutant mouse. 
Note that whilst basal visceromotor responses are unchanged in NaV1.9 -/-, inflammatory visceral hypersensitivity is lost. IS, inflammatory soup 
(refer to reference for constituents); PGE2, prostaglandin E2; PAR2 ag., PAR2 receptor agonist (SLIGR); BK, bradykinin; Cap, capsaicin.  
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In addition to ion channels associated with the transduction of mechanical 
stimuli, the contribution of other known regulators of neuronal excitability, 
including T-type calcium channels, KV7 and HCN2, have yet to be examined in 
detail in visceral afferents (Emery et al., 2011; Hirano et al., 2007; Sekiguchi & 
Kawabata, 2013). Importantly, the unique biophysical characteristics of NaV1.9, 
which produce a persistent Na+ current with slow activation/inactivation 
kinetics and hyperpolarised activation threshold, cannot be replicated by any 
other voltage-gated sodium channel (Catterall, Goldin, & Waxman, 2005). As 
such, the genetic deletion or pharmacological inhibition of NaV1.9 could not be 
compensated for by another NaV channel subtype. Indeed, NaV mRNA levels are 
largely unaffected by NaV1.9 deletion in mice (Amaya et al., 2006; Priest et al., 
2005) and transient intrathecal antisense knock-down of NaV1.9 in rat 
produced comparable inflammatory pain phenotypes to those observed in null 
mutant mice, suggesting developmental up-regulation of other NaVs is unlikely 
to explain these effects (Lolignier et al., 2011). Furthermore, normosensation in 
both somatic behavioural pain models and visceral colorectal distension models 
are unaffected by deletion of NaV1.9 (Amaya et al., 2006; Martinez & Melgar, 
2008; Priest et al., 2005).   
5.4.2 ROLE OF NAV1.9 IN ENTERIC NERVOUS SYSTEM FUNCTION 
 
Considerable efforts were taken to ensure that changes observed in afferent 
activation in this study were not confounded by the loss of NaV1.9 within 
intrinsic primary afferents neurones (IPANs) of the enteric nervous system 
(ENS), which are known to express NaV1.9 (Padilla et al., 2007; Rugiero et al., 
2003). Although the contribution of second order enteric neurones projecting 
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out of the gut (intestinofugal fibres) in these recordings cannot be ruled out, 
these would proportionally represent a small minority of the total splanchnic 
outflow at the recording site central to the inferior mesenteric ganglia 
(Luckensmeyer & Keast, 1995). It is also currently unknown whether 
intestinofugal fibres express NaV1.9.  Similarly, the contribution of rectospinal 
neuronal projections to the present multi-unit recordings cannot be excluded. It 
should be said that these fibres are low in frequency and thus far have only 
been associated with anatomical projections through dorsal roots L6/S1: spinal 
segments through which the lumbar splanchnic nerve is known not to project 
(Neuhuber et al., 1993). Potential impact of the loss of NaV1.9 from IPANs on 
local reflexes was controlled by the inhibition of intrinsic smooth muscle tone 
by inclusion of both nifedipine (L-type calcium channel blocker) and atropine 
(muscarinic acetylcholine antagonist) to the perfusion buffer. These 
methodological steps, in conjunction with both the magnitude of the effects 
observed and the paucity of evidence for cross-talk between the ENS and 
extrinsic afferents mediating extrinsic afferent sensitivity, would strongly 
suggest that the changes we observe are due to the modulation of neuronal 
excitability by NaV1.9 in visceral extrinsic afferents (Mueller et al., 2009). 
Indeed, at best, intrinsic neurones are only likely to influence the small 
proportion (10%) of extrinsic afferents terminating at myenteric plexi between 
colonic muscle layers (Brierley et al., 2004; Mueller et al., 2009) and are 
unlikely to influence the function of vascular afferents that comprise the 
significant proportion of spinal afferent fibres projecting to the colorectum. 
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Loss of NaV1.9 from the myenteric plexus has been shown to alter spontaneous 
contractile activities in the mouse colon, which will impact the propulsion of 
digestive content (Copel, Clerc, Osorio, Delmas, & Mazet, 2013). Specifically, the 
frequency of colonic migrating motor complexes (CMMCs) and intensity of 
contraction was increased in NaV1.9 -/- mice. As such, targeting NaV1.9 by 
pharmacological inhibitors may, in fact, facilitate colonic transit through 
synergistic action at both visceral afferent fibres and enteric neurones. This 
could be of considerable benefit to inflammatory bowel disease patients where 
existing efficacious visceral analgesics, namely opioids and anti-spasmodics, are 
typically associated with stasis and constipation (Ford et al., 2008; Mowat et al., 
2011).  
5.4.3 HUMAN NAV1.9 CHANNELOPATHIES AND PATHOPHYSIOLOGY 
 
The recent identification of human NaV1.9 channelopathies associated with 
congenital insensitivity to pain, episodic pain syndrome and painful neuropathy 
has facilitated the functional study of this channel in human sensation. Familial 
episodic pain has been attributed to different point mutations in NaV1.9 in two 
Chinese families (Zhang et al., 2013). Two separate mutations at p.Ala808Gly 
and p.Arg225Cys caused episodic pain predominantly in the lower distal 
extremities, which was worsened by fatigue. These mutations, in contrast to 
p.Leu811Pro, cause a significant increase in current density and leave the 
voltage dependence of activation and inactivation unchanged (Zhang et al., 
2013). This leads to significant increases in neuronal excitability, which was not 
attributed to changes in resting membrane potential or action potential 
threshold. Instead, increased action potential firing following current injections 
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is likely causal to the observed hyperexcitability of DRG neurones, which 
manifests as relapsing episodic pain occurring at a frequency of 2-5 days.  
Recently eight heterozygous variants of SCN11A were identified in 12 patients 
from a cohort of 393 patients with painful neuropathy (Huang et al., 2014). 
Mutations in SCN9A and SCN10A were not causal and detailed functional 
electrophysiological analysis was carried out on two mutations (p.Ile381Thr 
and p.Leu1158Pro) possessed by four patients, which were shown to confer 
gain-of-function characteristics to the NaV1.9 channel.  Symptoms presented 
late in life (>50 years of age) and consisted of numbness, tingling and typically 
dull burning pain in the lower limbs. These were associated with autonomic 
changes including diarrhoea, hyperhidrosis, dry mouth/eyes and altered blood 
flow. Specifically, p.Ile381Thr and p.Leu1158Pro mutations were located in 
membrane-spanning segments lining the pore (DI/S6) and in the voltage-sensor 
(DIII/S3) of the channel, respectively. Both mutations lead to hyperpolarising 
shifts in the voltage dependence of activation and, in the case of p.Ile381Thr, a 
depolarising shift in the voltage dependence of inactivation; whilst this 
remained unchanged for p.Leu1158Pro. Resting membrane potential was 
depolarised and action potential current threshold was reduced by both 
mutations, resulting in significant increases in action potential firing during 
depolarising current steps. Furthermore, controlling for recombinant 
expression levels of mutant NaV1.9 in transfected neurones using dynamic 
clamp, similar effects on RMP and AP firing hyperexcitability were observed.   
A single de novo p.Leu811Pro mutation located at the distal end of the S6 
transmembrane helix in domain II of NaV1.9 has been linked to the inability to 
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experience pain in humans (Leipold et al., 2013). Clinically, this results in 
multiple painless fractures and slow wound healing. Further, gastrointestinal 
function is also impaired with patients requiring temporary parenteral 
nutrition and possessing morphologically abnormal small intestine and 
enlarged colon (Leipold et al., 2013). This phenotype is driven by changes in 
NaV1.9 voltage-dependant gate closure and channel inactivation caused by the 
mutation. As such, NaV1.9 p.L811P possesses a leftward shift in activation and 
deactivation kinetics (~-29mV), and results in increased NaV1.9 Na+ current flux 
at rest, and a subsequent ~7mV depolarisation of the resting membrane 
potential. Leipold et al. hypothesise that other voltage-gated sodium channels 
and voltage-gated calcium channels are therefore progressively inactivated and 
the sensory neurone experiences conduction block (Herzog et al., 2001; Leipold 
et al., 2013). Given the extensive expression of NaV1.9 within small DRG 
neurones, this could result in a selective blockade of primary nociceptive 
pathways and an inability to sense pain. This hypothesis had been challenged by 
recent studies linking mutations in NaV1.9 with hyperexcitability of DRG 
neurones. Whilst the change in the voltage dependence of activation and 
deactivation associated with the p.L811P mutation are far greater than those 
seen in the Huang et al. and Zhang et al. mutations, the subsequent 
depolarisation in RMP observed by Leipold et al. of ~7mV is comparable to that 
seen by Huang et al. (Huang et al., 2014; Leipold et al., 2013; Zhang et al., 2013). 
As such it is difficult to reconcile these findings with current hypotheses 
correlating point mutations in both NaV1.7 and NaV1.9 to depolarising changes 
in RMP and the subsequent hyperexcitability of DRG neurones (Harty et al., 
2006; Huang et al., 2014). Indeed, Huang et al. go on to state that 
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‘hypoexcitability of mouse DRG neurones that express the NaV1.9 L811P 
mutation cannot be explained by the shift in RMP of these neurones’ (Huang et 
al., 2014). This is probably due to the expression of NaV1.8 in the vast majority 
of small DRG neurones, which unlike other voltage gated sodium channels, has 
voltage-dependencies of activation and inactivation 20-40mV more depolarised 
(Catterall et al., 2005). As such a 5-7mV depolarising shift in RMP is unlikely to 
drive significant proportions of NaV1.8 channels into inactivated states and will 
result in hyperexcitability of these neurones (D. L. Bennett, 2014; Huang et al., 
2014), however in those cells not expressing NaV1.8, hypoexcitability is the 
likely phenotype (Rush et al., 2006). Further, Huang et al. suggest that the 
hypoexcitabilility observed in DRG neurones expressing the NaV1.9 p.L811P 
mutation may potentially be explained by a sampling bias towards these cells, 
with cells expressing NaV1.8 significantly fatigued or subnormal (Huang et al., 
2014). Fluorescent dye-filled in vivo intracellular recordings of mouse DRG 
neurones possessing the NaV1.9 L811P mutation, with subsequent post-
functional expression labelling for NaV1.8 would help to answer this hypothesis.  
Interestingly, NaV1.5 and NaV1.9 have recently been shown to be the two 
sodium channels responsible for carrying the TTX-R Na+ currents observed in 
myenteric neurones (Osorio, Korogod, & Delmas, 2014). As such, given the lack 
of NaV1.8 in these neurones, in patients presenting with NaV1.9 p.L811P 
mutations, it would be predicted that myenteric neurones are hypoexcitable. 
The GI phenotype seen in NaV1.9 p.L811P mutants, with reduced peristaltic 
waves, may be a result of such myenteric dysfunction (Leipold et al., 2013). 
Whether myenteric neurones are hyperexcitable in NaV1.9 null mutant mice 
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manifesting as increased frequency of migrating motor complexes remains to 
be seen (Copel et al., 2013).   
In patients with episodic pain syndrome associated with NaV1.9 p.Ala808Gly 
and p.Arg225Cys mutations, the pain region was reported as feeling extremely 
cold and pain could be ameliorated by hot compress (Zhang et al., 2013). One 
possible rationale may be the co-expression of NaV1.9 by NaV1.8-positive 
neurones, which are known to mediate cold sensation and hence their 
hyperexcitability may exploit existing thermosensation pathways 
(Zimmermann et al., 2007). This is in stark contrast to the presentation of 
NaV1.7-dependent primary erythromelalgia where severe burning pain in the 
extremities may be relieved by ice bath or cold compress (Fischer & Waxman, 
2010). It is also tempting to speculate on the transient nature of pain bouts 
experienced by these patients, which tend to last between 5 and 20 minutes, 
approximately the duration of so-called NaV1.9 ‘kindling’ and run-down of 
current amplitudes during whole-cell patch-clamp experiments (Maruyama et 
al., 2004; Zhang et al., 2013). However, it remains to be seen whether such 
kindling events are merely an artefact of patch-clamp recording techniques. 
Finally, that the pain was significantly attenuated by paracetamol and NSAID 
drugs implicates inflammatory processes in its propagation and is complicit 
with the role of NaV1.9 described in this thesis (Zhang et al., 2013).  
What do these channelopathies tell us about NaV1.9 as an analgesic target for 
inflammatory pain? Importantly, cognitive function and brain development 
appears normal in patients possessing these NaV1.9 mutations (Huang et al., 
2014; Leipold et al., 2013; Zhang et al., 2013). This may have been unexpected 
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given the purported requirement of NaV1.9 in neurotrophin-evoked 
depolarisations in mammalian brain (Blum et al., 2002). Interestingly, patients 
with NaV1.9 p.L811P presented with delayed motor development and mild 
muscular weakness, although biopsies and electromyography were normal 
(Leipold et al., 2013). Such motor phenotypes were not explicitly mentioned for 
p.Ala808Gly and p.Arg225Cys mutations (Zhang et al., 2013) or p.Ile381Thr and 
p.Leu1158Pro mutations (Huang et al., 2014). Indeed, one patient is reported to 
have been a soldier previously, at least suggesting that motor or muscular 
deficits, if present, were not incapacitating (Zhang et al., 2013). NaV1.9 has been 
implicated in the development of motoneurone axons, with NaV1.9 -/- mice 
showing marked reductions in axon growth (Subramanian et al., 2012). This 
axon growth is activity-dependent on voltage-gated calcium channels and 
suggests that aberrant p.L811P NaV1.9 Na+ flux may impair or retard 
motoneurone development in patients with this mutation (Leipold et al., 2013). 
However, it is clear that these patients ultimately exhibit normal motor control, 
suggesting that compensation at least within motoneurones for NaV1.9 deficits 
can occur.  
The GI phenotype presented by Leipold et al., alongside rodent models of 
enteric neuronal function, suggests that NaV1.9 likely contributes to the 
effective function of the GI tract, including peristaltic propulsion (Copel et al., 
2013; Leipold et al., 2013; Padilla et al., 2007; Rugiero et al., 2003). In patients 
with familial episodic pain as a result of alterations in NaV1.9 reported no GI 
dysmotility (Zhang et al., 2013). Similarly, patients with painful neuropathy 
associated with NaV1.9 mutations did not report GI dysfunction (Huang et al., 
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2014). Collectively this data would suggest that the p.L811P NaV1.9 phenotype 
differs from other painful phenotypes associated with NaV1.9 mutations, not 
only in the context of pain sensation (or lack of) but also with regards to GI 
function. The aberrant function of DRG and myenteric neurones expressing 
NaV1.9 p.L811P mutations are, therefore, not fully explained by current 
hypotheses and further work is required to understand this phenotype fully.  
The data in this thesis, in conjunction with pain phenotypes of human mutants 
and our current understanding of the function of NaV1.9, suggests a significant 
role for the channel in the development of visceral inflammatory pain. Together 
these findings suggest that pharmacological blockade of NaV1.9 may prove an 
effective analgesic strategy in pathologies where the predominant pain is 
caused by acute or on-going inflammation. This may be particularly relevant for 
inflammatory bowel disease, where there is an unmet medical need for 
mechanistically novel analgesics. Indeed, given the multifactorial character of 
the pain in IBD, NaV1.9 blockers in conjunction with treatments for neuropathic 
pain (including pregabalin/gabapentin) may result in the most benefit for 
patients. Other relevant conditions where inflammatory or visceral pain is a 
principle component include acute inflammatory conditions such as 
appendicitis, dermatitis and tonsillitis, or chronic diseases such as pancreatitis 
and rheumatoid arthritis. 
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5.5 FURTHER WORK 
 
A number of important studies are required to consolidate the findings 
presented here. Investment in the development of NaV1.9 knock-out strains 
using transient and tissue-specific promoters, as has been undertaken for 
NaV1.7 and NaV1.8, would significantly drive the field forward (Abrahamsen et 
al., 2008; Minett et al., 2012). Specifically, floxed SCN11A under the control of 
NaV1.8-Cre would enable NaV1.9 knock-out in well characterised nociceptors. 
This could be extended to the use of Wnt1-Cre and Advillin-Cre-expressing mice, 
which would select for deletion within precursors of sensory and autonomic 
neurones, and trigeminal and DRG neurones, respectively. Furthermore, the 
development of knock-in NaV1.9-Cre mice crossed with globally expressed 
floxed dipheria toxin A (DTA)-subunit gene, would result in the death of NaV1.9-
Cre-expressing neurones. The absence of these neurones would provide a clear 
opportunity to functionally characterise colon-projecting neurones and 
understand the extent of NaV1.9 expression in visceral afferents.  
These mutant mice could also be used to investigate the role of NaV1.9 in 
visceral afferent function more generally, including in vascular afferent 
terminals of the kidney, lung and pancreas. With regards to the GI tract, 
characterisation of afferent function in lumbosacral pathways of NaV1.9 global 
null mice is also required, alongside characterisation in vagal pathways. As 
mentioned above, given the importance of NaV1.9 in neuronal sensitivity during 
inflammatory states, studies looking into the mechanical hypersensitivity to 
colorectal distension in rodent in vivo models of both post-infectious IBS and 
TNBS-induced colitis are necessary. Importantly, distension paradigms that 
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activated splanchnic, as well as pelvic, pathways should be employed to provide 
parity with existing ex vivo data. Such in vivo models could be combined with 
the use of supernatants derived from IBS and IBD tissues to provide translation 
to human disease.  
Finally, mechanistic studies focusing on the G-protein coupled current 
amplitude regulation of NaV1.9 in colonic sensory neurones are required; 
examining the ability for inflammatory mediators, including ATP, to up-regulate 
NaV1.9 currents and the likely impact of this on visceral neuronal function. 
Importantly, understanding whether ATP-mediated P2Y activation is a 
significant modulator of NaV1.9 function will further the understanding of 
NaV1.9 in visceral afferents.   
5.6 CONCLUSIONS 
 
Visceral afferents are polymodal and require mechanisms for regulating 
neuronal excitation induced by a range of innocuous and noxious mechanical 
and inflammatory stimuli. Indeed, visceral nociceptors are prone to modulation 
by inflammatory mediators, and may be recruited after being previously silent 
(Brierley, Carter, et al., 2005; Brierley, Jones, et al., 2005; Feng & Gebhart, 2011; 
Feng, La, Schwartz, et al., 2012). These results suggest that NaV1.9 represents a 
significant mechanism responsible for regulating visceral afferent sensitivity by 
noxious inflammatory, mechanical and human disease-derived stimuli. In 
summary, the data supports an important physiological role for NaV1.9 in the 
regulation of visceral afferent sensitivity during inflammation and one which 
will likely have direct clinical relevance to human visceral pain. 
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CHAPTER 6: APPENDICES 
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6.1 APPENDIX 1 – EXPRESSION STUDIES 
6.1.1 CORRELATION BETWEEN NAV1.9-IMMUNOREACTIVITY AND IB4-BINDING 
 
Previous studies have shown that IB4 binding is positively correlated to NaV1.9 
expression, however this has not been examined in the context of visceral 
afferents (Fang et al., 2006). If this finding is reproducible, then IB4-binding 
may prove a more versatile surrogate representative of NaV1.9 expression. To 
investigate this correlation further during expression studies performed in 
Chapter 2, the intensity of NaV1.9-immunoreactivity was correlated with IB4-
binding in colon-projecting (FB+) neurones and unlabelled (FB-) neurones from 
rat DRG. In Figure 49, positive correlations were observed with increasing 
relative intensity of NaV1.9 linked to increasing relative intensity of IB4. 
However, whilst the correlation is significant (Pearson two-tailed test, p < 
0.0001 (FB-) and p < 0.001 (FB+), Figure 49), it is relatively weak (FB+, R2 = 
0.24), especially within FB- neurones (FB-, R2 = 0.10). In the study by Fang et al., 
NaV1.9 expression was strongly correlated to IB4 binding in a very specific set 
of well characterised nociceptive neurones (Fang et al., 2006). It is likely that 
the very specific ‘nociceptive’ phenotype selected for by Fang et al., and any 
associated NaV1.9-IB4 correlation, is lost by the lack of functional data linked to 
this immunohistochemical analysis. 
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Figure 49. Correlation of relative intensity of NaV1.9 with IB4 in colonic (FB+) and 
unlabelled (FB-) populations. Correlation of relative intensity of NaV1.9+ neuronal 
profiles with relative intensity of IB4+ neurones profiles in FB- (A) and FB+ (B) 
populations. Line of best fit is shown with 95% confidence levels. 
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6.1.2 CORRELATION BETWEEN NAV1.9 MRNA TRANSCRIPT EXPRESSION AND 
NAV1.9 PROTEIN EXPRESSION 
 
In a pilot study to compare the expression of NaV1.9 mRNA transcript with 
NaV1.9 protein, isotopic in situ hybridisation was used in conjunction with 
immunohistochemistry in rat DRG sections. Antisense probes previously shown 
to be specific for NaV1.9 mRNA in mouse were hybridised to rat DRG sections 
already labelled with NaV1.9 antibody. The probes used were specific for mouse 
NaV1.9 (mNaV1.9) mRNA and therefore reduced binding efficiency was 
predicted in rat tissues (see Chapter 2 Methods (2.3.4 Isotopic in situ 
hybridisation probe selection) for NaV1.9 species homology and probe design). 
In this single experiment, NaV1.9 mRNA expression was shown to correlate with 
NaV1.9 protein expression (Pearsons correlation test, p < 0.0001, R2 = 0.42) 
further validating the specificity of the NaV1.9 antibody. Whilst this study 
provides a methodological link between in situ hybridisation and 
immunohistochemistry datasets, this was not replicated (N = 1) and therefore 
should not be over-interpreted.      
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Figure 50. Colocalisation of NaV1.9 mRNA and protein using in situ hybridisation and 
simultaneous immunohistochemistry. A Example fluorescent images showing 
NaV1.9-immunoreactivity (i), NaV1.9 mRNA expression as silver grain under 
polarised-light (ii) and merge (iii). Scale bar 50μm. B Scatter-plot of relative intensity 
of NaV1.9 mRNA transcript expression against NaV1.9 immunoreactivity (60 profiles, 
N = 1, p < 0.0001, R2 = 0.42). Line of best fit (solid line) is shown with 95% 
confidence intervals (dashed lines).  
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6.2 APPENDIX 2 – FUNCTIONAL STUDIES 
 
6.2.1 EFFECTS OF SELECTIVE P2Y RECEPTOR AGONISTS AND ANTAGONISTS ON 
COLONIC SPLANCHNIC NERVE ACTIVITY 
 
In extracellular electrophysiological recordings of whole-nerve afferent activity 
of the splanchnic nerve in mouse, the application of P2Y receptor agonists, ADP 
and UTP led to significant excitatory responses. Specifically, ADP has activity at 
P2Y1, P2Y11, P2Y12 and P2Y13 receptors and UTP is specific for P2Y2, P2Y4 and 
P2Y6 receptors. Of these, the positively Gq,11-protein coupled P2Y1 and P2Y2 
receptor subtypes have been associated with many pro-excitatory effects in 
neuronal cells and visceral  afferents (X. Chen et al., 2010; Yousuf et al., 2011). 
In order to investigate these effects further P2Y receptor subtype-specific 
agonists and antagonists were applied to whole-nerve splanchnic recordings of 
the distal colon in a tubular preparation (as described in Chapter 3.3.2 In vitro 
mouse colonic splanchnic afferent preparations). The concentrations used were 
based on usage in comparable ex vivo afferent nerve preparations. If this was 
not possible, then IC50 and EC50 concentrations at the receptor of interest were 
used to estimate an appropriate concentration to apply to colonic afferent 
preparations (see Chapter 4.3.8 Drugs). Wash-out of effect, reproducibility of 
application and concentration-dependent effects were all used to confirm 
specific pharmacology. Independent application of supramaximal 
concentrations of selective P2Y1 agonist MRS2365 (10μM) and selective P2Y2 
agonist PSB1114 (3μM and 10μM) failed to robustly evoke afferent excitation in 
colonic afferent tubular preparations (Figure 51A & B). Indeed, antagonism of 
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P2Y1 receptors with 3μM MRS2500 did not block either 1mM ADP responses or 
1mM ATP responses (Figure 51C). Further to this, pre-incubation with selective 
P2Y2 antagonist, 10μM AR-C118925X also failed to inhibit 1mM UTP responses 
and 1mM ATP responses (Figure 51E). Finally, potential excitatory effects of 
P2Y12 receptor activation by 1mM ADP or 1mM ATP were discounted by pre-
incubation with selective P2Y12 antagonist, ticlopidine (100μM; Figure 51D). 
The lack of effectiveness of P2Y receptor selective ligands in this preparation, 
when compared to responses evoked by ADP and UTP suggests that the 
concentrations of, or the ligands, themselves may not be amenable to afferent 
nerve preparations. Given the concentrations of purines (1-10mM ATP, ADP 
and UTP) required to robustly excite colonic afferents it is plausible that 
selective P2Y receptor ligands are also restricted by equivalently active 
enzymatic degradation pathways. This is especially relevant given the 
analogous chemotypes that selective P2Y receptor ligands share with 
endogenous purine agonists. Alternatively, it is possible that independent 
selective P2Y receptor subtype activation or antagonism is inadequate to 
directly excite or inhibit colonic afferents. 
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Figure 51. Application of selective P2Y receptor agonists and antagonists to colonic 
splanchnic nerve preparations. A Peak response to application of selective P2Y1 
receptor agonist, MRS2365 (10μM) to colonic splanchnic nerve tubular preparation 
(N = 2). By way of comparison, 1mM ADP (N = 6) and 1mM ATP (N = 6) responses 
are also shown. B Peak response to application of selective P2Y2 receptor agonist, 
PSB1114 (3μM and 10μM; N = 1 at each concentration), plotted with 1mM UTP (N = 
6) and 1mM ATP (N = 6) responses. C Peak responses to 1mM ADP (N = 2) and 1mM 
ATP (N = 3) following pre-incubation with selective P2Y1 antagonist, MRS2500 
(3μM) compared to 1mM ADP and 1mM ATP (N = 6) without pre-treatment. D  Peak 
responses to 1mM ADP (N = 1) and 1mM ATP (N = 2) following pre-incubation with 
selective P2Y12 antagonist, ticlopidine (100μM) compared to 1mM ADP and 1mM 
ATP (N = 6) without pre-treatment. E Peak responses to 1mM UTP (N = 1) and 1mM 
ATP (N = 2) following pre-incubation with selective P2Y2 antagonist, AR-C118925X 
(10μM) compared to 1mM ADP and 1mM ATP (N = 6) without pre-treatment. 
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